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Abstract 
Background  
Hypertension is the main cardiovascular risk factor. Worldwide, 40% of adults aged 25 years 
and over have hypertension. Only around 25% of hypertensive patients had controlled hy-
pertension (CH). I assessed the association between individual factors, physician factors 
and health system factors with having CH 
Methods 
Population included 17252 hypertensive adults (HA) registered with 28 general practices in 
Wandsworth, London between 1998 and 2007. Comparison of two blood pressure targets 
was performed by cross-sectional analysis. Changes in antihypertensive prescribing were 
evaluated using logistic models. A Bayesian frailty survival model was developed to assess 
the relationship between potential risk factors and CH with blood pressure <=140/90 mm Hg.  
Results  
In 2007, 26 (93%) practices had more than 70% HA with CH using the QOF target. Using 
the NICE target of 140/90 mm Hg 4 (14.2%) of practices had more than 70% HAs with CH.  
In 1998 49.0% HA were not prescribed antihypertensive medication but only 14.8% in 2007. 
The introduction of the 2006 NICE guidelines was associated with an increase in recom-
mended monotherapy prescribing. 37% of 11373 HA used for survival analysis had CH in 
1998 and 62.4% had CH in 2007. Being older, increases in body mass index and higher lev-
els of cholesterol were negatively associated with having CH, hazard ratio (HR) 0.99 (95% 
credible interval 0.99 – 0.99), HR 0.93 (95% credible interval 0.88 – 099) and HR 0.89 (95% 
credible interval 0.79 – 0.99) respectively. HA registered after the introduction of Quality and 
Outcomes Framework (QOF) were more likely to have CH, HR 2.05 (95% credible interval 
1.94 – 2.16).   
Conclusion  
In this cohort of HA being treated in primary care, individual factors were mainly associated 
with not having CH. Blood pressure control rates increased over the period. The use of na-
tional hypertension guidelines and the QOF could contribute to this improvement. 
 
5 
 
 
Acknowledgments 
 
I would like to thank to the Government of Colombia, Departamento de Ciencia, Tecnologia 
e Informacion (COLCIENCIAS) and the Academic and Professional Programs for the Ameri-
cas (LASPAU) for granting my studies. I also thank to Universidad del Valle, Cali Colombia 
for funding my salary during this period.   
 
I thank to my supervisors Azeem Majeed, Christopher Millett and Marta Blangiardo for allow-
ing me being their student. I must acknowledge their help and advice. I would like thank to 
Vasa Curcin for his explanations of data assembling.  I thank to the primary care practices to 
participate in this study. I would like to thank to all members of Department Primary Care 
and Public Health for their hospitality during this time of my life. In particular, I thank to Sal-
man Rawaf for giving me the opportunity to participate in WHO meetings about primary care.  
 
My eternal gratitude to my family for their invaluable support  
 
 
 
 
 
6 
 
Table of  contents 
 
Declaration of originality 2 
Copyright Declaration 3 
Abstract 4 
Acknowledgments 5 
Table of contents 6 
List of tables 10 
List of Figures 13 
List of boxes 15 
Abbreviations 16 
Chapter 1 Introduction 20 
1.1 Definition of hypertension 20 
1.2 Epidemiology of hypertension 24 
1.2.1 Global trends 24 
1.2.2 The relationship between hypertension and cardiovascular diseases 28 
1.2.3 Risk factors for hypertension 32 
1.2.4 Treatment of hypertension 35 
1.3 Definition of Blood Pressure Control 43 
1.3.1 The definition of blood pressure targets 43 
1.3.2 Targets for specific populations 52 
Chapter 2 Factors affecting blood pressure control 65 
2.1 Patient-related factors 66 
2.1.1 Adherence to interventions 66 
2.1.2 Individual factors 68 
2.2 Physician-related factors 75 
7 
 
2.3 Health system factors 78 
Chapter 3 Epidemiology of hypertension in England 110 
3.1 General trends 110 
3.2 Blood pressure control in England 112 
3.3 The blood pressure targets for the management of hypertension 115 
3.3.1 The assessment of cardiovascular risk 115 
3.3.2 Patients at low and middle cardiovascular risk 118 
3.3.3 Targets for specific groups 120 
3.4 Factors affecting blood pressure control: evidence from studies carried out in 
England 121 
Chapter 4 Primary care 123 
4.1 Primary care concept 123 
4.2 Definition of Primary Care attributes 126 
4.3 Impact of primary care on the management of cardiovascular diseases 128 
4.4 Primary care in England 129 
4.4.1 Organization of Primary care in England 130 
4.4.2 The Quality and Outcome Framework 132 
4.5 Impact of primary care on the management of cardiovascular diseases in 
England 135 
Chapter 5 Aim and objectives 137 
Chapter 6 Description of study setting and sample characteristics 138 
6.1 Study setting 138 
6.2 Study design 146 
Chapter 7 Differences in the classification of patients with controlled hypertension 
between the Quality and Outcome Framework and the National Institute for Health 
and Clinical Excellence blood pressure targets 149 
7.1 Background 149 
8 
 
7.2 Methods 149 
7.3 Results 153 
7.4 Discussion 186 
7.5 Strengths and weaknesses of the study 194 
7.6 Conclusion 195 
Chapter 8 Impact of ethnic-specific guidelines for antihypertensive prescribing in 
primary care in England: longitudinal study 197 
8.1 Guidelines for the management of hypertension 197 
8.2 England guidelines for the management of hypertension in primary care 200 
8.2.1 Impact of hypertension guidelines on the management of hypertension in 
England 203 
8.3 Study 206 
8.3.1 Methods 207 
8.3.2 Results 211 
8.3.3 Discussion 241 
8.3.4 Strength and Limitations 247 
8.3.5 Conclusion 248 
Chapter 9 A Bayesian model for the assessment of factors affecting blood pressure 
control in a retrospective cohort of hypertensive patients 251 
Background 251 
9.1 The Bayesian framework 252 
9.1.1 Bayesian statistical inference 254 
9.2 The rationale of using a Bayesian approach in the current analysis 255 
9.2.1 Potential limitations on using a Bayesian framework 257 
9.2 Methods 259 
9.2.1 The Data 259 
9 
 
9.2.2 The model 259 
9.2.3 Data Processing 266 
9.3 Results 267 
9.4 The Frequentist model 293 
9.5 Discussion 296 
9.6 Strengths and limitations 302 
9.7 Conclusion 304 
Chapter 10 General discussion, conclusion and future work 306 
10.1 Summary of main findings 306 
10.2 Comparison with previous research 308 
10.3 The implications of current model 319 
10.3 Strengths and Limitations 320 
10.4 Future research 322 
10.5 Implications for policy and practice 324 
10.5.1 The assessment of blood pressure control in primary care 324 
10.5.2 The orientation of blood pressure control in primary care 326 
10.6 Conclusion 328 
11 References 330 
Appendix A Publications and outputs from this thesis 415 
Appendix B Characteristics of the studies included in the systematic reviews 
described in chapter one 416 
Appendix C Model code 422 
 
 
10 
 
List of  tables 
Table 1 Classification of blood pressure levels in hypertension guidelines ..................................................... 23 
Table 2 Associated hazard risk of stroke mortality with each 20 mmHg lower systolic blood pressure .......... 30 
Table 3 Associated hazard risk of coronary heart disease mortality with each 20 mmHg lower systolic blood 
pressure by sex ...................................................................................................................................... 30 
Table 4 Risk of cardiovascular events in individuals aged 35-64 years with blood pressure >140/90 mmHg .. 31 
Table 5 Thresholds for starting antihypertensive treatment established in hypertension guidelines ............. 37 
Table 6 Description of systematic reviews assessing blood pressure control targets ..................................... 46 
Table 7 Blood pressure targets for hypertensive patients on antihypertensive treatment............................. 63 
Table 8   Characteristics of included studies reporting factors affecting blood pressure control .................... 87 
Table 9 Factors associated with blood pressure control ............................................................................... 106 
Table 10 Trends in hypertension prevalence and control. 2003 -2010 England ............................................ 113 
Table 11 Classification of blood pressure levels in England hypertension guidelines ................................... 114 
Table 12 Blood pressure targets recommended in England hypertension guidelines between 1999 and 2011
 ............................................................................................................................................................ 117 
Table 13 Distribution of population resident in Wandsworth by age, 2001 and 2011 .................................. 139 
Table 14 Distribution of population resident in Wandsworth by race/ethnicity, 2001 ................................. 144 
Table 15 Distribution of population resident in Wandsworth by race/ethnicity, 2011 ................................. 144 
Table 16 Definition of study variables .......................................................................................................... 148 
Table 17 Characteristics of hypertensive patients, 2007 .............................................................................. 154 
Table 18 Comparison of mean systolic blood pressure and mean diastolic blood pressure mmHg in men by 
age and cardiovascular comorbidity, 2007 .......................................................................................... 160 
Table 19 Comparison of mean systolic blood pressure and mean diastolic blood pressure mmHg in women 
by age and cardiovascular comorbidity, 2007 ...................................................................................... 162 
Table 20 Comparison of systolic blood pressure mmHg for men by race/ethnicity and presence of 
cardiovascular comorbidity, 2007 ........................................................................................................ 164 
Table 21 Comparison of diastolic blood pressure mmHg for men by race/ethnicity and presence of 
cardiovascular comorbidity, 2007 ........................................................................................................ 165 
Table 22 Comparison of systolic blood pressure mmHg for women by race/ethnicity and presence of 
cardiovascular comorbidity, 2007 ........................................................................................................ 166 
Table 23 Comparison of diastolic blood pressure mmHg for women by race/ethnicity and presence of 
cardiovascular comorbidity, 2007 ........................................................................................................ 167 
Table 24 Cross-tabulation between NICE and QOF targets ........................................................................... 169 
Table 25 Percentages of patients with controlled hypertension by age, sex and race/ethnicity .................. 170 
Table 26 Comparison of patients with controlled hypertension between those with and without 
cardiovascular comorbidity¥ ............................................................................................................... 172 
11 
 
Table 27 Odds ratio of patient characteristics associated with being classified as a patient with controlled 
hypertension ....................................................................................................................................... 178 
Table 28 Percentage of diabetic patients with controlled blood pressure by age, sex and race/ethnicity 
(N=3360).............................................................................................................................................. 182 
Table 29 Comparison of diabetic patients with controlled hypertension between those with and without 
cardiovascular comorbidity N(3360) .................................................................................................... 183 
Table 30 Odds ratio of patient characteristics associated with being classified as a patient with controlled 
hypertension for all diabetic patients (N 3360) .................................................................................... 184 
Table 31 Odds ratio of patient characteristics associated with being classified as a patient with controlled 
hypertension for all diabetic patients without cardiovascular comorbidity (N=2308) .......................... 185 
Table 32 Variations in antihypertensive therapy recommendations established in England hypertension 
guidelines ............................................................................................................................................ 201 
Table 33 Studies conducted in England showing the use of therapeutic recommendations established in the 
time-related hypertension guidelines between 1999 and 2012 ........................................................... 204 
Table 34  Patients characteristics by NICE patient groups, 2007................................................................... 212 
Table 35 Variation in percentages of all hypertensive patients on antihypertensive treatment between 1998 
and 2007 ............................................................................................................................................. 214 
Table 36 Variation in percentages of all hypertensive patients on antihypertensive treatment by presence of 
cardiovascular comorbidity between 1998 and 2007 ........................................................................... 219 
Table 37 Variation in percentages of newly* registered hypertensive patients on antihypertensive treatment 
between 1998 and 2007 ...................................................................................................................... 221 
Table 38 Variation in the percentage of newly* hypertensive patients on antihypertensive treatment by 
comorbidity between 1998 and 2007 .................................................................................................. 223 
Table 39 Variation in percentages of all antihypertensive patients on antihypertensive drug monotherapy 
between 1998 and 2007 ...................................................................................................................... 228 
Table 40 Variation in the odds of being prescribed antihypertensive drug class in each NICE patient group 
between 1998 and 2007 ...................................................................................................................... 230 
Table 41 Variation in the percentage of newly* registered patients on drug monotherapy class between 
1998 and 2007 ..................................................................................................................................... 233 
Table 42 Variations in the odds ratio of being prescribed antihypertensive drug monotherapy class for newly 
registered hypertensive patients between 1998 and 2007 .................................................................. 235 
Table 43 Variation in the percentage of hypertensive on first line monotherapy recommended treatment 
between 1998 an 2007 ........................................................................................................................ 238 
Table 44 Variation in the odds of being prescribed the first line NICE recommended monotherapy between 
1997 and 2008 ..................................................................................................................................... 240 
Table 45 Baseline patient characteristics ..................................................................................................... 271 
12 
 
Table 46 Posterior hazard ratio associated with associated with variables included in the model 1 (N=11373)
 ............................................................................................................................................................ 278 
Table 47 Posterior hazard ratio associated with variables included in the model 2 (N=9679) ...................... 279 
Table 48 Posterior hazard ratio associated with variables include the model 3 (N = 6947) .......................... 282 
Table 49 Posterior hazard ratio of patient characteristics included in the model 4(N=7885) ........................ 287 
Table 50 Posterior hazard ratio associated with variables included in the model 5 (N=1794) ...................... 291 
Table 51 Time calculation for the Frequentist model ................................................................................... 293 
Table 52  Hazard ratio associated with factors affecting blood pressure control in the Frequentist model 2 
(N=9679).............................................................................................................................................. 295 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 
List of  Figures  
Figure 1 Prevalence of hypertension in men aged 25 years over, standardised by age 2008 .......................... 25 
Figure 2  Prevalence of hypertension in women aged 25 years over, standardised by age 2008     Source 
Global status report on noncommunicable diseases, WHO  2010 (40) ................................................... 26 
Figure 3  1 Percentage of adults aged 25 years and over with high blood pressure by WHO region*, 1980 and 
2008 ...................................................................................................................................................... 26 
Figure 4 Wandsworth location in London .................................................................................................... 138 
Figure 5 Distribution of patients by race/ethnicity in each practice, 2007 ................................................... 156 
Figure 6 Distribution of systolic blood pressure mmHg by age, 2007 N=15761 ............................................ 157 
Figure 7 Distribution of diastolic blood pressure mmHg by age, 2007 N=15761 ........................................... 158 
Figure 8 Distribution of systolic and diastolic blood pressure for men, 2007................................................ 159 
Figure 9 Distribution of systolic and diastolic blood pressure mmHg for women, 2007 ............................... 161 
Figure 10 Distribution of hypertensive patients by blood pressure levels .................................................... 168 
Figure 11 Distribution of patients with controlled hypertension by sex and age .......................................... 171 
Figure 12 Distribution of patients with controlled hypertension by race/ethnicity ...................................... 173 
Figure 13 Percentage of hypertensive patients with controlled blood pressure by practice ......................... 174 
Figure 14 Distribution of patients with controlled hypertension by deprivation index ................................ 175 
Figure 15 Distribution of patient with and without cardiovascular comorbidity by deprivation index ......... 175 
Figure 16 Variation in the probability of being classified as patient with controlled blood pressure* .......... 179 
Figure 17 Variation in the proportion of all include patients on antihypertensive treatment, between 1998 
and 2007 ............................................................................................................................................. 213 
Figure 18   Variation in the proportion of all patients on antihypertensive treatment by NICE groups between 
1998 and 2007 ..................................................................................................................................... 216 
Figure 19 Variation in the proportion of all patients on antihypertensive treatment by presence of 
cardiovascular comorbidity between 1998 an 2007 ............................................................................. 218 
Figure 20 Variations in the percentage on antihypertensive treatment in newly registered patients between 
1998 an 2007 ....................................................................................................................................... 222 
Figure 21 Variation in the percentage of newly registered patients on antihypertensive treatment by 
comorbidity ......................................................................................................................................... 224 
Figure 22 Variation in the percentage hypertensive patients on drug monotherapy class from 1998 to 2007
 ............................................................................................................................................................ 229 
Figure 23 Variation in the percentage of newly registered hypertensive patients on drug monotherapy class 
between 1998 and 2007 ...................................................................................................................... 234 
Figure 24 Variation in the percentage of hypertensive patients on the first line monotherapy recommended 
treatment between 1998 and 2007 ..................................................................................................... 239 
Figure 25 The Bayesian framework .............................................................................................................. 254 
14 
 
Figure 26 Illustration of the time calculation ............................................................................................... 261 
Figure 27 Directed acyclic graph (DAG) for describing the frailty survival Bayesian model ........................... 264 
Figure 28 Cohort profile ............................................................................................................................... 269 
Figure 29 Distribution of patients include in the survival cohort by number of blood pressure records over 
the 10 years period .............................................................................................................................. 270 
Figure 30 Distribution of patients by number of blood pressure records for those without variation in blood 
pressure control .................................................................................................................................. 270 
Figure 31 Mean systolic blood pressure at first record in the cohort group (N11373) .................................. 274 
Figure 32 Mean diastolic blood pressure at first record in the cohort group (N=11373) ............................... 275 
Figure 33  Annual mean systolic blood pressure in the cohort group (N=11373) .......................................... 275 
Figure 34 Annual mean diastolic blood pressure in the cohort group (N=11373) ......................................... 276 
Figure 35  Box plot of the hazard ratio for having controlled blood pressure by race/ethnic Models 1 and 2
 ............................................................................................................................................................ 280 
Figure 36 Distribution of hazard ratio associated with BMI in population from models 2 and 3 .................. 283 
Figure 37 Box plot of mean for random effects in 28 practices Models 2 and 3 ........................................... 284 
Figure 38 Box plot of hazard ratio for having controlled blood pressure by race/ethnic. Models 3, 4 and 5 285 
Figure 39 Distribution of posterior hazard ratio by body mass index. Models 4 and 5 ................................. 288 
Figure 40 Box plot of mean for the random effects in 28 practices. Models 4 and 5 .................................... 289 
Figure 41 Beta coefficient of age for a gamma (0.0001, 0.0001) prior distribution ....................................... 292 
Figure 42 Beta coefficient of age for a gamma (1, 05) prior distribution ...................................................... 292 
 
 
 
 
 
 
 
 
 
15 
 
List of  boxes 
Box 1 Main classes of lowering blood pressure drugs .................................................................................... 36 
Box 2 Classification of individuals by blood pressure levels in Health Survey for England ............................ 112 
Box 3 Definitions of Primary Care ................................................................................................................ 125 
Box 4 Similarities and differences between Primary Care and Primary Health Care ..................................... 127 
Box 5 The 2007/2008 hypertension QOF indicators ..................................................................................... 133 
Box 6 The 2011/201 QOF indicators ............................................................................................................. 134 
Box 7 Race/Ethnicity classification in the 2001 and 2011 England census .................................................... 143 
Box 8  Domains of deprivation index ........................................................................................................... 145 
Box 9 Clinical QOF blood pressure indicators for cardiovascular diseases .................................................... 150 
Box 10 First line monotherapy treatment established in the 2006 NICE hypertension guidelines ................ 208 
Box 11 Definition of the outcomes............................................................................................................... 208 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
 
Abbreviations 
AASK African American Study of Kidney Disease 
ASCPTT-LLA The Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering 
Arm (ASCOT-LLA) trial 
ACCORD The Action to Control Cardiovascular Risk in Diabetes trial  
ABCD-H  The Appropriate Blood Pressure Control in Diabetes tria (H = hyper-
tensive patients)  
ABCD- N The Appropriate Blood Pressure Control in Diabetes  Trial (N= nor-
motensive patients)  
ABCD-2V  The Appropriate Blood Pressure Control in Diabetes  Trial 
ARB Angiotensin receptor blockers 
ACEI Angiotensin-Converting Enzyme inhibitor 
ACCOMPLISH  The Avoiding Cardiovascular Events through Combination Therapy 
in Patients Living with Systolic Hypertension Trial  
ADVANCE  The Action in Diabetes and Vascular Disease: Preterax and Diami-
cron Modified Release Controlled Evaluation trial 
AFR African region 
ALLHAT  The Antihypertensive Lipid-Lowering Treatment to Prevent Heart 
Attack Trial 
AMR Region of Americas 
ARB  Angiotensin receptor blockers  
AOR Adjusted Odds Ratio 
ABPM  Ambulatory blood pressure monitoring  
BB  Beta blockers  
BHS  British Hypertension Society  
BP Blood pressure 
BMI Body Mass Index 
BRFSS The Behavioural Risk Factor Surveillance System Survey  
CASE-J The Candesartan Antihypertensive Survival Evaluation trial  
CCB Calcium channels blockers  
17 
 
CKD Chronic kidney disease 
CI  Confidence Interval 
CHD  Coronary heart disease 
CH  Controlled hypertension  
DAG Direct acyclic graph 
DASH Dietary Approaches To Stop Hypertension  
DBP Diastolic blood pressure  
DD Diuretics  
DM  Diabetes mellitus  
ESKD End stage kidney disease 
EMR  Eastern Mediterranean  
ENCORE  The Exercise and Nutrition interventions for CardiOvasculaR hEalth  
study 
ESH-ESC European Society of Hypertension-European Society of Cardiology 
FEVER  The Felodipine Event Reduction study  
GEE Generalized estimating equations  
GMS  General Medical Services 
GP  General Practitioner 
GPRD General Practice Research Database 
gr grams 
HBPM  Home blood pressure monitoring 
HDFP  The hypertension detection and follow-up program  
HR  Hazard ratio  
HSE  Health Survey for England 
HTA Hypertension  
HOT  The Hypertension Optimal Treatment study   
HYVET  The Hypertension in the Very Elderly Trial  
IDH Isolated diastolic hypertension  
IMD  Index of Multiple Deprivation 
18 
 
INVEST  The International VErapamil SR-Trandolapril study 
IOM  Institute of Medicine 
ISH  Isolated systolic hypertension  
JATOS  The Japanese Trial to Assess Optimal Systolic Blood Pressure in 
Elderly Hypertensive Patients  
JNC 7 The Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure 
 
J-Health study  The Japan Hypertension Evaluation with Angiotensin II Antagonist 
Losartan Therapy 
LDL  Low-Density Lipoprotein 
mmHg millimetres of mercury 
MCMC Markov chain Monte Carlo  
MONICA  Monitoring Trends and Determinants in Cardiovascular Disease  
MDRD  The modification of Diet in Renal Disease study  
MRC  The Medical Research Council’s trial of drug treatment of mild hyper-
tension 
MRC2 The Medical Research Council trial of treatment of hypertension in 
older adults 
MRFIT The Multiple Risk Intervention Trial  
NHANES  National Health and Nutrition Examination Survey 
NHS  National Health Service 
NICE  National Institute for Health and Clinical Excellence 
ONTARGET The Ongoing Telmisartan Alone 
and in Combination With Ramipril Global Endpoint Trial 
PRA Plasma rennin activity  
PREMIER  The Life Interventions for Blood Pressure Control trial   
ProFESS The Prevention Regimen for Effectively Avoiding Second Strokes 
trial  
PROGRESS The perindopril protection against recurrent stroke study 
PC Primary Care 
PHC  Primary Health Care  
PCH  Patient with controlled hypertension 
PCT   Primary Care Trust 
19 
 
PSA  Public Service Agreement 
QMAS  Quality Management and Analysis System 
QOF  Quality and Outcomes Framework 
QMAS  The Quality and Outcomes Framework  
REGARDS The Reasons for Geographic and Racial Differences in Stroke study  
REIN-2 The Blood-pressure control for renoprotection in patients with non-
diabetic chronic renal disease multicentre, randomised controlled 
trial  
SHEP The Systolic Hypertension in the Elderly Program  
SBP  Systolic blood pressure 
SDH Systolic/diastolic hypertension 
STOP-
hypertension 2 
The Swedish Trial in Old Patients with Hypertension-2 study 
Syst-Eur The Multicenter Trial on the Treatment of Isolated Systolic Hyperten-
sion in the Elderly 
sd Standard deviation  
SOA Super output areas 
THIN  The Health Improvement Network 
TONE  Trial of Non-pharmacologic Interventions in the Elderly 
TROPHY  The trial of  preventing hypertension  
TRASCEND  The Telmisartan Randomized Assessment Study in ACE-Intolerant 
Subjects With Cardiovascular Disease 
UR  European Region  
UK  The United Kingdom 
UKPDS  United Kingdom Prospective Diabetes Study 
VA  Department of Veterans Affairs  
VALISH  The Valsartan in Elderly Isolated Systolic Hypertension Study 
VALUE  The Valsartan Antihiypertensive Long-term Use Evaluation study  
WHO   World Health Organisation 
WPR Western Pacific Region  
20 
 
Chapter 1 Introduction  
1.1 Definition of hypertension  
 
Blood pressure is the force that vascular volume exerts on the vascular system. It is the 
product of cardiac output and peripheral vascular resistance. Cardiac output determines the 
highest level of blood pressure, which is called systolic blood pressure (SBP); and peripheral 
resistance determines the lowest level of blood pressure, called diastolic blood pressure 
(DBP) (1). 
 
A raised blood pressure has been linked to an increased risk of developing cardiovascular 
diseases (2-4). Initially the term hypertension emerged to classify raised blood pressure as a 
disease (5). However, this classification is debatable because symptoms or signs of organ 
damage  are not always evident  in the  early stages of a mild raise of blood pressure (6). 
Moreover, the hypertension–related cardiovascular risk is still present at a lower blood pres-
sure level of 115/75 mm Hg (7) and increases in blood pressure levels are an independent 
risk factor for cardiovascular diseases (8). Therefore, hypertension has been mainly consid-
ered as cardiovascular risk factor (9). For adults aged 18 years and over, essential hyper-
tension, primary hypertension, raised blood pressure or high blood pressure is defined as 
idiopathic increases in blood pressure levels which are associated with increases in the risk 
of cardiovascular diseases. These increases may or may not be associated with symptoms 
or evidence on damaged organ (6, 9-10). I will use hypertension as a term referring either to 
high blood pressure or raised blood pressure.  
 
The definition of hypertension is based upon a blood pressure threshold. The threshold is a 
matter of uncertainty due to the presence of the hypertension-related cardiovascular risk at 
lower blood pressure levels (7-8). This cardiovascular risk also increases linearly with in-
creases in blood pressure levels (7, 11). Hence, blood pressure levels have been estab-
lished to set intervention thresholds. The threshold for defining  hypertension is considered 
to be the point at which the reduction of blood pressure should be more beneficial than dan-
21 
 
gerous (12). However, using these thresholds may lead to exclude hypertensive individuals 
from interventions because some individuals with particular cardiovascular risk could also 
have blood pressure below these thresholds. As a result, different definitions of hypertension 
have been postulated in the current hypertension guidelines (Table 1) (13-17). Despite these 
differences, a blood pressure equal to or above 140/90 mmHg in adults aged 18 years and 
over is accepted as the minimum limit required for the diagnosis of hypertension. The Eng-
land hypertension guidelines will be mentioned in a separate section.  
 
Based on the National Health and Nutrition Examination Survey (NHANES) III, Franklin et al 
described three age-related sub-types of hypertension presented in Western populations. 
The most common subtype in individuals aged below 50 years was isolated diastolic blood 
pressure (IDH) (SBP<140 mm Hg, DBP >90 mm Hg); in those aged 60 years and over it was 
isolated systolic blood pressure (ISH) (SBP>140 mm Hg, DBP <90 mm Hg); and in those 
aged 50 to 60 years it was systolic/diastolic hypertension (SDH) (SBP>140 mm Hg, DBP>90 
mm Hg) (18). Some definitions used in the guidelines reflect these patterns. 
 
Diagnosis of hypertension  
The measurement of blood pressure is influenced by two sources of error. One is due to the 
random error attributed to individual variability of blood pressure.  Blood pressure fluctuates 
constantly during a day dipping during the first periods of sleep (19). Extreme values taken in 
an occasional measure tend to be lower in repeated measurements (8). The other source of 
error is explained by conditions affecting the technique used for the measurement. Failure to 
identify the Korotkoff sounds and the tendency of health workers to round readings up or 
down and to bias the reading towards an expected value are common errors in the meas-
urement of blood pressure (20-21). For example, in an analysis of clinical records from pa-
tients being attended in primary care Fishman et al found that systolic blood pressure  and 
diastolic blood pressure registered in clinical records were 3.7 mmHg and 2.8  mmHg lower 
compared to that reported by an external assessment (22).  
 
The measurement of blood pressure is also affected by a transitory increase in blood pres-
sure levels during the clinical assessment of blood pressure, named the “white coat effect” 
observed in some individuals (16). This response occurs in individuals who have lower am-
22 
 
bulatory blood pressure levels which usually fall into a normotensive category. The cause of 
this response has not been totally clarified but it has been understood as a hyperactive reac-
tion to the presence of clinical staff which is enhanced by aging arterial changes (23). In a 
study of 600 ambulatory individuals, Hong et al reported that the hypertension rates taken in 
the presence of physicians were nearly 15% higher than those taken in their absence 
(p<0.05) (24). Moreover, the use of automated devices in the assessment of blood pressure 
may reduce the frequency of these transitory blood pressure readings (25).  
 
The standard method for the diagnosis of hypertension is based on the measurement of 
blood pressure using mercury or aneroid sphygmomanometers during clinical visits (13-15, 
26-27). Alternatively automated device have been used (28). Two other methods have also 
been standardized for the measurement of blood pressure such as home blood pressure 
monitoring (HBPM) and ambulatory blood pressure monitoring (ABPM). The correlation coef-
ficient between clinic and ambulatory measurement has been reported around 0.7 (29). 
Clinic blood pressure measurements tend to be higher than those observed in ambulatory 
assessment (30).  
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Table 1 Classification of blood pressure levels in hypertension guidelines 
 
     From reference WHO(14),  ESH-ESC (15-17) , JNC VII (13)
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1.2 Epidemiology of hypertension 
1.2.1 Global trends  
 
Worldwide the prevalence of hypertension ranged from 20% to 45%, averaging 40%,  
among adults aged 25 years and over in 2008 (31-32). From 1980 to 2008 the prevalence of 
hypertension and blood pressure levels have decreased in developed countries (32-33). 
Conversely, in developing countries both the prevalence of hypertension and blood pressure 
levels rose during the same period (32, 34). The highest reduction has been observed in 
Europe and the highest increase was observed in Africa (32, 34). Prevalence rises with age 
so the number of people with hypertension may increase over the next few decades due to 
improvements in life expectancy and the ageing of the population  (35) (Figure 1 -3) 
 
At population level blood pressure follows a log normal distribution with a positive skew to-
wards high levels (36). For each 1 mmHg variation in the mean population blood pressure, 
there may be a 0.74% variation in the prevalence of hypertension in the population (37). 
Blood pressure levels vary across countries and between sex. Surveys from 22 countries 
collected from 1985 to 1993 as part of the MONICA project revealed that for men mean sys-
tolic blood pressure ranged from 124 mmHg to 148 mmHg and mean diastolic blood pres-
sure from 75 to 93 mmHg, while for women mean systolic blood pressure ranged from 128 
mmHg to 145 mmHg and mean diastolic blood pressure from 74 mmHg to 90 mmHg. 14% of 
population blood pressure variance was attributed to BMI (38). In an analysis of 23796 men 
and 24986 women from the MONICA project Merlo et al, also found that individual blood 
pressure levels are influenced by population conditions. The population component could 
explain about 7-8% of the differences in blood pressure between individuals. The contribu-
tion of the population factors to individual blood pressure levels was higher in those hyper-
tensive individuals on treatment and/or who were overweight (39). In a systematic review of 
data from 786 countries, Danaei et al reported that between 1980 and 2008 mean systolic 
blood pressure decreased from 130.5 mmHg to 128.1 mmHg in men and from 127.2 mmHg 
to 124.4 mmHg in women (34). The highest mean systolic blood pressure was reported in 
men from Western Europe with 131.3 mmHg and the lowest systolic blood pressure was 
reported in women from Australasia with 117.6 mmHg.   
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Figure 1 Prevalence of hypertension in men aged 25 years over, standardised 
by age 2008  
 Source Global Status Report on Non-communicable Diseases, WHO 2010 (40)  
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Figure 2  Prevalence of hypertension in women aged 25 years over, standard-
ised by age 2008
     Source Global status report on noncommunicable diseases, WHO  2010 (40) 
Figure 3  1 Percentage of adults aged 25 years and over with high blood pres-
sure by WHO region*, 1980 and 2008  
 
*WHO regions  
AFR African region AMR Region of the Americas EUR European Region SEAR South-East Asia Re-
gion EMR Eastern Mediterranean Region WPR Western Pacific Region 
Source World Health Statistics (32)  
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The reasons for the observed reductions in blood pressure levels have not been totally elu-
cidated. In their analysis of the national survey from Japan, Ikeda et al partially attribute the 
decline to an increase in antihypertensive prescribing and lowered mean body mass index in 
the young population (41). In an analysis of data from the MONICA project, Tunstall-Pedoe 
et al found that the decline in blood pressure levels may have been driven by interventions 
different from antihypertensive medication (42). In Finland, the decline in blood pressure has 
been associated with national health promotion initiatives. The most relevant initiatives in-
cluded the introduction of comprehensive primary care services, massive education on diet 
habits, salt labelling regulation in some products and mass promotion of physical activity (42-
44).  
 
Globally hypertension accounts for 13%, 51% and 45% of total deaths, stroke cases and 
ischaemic heart disease cases respectively (45-46). It is the biggest contributor to the total 
cardiovascular mortality  and so the most important modifiable risk factor worldwide (46). 
80% of hypertension-related mortality occurs in low and middle income countries. In 2006, 
Lawes et al reported that population with mean systolic blood pressure higher than 115 mm 
Hg contributed to 62% of stroke, 49% of ischemic cardiac, 76% of hypertensive disease and 
14% of other cardiovascular disease worldwide (47). Although the hypertension cardiovascu-
lar risk increased with blood pressure levels, the largest amount of deaths is observed in 
those with lower blood pressure levels.   
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1.2.2 The relationship between hypertension and cardio-
vascular diseases  
 
The association between blood pressure and cardiovascular diseases has been well estab-
lished (7-8). The dose-response association is strong and log-linear across all blood pres-
sure levels down to levels of 115/75 mm Hg (7-8). Hypertension-related cardiovascular risk 
increases with increases in blood pressure levels but the association varies with age.  
Among those aged between 40 and 69 years, for each difference of 20 mm Hg in usual sys-
tolic blood pressure or 10 mm Hg in usual diastolic blood pressure, there is a twofold differ-
ence in vascular mortality and a twofold difference in stroke rate. This association is about 
half for older (80-89 years) and younger (40 – 49 years) individuals (7). In other words,  the 
strength of the association is lower at extreme ages and declines with increasing age (2). 
 
Systolic blood pressure and diastolic blood pressure are both predictors of cardiovascular 
diseases. However systolic blood pressure and pulse blood pressure become stronger pre-
dictors than diastolic blood pressure after 50 years (48 , 49-50). The relationship between 
blood pressure and cardiovascular morbidity and mortality  is independent of age, sex, body 
mass index, smoking and cholesterol (48). These associations have been consistent across 
different populations (8, 51-52). 
 
Hypertension-related damage evolves over a long time (53). Initially, hypertension produces 
variations in lipid and glucose metabolism (54). It accelerates the age-related changes in the 
vascular wall leading to an increase large artery thickening and stiffness and endothelia dys-
function (55). The damage compromises all arterial system but vascular tissues located in 
myocardium, brain and kidney are particularly affected. The long-term effect results in organ-
related diseases such myocardium infarct, stroke or chronic kidney disease (53, 56). The 
final impact on health is a reduction of at least five years in life expectancy which is also ob-
served in patients with antihypertensive medication (57-58).  
 
Hypertension is a risk factor for stroke (2, 59), coronary heart disease (50, 60), congestive 
heart failure (53), renal failure (56) and peripheral vascular disease (61). It has also been 
associated with non-cardiovascular diseases such as cognitive decline (62-63) and all-cause 
mortality (64). The strength of the association is stronger for stroke than for other cardiovas-
cular diseases (8, 65). The size of hypertension-related cardiovascular risk varies between 
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sex, age and populations. In a review of eight trials that included hypertensive individuals 
aged 60 years and over, Staessen et al showed that the risk for stroke was 1.12 (p=0.02)  
and 1.04 (p=0.37) for coronary events with each 10 mm Hg increase in baseline systolic 
blood pressure (64). By comparison, middle aged individuals are more likely to suffer from 
ischemic cardiovascular disease (66). In the Chinese population, stroke is a more common 
hypertension complication rather than coronary heart diseases, and may account up to 45% 
of total deaths attributable to hypertension (67). Opposite association has been observed in 
population of Caucasian origin for whom coronary heart diseases are the most important 
cause of hypertension-related mortality (68) The relative risk of any hypertension related 
event is lower in women aged below 55 years then men of the same age. Individuals aged 
below 40 and those over 80 have lower risk of cardiovascular event than those aged be-
tween 40 and 80 (7, 68). The differences in follow-up and in the definition of hypertension 
may contribute to explaining the variations in the size of the association observed in some 
studies (69) (Table 2-4).    
30 
 
 
Table 2 Associated hazard risk of stroke mortality with each 20 mmHg lower 
systolic blood pressure 
Age  Western cohort (7) (95% CI)  Asian pacific cohort (52)  (95% CI) 
50 – 59 years 0.38 (0.35 – 0.40) 0.46 ( 0.44 – 0.47) 
60 – 69 years  0.43 (0.41 – 0.45)  0.64 (0.62–0.66) 
70  – 79 years  0.50 (0.48-0.52)  0.75 (0.72–0.78)* 
80 – 89 years  0.67 (0.63 – 0.71)  NA 
*Age category 70 years and over 
 
Table 3 Associated hazard risk of coronary heart disease mortality with each 
20 mmHg lower systolic blood pressure by sex* 
Age  Male (95% CI)  Female (95% CI)  
40 – 59 years  0.50 (0.46 – 0.54)  0.40 ( 0.32 – 0.49)  
50 – 59 years 0.50 (0.42 – 0.52)  0.49 (0.45 – 0.54)  
60 – 69 years  0.55 (0.54 – 0.57)  0.50 (0.47 – 0.53)  
70 – 79 years 0.62 (0.60 – 0.64)  0.55 (0.53 – 0.58)  
80 – 89 years  0.69 ( 0.65 – 0.73)  0.64 ( 0.60 – 0.68)  
*Reference   (7)  
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Table 4 Risk of cardiovascular events in individuals aged 35-64 years with 
blood pressure >140/90 mmHg** 
Cardiovascular events  Age-adjusted biennial 
rate per 1000 
Age-adjusted risk ratio 
 Men  Women Men  Women 
Coronary heart disease 45 21 2.0* 2.2* 
Stroke 12 6 3.8* 2.6* 
Peripheral arterial disease 10 7 2.0* 3.7* 
Cardiac failure  14 6 4.0* 3.0* 
Cardiovascular events  65 35 2.2* 2.5* 
*p<0.001 
**From Framingham study (68) 
 
Hypertension coexists with other cardiovascular disease risk factors. In the Framingham 
study a clustering of risk factors such as adiposity, elevated blood sugar, elevated triglyc-
eride, high cholesterol and alcohol intake was observed in newly hypertensive individuals 
(68). It was found that at least 25% of hypertensive individuals have an additional cardiovas-
cular risk factor and moreover the prevalence of others risk cardiovascular factors increased 
with age.  49% of men with systolic blood pressure equal to or above 138 mm Hg and 54% 
of women with systolic blood pressure equal to or above 130 mm Hg had more than two 
additional cardiovascular risk factors (68). Similar findings have been observed in other lon-
gitudinal studies. For instance, in  a cohort of 8686 women and 10503 men, Lowe et al found 
that 37% of men and 33.9 % of women had more than one cardiovascular risk factor such as 
hypertension, smoking and high cholesterol  (70).  
 
Hypertension is an independent cardiovascular risk factor. However the hypertension-related 
cardiovascular risk is modifiable by the presence of other cardiovascular risk factors.  Indi-
viduals with two or more risk factors are at higher cardiovascular risk than those with one 
cardiovascular risk factor. In the Framingham study, the probability of suffering from stroke 
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was 20% for a 70 year old hypertensive individual on antihypertensive treatment without 
other cardiovascular risk factors but 40% for those of the same age with four additional risk 
factors such as diabetes, smoking, previously diagnosed coronary heart disease and atrial 
fibrillation (71). Then although the hypertension-related cardiovascular relative risk slightly 
varied with the presence of other cardiovascular risk factors, the hypertension cardiovascular 
absolute risk measured as percent of event risk per year varied with the presence of other 
cardiovascular risk factors (72).  
 
1.2.3 Risk factors for hypertension  
 
There are variations in blood pressure levels across age categories and sex. Studies carried 
out in Western societies have revealed that whereas systolic blood pressure rises continually 
with age starting at 30 years; diastolic blood pressure rises continually until 50 years and 
then remains stable or slightly decreases (73). This increase is related to initial value of 
blood pressure and occurs in a stepwise fashion over a period of at least four years (74). 
Men develop higher systolic blood pressure levels up to the age of 50 in comparison with 
women of the same age, but women aged over 50 years have higher systolic blood pressure 
levels than men (73, 75). However these trends have not been observed in populations living 
in rural areas (76). Hence these patterns have been considered to be related to environ-
mental factors occurred in western societies rather than only as a result of physiological 
changes (77).   
 
Individuals of different racial origin have different patterns of blood pressure. Adults of Afri-
can origin living in developed countries have higher blood pressure levels in comparison with 
individuals of white origin (78-80). They also have a higher prevalence of hypertension (81) 
and higher incidence of hypertension-related cardiovascular disease (82). Unlike African 
descendents living in Western societies, African citizens living in rural African areas have 
lower blood pressure levels (83). In Africa, rural populations have lower blood pressure lev-
els than urban populations (83-84). However a similar prevalence of hypertension in African 
and white populations living in a developing country has also been reported (85-86). Then 
genetic and environmental conditions have been associated with raised high blood in mi-
grant individuals with African origin (87-89). In contrast migrants from South Asia living in 
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developed countries tend to have lower blood pressure levels than white population (90-91). 
Other migrant populations such as Chinese and Hispanic residents in developed countries 
have developed patterns of blood pressure levels similar to those observed in the white 
population (81, 92-94).  
 
Parental raised blood pressure  is a risk factor for developing high blood pressure levels 
(95).  High correlation of blood pressure levels among twins  also  supports a familial pattern 
(96) . A variety of genetic determinants associated with blood pressure levels have been 
identified (97-99). Recently, Ehret et al described a genetic risk score which included 29 ge-
nome variants linked to blood pressure regulation. It explained up to 2.5% of the variation in 
blood pressure level and was also associated with developing hypertension, left ventricular 
wall thickness, stroke and coronary heart disease (100). This evidence established that there 
are multiple genes which have  contributed to the increment of blood pressure in adults  
(101). However, the association between blood pressure levels in childhood and in adult-
hood  has not been completely understood possibly due to differences in the method used 
measure blood pressure in infants and adolescences  (102). Additionally, the association 
has also been weak  (103) though multiple measurements may improve the prediction (104). 
Then genetic determinants are not a sufficient cause in themselves as  environmental fac-
tors  also play a significant causal role in the development of hypertension (105).  
 
Sodium intake has been also linked to raise blood pressure. The lower the salt consumption, 
the lower the blood pressure level (106-107). Levels of sodium excretion have also been 
found to have significant and independent positive association with systolic blood pressure 
(108). This association has also favoured increases in systolic blood pressure levels with 
age (109). Populations who migrate from low salt to higher salt intake environments evolve 
to hypertensive status (110-111). The relationship between salt and hypertension has also 
been demonstrated by interventions aimed at reducing salt intake. A decline of 3 mm Hg 
systolic blood pressure was associated with a decrease of 2g in daily urine sodium chloride 
excretion in volunteers exposed to a diet education program (112-113). Hypertensive indi-
viduals under a sodium restricted diet significantly lowered their blood pressure levels (114).  
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Population strategies reducing salt consumption were followed by a reduction of 10 mmHg in 
the population-average systolic and diastolic blood pressure (115). These observations have 
also been documented in non-human primates. Providing a diet with a progressively higher 
content of sodium significantly elevated their blood pressure in chimpanzees (116). In a co-
hort of 3681 individuals recruited for the FLEMENGHO study, Stolarz-Skrzypek et al also 
found that for each 100-mmol increase in sodium excretion, there was a 1.71 mmHg in-
crease in systolic blood pressure (117). Hence excess salt intake is an independent causal 
but not sufficient factor of raised blood pressure. 
 
Body index mass has been associated with an increasing probability of having higher blood 
pressure levels. The incidence of hypertension appears to increase linearly with increases in 
body index masses (83, 118). This association has been identified across different ethnicity 
groups (119-120). However the strength of the association may differ between ethnic  
groups and also starts at a different body mass index thresholds using for the definition of 
overweight (120). This may be explained by genetic predisposition in different ethnicities 
(121-123). Reassuring a higher body index mass is a risk factor for raised blood pressure, 
though the causal pathway has not been clarified yet.  
 
Others factors have been associated with raised blood pressure. For instance, having a low 
birth weight increased the probability of being hypertensive in adulthood. The strength of the 
association varies across different studies but the association is consistent (124-126). An-
other factor is the concentration of potassium in daily diets. Low potassium intake has been 
related to increases in blood pressure levels (127-128). A paternal hypertensive response to 
low potassium intake has been described (129). Consequently, diets with low salt content 
and higher potassium content have been recommended to lower blood pressure (130). An 
association between other nutrients such as magnesium, calcium and phosphorus and 
higher blood pressure levels has been less well established (131-132). Diverse habits have 
also linked to hypertension. The risk of being hypertensive increases in alcohol drinkers 
(133). The association is positive but seems to follow a J-shape pattern (134-135). Smoking 
has mainly been related to a temporary increase in blood pressure though this effect could 
potentially be a determinant of hypertension (136-137).  
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Socio-economic conditions have been additionally associated with increases in blood pres-
sure levels. In their analysis of the MONICA project, Merlo et al found a positive gradient 
between education and high blood pressure levels. Thus women and men with the lowest 
educational background had 3  and 2 mm higher systolic blood pressure respectively com-
pared to those with the highest education background (39). By contrast, Orduñez et al found 
the effect of education on blood pressure levels was sex-dependent (85). Regardless of 
race/ethnicity women whit highest level of education were less likely to have hypertension 
compared to those with lowest level of education. But an opposite association was observed 
in men (85). In a study of 11357 individuals with genetic ancestry, Non et al found that differ-
ences in blood pressure between whites and blacks were due to differences in education 
rather than genetic factors (87). Prince et al found a heterogeneity effect of education on 
blood pressure levels across 12 population samples of older individuals from 8 non-
developed countries. Participants with higher education scores living in Cuba, China, Do-
minican Republic and China were less likely to have hypertension. By contrast those with a 
similar level of education living in Peru, rural Mexico and India were more likely to have hy-
pertension. The association also varied between women and men (138).   
 
1.2.4 Treatment of hypertension  
Pharmacological intervention  
 
The aim of hypertension treatment is to reverse hypertension-related cardiovascular risk.  
Evidence from clinical trials extensively supports the benefit of lowering blood pressure pro-
duced by pharmacological interventions. For each 10 mm reduction in systolic blood pres-
sure or 5 mm Hg reduction in diastolic blood pressure, there is a 22% reduction in coronary 
heart diseases and a 35% reduction in stroke (139). This effect seems to be similar among 
all antihypertensive drug classes with slight differences. Calcium channels blockers (CCB)  
seem to produce a higher reduction in the relative risk of suffering from stroke (139) and a 
lower reduction in heart failure. Beta blockers (BB) class drug had a greater effect in pre-
venting recurrent coronary heart diseases in those with a history of coronary heart disease. 
(139)   
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The reduction in cardiovascular hypertension associated risk is correlated with reductions in 
blood pressure levels (140). This effect has been observed regardless of baseline blood 
pressure levels. In a meta-analysis of 32 clinical trials, Czernichow et a demonstrated that 
the relative reduction in cardiovascular outcome was similar across all range of baseline 
blood pressure levels (141). The impact of hypertensive treatment has also been observed 
across all age groups. In a meta-analysis of 37 clinical trials, Turnbull et al found that the 
relative risk reduction in cardiovascular events is similar in patients aged above and below 
65 years (142). This reduction has not varied between antihypertensive drug classes. Differ-
ences in the lowering blood pressure effect have been observed between ethnic groups. 
Black patients tended to have a lower response to ACEI and BB (143). However the guide-
lines do not establish any particular recommendation about the first line recommendation 
related to race/ethnicity. Only the England hypertension guidelines has established an eth-
nic-age algorithm (144).The main antihypertensive drug classes and their mechanism of 
action are shown in box 1.  
 
Box 1 Main classes of lowering blood pressure drugs  
Drug class  Main antihypertensive mechanism of action  
Diuretics (Thiazide class ) (DD) To block renal sodium absorption in the early 
part of distal tubule (145) 
Beta blockers (BB)  To block postsynaptic receptors of noradrena-
line system (145) 
Angiotensin converting enzyme inhibitors 
(ACEI) 
To inhibit angiotensin converting enzyme result-
ing in lower levels of angiotensin II and aldos-
terone levels (145) 
Angiotensin receptor blockers  (ARB) To inhibit the angiotensin II receptor producing 
vasodilatation lead to a reduction in peripheral 
resistance (145) 
Calcium channel blockers (CCB) (Dihy-
dropiridines class) 
To block L type calcium channels in vascular 
cells producing vasodilatation (145) 
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The initiation of antihypertensive medication is based on the level of blood pressure and the 
assessment of the individual absolute cardiovascular risk (13-17). The threshold for com-
mencing treatment varies among guidelines (Table 5). There are different scores to assess 
the absolute cardiovascular risk but the Framingham score is the one most commonly rec-
ommended. The drawback of using the Framingham score is the potential overestimation of 
cardiovascular risk in populations different from Americans (146). Despite differences be-
tween guidelines, patients are classified at low cardiovascular risk, middle cardiovascular 
risk and high cardiovascular risk with regard to cardiovascular scores and/or the presence of 
an additional cardiovascular comorbidity. Patients at low cardiovascular risk are those with 
hypertension but without other cardiovascular risk factors and/or other established cardio-
vascular diseases. Those at middle cardiovascular risk have more than one cardiovascular 
risk factor and patients at higher cardiovascular risk have more than 2 or cardiovascular risk 
factors and/or additional cardiovascular diseases  (13-16).  
 
Table 5 Thresholds for starting antihypertensive treatment established in hy-
pertension guidelines 
Guidelines Assessment of cardiovascular risk  Blood pressure 
threshold mmHg* 
WHO (14) Framingham score 
Target-organ damage 
Other cardiovascular comorbidities 
>=140/90 mmHg  
ESH-ESC 
(15-17) 
Chart based on blood pressure levels, cardio-
vascular risk factors,  diabetes, renal disease 
and established cardiovascular disease 
140-150/90-99 mmHg 
JNC 7  (13) Framingham score 
Evaluation of damaged organ  
<=140/90 mmHg  
*Threshold for patients without other comorbidities and no other cardiovascular risk factors 
and without response to non-pharmacological interventions 
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Non-pharmacological treatment 
 
Non-pharmacological interventions have been demonstrated to be effective in lowering blood 
pressure. These interventions include low salt consumption, weight reducing diet, regular 
exercise, maintaining adequate BMI and moderate alcohol consumption (147-148). Salt in-
take reduction has consistently led to low blood pressure. In a meta-analysis of twenty nine 
clinical trials, He et al showed that a reduction of 4.6 gram in salt intake correlated with a 4.6 
mmHg reduction in systolic blood pressure (149). The effect on lowering blood pressure was 
observed in a short time after starting a salt restriction diet. Among those studies including 
only hypertensive patients, the salt intake fell from 9.5 gr/day (7.3– 11.2 g/day) to 4.4 gr/day 
(3.1-6.8g/day). A reduction in 6gr/day salt intake was associated with a decrease of 10.8 mm 
Hg (3.5 mm Hg – 18.2 mm Hg) in systolic blood pressure. There was no association be-
tween salt intakes and diastolic blood pressure (12). Bray et al observed that the salt-related 
blood pressure reductions are higher in individuals of black origin and older patients than in 
white and younger individuals (150). The guidelines differ in the recommendations about salt 
consumption. The JNC 7 report recommends 2gr/day in salt intake and the 2011 NICE 
guidelines establish a minimal consumption between 3 and 7 gr/day for all hypertensive pa-
tients (13, 144).  
Exercise has the potential to reduce blood pressure levels independently of weight loss. In a 
meta-analysis of 54 clinical trials testing the impact of aerobic exercise on blood pressure, 
Whelton et al found that regardless of hypertension status and race/ethnicity participants 
exposed to aerobic exercise achieved a reduction of 3.8 mm Hg and 2.6 mm Hg in systolic 
and diastolic blood pressure respectively (151). Similarly, Cornilesen et al found that any 
type of physical activity was associated with a reduction of between 1.8 mm Hg and 10.9 
mm Hg in systolic blood pressure. The effect was observed in hypertensive and non-
hypertensive patients (152). There may a threshold in the effect of exercise on blood pres-
sure. In a clinical trial comparing groups with different frequencies in physical activity, Ishi-
kawa et al found that those doing physical activity during 61 and 90 minutes per week 
achieve lower blood pressure than those doing 30-60 minutes per week. However, those 
doing more than 90 minutes did not achieve longer reductions (153). A regular aerobic exer-
cise with a minimum duration of 30 minutes almost every day of the week has been recom-
mended as a part of the non pharmacological treatment for hypertensive patients (13).  
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Losing weight has been associated with reductions in blood pressure levels. In a clinical trial 
assessing the benefit of exercise and losing weight in participants without high blood pres-
sure or with stage 1 or 2 hypertension, Blumenthal  et al demonstrated that those who lost 
weight experienced a higher reduction in blood pressure than those who did not modify 
weight though they both following the exercise recommendation (154). The level of adher-
ence to interventions was 84%. Reducing weight using diet results in lower blood pressure 
levels than those produced by pharmacological interventions (155). Lowering weight is also 
associated with a lower incidence of hypertension (156). For instance, Stevens et al reported 
that even small reductions in weight as low as 0.2 kilograms reduced the risk of developing 
hypertension (157). In the TONE trial hypertensive patients aged 66 years and over attaining 
only small reductions in weight were less likely to reach reduced blood pressure levels com-
pared to those who achieved the mean weight reduction of 4.7 kilograms (151).  
 
Interventions aimed at lowering weight usually concurred with diet and exercise interven-
tions. The DASH trial demonstrated the independent effect of a diet based on fruits, vegeta-
bles and reduced saturated fat in lowering blood pressure levels (158). Hypertensive partici-
pants who were assigned the recommended diet achieved blood pressure reductions be-
tween 5 and 11 mm Hg. From a review of eighteen clinical trials, Mulrow et al concluded that 
the impact of weight loss diets on lowering blood pressure is modest but may be enough to 
reduce the use of antihypertensive medication (159). However, the long term effect of weight 
loss diets is uncertain. The clinical trials testing these diets have usually included small 
numbers of patients with hypertension at early stages. Additionally, the studies were con-
ducted over short follow-up periods (160). Some guidelines advice is to maintain a BMI be-
tween 18.5 and 24.5 kg/m² and regular consumption of DASH diet (13) 
 
Reduction in alcohol consumption has also led to reductions in blood pressure. In a meta-
analysis of fifteen clinical trials testing interventions for alcohol reduction in hypertensive and 
normotensive individuals, Xin et al found a mean reduction of -3.31 mmHg (-2.52 to -4.1 mm 
Hg and -2.04 mm Hg (-1.49 to -2.58 mm hg) in systolic blood pressure and diastolic blood 
pressure respectively to be associated with a 67% reduction in alcohol consumption (161). 
However among the included trials only seven reported significant reductions in blood pres-
sure. Moreover, the studies had a short follow up period so that the effect of cardiovascular 
morbidity was not evaluated. Evidence of the relationship between cardiovascular morbidity 
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and alcohol consumption has been contradictory. Whereas some studies have revealed that 
alcohol consumption increases the risk of stroke (162), others have reported that light con-
sumption of alcohol reduces the risk of coronary disease (163). Nevertheless, hypertension 
guidelines advise drinking moderates amount of alcohol (13). 
 
Other non-pharmacological interventions for the management of hypertension have been 
less well supported. Steffen et al performed a review and meta-analysis of clinical trials and 
cohort studies to assess the effect of caffeine and blood pressure. They included ten clinical 
trials and five cohort studies. Their analysis of clinical trials did not reveal significant differ-
ences in blood pressure between groups with and without consumption of coffee and neither 
did the cohort studies reveal a higher incidence of hypertension in those expose to coffee 
intake compared to those not being exposed (164). The heterogeneity observed across the 
studies limit the extent to which a definite answer may be given about the association be-
tween coffee and blood pressure.  
 
Evidence supported potassium supplement has been contradictory. In an analysis of thirty 
three clinical trials testing the effect of potassium on blood pressure reduction, Whelton et al 
reported that supplementing with oral potassium led to significant reductions in blood pres-
sure levels (165). By contrast, in a review of six clinical trials, Dickinson et al did not find a 
significant effect of potassium supplementation on blood pressure levels (166). However, the 
short follow-up in the clinical trials prevent from establishing the relationship between potas-
sium and blood pressure. Similarly, there is no supportive evidence on the association be-
tween blood pressure and calcium or magnesium. That may be due to the small number of 
included patients, the short follow-up period and the lack of adequate randomised allocation 
observed in some studies testing the effect of diets with calcium and magnesium supple-
mentation on hypertension (167-169).  
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Relaxation therapies have also been intended to lower blood pressure. In a meta-analysis of 
24 clinical trials testing meditation techniques in hypertensive population, Ospina et al found 
that Tai Chi, yoga, and yoga combined with biofeedback reduced systolic blood pressure 
significantly compared to no treatment. Yoga with biofeedback was superior at reducing 
blood pressure than education. Transcendental meditation was better than progressive mus-
cular relaxation in lowering blood pressure. The Zen Buddhist relaxation method resulted in  
lower reductions in diastolic blood pressure than blood pressure assessments (170). How-
ever the small numbers of patients with a short follow-up included in the studies prevent 
conclusions being drawn with regard to the benefits of this techniques for the management 
of hypertension (170).  
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Key points  
 There is no threshold to define normal blood pressure 
 The hypertension-related cardiovascular risk is presented across the whole of range 
of blood pressure levels down to levels of 115/75 mmHg.  
 For adults aged 18 years and over hypertension is a level equal to or above 140/90 
mmHg of blood pressure 
 In Western societies, blood pressure levels increase with age. 
 Excess salt intake and higher body mass index have been positively associated with 
increased levels of blood pressure across different social and environmental condi-
tions.  
 Differences in blood pressure levels between race/ethnic groups have been de-
scribed. Globally, African-descendent individuals living in western societies have 
higher blood pressure levels than other race/ethnic groups. 
 Hypertension is a risk factor for stroke, coronary heart disease, heart failure and 
chronic kidney disease.  
 Nearly 40% of individuals aged 25 years and over suffer from hypertension world-
wide 
 Since 1980 there has been a reduction in blood pressure levels in developed coun-
tries and an increase in blood pressure levels in developing countries.  
 50% of total cardiovascular mortality is attributed to hypertension worldwide.  
 80% of hypertension-related cardiovascular diseases occur in middle and low income 
countries.  
 Hypertension is a modifiable cardiovascular risk factor. 
 For each 10 mmHg reduction in systolic blood pressure or 5 mmHg reduction in dia-
stolic blood pressure, there is a 22% reduction in coronary heart diseases and a 35% 
reduction in stroke.
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1.3 Definition of Blood Pressure Control  
 
The aim of lowering blood pressure is to reverse the hypertension-related cardiovascular risk 
(171). Reductions in blood pressure lead to reductions in hypertension-related cardiovascu-
lar risk. With a 10 mm Hg reduction in systolic blood pressure or 5 mmHg in diastolic blood 
pressure, the risk of coronary heart disease and stroke events drops by 24% and 33% re-
spectively (139, 172).  However, to what extent blood pressure levels must be lowered is a 
matter of controversy (173). Clinical guidelines have postulated that the achievement of a 
recommended blood pressure level, i.e. defined targets, determines the control of blood 
pressure. Hypertensive patients are classified into those with controlled or uncontrolled hy-
pertension based upon whether or not they achieve that target (13-14, 16, 144, 174). This 
section reviews the definition of targets for blood pressure control.  
 
1.3.1 The definition of blood pressure targets 
 
Blood pressure should be reduced to a level at which the reduction is more beneficial than 
harmful (12). The association between blood pressure and cardiovascular risk however cre-
ates uncertainty over the definition of that level. On the one hand, observational studies con-
ducted at a population level have demonstrated that the association between blood pressure 
levels and cardiovascular mortality and morbidity exists across all ranges of blood pressure 
levels even  at low values of  110/70 mmHg (7-8). This evidence therefore supports the idea 
that the lower the blood pressure, the better. On the other hand, clinical trials carried out on 
hypertensive patients have consistently shown that reductions in blood pressure levels result 
in significant reductions in the hypertension-associated cardiovascular risk (172, 175). This 
effect has also been shown to be independent from the patient’s baseline blood pressure 
(139, 172, 175). In other words, data from clinical trials reinforce the findings from cohort 
studies in showing that that there is no a blood pressure threshold at which cardiovascular 
risk is not longer associated with blood pressure.   
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Despite the known benefits from lowering blood pressure, the relationship between blood 
pressure reductions and cardiovascular mortality seems to follow a J curve pattern (176-
177). Thus extreme reductions in blood pressure levels could lead to cardiovascular mortal-
ity. Messerli et al illustrated this relationship in a secondary analysis of the INVEST trial 
(178). They found that hypertensive patients with coronary heart disease who achieved a 
blood pressure levels below 129/74 mmHg had a higher risk of dying from all cause mortality 
in comparison to those with higher blood pressure levels. Patients with a lower baseline sys-
tolic blood pressure were found to have a higher prevalence of myocardial infarction, heart 
failure and cancer. The presence of heart failure was the most significant comorbidity asso-
ciate with the outcome (178).   
In a cohort of elderly patients, Merlo et al found that hypertensive patients  on treatment who 
achieved diastolic blood pressure below 90 mmHg had fourfold increase in incidence of is-
chaemic cardiac events (179). The nadir of the J curve seems to appear at levels below 
135/85 mm Hg (179-180). Bangalore et al reported that the achievement of systolic blood 
pressure below 135 mm Hg is associated with a slight but significant reduction in stroke and 
heart failure. They warned that this modest benefit may be counterbalanced by the higher 
risk of hypotension (181). However, in the Cardiovascular Health Study, Psaty et al did not 
find that systolic blood pressure between 125 and 135 mmHg increased the risk of stroke 
and/or myocardial infarction among elderly hypertensive individuals (182). Similarly, Hans-
son et al report that hypertensive adults can achieve diastolic blood pressure below 80 
mmHg without increases in adverse effects (183). Aronow et al recommend that a target of 
below 140/90 mmHg for the management of hypertensive elderly adults. They advised that 
this target is based on expert opinions rather than evidence from clinical trials (184). Addi-
tionally, the increase in cardiovascular risk associated with lower blood pressure has mainly 
been documented in patients with established coronary heart diseases (178, 185). Conse-
quently, there are questions over whether this adverse effect is due to antihypertensive 
treatment or the patient’s conditions.  Nevertheless, these observations have raised doubts 
upon using the idea of “the lower, the better”, for the management of hypertensive patients 
and particularly in those with coronary heart diseases.   
 
Regarding the limitations of defining a blood pressure threshold, there has been a need to 
identify a level to which blood pressure should be lowered. Randomised clinical trials com-
paring patients allocated to different blood pressure targets have been considered the goal 
standard for establishing that level (186-187). Two systematic reviews, using similar sources 
45 
 
of information, summarised the results from clinical trials assessing two or more blood pres-
sure targets (188-189).  Arguedas et al searched articles in MEDLINE (1966- April 2008), 
EMBASE (1980 – April 2008) and Cochrane Central Register of Controlled Trial (CENTRAL) 
(until April 2008) (188) and Lv et al did in MEDLINE via OVID (1950 – July 2011) EMBASE 
(1966 – July 2011) and the Cochrane Library database (189).  Whereas Arguedas et al did 
not find significant reductions in total and cardiovascular  mortality and morbidity associated 
with lower blood pressure targets (188), Lv et al reported that lower blood pressure targets 
produced reductions in cardiovascular morbidity such as stroke and end stage kidney dis-
ease (ESKD) but not in total  and cardiovascular mortality (189).  
 
A comparison of both reviews is presented in table 6. The period of both reviews overlaps 
until April 2008. The number of articles included by Lv et al is higher because they used 
wider inclusion criteria for blood pressure targets, a longer time period and full age range of 
patients including children (189). They also included all the studies selected by Arguedas et 
al (188-189). None of the reviews found significant heterogeneity in the mortality cardiovas-
cular and total mortality outcomes between the studies included. Thus, in all clinical trials 
included the rate of total and cardiovascular mortality observed in the group with less inten-
sive targets was similar to that of in the group with the standard target. Lv et al attributed the 
difference in the other results to the lower power of the review conducted by Arguedas et al 
(188-189). However, I present other potential explanations for the observed discrepancies. I 
also take into consideration other possible reasons for interpreting the lack of differences in 
cardiovascular mortality between groups with intensive and standard blood pressure targets.   
 
A summary of all clinical trials included in both reviews is presented in appendix B. I have 
excluded the SCAPE trial because it was conducted in patients below 18 years (190)  and 
the current review only applied to hypertensive patients aged 18 years and over. The age of 
the included patients ranges from 17 to 90 years but most of them were over 40 years. The 
percentage of men was higher in the studies with a population aged mainly below 60 years. 
By contrast the percentage of females increased in those trials carried out on patients over 
60 years. Except for two trials (191-192), the race/ethnic origin of the included population 
was mainly white. Patients were mainly at high cardiovascular risk with five out of all trials 
conducted only in patients with diabetes.    
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Table 6 Description of systematic reviews assessing blood pressure control 
targets 
Characteristic Arguedas et al (188)  Lv et al   (189) 
Period  1966 - April 2008  1950 - July 2011 
Research question  Determine the association 
between lower blood pres-
sure targets and reduction in 
total mortality and morbidity  
Assess evidence for using 
lower blood pressure targets  
Language No language restriction  No language restriction  
Population  Adults (No age was defined) No age restriction  
Interventions  Comparisons between two 
targets (135/85 mmHg vs 
140/90 mmHg) 
Comparisons between tar-
gets  
Type of studies  Randomised clinical trials  Randomised clinical trials  
Outcomes    
Primary  All-cause mortality  (Cardio-
vascular  and non- cardio-
vascular mortality)  
Total serious adverse events 
Major cardiovascular mortal-
ity (myocardial infarction, 
stroke, heart failure and car-
diovascular death) 
Secondary  
 
Systolic and diastolic blood 
pressure achieved  
 
Withdrawals due to adverse 
effects  
 
Mortality by each cause in-
cluded in primary outcome  
 
End stage kidney disease  
Adverse outcomes 
 
 
Bias assessment  
Cochrane Reviewers Hand-
book  
Cochrane Reviewers Hand-
book  
Individual data included  No  No 
Test for heterogeneity  I₂  I₂  
Outcome assessment  RR  RR 
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Continuation table 6 
Characteristic Arguedas et al (188)  Lv J et al   (189) 
Statistical methods  Fixed effects model  
Random effects model if het-
erogeneity was significant 
Random effects model  
Results    
Total clinical trials in-
cluded  7 15 
Total patients included  22089 37894 
Total mortality events  384 1584 
Total major cardiovascular  
events  998 1984 
Total end stage renal dis-
ease cases  252 941 
End achieved blood pres-
sure levels  
 
Lower blood pressure group 
Mean systolic blood pressure 
139.3 mm Hg 
Mean diastolic blood pres-
sure 81.5 mm Hg 
Standard blood pressure 
group 
Mean systolic blood pressure 
143.2 mm Hg 
Mean diastolic blood pres-
sure 85.1 mm Hg 
 
Not reported  
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The trials included in the reviews used different definitions of targets. Six trials used diastolic 
blood pressure (185, 191, 193-196), four used systolic blood pressures (197-200), two used 
systolic and diastolic blood pressure (193, 201) and two used mean blood pressure (192, 
202). The trials using diastolic blood pressure may have underestimated the effect of lower-
ing blood pressure particularly in patients aged over 55 years. Diastolic blood pressure tends 
to decrease with age such that the strength of the association between diastolic blood pres-
sure and cardiovascular mortality becomes weak with age (48-49, 65, 73, 203). Compared 
with diastolic blood pressure, systolic blood pressure contributes more to predicting the risk 
of hypertension-related cardiovascular mortality particularly in those at the age of 55 years 
and over (48, 50, 65, 204). Therefore, using systolic blood pressure has been recommended 
as a target for the management of hypertension (10, 60, 204-205). Some Clinical trials report 
mean achieved blood pressure as an outcome of the interventions. Using mean blood pres-
sure as a target may not accurately identify who is achieving lower blood pressure levels. 
That is because of by calculating mean blood pressure as 2/3 diastolic plus 1/3 systolic, it  is 
possible that  two different measurements of blood pressure can produce the same mean 
blood pressure (188). Consequently, the trials assessing reductions in systolic blood pres-
sure may provide more appropriate conclusions on the impact of using a specific blood pres-
sure target.    
 
The changes in blood pressure levels over the follow up period varied across the studies. 
Five of the included trials reported the percentage of patients who achieved blood pressure 
targets (185, 197-198, 201-202). Among them, the percentage of hypertensive patients ran-
domised to the intensive blood pressure target who achieved the expected target ranged 
from 56% to 72 %. Except for one study (197), lower percentages of hypertensive patients 
with controlled blood pressure were observed in patients allocated to intensive blood pres-
sure targets. The mean difference in systolic and/or diastolic blood pressure between a 
standard blood pressure target group and an intensive blood pressure target group was sig-
nificant in six of the included trials (191, 197, 199-202). Five trials reported significant differ-
ences in the achieved blood pressure based on the comparison of mean achieved systolic 
and/or diastolic blood pressure between both groups (193-194, 196, 198, 206). The reported 
differences are mainly based on p values with three trials reporting confidence intervals of 
the comparing estimators. Although the p value provides certainty that the probability of the 
difference is not due to chance, use of confidence interval is recommended to establish the 
magnitude of the differences (207-209). The distribution of blood pressure achieved by in-
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tensive and standard blood pressure values was described in two trials (185, 192, 210). The 
distributions have similar ranges of values but with a different mean. Hence it seems that the 
distribution of blood pressure levels achieved by intensive and standard blood pressure con-
trol may overlap despite significant differences in the mean end blood pressure.  
 
Therefore using blood pressure achieved by patients included in clinical trials as a blood 
pressure target has been questioned. The associations between final achieved blood pres-
sure and clinical outcomes may have been influenced by confounding variables (210). Davis 
et al illustrated this potential limitation in the interpretation of the African American Study of 
Kidney Disease (AASK) clinical trial results (210). This study was included in both reviews. 
Davis et al analysed data from AASK trial by using two approaches: intention to treat analy-
sis and analysis based upon stratification by final achieved blood pressure regardless of 
allocation to the treatment or control group. The intention to treat analysis revealed that there 
were no significant differences in the rate of decline in glomerular filtration rate and total 
composite outcome (dialysis, transplantation or death) in spite of the treatment and control 
groups achieving different mean blood pressure. By contrast, the analysis based on stratifi-
cation by final achieved mean blood pressure regardless of treatment allocation showed 
faster decline in the glomerular filtration rate and increased risk of total composite outcome 
for each 10 mmHg increase in achieved mean blood pressure. Although there were no dif-
ferences in baseline characteristics between the two randomised groups, there were differ-
ences in patient characteristics between those with lower mean blood pressure and those 
with higher mean blood pressure at the end of the study. Patients with less comorbidity, 
higher adherence and less severe disease were more likely to achieve lower blood pressure 
targets and this may have driven the different conclusions reached by the two different 
methods of analysis.   
 
Arguedas et al also reported that the effect of the assessed interventions on lowering blood 
pressure varied between studies (188). In other words there was a significant heterogeneity 
in blood pressure reductions across studies. The authors did not report the reasons for this 
observation. Lv et al did not mention whether blood pressure reductions were heterogene-
ous across the selected trials (189). As far as is known the blood pressure lowering effect is 
similar among all classes of antihypertensive drugs (139, 211). Therefore the observed dif-
ferences in achieved blood pressure reductions may be attributed to differences in patient 
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characteristics in the different clinical trials. Lower baseline blood pressure levels may favour 
a particular group of patients for example those without additional comorbidity or those with 
advanced renal disease (210, 212-213). Similarly, patients with higher systolic blood pres-
sure levels may attain lower reductions in blood pressure. Reductions in systolic blood pres-
sure have been more difficult to reach than reductions in diastolic blood pressure (18, 214). 
Differences in follow-up periods may also affect to what extent blood pressure has been 
lowered.   
 
The association between cardiovascular mortality and blood pressure targets varies between 
each meta-analysis. Arguedas et al did not find significant differences in cardiovascular mor-
tality between intensive target group and standard target groups in spite of reporting signifi-
cant differences of 6.8 mmHg in achieved systolic blood pressure and 5.4 mmHg in achieved 
diastolic blood between both groups (188). This negative result may differ from that has 
been observed in clinical trials evaluating the efficacy on antihypertensive drugs. In 17 clini-
cal trials conducted before 1994 the mean diastolic blood pressure difference ranged from 4 
to 6 mmHg. These differences were associated with an average 21% reduction in cardiovas-
cular mortality (215). A 2001 meta-analysis of 9 clinical trials showed that differences in sys-
tolic blood pressure as low as 5 mm Hg between experimental groups produced a significant 
reduction in the risk of cardiovascular mortality (216). Lv et al reported a reduction of 11% in 
the relative risk of cardiovascular events associated with using intensive blood pressure tar-
gets. However they did not find differences in cardiovascular mortality risk between both 
groups (189). Two of the included studies report a lack of statistical power to detect signifi-
cant differences in cardiovascular mortality between both groups (199-200). The results of 
the AASK trial corresponded to the period after finishing the original trial, in which less than 
50% of the initially included patients remained (217). Because the authors did not establish 
the criteria for defining the intensive blood pressure targets, the reported findings mainly 
strengthen the idea that reductions in blood pressure lead to reductions in cardiovascular 
mortality rather than there being any benefit from using intensive blood pressure targets.  
 
Arguedas et al reported no associations between intensive blood pressure targets and re-
ductions in the risk of stroke (188). The finding was mainly due to the results from the HOT 
trial. As mentioned in this trial the achieved blood pressure levels between the randomised 
groups overlapped (185). By contrast Lv et al documented that using intensive blood pres-
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sure targets was associated with reductions in the risk of stroke (189). The result was ex-
pected due to the strong association between stroke and blood pressure (7). In clinical trials, 
the achievement of systolic blood pressure to levels of 140 mm Hg and as low as 120 mm 
Hg has consistently been associated with a reduction in the risk of stroke (218-221). It 
seems that the lower the better apply to achieving the highest reduction in the risk of stroke.  
 
The reviews also differ in their findings concerning the association between using intensive 
blood targets and the risk of end stage kidney disease. The difference is essentially ex-
plained by the analysis of the MDRD trial (202). Whereas Arguedas et al included the results 
from the original trial (188, 202). Lv et al included the results of the study which used the 
extended follow-up period. This complementary analysis was done without taking into ac-
count the original randomization procedure and including less than 50% of the original num-
ber of patients (189, 222). Hence the conclusion from this analysis may be biased.   
 
Given the evidence provided by these two reviews, it appears that the definition of the blood 
pressure target for the management of hypertensive patients is a matter of uncertainty. The 
lack of associations reported by Arguedas et al may be due to the blood pressure targets 
used in the included studies, mainly diastolic blood pressure, and the low numbers in the 
patient with the expected outcome. Lv et al reported some benefits associated with the use 
of intensive blood pressure targets. The analysis of mixed population, one study includes 
patients below 18 years and the inclusion of trials using data from post hoc analysis may 
detract from drawing any conclusions regarding a target level for the management of hyper-
tension. However this review provided additional evidence regarding the benefit of intensify-
ing the lowering of blood pressure, particularly in hypertensive patients at a high cardiovas-
cular risk. 
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1.3.2 Targets for specific populations 
Patients at high cardiovascular risk   
 
Lower blood pressure targets have been recommended for patients at a high cardiovascular 
risk. This patient group includes hypertensive patients with at least one of the following con-
ditions: diabetes, chronic renal disease, stroke, coronary heart disease or heart failure. Pa-
tients with an additional cardiovascular risk and blood pressure levels over 180/100 mmHg 
are also considered within this category (13-15, 223). A blood pressure level of 135/85 or 
below 130/80 mmHg has been recommended as a target for patients at higher cardiovascu-
lar risk (13, 16, 224-226). The 1993 WHO hypertension guidelines initially advised using 
lower blood pressure targets without considering any particular level (227). The recommen-
dation was supported by the SHEP study in which lowering blood pressure in patients over 
60 years with baseline diastolic blood pressure of 77 mmHg led to reduction in major cardio-
vascular events (219, 227). Early clinical trials carried out mainly in hypertensive patients at 
a higher cardiovascular risk reported mean achieved blood pressure between 138/82 mmHg 
and 149/92 with percentages of patients achieving blood pressure below 140/90 mmHg 
ranging between 49% and 64% (185, 220-221, 228-234). Globally, these studies showed 
that patients with lower blood pressure levels experienced a greater reduction in hyperten-
sion-related cardiovascular risk than those with higher blood pressure levels. None of the 
studies aimed to assess any particular target except for the HOT trial (185).  
 
 
Recent clinical trials are inconclusive with regards to the definition of blood pressure targets. 
The FEVER study reported that hypertensive patients at a high cardiovascular risk achieving 
a blood pressure of 138.1/82.3 mmHg experience a 27% reduction in the relative risk of 
stroke in comparison with those achieving a blood pressure of 142.5/85 mmHg (235). The 
findings may not totally apply to other populations because the study includes only a Chi-
nese population. The association between blood pressure and stroke is stronger in a Chi-
nese population than that observed in other populations (52, 236). In the ONTARGET trial, 
hypertensive patients at a high cardiovascular risk with mean achieved blood pressure of 
132/75.8 mmHg had no differences in the risk of cardiovascular mortality compared to those 
with mean achieved blood pressure of 135.4/77.8 mmHg (237). Those patients with higher 
reductions in blood pressure also exhibited higher rates of hypotensive symptoms, syncope 
53 
 
and renal dysfunction. The side effects were associated with the combination of telmisartan 
and ramipril (237). The ProFESS trial showed that there were no differences in the stroke or 
major cardiovascular events between patients who achieved mean blood pressure of 
136.8/78.0 mmHg and those who achieved 140.3/80 mmHg. The follow-up period was 2.5 
years and stroke events that occurred during the first six months were excluded from the 
total outcome (238). The aim of the study was to compare the effects on stroke between 
telmisartan and placebo (238). Similar results were found it in the TRANSCEND trial (239).  
 
The ACCOMPLISH trial found that hypertensive patients on Benazepril plus amlodipine 
treatment who achieved mean blood pressure of 131.6/73.3 mmHg had a 16% relative risk 
reduction in all cardiovascular events and death from cardiovascular cause than those on 
benazepril plus hydroclorotiazide who achieved mean blood pressure of 132.5/74.4 mmHg 
(240). Although the difference in mean blood pressure between both groups was significant, 
the authors attributed the results to the effect of the drug beyond blood pressure reductions. 
72.5% of hypertensive patients achieved blood pressure below 140/90 mmHg without report-
ing side effects due to lower blood pressure levels. 60% of included patients were diabetic 
(240). In the VALUE study there were no differences in the risk of cardiovascular mortality 
between patients who achieved a mean blood pressure of 139.3/79.2 mmHg and those pa-
tients who achieved 137.5/77.7 mmHg (241). The trial reported a mean difference of 2.1/1.6 
mmHg between both groups over the follow-up period. The percentage of patients with a 
blood pressure below 140/90 mmHg was 60.5% (242).  It is worth noting, these levels were 
observed in patient with mean age of 67.2 years and no major side effects were reported 
(241).    
 
Evidence from post hoc analyses of clinical trials has also been considered for the definition 
of targets (243). Mancia et al reported that hypertensive patients at a higher cardiovascular 
risk who achieved blood pressure levels below 130/80 mmHg have lower significant hazard 
ratio of stroke than those who achieved blood pressure levels above 140/90 mmHg. How-
ever, there are no significant differences in the hazard ratio of cardiovascular diseases. This 
was a secondary analysis of the ONTARGET trial in which patients with lower baseline blood 
pressure levels tended to have higher blood pressure control rates (244). A post analysis of 
the CASE-J trial showed that hypertensive patients with diabetes or chronic kidney disease 
who achieved systolic blood pressure above 130 mmHg had higher incidence of cardiovas-
cular diseases than those with systolic blood pressure below 130 mmHg. The analysis also 
showed that the association is stronger for this group of patients than for those at a lower 
54 
 
cardiovascular risk (245). Hence the study supports the concept of using lower blood pres-
sure targets in the management of hypertensive patients at high cardiovascular risk. A post 
hoc analysis of the PROGRESS trial showed that hypertensive patients who have cere-
brovascular disease with a baseline systolic blood pressure less than 120 mmHg have simi-
lar reductions in the risk of stroke to those with a higher baseline systolic blood pressure. 
Hence the achievement of systolic blood pressure below 120 mmHg seems to have a  bene-
ficial on the prevention of stroke without an increase in mortality or side effects (218). 
 
Diabetic patients 
 
For hypertensive patients with diabetes, the use of targets below 140/90 mmHg have been 
promoted by different guidelines (13, 243). Whereas, the JNC 7 recommends a blood pres-
sure below 130/80 mmHg (13), the European Society of Hypertension recommends a blood 
pressure target between 130-139/80-85 mmHg (15). The recommendation initially arose 
from the analysis of subgroups in the SHEP and HOT trials (246-247). The HOT trial showed 
that diabetic patients who achieved diastolic blood pressure below 80 mmHg have a 30% 
lower risk of total cardiovascular mortality than those without diabetes with similar diastolic 
blood pressure (246). Ghaede et al reported that diabetic patients exposed to a multi-
factorial intervention who achieved blood pressure below 135/85 mmHg had 47% lower risk 
of cardiovascular morbidity than those who received the standard intervention and achieved 
150/86 mmHG blood pressure (248). The more intensive blood pressure target of systolic 
blood pressure below 130 mmHg was achieved by 45% of patients allocated to the intensive 
blood pressure intervention group. The aim of the study was to evaluate the impact of an 
intensive program for the management of diabetic patients (248).  
 
The ADVANCE study reported that diabetic patients who achieved mean blood pressure of 
134/74 mmHg experienced a 9% reduction in the relative risk of macrovascular and mi-
crovascular complications compared with those who achieved 140/76 mmHg blood pressure 
(249). The mean difference between both groups in systolic and diastolic blood pressure 
was 5.6 mmHg and 2.2 mmHg respectively (249). The ABCD trials compared the benefit of 
using a lower blood pressure target in diabetic patients with and without hypertension (193, 
196). The ABCD-N trial reported lower incidence of stroke and slower progression of neph-
ropathy in participants who achieved blood pressure below 128/75 mmHg than those who 
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achieved 37/81 mmHg (193). The ABCD-2V (ABCD part 2 with VALSARTAN) trial showed 
that diabetic patients without hypertension who achieved blood pressure below 120/80 
mmHg had lower progression of urinary albumin excretion over the follow-up period. This 
trial was stopped early and included only 129 patients (196).  
 
In contrast, the ACCORD trial and the ABCD-H trial found that diabetic lowering systolic 
blood pressure below 130 mmHg in diabetic patients was not associated with higher reduc-
tions in hypertension-related mortality and morbidity that those attained whit blood pressure 
levels above 130 mmHg (194, 199). In the ACCORD trial also there were no differences in 
the total and cardiovascular mortality between the diabetic patients who achieved systolic 
blood pressure below 119.3 mmHg and those who achieved 133.5 mmHg. Nonetheless, a 
significant difference in the rate of stroke between both groups was observed (199). How-
ever the study had a low incidence of cardiovascular events reducing its statistical power to 
evaluate the differences in outcomes between both groups (199). In the ABCD-H trial there 
were no differences in total cause mortality between diabetic patients with end blood pres-
sures of 132/78 mmHg and those with 156/98 mmHg (194). This trial did not report the total 
number of patients who completed the follow up period (194).  
 
Evidence from observational studies also did not completely support the benefit of using 
lower blood pressure targets in individuals with diabetes. A post hoc analysis of 6400 pa-
tients with diabetes and coronary artery disease revealed that the mortality rate of all cause 
mortality did not vary significant between patients with diabetes and coronary heart disease 
who achieved systolic blood pressure below 130 mmHg and those who achieved systolic 
blood pressure between 131 mmHg and 140 mmHg. The results may be confounded be-
cause of the significant differences in baseline characteristics between the groups (250). In 
an observational study of 126092 diabetic patients, Vamos et al additionally reported that the 
achievement of blood pressure target below 130/80 mmHg was not associated with a reduc-
tion in the risk of all mortality causes (251). Two meta-analyses documented that diabetic 
patients who achieved blood pressure below 130/80 mmHg tended to have a lower inci-
dence of stroke compared with those who achieved higher blood pressure levels. However, 
the beneficial effect on total and cardiovascular mortality was not significant and the side 
effects tended to increase (252-253). Hence the effects of achieving systolic blood pressure 
below 130 mmHg pressure seem to be heterogeneous (181, 244, 252).  
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Patients with chronic kidney disease 
 
A blood pressure target below 130/80 mmHg has been recommended for patients with 
chronic kidney disease (13). The strength of evidence supporting this target is questionable. 
I previously referred to the MDRD trial and the AASK trial. The REIN-2 trial compared the 
effect of two targets on time to end-stage renal disease in hypertensive patients with non-
diabetic proteinuric nephropathy. Thus patients were randomly allocated either to a target of 
diastolic blood pressure below 90 mmHg or a blood pressure below 130/80 mmHg. The 
study did not find significant differences between the two groups. However neither the pa-
tients nor the investigators were blinded. Additionally, the percentage of patients’ lost was 
around 35% during the follow -up period. Hence, the conclusions derived from the study may 
be biased (195). 
 
Elderly patients  
 
The blood pressure target for the elderly population has also been questioned. The MRC2 
trial earlier documented that lowering blood pressure to or below 155/85 mm Hg in hyperten-
sive patients with a mean age of 70.2 years resulted in a reduction of 25% and 17% in the 
rate of stroke and all cardiovascular events respectively (254). The SHEP trial reported that 
patients with mean age of 72 years who achieved an average blood pressure of 143/68 
mmHg had a 36% lower risk of stroke than those who achieved average blood pressure of 
155/68 mm Hg (219). In addition, they had a reduction in all cause mortality and cardiovas-
cular events without increases in adverse events (219). The Syst-Eur trial reported that eld-
erly hypertensive patients with end mean blood pressure of 150.8/78.5 mmHg had a lower 
incidence of stroke but not of cardiovascular mortality than those with mean blood pressure 
of 160.9/83.5. The follow-up period in this study was two years what may affect the probabil-
ity of finding differences in total cardiovascular mortality (255). The HYVET trial showed that 
patients with age of 80 years and over who achieved mean blood pressure of 144.7/78.4 
mmHg had significantly lower rates of total mortality and stroke than those who achieved 
159.4/83.8 mmHg blood pressure (256-257). The researchers used a target of systolic blood 
pressure less than 150 mmHg in elderly patients who also had low frequency of cardiovas-
cular disease (257). The STOP-hypertension 2 trial reported reductions in blood pressure 
from 187/100 to 159/80 in hypertensive patients with mean age of 72 years. These reduc-
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tions were observed in the group on conventional antihypertensive therapy and those with 
newer antihypertensive drugs. There were no differences in all cardiovascular events be-
tween both groups (232). 
Recent clinical trials have shed light on the benefit of lowering blood pressure in elderly.  In 
the JATOS study, elderly hypertensive patients who achieved systolic blood pressure below 
140 mmHg did not have significant improvements in cardiovascular mortality in comparison 
with those who achieved systolic blood pressure over 140 mmHg (198). An interaction effect 
between age and blood pressure reduction was reported. Thus patients aged over 75 years 
could benefit less from using lower targets than those aged below 75 years (198). However, 
the trial lacked statistical power to show significant differences in the outcome (198). In the 
VALISH trial, patients over 60 years were randomised either to systolic blood pressure target 
of less than 140 mmHg or systolic blood pressure target of 140-150 mmHg (200). Patients 
on the lower target achieved a mean blood pressure of 136.6/74.8 mmHg and those on the 
higher target achieved 142.0/76.5 mmHg. Despite the differences, there were no significant 
differences in mortality but the authors adverted that the study is underpowered to identify 
differences in outcome. Of note, patients with lower blood pressure level did not have excess 
in side effects (200). 
 
Using lower targets for elderly patients could also be harmful. In the INVEST trial, a sub-
analysis of the oldest hypertensive patients with coronary heart disease illustrated that the 
achievement of blood pressure below 140 mmHg was associated with a higher risk of total 
cause of mortality in those aged 80 years and over. The authors suggested that the thresh-
old for safe reductions in systolic blood pressure decreases with increases in age (258).  
Fagard et al also provided evidence on the association between an increase of all causes of 
mortality and the achievement of diastolic blood pressure below 55 mmHg in elderly patients 
with coronary heart disease. The result came from the follow-up period of the Systolic Hyper-
tension in Europe (Syst-Eur) Trial (176). The J-Health study presented same associations 
between blood pressure reductions and cardiovascular mortality in a cohort of 26512 Japa-
nese patients with the mean age at 62 years (259). A similar association was observed 
among hypertensive patients of white and African-American ethnicity  in the NANHES survey 
(260).  
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To sum up, the blood pressure target for elderly hypertensive patients is still uncertain. The 
differences in patient profile between studies and the potential side effects of lowering blood 
pressure limit the ability to definite a potential target for this patients group.  
 
The 140/90 mm Hg blood pressure as blood pressure control tar-
get 
 
The clinical guidelines recommend the level of 140/90 mmHg as the blood pressure target 
for the management of hypertensive patients particularly in those at middle and low cardio-
vascular risk (13-15, 261).The guidelines acknowledge that this target is based on consen-
sus views of experts assessing the available evidence. To date, there is no a clinical trial 
supporting the use of this threshold as a blood pressure target. By contrast, the use of this 
level is under scrutiny (262).  
The use of 140/90 mmHg has been recommended as blood pressure target mainly for pa-
tients at low and middle cardiovascular risk since 1993 (263-265). The criteria for selecting 
this threshold relied mainly on observational studies (38-39, 266). The studies revealed that 
25% of population seems to be above its mean population systolic and diastolic blood pres-
sure levels (39). The level of 140 mm systolic blood pressure and 90 mmHg diastolic blood 
pressure seems to be the cut off over this percentage are located (39). Port et al suggested 
that a systolic blood pressure of 140 mmHg may be the threshold below which the relation-
ship between all cause mortality and systolic blood pressure seems to be linear and con-
stant. The conclusion arose from performing a logistic spline model rather than linear logistic 
model to assess the relationship between mortality and systolic blood pressure (267). Evi-
dence from observational studies including a large number of patients demonstrated that 
even a blood pressure of 115/75 mmHg  is associated with cardiovascular risk (7). Van den 
Hoogen et al reported that having a usual systolic blood pressure of 140/90 mmHg is consis-
tently associated with similar relative risk of dying from coronary heart disease though the 
absolute risk is variable worldwide (51). Vasan et al also documented that individuals with 
blood pressure in the range of 130–139 mmHg systolic blood pressure and 80–85 mmHg 
diastolic blood pressure are more likely to have a cardiovascular events over a 10 years fol-
low-up period compared with those with blood pressure below these levels (11). These as-
sociations have also been observed in younger people aged between 18 and 39 years 
(268).  
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Clinical trials supporting the use of this target for the management of hypertensive patients 
at low or middle cardiovascular risk are scarce with early clinical trials accounting for most of 
them. The hypertension detection and follow-up program (HDFP) revealed that hypertensive 
patients with a baseline blood pressure between 90 and 104 mmHg who achieved diastolic 
blood pressure below 90 mmHg in a stepped care had 20% lower mortality than those in 
referred care (269). The Multiple Risk Factor Intervention Trial (MRFIT) showed that men 
with blood pressure as low as 115/75 mmHg were benefit from reductions in blood pressure. 
The protocol did not establish a particular threshold for the management of patients (270). 
The MRC trial assessed the management of hypertension in younger patients mean aged 35 
and 64 years (271-272). The trial compared patients randomised to bendrofluazide or pro-
panolol with placebo. A diastolic equal or below 90 mmHg was used as the target for the 
management of patients. The trial reported that the treatment group had lower stroke rates 
compared to that observed in the placebo group. The lower rates were associated with the 
higher reductions in blood pressure attained by those with active treatment. There was no 
difference in the rate of cardiovascular mortality between both groups. The TRHOPY trial 
evaluated the effect of using antihypertensive therapy in patients aged between 30 and 65 
years with systolic blood pressure between 130 mmHg and 139 mmHg and diastolic blood 
pressure below 90 mmHg on the development of hypertension. Although patients on treat-
ment have lower blood pressure levels, the associations with cardiovascular mortality were 
not reported (273). A secondary analysis of the  FEVER trial revealed that hypertensive pa-
tients aged 65 years and over without other cardiovascular diseases or diabetes and pa-
tients who achieved blood pressure levels below 140/90 mmHg had lower incidence of 
stroke and other cardiovascular events (262). However the reported associations come from 
a post hoc analysis of the original trial so that need to be confirmed by other studies. 
 
Currently, there is a lack of evidence from randomised controlled trials supporting a specific 
target for hypertensive patients at low or middle cardiovascular risk. The limitations for as-
sessing blood pressure targets in this patient group risk are attributed to the high sample 
size and the long follow-up period needed to find differences between intervened groups. 
That are due to the lower incidence of cardiovascular events occur in this population in com-
parison to what is observed in hypertensive patients at higher cardiovascular risk. .  
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Summary 
Most of the available evidence for the management of hypertension has been derived from 
studies conducted in patients at high cardiovascular risk. The majority of studies aim at 
comparing pharmacological interventions with few studies comparing blood pressure targets. 
The achieved blood pressure reported in these studies has commonly been translated into 
potential thresholds for the management of hypertensive patients.  
There are also some doubts as to what extent targets derived from these clinical trials can 
be applied to whole range of hypertensive patients. Clinical trials have been conducted 
mainly in populations of Caucasian origin so that patients of different ethnic background may 
need a different approach. Blood pressure levels vary between different ethnic groups (34, 
38, 51). The number of women included in these studies has been considered low particular 
in studies with patients below 60 years. Variations in blood pressure levels between the sex 
also raise questions about the use of equal targets for women and men (73, 274).  
Summarizing the currently available evidence, the extent to which blood pressure should be 
lowered is still a matter of uncertainty. Clinical guidelines recommend differential targets for 
blood pressure reductions in hypertensive patients according to the classification of their 
cardiovascular risk. The targets are based on an appraisal of the available evidence. This 
evidence mainly came from clinical trials testing pharmacological interventions to reduce 
blood pressure. There is a lack of randomised clinical trials comparing blood pressure tar-
gets that producing definite results. It seems that lowering blood pressure down to a systolic 
blood pressure of 135 mmHg or diastolic blood pressure of 75 mmHg leads to significant 
reductions in hypertension-related cardiovascular risk in hypertensive patients regardless of 
age, sex or their cardiovascular risk.  Evidence supporting higher reductions is contradictory. 
Some studies, mainly observational or post hoc analysis, showed that reducing blood pres-
sure below these levels may result in an increase of cardiovascular mortality particularly in 
those with coronary heart disease and elderly patients.  
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1.3.3 Current definition of targets 
 
The use of blood pressure targets for the management of hypertensive patients is estab-
lished in clinical guidelines worldwide. Table 7 shows the current guidelines being used in 
the different geographical areas. The definitions of blood pressure targets used in England 
will be presented in a separate section.  
 
The guidelines agree on recommending the blood pressure targets for the management of 
hypertensive patients at low and middle cardiovascular risk without additional cardiovascular 
comorbidity. Globally they recommend a blood pressure equal to or below 140/90 mm Hg as 
the aim of the therapy. The guidelines mainly differ in the recommended targets for patients 
at high cardiovascular risk. The JNC 7 proposed a lower blood pressure target for these pa-
tients compared to that proposed in other guidelines (13)  (Table 7). 
 
The use of blood pressure targets  
Despite the described limitations, the achievement of a blood pressure target is regarded as 
a standard of care in the management of hypertensive patients. Blood pressure targets have 
been used for different purposes. 
In the clinical context, the guidelines established thresholds to help doctors guide the man-
agement of hypertensive patient (13-14, 174). Decisions on drug therapy are based on the 
achievement of the recommended target. Physicians classify patients into a hypertensive 
patients with controlled or uncontrolled hypertension based on the achievement of that 
threshold (13-14, 174, 261). The classification may not accurately reflect the concept of 
blood pressure control in the sense of the achievement of the maximal reduction in blood 
pressure-related cardiovascular risk. Patients classified as those with controlled hyperten-
sion are still at higher risk than those patients without hypertension with similar characteris-
tics (58, 275-277). 
In primary care services blood pressure targets have also been used as indicators to meas-
ure the quality of care provided by health services (278). The performance of services is 
assessed based on the amount of hypertensive patients had blood pressure below the de-
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fine blood pressure target (279). The use of this measurement relies on placing its account-
ability for blood pressure control with health care providers (279-280).    
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Table 7 Blood pressure targets for hypertensive patients on antihypertensive treatment  
Guideline  WHO (14) 
 
ESH-ESC (15-17)  JNC 7  (13) 
 
Patients at low and middle cardiovascular 
risk  
<140/90 mmHg <140/90 mmHg <140/90 mmHg 
Patients at higher cardiovascular risk  <130/85 mmHg ₁ 130-139/80/85 mmHg₂  <130/80 mmHg₃ 
₁Referred to patients with diabetes, renal insufficiency and established cardiovascular disease 
₂Referred to patients with diabetes and should be considered for patients with established cardiovascular diseases.  
₃Referred to patients with diabetes or chronic kidney disease 
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Key points 
 The hypertension guidelines recommend blood pressure thresholds as a target for 
the management of hypertension.  
 The recommended targets have been mainly based on the blood pressure levels 
achieved by hypertensive patients included in clinical trials.  
 The clinical trials mainly aimed to assess the efficacy of antihypertensive drugs.  
 Patients included in clinical trials have mainly been patients at a high cardiovascular 
risk.  
 Few trials have compared the efficacy of using blood pressure targets for the man-
agement of hypertensive patients.  
 Hypertension guidelines agree on a target equal to or below 140/90 mmHg as a 
blood pressure target for hypertensive patients at a low and middle cardiovascular 
risk.  
 Hypertensive guidelines recommend lower blood pressure targets for hypertensive 
patients at high cardiovascular risk.  Guidelines differ in these targets.  
 There is a need of evidence on blood pressure thresholds for hypertensive patients 
at low cardiovascular risk and middle cardiovascular risk.  
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Chapter 2 Factors affecting blood pressure 
control  
 
Despite the available interventions, the target of 140/90 mmHg is not attained by the majority 
of hypertensive patients. The proportion of patients achieving this target is still below 50% 
worldwide (281). The proportion of hypertensive patients achieving this target varies be-
tween different countries. The lowest rates of blood pressure control have observed in de-
veloping countries. For instance in a survey from Asian countries, Van Minh et al reported 
that only 5.4% of hypertensive participants had blood pressure  below 140/90 mmHg (282). 
By contrast, in a comparison between the NHANES 1988-1994 and 1999-2008 Egan et al 
found the percentage of hypertensive patients with controlled blood pressure increased from 
27.3% to 50.1% over the period (283). A similar trend has been observed in England (283-
284).  
 
In studies from countries with advanced primary care services, the percentage of hyperten-
sive patients with blood pressure below or equal to 140/90 mm Hg has been shown to vary 
from 20.3% to 54% among those receiving care within these settings (285-287). The 
achievement of controlled blood pressure depends upon individual conditions, social condi-
tions and the quality of care from health providers. Then diverse factors have been associ-
ated with poor blood pressure control. These factors have been classified into patient-related 
factors, physician-related factors and health system-related factors (288-289).  This chapter 
presents a summary of factors affecting blood pressure control. 
I identified the potential factors from studies assessing blood pressure control in hyperten-
sive patients aged 18 years and older using a target of 140/90 mmHg. The studies were ei-
ther conducted at population level or in primary care services from January 2000 up to De-
cember 2012. The source for the review was PUBMED database. I excluded studies that 
reported blood pressure control rates without information about factors affecting blood pres-
sure control. 
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I selected 64 studies conducted in 47 countries. 24 studies were carried out at population 
level. Among these, except for three studies (138, 282, 290), population were selected 
based on a sample sized calculation. 40 studies were conducted in primary care. In these 
studies, the study populations were hypertensive patients being treated in primary care or 
the community. In three studies the population was selected using other sources such as 
those participating in another community study (205), and sample sized based on a census 
(291-292). Blood pressure was mainly measured using a mercury sphygmomanometer or 
Omron monitor. The studies reported a diverse range of factors as discussed below (Table 
8-9) 
 
2.1 Patient-related factors  
 
Patient-related factors constitute the most frequent factors reported in the studies. Among 
these are age, sex, race/ethnicity, the presence of other comorbidities, adherence to inter-
ventions and socio-economic conditions.  
 
2.1.1 Adherence to interventions 
 
The WHO defines adherence to long term therapy as “ the extent to which a person’s 66es-
peciour – taking medication, following a diet, and/or executing lifestyle changes, corresponds 
with agreed recommendations from a health care provider” (293). The definition incorporates 
the two concepts of  adherence and persistence with therapy (294).  Adherence is consid-
ered as the adequate use of therapy that follows physician recommendations.  Persistence 
is defined as the continuous  use of antihypertensive medication for a defined period of time 
(294). Poor adherence to antihypertensive medication is commonly observed among anti-
hypertensive patients. In a population survey from China, Tian et al found that only 27.7% of 
hypertensive patient were taking antihypertensive medications regularly. The reasons for not 
taking medications were not having enough money to purchase them and not being aware of 
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the health risk related to hypertension (295). In an analysis of prescribing records from 
22918 hypertensive patients, Caro et al detected that only around 50% of patients continued 
on antihypertensive treatment six months after starting therapy (296). In a  review of 20 stud-
ies assessing adherence to antihypertensive medication Fitz-Simon et al reported that  the 
percentage of patients regularly taking antihypertensive medication varied between 4% and 
86 % (297). 
 
In an analysis of clinical records of 4378 hypertensive patients Vrijens et al, found that up to 
50% of patients stopped taking antihypertensive medication over one year (298). They also 
reported that among patients continually taking antihypertensive medication at least 10% of 
scheduled prescriptions were omitted. In a study of 82824 hypertensive patients aged 65 
years and over, Morgan et al found that only 50% of newly treated hypertensive patients 
reported continue use of antihypertensive drugs after having the initial prescription (299). By 
comparison, some authors have been reported good adherence to antihypertensive medica-
tions. In a cohort of 207473 patients with mean age 74 years, Friedman et al reported that 
adherence and compliance with antihypertensive medication increased up to levels between 
50% and 75% over a seven year follow-up period (300). Similarly, Inkster et al reported a 
91% level of adherence among hypertensive patients in primary care (301). Then although 
adherence is commonly reported, its frequency varies across studies. 
 
The consequences of poor and/or good adherence varied between different studies. In a 
review of adherence to medication including nine studies related to antihypertensive treat-
ment, DiMatteo et al reported that hypertensive patients with good adherence were  more 
likely to have controlled blood pressure compared to those with poor adherence, odds ratio 
3.5 (95% CI 1.60 – 7.37) (302).  By contrast, in an analysis of 110 outpatients, Nuesch et al 
also established  that the level of compliance did not explain the failures in lowering blood 
pressure (303). From a review of 30 studies assessing adherence to antihypertensive medi-
cation, Wetzels et al concluded that the association between poor adherence and poor blood 
pressure control is not totally supported by the available evidence (304). Some studies did 
not find differences in adherence between those with good and poor blood pressure control. 
Those studies which support the association between poor adherence and poor blood pres-
sure control did not have a control group. Grezzana et al reported that despite having ade-
quate adherence to antihypertensive medication, hypertensive patients did not achieve 
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blood pressure targets (305). The lack of a standard method for assessing adherence to 
medication is one the reasons for these divergences between studies. It also results in dif-
ferent estimations of adherence to antihypertensive medications between studies (293, 306-
307). Therefore, although a lack of adherence to antihypertensive medications is frequently 
among hypertensive patients, its impact on blood pressure control has not precisely been 
estimated.  
The consequences of poor adherence to antihypertensive medication go beyond poor blood 
pressure control. Bailey et al reported that there was a reduction in the risk of stroke associ-
ated with increases in the level of adherence to antihypertensive medication. Thus for each 
15% increase in the adherence score, there was a reduction of 0.91 (CI 95% 0.86-0.97) in 
the hazard ratio of stroke (306). Corrao et al reported that compared to those patients stop-
ping antihypertensive medication at any time, those who did not stop medication had a re-
duction of 37% in coronary or cerebrovascular outcomes (308). This evidence came from 
data collecting from general practices and so can be considered to reflect possible achieve-
ments within current clinical practice (308). From analysing medical records of 18806 newly 
diagnosed hypertensive patients receiving care in 700 general practices in Italy, Mazzaglia 
et al reported that those with higher levels of adherence had a  nearly 40% reduction in their 
risk of having acute cardiovascular events (309).  Similarly from analysing a cohort of 59647 
hypertensive patients, Dragomir et al reported that those with poor adherence to medication 
had an increased risk of having coronary disease, cerebrovascular disease and chronic re-
nal failure (310). Hence, adherence to medication should be considered an important factor 
for improving blood pressure control.    
 
2.1.2 Individual factors  
 
Being older is commonly associated with poor controlled blood pressure. This association 
has reported either in studies conducted at population level or the community (18, 205, 282-
283, 287, 295, 311-328).  It may be due to age-related increases in blood pressure leading 
to a higher prevalence of isolated systolic hypertension in individuals over 50 years (73). The 
association has been observed regardless of race/ethnic origin, socio-economic and educa-
tion status. By contrast, only a few studies have reported that younger patients such those 
below 40 years have been less likely to have controlled blood pressure (283, 318, 328-330).  
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The relationship between sex and poor blood pressure control has been contradictory. Some 
studies revealed a negative association between women and blood pressure control (205, 
313, 315, 320, 331-334). By contrast others studies revealed that women were more likely to 
have controlled blood pressure (287, 311, 334-343). In one study the relationship between 
women and blood pressure control changed with age. Compared to men, younger women 
were more likely to have controlled blood pressure and older women were less likely to have 
controlled blood pressure (328). Moreover, some studies reported being male as a predictor 
for inadequate blood pressure control (290, 312, 316-317, 344-350). Due to these discrep-
ancies, there does not seem to be strong evidence supporting any particular association 
between sex and poor blood pressure control.   
 
Race/ethnic origin has been associated with variation in the probability of having controlled 
blood pressure. Black patients living in Western societies have been reported less likely to 
have controlled blood pressure compared to those of white origin (283, 313, 329, 347, 351-
352). Wong et al found that hypertension is the most significant contributor to differences in 
mortality between black and white race/ethnicity. It accounts for 15% of total difference in 
year lost between both groups (353). In an assessment of NHANES trends between 1998 
and 2008, Egan et al reported that there has been a constant increase in the percentage of 
hypertensive patients with controlled hypertension in all ethnic groups. But white patients 
remain with higher blood pressure control rates than black patients and those of Hispanic 
origin (283). Similarly, Howard et al revealed that despite being aware of hypertension and 
having antihypertensive treatment, hypertensive patients of black origin were less likely to 
have controlled blood pressure than those of white origin (354). The association declines but 
remains significantly after adjustment for demographic and socio-economic conditions (354). 
Despite these trends, Wyatt et al pointed out that better blood pressure control in African 
Americans is achievable. In a cohort of 5249 American African they found that 66% of hyper-
tensive patients on treatment had controlled blood pressure (355). They argued that this 
sample of African American population had a high level of education and better access to 
health than other African American populations.  
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Some factors have been associated with lower blood control rates in patients of black origin. 
Analysing data from a retrospective cohort of hypertensive patients managed in primary 
care, Kressin et al suggested that social conditions such as health benefits, patient’s beliefs 
and adherence to medication accounted for lower blood pressure control rates in patients of 
black origin (352). In an analysis of 608 patients of white and black race/ethnicity,  Bostworth 
et al found that age, worry about hypertension and poor adherence to antihypertensive 
medication were associated with poor blood pressure control in black patients (356). Simi-
larly, in analysis of 40492 hypertensive patients on antihypertensive medication, Siegel et al 
reported that the lowest rates of blood pressure control were in those of black origin and 
those suffer from depression (357). However in a cross sectional of the REGARDS study, 
Durant et al showed that lower adherence to medications did not totally explain the lower 
blood pressure rates observed in black patients (358). Lower blood pressure control rates in 
black patients have been documented despite receiving an intensification of treatment (359).  
 
Rehman et al explored the impact of health care services on black hypertensive patients. 
They found that black men receiving care at the Department of Veterans Affairs (VA) had 
better blood pressure control than those who received care in non-VA services. However, in 
both clinical settings patients of white origin were more likely to achieve blood pressure con-
trol targets (360). In an observational study using medical registers from 51722 hypertensive 
patients, Ishisaka et al identified that those of non-white race/ethnic origin (Asian Ameri-
can/Pacific, Islander, black, Hispanic and other ethnicities) had lower adherence to anti-
hypertensive medication (361). In the ALLHAT clinical trial which included 33357 hyperten-
sive patient  recruited from the community, Cushman  et al found that patients of black origin 
were less likely to achieve controlled blood pressure  than those of other race/ethnic origin, 
odds ratio 0.69  (95% CI 0.65 – 0.73) (362). Glymour et al found that differences in stroke 
incidence between patients of black origin and those of white origin disappear when the 
analysis takes into account social economic conditions (363). 
 
Life style  
Among the studies presented in table 8, two studies reported positive associations between 
non-pharmacological interventions such as low salt intake, weight loss, doing physical 70es-
pecity with having controlled blood pressure (311, 317). The negative impact of not using 
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these interventions was also documented in four studies (290, 327, 344, 346). The associa-
tions were observed taken into account age, sex and/or race/ethnicity. Consequently, these 
non-pharmacological interventions have been proved to reduce blood pressure levels (364). 
However, these interventions may be underused. In a national survey conducted in China, 
Gu et al reported that only 55% of hypertensive individuals were advised on using non 
pharmacological interventions (330). 45% of them were currently using more than one inter-
vention and salt reduction was the most frequently non-pharmacological intervention used 
(330). Additionally the assessment of these interventions has not frequently been reported in 
the cited studies. The majority of the studies reported antihypertensive prescribing as the 
indicator for assessing the management of hypertension using a structured interview.  
 
Poor adherence to non-pharmacological interventions has also been reported. In an open 
intervention study carried out with individuals with mildly elevated blood pressure, Korhonen 
et al found that despite having received intense counselling and low salt content products,  
only 20% of total participants reduced salt consumption to less than 5g/day (365). The 
PREMIER clinical trial of 810 hypertensive patients with mean blood pressure of 135/85 mm 
Hg showed that patients who were either under an intense education intervention or DASH 
diet plus intense education, achieved lower blood pressure levels than those who receive 
only advice. But only 28%, 34% and 34% of included participants were adherent to salt re-
duction, weight reduction and fruit and vegetable consumption recommendations 71es-
pecttively (366). In a longitudinal study of 389 hypertensive patients, Otha et al found that 
only 2.3% of included patients met the target of consuming less than 6 gr/day salt consump-
tion over a 3.5 years follow up period (367). Therefore the effectiveness of salt reduction in 
current clinical practice may be unknown and also confounded by the presence of other in-
terventions (368).   
 
Different associations between smoking and having controlled blood pressure have been 
reported. McNagny et al reported that compared to patients with controlled hypertension, 
those with uncontrolled hypertension were more likely to be current smokers (369). In an 
analysis of 122 hypertensive patients, Chmiel et al  found that smoking was positively asso-
ciated with having uncontrolled blood pressure (370). In a Swiss survey the rate of blood 
pressure control was higher in non-smokers  (286).  
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Presence of comorbidity  
Increases in BMI have been associated with poor blood pressure control. The association 
has been consistently reported across the studies (205, 282, 287, 290, 292, 311, 315, 325, 
370-374). Lloyd et al revealed that those with higher BMI were less likely to have controlled 
pressure (205). Sandoval et al found that those with high BMI were less likely to have con-
trolled blood pressure (292). Chmiel  et al reported that increases in BMI was highly corre-
lated with higher blood pressures in hypertensive patients with uncontrolled blood pressure 
(370). Similar associations have been reported using BMI categories. Labeit et al found that 
patients with a body index mass (BMI) above 30kg/m² had a nearly 30% lower probability of 
having controlled blood pressure (287). Abaci et al also reported that a BMI over 25 kg/m² 
was negatively associated with having controlled blood pressure (325). Because increases 
in body mass index are a risk factor for hypertension (120), patients with a higher body mass 
index may experience more limitations in lowering blood pressure.  
 
The association between the presence of other comorbidities and blood pressure control 
varied across the studies. 24 studies reported that having an additional cardiovascular co-
morbidity reduced the probability of having controlled blood pressure below 140/90 mmHg 
(205, 285-286, 292, 313, 323, 325-327, 332, 344, 349, 372, 374-384). These studies mainly 
included older hypertensive patients being prescribed more than one antihypertensive drug. 
Diabetes and chronic renal disease are of the most frequently cardiovascular comorbidity 
occurring in these patients. It seems that this patient group have longstanding hypertension 
and also higher baseline blood pressure levels. Patients with long established hypertension 
have been found more likely to have uncontrolled blood pressure (344). This may indicate 
that a simultaneous control of more than one cardiovascular risk factor is hardly achieved. 
By contrast, eight studies found that hypertensive patients having an additional cardiovascu-
lar comorbidity were more likely to have controlled blood pressure (287, 292, 344, 349, 373, 
384-386). Within these studies coronary heart disease and stroke were the most commonly 
associated cardiovascular comorbidity reported. Patients on antihypertensive treatment were 
also older. That could be due to the quality of care provided to these patients. Petersen et al 
revealed that hypertensive patients with an additional comorbidity received better or equal 
care than those without other comorbidities and so they were more likely to have controlled 
hypertension (387).  
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Other non-cardiovascular comorbidities have also been related to blood pressure control. 
The relationship between depression and blood pressure control has been contradictory. 
Bautista et al in a longitudinal study of 178 patients reported that hypertensive patients with 
depression and anxiety were more likely to be non-adherent to antihypertensive medication 
(388). Michal et al assessed the relationship between depression and hypertension in a 
cross-sectional study of 5000 patients from Germany general practices. Compared to those 
without hypertension, patients unaware of hypertension were less likely to have depression 
or symptoms of depression (389). There was no association between having controlled hy-
pertension and depression (389). In a meta-analysis of eight observational studies which 
assessed the relationship between depression and adherence to antihypertensive medica-
tion, Eze-Nliam et al found that a positive association between depression and poor adher-
ence to antihypertensive medication. Additionally patients with both poor adherence and 
depression were more likely to have uncontrolled blood pressure in all the studies. However, 
the methodological differences observed between the studies prevented from establishing a 
conclusive association between both conditions (377). 
 
Some surveys revealed that patients receiving a high number of hypertensive medication 
were less likely to have controlled blood pressure (312, 322).  Hypertensive patients receiv-
ing more than two hypertensive drugs may have associated comorbidity and also higher 
blood pressure levels that make it difficult to achieve blood pressure targets. Poor adherence 
to greater number of antihypertensive medications could also explain the finding. Claxon et 
al in  a review of 76 studies using electronic monitoring to assess patient adherence to anti-
hypertensive medication found that the higher the number of drugs prescribed, the lower the 
adherence (390) Similarly in a meta-analysis of 51 studies of drug prescription for chronic 
diseases, Coleman et al found that patients are more adherent to one prescribed drug than 
two or more drugs (391). Dennison et al revealed that patients with few antihypertensive 
medications were more likely to have blood pressure below 140/90 mmHg (342). However, 
Hedblad et al did not observe an association between the number of hypertensive drugs and 
reductions in blood pressure levels (314). 
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Social and economic conditions 
Socio economic status is a complex concept which depends on the interaction of variables 
such as education, occupation, income, wealth and place of residence (392). These condi-
tions have been found as determinant of blood pressure control and hypertension-related 
morbidity. In an ecological study of 3.5 millions death occurred in Europe between 1990 and 
2000, Mackenbach et al pointed out that inequalities in all cause mortality rates, including 
hypertension, may be due  differences in access to health care and healthy habits across 
socio economic strata (393). From the NHANES, Fryar et al reported that there has been a 
reduction in the percentage of individuals with uncontrolled hypertension from 1999 to 2010. 
However, that reduction was less evident for lower income adults who had the highest per-
centage of individuals with uncontrolled hypertension (394). Of note, a consistent association 
between low socio economic status and stroke incidence has been observed (395). By com-
parison, Kagamimori et al showed that the effect of socio economic status on health out-
comes is less marked in Japan than in Western societies. They considered that the smaller 
socio economic differences across social strata could explain this finding in Japan (396).  
 
A high level of education was associated with better blood pressure control (292, 311, 313, 
321, 324, 384). In study conducted in 184 general practices with free access to care, 
Paulsen  et al identified that patients with less than 10 years education were less likely to 
achieve blood pressure control compared to those with higher levels of education (384). In 
the analysis of NHANES 1999-2004, Ostchega et al found that hypertensive patients with 
lower levels of education and in the lowest socio-economic category were less likely to have 
controlled blood pressure (313). Sandoval et al found that low education was associated with 
poor blood pressure control (292). Wong et al found that individuals with lower education 
background had 3.5 times higher life years lost than those with higher education. Ischemic 
heart disease was the most important contributor to this disparity accounting for 11.7% the 
total difference in years lost between both groups. Hypertension accounted for 3.5% of that 
difference (353). This association was found regardless of age and sex condition (311). 
However in a population survey taking in Cienfuegos (Cuba) Ordunez-Garcia et al did not 
find an association between education and blood pressure control. This observation may be 
attributed to universal access based on an extensive primary care services presented in that 
country (334). 
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Other social factors have also been associated with poor blood pressure control. In an 
analysis of 222 patients from outpatient clinics, Morgado et al identified that those living 
alone were less likely to have controlled blood pressure (375). In addition, those who were 
single were less likely to have controlled blood pressure than those who had a partner (384). 
In a longitudinal study of 6083 hypertensive patients aged 65 to 84 years, Chowdhury et al 
found that  those living in inner regional areas were more likely to have uncontrolled blood 
pressure than those living in major cities (397).  
 
Other individual aspects have also been associated with poor blood pressure control. Hyper-
tensive individuals unaware of a blood pressure target, with hypertension-related morbidity 
and with poor knowledge about hypertension could be more likely to have uncontrolled blood 
pressure. Personal perceptions about hypertension may also explain poor blood pressure 
control (322, 398-399). In a qualitative study, Ogedegbe et al found that hypertensive pa-
tients believed that antihypertensive medications can cure high blood pressure levels, anti-
hypertensive drugs can be stopped and these drugs are only needed to relief symptoms 
(400).   
 
2.2 Physician-related factors  
 
Physician performance is a key factor for the attainment of controlled hypertension (401). 
Physician communication skills, physician acknowledgment on the management of hyper-
tension and clinical inertia are part of relevant physician-related factors which have been 
directly associated with blood pressure control. 
Clinical inertia, the lack of treatment intensification and/or initiation when needed by patients 
with regard to blood pressure levels, has been considered one of the most common factors 
to prevent the achievement of better blood pressure control rates in primary care settings 
(402-403). The percentage of clinical visits in which physicians have not intensified the anti-
hypertensive treatment for hypertensive patients with high blood pressure levels may vary 
between 20% and 45% (402, 404-406). In an analysis of 169 patients receiving care from 
different providers, Hyman et al found that physician did not intensify treatment despite ob-
serving systolic blood pressure levels above 140 mmHg (401). Similarly Guthrie et al found 
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that in a range of 16%–30% consultations physicians did not intensify treatment. Additional-
ly, physician took decisions on changing treatment based on a higher target than that rec-
ommended in the guidelines (402). In an assessment of clinical records from 3742 treated in 
primary care, Viera et al documented that 53% of patients did not achieve blood pressure 
control despite being continually treated. Physicians intensified treatment only in 46% of the 
time even though blood pressure measurements were above the expected target (407).  
 
Intensification of treatment has been associated with better blood pressure control. Hicks et 
al reported that intensification of treatment had a positive effect on blood pressure control 
regardless of race/ethnicity (347). Physician may dismiss assessing patient adherence to 
medication to adjust antihypertensive treatment. In an analysis of pharmacy records from 
38327 hypertensive patients, Heisler et al demonstrated the frequency of intensifying treat-
ment was between 31% and 34% among hypertensive patients with moderate or poor adhe-
rence to antihypertensive medication (408). 
 
Clinical guidelines intend to assist physicians on antihypertensive therapeutic decisions. 
Some surveys have revealed that physicians neither used the guidelines as resource for 
prescribing antihypertensive drug therapy or considered the information contained within the 
guidelines as a useful source (409).  Physician criteria on commencing treatment, drug effi-
cacy and/or blood pressure targets may differ from the recommendations established in the 
guidelines (385, 405, 410-417). Physicians also argued that universal prescriptions may not 
apply to all range of hypertensive patients visiting primary care services and a one size fits 
all prescription may reduce medical autonomy (416, 418-421).  
 
Physician adherence to guidelines may however have been underestimated (422). There is 
no standard measurement to estimate the level of physician adherence to the former guide-
lines. Hence, the lack of standards makes it difficult to accurately estimate the level of 76es-
peccian adherence. (423-425). The assessment on how physicians used hypertension 
guidelines has not always used the recommendations established in the time-related guide-
line (426). The presence of other diseases may detract physicians from using the recom-
mendations established in the guidelines (405, 427). In fact, some reports showed that phy-
sicians are in favor of using guidelines for the management of hypertension (428-430). 
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Moreover, some physicians consider waiting to achieve the total drug effect before intensify-
ing antihypertensive treatment even observing high blood pressure levels in hypertensive 
patients (403). Some evidence also illustrated that physician knowledge on the management 
of hypertension is appropriate (403).  
 
During clinical visits, the instructions given to the patients directly influence patient adher-
ence to antihypertensive medication (431). For instance, through interviewing antihyperten-
sive patients Svensson, et al found that compliance with antihypertensive prescription was 
highly dependent on the patient-physician relationship (432). Qureshi et al conducted a clini-
cal trial in the community to assess the impact of a program which provides general 77es-
peccians with education about hypertension management and communication skills regard-
ing blood pressure control. They demonstrated that patients who received care from general 
practitioners allocated to an education program achieved lower blood pressure levels. Better 
physician communication skills, which resulted in more explanations about hypertension to 
the patient, was the most influential part of the program (433). In an observational study of 
2621 hypertensive patients being treated in primary care, Ferrari et al showed that the blood 
pressure target used for the management of each individual patient is highly dependent on 
physician criteria (420). In fact Banegas et al documented that physicians did not consider 
intensifying treatment when blood pressure levels are slightly above the blood pressure tar-
get (434).  
 
The effect of physician advice has also been recognised. In a survey of two hundred patients 
participating in a clinical trial, Jones et al reported that patients with a higher level of trust in 
their physician`s recommendations were more likely to participate in loss weight activities 
recommended for lowering blood pressure  (435). However the association between patient 
trust in physician and blood pressure has not been consistently documented. Durant et al 
reported that trust in a physician did not modify the probability of having controlled pressure 
among patients of white and black origin (358).   
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2.3 Health system factors 
 
Health system factors included those related to access to health care and the performance 
of health services. Access to services, which involve health care supply and service use, has 
been a determinant of blood pressure control (436). The impact of health services on blood 
pressure control has been observed worldwide regardless of health system organization. 
Duru et al assessed the impact of insurance on blood pressure control using data from the 
NHANES survey carried out between 1999 and 2002 (437). They found that hypertensive 
patients without insurance were less likely to have controlled blood pressure  than those with 
private health insurance, odds ratio (0.63 95% CI 0.44-0.92). In an independent analysis of 
NHANES III survey (1998-2004), Ostchega et al and He et al also reported that individuals 
with health insurance and with frequent health care visits had better blood pressure control 
compared to those without health coverage and fewer health care visits (313, 317). Durant et 
al additionally found that patients suffering from stroke and hypertension without insurance 
were less likely to have controlled blood pressure compared to those with insurance. The 
association was positive despite variations in medical supply present in the area (438). In 
analysis of civil participants in the Framingham cohort, Brooks et al found a similar associa-
tion (439). 
 
Similarly, improving access to health care by developing primary care services has resulted 
in a better blood pressure control (440-441). Sandoval et al reported an increase in blood 
pressure control rates among hypertensive patients with access to primary care centres after 
the implementation of program supported by local government (292). Souza et al reported a 
reduction in hospitalizations due primary care-sensitive cardiovascular conditions, which 
includes hypertension, associated with the introduction of Family Health Program in South-
ern Brazil (442). Ordunez-Garcia et al also reported higher blood pressure rates in a low-
income country with a well organized primary care compared to those rates observed in high 
income countries (334). Although a set of initiatives have led to a reduction in cardiovascular 
mortality in Finland, the first step of the program was the development of comprehensive 
primary health care (44). 
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However access to health services is not a sufficient condition to improve blood pressure 
control. The availability of antihypertensive medication affects the probability of having con-
trolled blood pressure. For instance, Cameron et at reported that the availability of medica-
tions for chronic conditions such as hypertension was lower in public health services than in 
private health services compared to the availability of medications for acute diseases. This 
gap was observed in low income and middle income countries (443). In an analysis of data 
from the third NHANES 1992-1994 survey, Hyman et al did not find an association between 
having insurance and having frequently visited a physician and increases in the probability of 
having controlled blood pressure (316). In a survey conducted among a working population 
in Japan, Tanaka et al observed that the percentage of hypertensive patients on treatment 
was 41% despite being periodically assessed by an employment medical advisor (444).  
 
Variations in the performance of services also affect the probability of having controlled 
blood pressure.  In an evaluation of 1100 federally funded health centre services in the USA, 
Lebrun et al reported that centres with high volume of patients, longer established funding 
and with more than 5% of patient involved in hypertension control programs not only had 
better blood pressure control rates but also less inequalities in their outcomes (445). By 
comparison in the UK, a country which has universal access to health care and a strong pri-
mary care system, Ashworth et al found that general practices located  in less deprived ar-
eas provides patients with better quality of care compared to those located in most deprived 
areas. The assessment of the performance was based on the QOF indicators which included 
blood pressure control rates (446). Hence, there is no standard strategy to organize health 
services to improve blood control. A diverse range of interventions has been postulated to 
improve the process of care offered to hypertensive patients in primary care settings, com-
munity services or outpatient clinics.  
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Strategies used to improve blood pressure control in primary care 
Multiple strategies have been used to improve blood pressure control in primary care set-
tings. The strategies are oriented to improve the performance of physicians, patient 80espe-
ciour and knowledge about hypertension and health services organization.  
Glynn et al carried out a systematic review of clinical trials evaluating at least one of the fol-
lowing interventions: 1) self-monitoring, 2) educational interventions directed at the patient, 
3) educational interventions directed at the health professional, 4) health professional (nurse 
or pharmacist) led care, (5) organisational interventions that aimed at improving the delivery 
of care and (6) appointment reminder systems. The authors included 72 clinical trials mainly 
conducted in primary care. Improvements in blood pressure control were largely attributed to 
regular follow-up of patients and an increase in the use of antihypertensive drugs. There was 
no conclusive evidence of the benefit of self-monitoring and appointment reminders (447). 
By contrast, Stéphane Rinfret et al attributed a significant increase in the proportion of pa-
tients with controlled hypertension to a multidisciplinary information technology–supported 
program. The program included both self-monitoring and a software warning the physician 
about the inadequate management of hypertensive patients (448).  
 
Clark et al examined the role of nurses in blood pressure control by analysing 32 random-
ised clinical trials (449). In these studies, the nurses supported the blood pressure control 
program by giving telephone monitoring, conducting community monitoring, prescribing anti-
hypertensive medication or leading the established program. The authors concluded that the 
higher reduction in blood pressure levels reported in nurse intervention groups may be ex-
plained by the use of a treatment algorithm. Regarding the clinical scenario in which those 
studies were conducted, a nurse prescribing antihypertensive drugs seems to be a potential 
intervention for improving blood pressure control in both primary care and community set-
tings.  
 
Similarly, Walsh et al evaluated 44 interventions which reported using quality improvement 
strategies to improve blood pressure control (450). These strategies included provider edu-
cation, provider reminders, facilitated relay of clinical information, patient education, self-
management, patient reminders, audit and feedback, team change or financial incentives. 
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Patients included in the intervention groups regardless of the type of strategy achieved 
higher reductions in blood pressure levels. None of the reported interventions was inde-
pendently associated with that reduction. Fernandez et al conducted a quasi-experimental 
study to assess the impact of physician education on the management of hypertension in 
five primary care centres. After the intervention patients assigned to intervention groups had 
a 92% increase in the odds of having controlled blood pressure (451).  
 
Schroeder et al assessed 38 studies which evaluated 58 interventions for improving adher-
ence to treatment in patients with high blood pressure (452). These interventions included 
simplification of drug regimens, patient education, patient motivation, support reminders and 
complex interventions. Adherence was mainly measured by electronic monitors. Improve-
ments in blood pressure control were only identified in seven studies. The authors concluded 
that reducing the number of antihypertensive drugs was the most significant intervention in 
improving adherence to medication though the impact on blood pressure control was un-
known.   
 
Team-based core has been one the strategies used to improve blood control in primary care 
settings. The team care made up of pharmacist nurses and physicians. In a meta-analysis of 
37 studies Carter et al showed that after involving team groups in the management of blood 
pressure, there has been a reduction in blood pressure levels (453). The impact of each 
member of the team varied between studies but was consistently. Thus, the associated odds 
ratio for the effect of nurses and pharmacists on the improvement of blood pressure control 
was 1.69 (95% CI 1.48 – 1.93) and 2.89 (95% 1.83 – 4.85) respectively. The function of 
these team members varies. Pharmacists both advise physicians on medication use and 
also provide life style recommendations to patients, while nurses gives lifestyle advice and 
education on self-management to patients (453). Walsh et al performed a systematic review 
of forty four studies evaluating quality improvement strategies for the improvement of blood 
pressure control. They found that those including team groups result in the highest reduction 
of blood pressure levels compared to other interventions (450).  
 
Community health workers (CHW), defined as those without formal health education, have 
been considered a strategy to improve access to health in community and rural areas. 
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Brownstein et al carried out a systematic review of fourteen studies including eight random-
ised clinical trials and six observational studies assessing the impact of community health 
workers in blood pressure control mainly in underserved communities with population be-
longing to minorities. The roles of CHW were to provide patients with health education; offer 
health services such making referrals, taking blood pressure or social support. Although the 
studies are not comparable, it seems that CHW result in improving on adherence to treat-
ment. (454). Jafar et al conducted a clinical trial that compared the effectiveness of CHW 
plus physicians to only physician for the management of hypertension in a community ser-
vices in Pakistan. Patients assigned to the group including CHW achieved an average 10.8 
mm Hg (95% CI 8.9 – 12.8 mm Hg) lower blood pressure than those who received care only 
by physicians (454). Farzadfar et al evaluated a national program for diabetes and blood 
pressure control base on CHW offering health care in a rural community in Iran. The pro-
gram led to significant improvements in diabetes control with less impact on blood pressure. 
However the study suggested the lack of standardised hypertension guidelines may reduce 
the impact of CHW (455). Tuner et al reported a positive effect on blood pressure reduction 
in an intervention that used a peer coach to call patients with uncontrolled hypertension 
(456). Jungling et al reported a positive impact of group visit in the management of blood 
pressure control in primary care (457).  
 
Home blood pressure monitoring (HBPM) has been identified as a strategy to improve blood 
pressure control. In a clinical trial conducted in primary care, Halme et al demonstrated that 
hypertensive patients who used an automatic device to measure blood pressure at home 
achieved significant reductions in systolic blood pressure of 7.8 mm Hg. The group under 
standard blood pressure who achieved a reduction of 4.5 mm Hg in systolic blood pressure 
but the difference between the baseline blood pressure levels and end blood pressure levels 
was not significant (458). The percentage of patients who achieved a blood pressure target 
of 140/85 mm Hg was higher in those using self-monitoring though that difference was ob-
served comparing only home blood pressure records. The percentage of patients with con-
trolled blood pressure was similar using proportions based on office measurements. They 
also reported that physicians intensified antihypertensive more frequently in patients who 
have home blood pressure records (458).  In a review of 38 studies, Argarwal et al found 
that using HBPM resulted in lower systolic blood pressure compared with control group. 
However there was a significant heterogeneity in the outcome and the studies were con-
ducted in different clinical settings (459).  
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The implementation of non-pharmacological interventions for the management of hyperten-
sion has led to improvements in blood pressure control. Kastarinen et al in a clinical trial car-
ried out in primary care settings found that providing advice on salt reduction, lowering 
weight, moderate alcohol consumption, exercise and quitting  smoking  led to reductions in 
blood pressure levels as low as with pharmacological interventions (460). Patients were 
given formal education about the mentioned factors by a physician; a nurse and a nutritionist 
over two years follow up. Similarly, in a clinical trial conducted in general practices Reid et al 
found that the introduction of lifestyle modification interventions in diet and exercise led to a 
reduction in antihypertensive medication (461). 
In a cross sectional study of 27 family practices, Putnam et al also identified that patients 
with diabetes and controlled hypertension were those that reported low salt consumption and 
higher adherence to medication (462). Churilla et al determined the prevalence of physical 
activity patterns between hypertensive and non-hypertensive patients using the 2007 Behav-
ioural Risk Factor Surveillance System (BRFSS) Survey. They found that hypertensive indi-
viduals were less active than non-hypertensive individuals (463) 
In the ENCORE trial hypertensive patients were recruited from the general community to 
assess the independent impact of the DASH diet on blood pressure (464). They found that 
differences in cultural patterns affected adherence to the interventions as African American 
participants were less likely to follow the recommendations compared to white participants 
(464). Some cultural patterns presented in the African-American population could affect ad-
herence to the diet. Historically, the African-American population had high consumption of 
salt and high-fat products and low consumption of vegetables (465-466). These diet patterns 
have been associated with familial habits and ancestral traditions (467-468). The diet has 
also been called soul food meaning a spiritual and satisfactory food among the African 
American population (469).   
 
 
 
 
 
 
 84 
 
2.4 Considerations that should be taken into account when inter-
preting studies assessing factors affecting blood pressure control 
 
The studies presented in the review are not completely comparable. Populations differ in 
age, race/ethnicity, social conditions and health care provision. For instance, hypertensive 
patients from South Africa are younger (mean age 52 years) (342) than those from  coun-
tries such France (mean age 60 years) (372). Race/ethnicity represent those of black, white 
or Hispanic origin in studies from US  (283) but individuals of Chinese, Malay and Indian 
origin in a study from Singapore (348). Whereas primary care is a public service with univer-
sal access in some European countries (349, 384), private and public health providers are 
responsible for primary care services in US (326). Differences in blood pressure control be-
tween public and private services have been reported. It seems that blood pressure control 
rates are higher in private services than that in public services (437).  
  
The studies used different methods to measure blood pressure such as the mercury sphyg-
momanometer and the Omron blood pressure monitor with a standard protocol. Ostchega et 
al comparing the blood pressure measurements obtaining from these methods in partici-
pants from a national survey. They used an Omron HEM–907XL device. They found a 
higher correlation for systolic blood pressure (0.94) and lower correlation for diastolic blood 
pressure (0.83) between both measurements. The levels reported by OMRON device were 
lower than those produced by the sphygmomanometer (470). That could influence the differ-
ences in blood pressure control rates between countries and also the reported associations.  
 
The associations between factors and blood pressure control have mainly derived from 
cross sectional studies conducted at population level or in primary care. Some considera-
tions may have been taken. Firstly although these studies give information about blood pres-
sure control across factor categories, they cannot assess the causal relationship between 
some factors and blood pressure control. The measurement of factors simultaneously with 
the outcome could overestimate the association between factors presented by the time the 
study was conducted. In contrast, the association between those factors with a time lag ef-
fect may be underestimated (471), Studies conducted in primary care could be affected by 
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selection bias. That is because those registered with or visited providers may not account for 
all hypertensive patients. They also may have particular conditions. Additionally in some 
studies patients and/or practices were recruited based on voluntary participation. Thirdly 
studies used a level of blood pressure measured at one occasion to define blood pressure 
control. One measure could not properly identify who has controlled blood pressure due to 
the individual variability in blood pressure (19).  
 
Populations differ in health system characteristics. Whereas in some countries primary care 
services are a universal service with free access (328, 334), in others primary care services 
are offered by both private and public providers (317, 342). Although blood pressure control 
rates are reported low in both scenarios, differences in blood pressure control between pub-
lic and private services have been reported. Studies seem to revel that blood pressure con-
trol rates are higher in private sectors (437).  
 
Summary 
The achievement of controlled blood pressure depends on the interaction between patient 
factors, physician factors and health system factors. Studies analysing the importance of 
each factor are mainly national surveys and cross sectional studies conducted at primary 
care settings. The associations between some factors and blood pressure control varied 
across the studies. Becoming older has been the most frequent and consistent factor asso-
ciated with poor blood pressure control. The relationship between sex and blood pressure 
control varied between studies and also has been contradictory. Although studies at popula-
tion level revealed that some race/ethnic groups such as black groups are less likely to have 
controlled blood pressure, this association have not been replicated in context with different 
social structure. There seems that factors different from race/ethnicity account for some of 
this association. Increases in BMI/overweight have been consistently associated with poor 
blood pressure control. The relationship between socio economic aspects and blood pres-
sure control varied across studies. However lower education levels have been more consis-
tently associated with poor blood pressure control.  
 
Patient adherence to recommendations for lowering blood pressure does not seem to be 
sufficient to achieve the expected efficacy of pharmacological interventions. For instance, up 
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to 50% of hypertensive patients who started taking antihypertensive medication stopped it 
over the first year of use. Patients with low adherence to antihypertensive medication are at 
higher risk of having hypertension-related cardiovascular diseases. Hence the benefit of us-
ing antihypertensive is lower than that observed in clinical trials may be due to non-
compliance with the medical indications. Moreover, patient adherence to pharmacological 
and non pharmacological interventions have not frequently assessed in the studies con-
ducted at population level or primary care services.  
 
Physician related factors have been assessed in observational studies aimed at assessing 
physician performance. They have not always being incorporated in the assessment of indi-
vidual factors. Inertial clinical, unaware of clinical recommendations, poor adherence to hy-
pertension guidelines and a low strength of the relationship between physician and patient 
have been associated with not to have controlled blood pressure. However, clinical inertia 
has consistently been found as an explanation of having uncontrolled hypertension. The 
association between other physician factors and blood pressure control varied across the 
studies.  
Health system factors refer to access to health services and the performance of service. 
Access to service may be the first step to improve blood pressure control. There is no one a 
consistent health system factor associated with blood pressure control. However it seems 
that offering regular visits to hypertensive patients, periodical physician education about hy-
pertension guidelines, provide patient with education about blood pressure and team man-
aged approaches are of more successful interventions to improve blood pressure control in 
primary care services.  
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Table 8   Characteristics of included studies reporting factors affecting blood pressure control  
Study  Type of 
study  
Setting  Sample 
sized 
method  
 
Blood 
pressure 
method 
Blood pres-
sure control 
rates 
Factors associated with blood pressure control 
Type of association  
Studies at population level Poor control  Good control  
Hyman et al 
(316) 
2001  
 
Cross sec-
tional  
NANHES  III 
US 
Population 
aged 25 
years and old 
Sample 
including 
oversam- 
pling for 
race/ethnic 
minorities  
Using mer-
cury sphyg-
momanome-
ter with stan-
dard protocol 
23% among 
treated  
Male  
Age 65 years and over  
Not visiting a physician  in 
the previous 12 months  
 
 
He J et al  
2002 (317) 
 
Cross sec-
tional survey  
NANHES  III 
US 
Population 
aged 18 
years and 
over  
National 
Population  
As ref 316 As ref 316   Mexican American origin  
Men  
Those aged 75 years and 
older 
 
Regular access  to health 
services/same provider  
Private insurance  
Having blood pressure 
measurement before six 
months 
Any modification of  lifestyle 
(Weight loss, sodium re-
duction or exercise) 
Former married 
 
  
 88 
 
Study  Type of 
study  
Setting  Sample 
sized 
method   
Blood 
pressure 
method 
Blood 
pressure 
control 
rates 
Type of association 
Poor control  Good control  
Gu et al 
(330) 
2002 
 
 
 
Cross sec-
tional survey  
China popu-
lation  Aged 
35 to 74 
years  
Stratified 
sampling  
Using mer-
cury sphyg-
momanome-
ter with stan-
dard protocol 
8.1% among 
all hyperten-
sive popula-
tion.  
Comparison frequencies  
Those between 35 and 44 
years  
 
Check non pharmacological 
interventions  
Cifkova et 
al(472) 
 
2004  
 
 
Four 
Cross sec-
tional surveys  
National 
survey  
Czech Re-
public 
Population 
aged 25 – 64 
years  
Randomly 
selected 
from the 
General 
Health In-
surance 
Company 
register 
Using mer-
cury sphyg-
momanome-
ter with stan-
dard protocol 
Increase 
from 3.9%  to 
17% in all 
hypertensive 
patients  
Increased 
13.2% to 
34.6% 
Among hy-
pertensive on 
treatment 
 Women  
Wang et al 
(318) 
2004 
 Cross sec-
tional survey  
(1992-1994)  
1998  
 
Population 
based China  
Aged 35 to 
59 years   
Subsample 
from na-
tional sur-
vey  
Using mer-
cury sphyg-
momanome-
ter with stan-
dard protocol 
6% con-
trolled 
among all 
hypertensive 
population 
Urban areas better than 
rural 
In Urban areas those aged 
35-39 years had lower 
blood pressure control 
rates. In rural areas older 
patients had lower blood 
pressure control rates. 
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Study  Type of 
study  
Setting  Sample 
sized 
method 
reported  
Blood 
pressure 
method 
Blood 
pressure 
control 
rates 
Type of association 
Poor control  Good control  
Agyemang et 
al (319) 
 
 
Prevalence 
study  
 
Ghana popu-
lation  
Random 
selection of 
residents in 
a village  
Omron 
M5-I monitor 
6.2% among 
those on 
treatment 
Age >= 50 years 
 
Being trader  
 
Agyemang et 
al (311) 
 
 
Cross sec-
tional study  
Population 
from South 
Amsterdam  
Random 
sample  
Omron M4 
device  
48.5% had 
systolic<140 
mm Hg 
among those 
on treatment  
For Dutch  race/ethnicity  
Over-
weight/obesity/abdominal 
obesity 
For African Surinamese  
Obesity/Abdominal obesity  
For Hindustani Surinamese  
Older age  
For Dutch race/ethnicity  
High education  
Physical activity  
For African Surinamese 
Female  
Family history of hyperten-
sion  
Ordunez-
Garcia et al 
(334) 
2006  
Survey  Population 
Cienfuegos 
(Cuba) 
Aged 15 – 74 
years 
Sample 
designed 
considering 
equal prob-
ability for all 
groups 
Using mer-
cury sphyg-
momanome-
ter with stan-
dard protocol 
65.3% 
among 
treated 
39.9% total 
population 
 Women  
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Study  Type of 
study  
Setting  Sample 
sized 
method   
Blood 
pressure 
method 
Blood 
pressure 
control 
rates 
Type of association  
Poor control  Good control  
De Macebo 
et al (343) 
2007 
Cross sec-
tional  
 
Population 
based Portu-
gal  
18 and 90 
years 
Multistage 
cluster 
sampling 
method 
OMRON M4-
1 sphygmo-
manometer 
11.2% 
among all 
hypertensive 
individuals 
 Women  
Being younger  
Lower  waist-hip ratio 
Ostchega et 
al (313) 
National sur-
vey  
2008  
Subsample 
from 
NHANES  
(Hyperten-
sive patients)  
Sample 
including 
oversam-
pling for 
race/ethnic 
minorities 
Using mer-
cury sphyg-
momanome-
ter with stan-
dard protocol 
NA  Women  
Diabetes  
Poverty income  
Old or very old patients  
Non-Hispanic blacks 
Fewer visits to doctor 
 
 
Gu et al  
2008  
(320) 
 
 
Cross sec-
tional  
National sur-
vey  
NANHES  
 
Subana- 
lysis of 
hyperten 
sive pa-
tients  
Using mer-
cury sphyg-
momanome-
ter with stan-
dard protocol 
Men 53.7%  
Women 
42.9% 
On treated 
Women  
Becoming older  
Non-Hispanic black  
Mexican American  
 
Victor et al 
(329) 
2008 
 
Cross sec-
tional 
Population 
based Dallas 
Aged 18 – 64 
years  
Sample 
population 
with over-
sampling 
for minori-
ties groups 
Electronic 
oscillometric 
monitor   
 
26.9% all 
hypertensive 
patients  
 Having a regular physician   
Being on treatment  
Perception on a good 
health  
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Study 
 
 
Type of 
study 
Setting Sample 
sized 
method  
Blood 
pressure 
method 
Blood 
pressure 
control 
rates 
Type of association  
Poor control  Good control  
Damasceno 
et al 2009 
(339) 
 
Cross sec-
tional  
Population  
Mozambique  
Aged 25 and 
64 years  
Sample 
based on 
census 
Semiauto-
matic 
sphygmoma-
nometer 
(Omron 3) 
3.1% all hy-
pertensive 
patients  
 Women 
Van Minh et 
al (282) 
2009 
Cross sec-
tional study  
 
Bangladesh, 
Indonesia, 
Vietnam, 
Thailand and 
India 
Aged 25 to 
64 years 
Surveil-
lance sys-
tem  
Not to men-
tion on 
sample size 
strategy  
Omron M3 5.4% all hy-
pertensive 
patients 
Become older 
High level of education  
Overweight  
 
Malthotra e 
al  2010 
(345) 
Cross sec-
tional  
Elderly par-
ticipants in 
national sur-
vey Singa-
pore  
Aged 60 
years and 
over  
Sampling 
from na-
tional regis-
ters  
Omron HEM-
780N 
24.1% all 
hypertensive 
patients  
Malay ethnic/race 
Men 
 
 
Ebrahimi et 
al  
(321) 
 
 
 
Cross sec-
tional  
2010 
 
National 
survey  
Iran  
Aged 15 to 
64 years 
Multistep 
cluster 
sampling  
Aneroid 
sphygmoma-
nometer 
34.5% 
among 
treated pa-
tients 
Men  
Increases in age 
Middle educated people  
Academic education  
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Study 
 
 
Type of 
study 
Setting Sample 
sized 
method  
Blood 
pressure 
method 
Blood 
pressure 
control 
rates 
Type of association  
Poor control  Good control  
Egan et al  
(283) 
Cross sec-
tional national 
survey  
2010 
US  
Population  
NANHES  
III 
Population 
aged 18 
years and 
old 
Sample in-
cluding over-
sampling for 
race/ethnic 
minorities  
50.1% 
among 
treated hy-
pertensive 
individuals 
Those age 18 to 39 years  
Those aged 60 years and 
older  
Those of Hispanic origin 
and black race/ethnicity 
 
Tian et al  
2011  (295) 
Survey  Urban popu-
lation China 
Three 
stage strati-
fied sample  
A standard-
ized 
mercuric-
column 
sphygmoma-
nometer 
3.7% all pa-
tients   
Becoming older 
Smoke  
 
 
Godet-
Mardirossian 
et al (312) 
Cross sec-
tional survey  
2012 
France popu-
lation  
Aged  
18 to 74 
years  
Multistep 
sample 
design  
OMRON M5-
I 
25.6% all 
hypertensive 
patients  
Men  
Become older  
Those with more than three 
antihypertensive medica-
tion  
 
Guessous et 
al (346)   
2012 
Cross sec-
tional  
Geneva  Represen-
tative strati-
fied sample   
Omron  
HEM-907 
60% among 
treated pa-
tients 
Male  
Sedentary 
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Study 
 
 
 
Type of 
study 
Setting Sample 
sized 
method  
Blood 
pressure 
method 
Blood 
pressure 
control 
rates 
Type of association 
Poor control  Good control  
Dzudie et al 
(290) 
2012 
Cross sec-
tional  
 
Cameron  
Urban areas 
Population 
aged 15 
years and 
over  
Sample 
size not to 
define  
Participates 
were in-
vited by 
social 
communi-
cation me-
dia  
Omron m3 
hem-7200-e  
24.6% 
among 
treated pa-
tients  
Male gender  
High BMI  
Physical inactivity  
Being from regions different 
from Centre and Littoral  
Prince et al  
(138) 
 
 
Cross sec-
tional survey  
2012 
Sample 
population  
aged 65 
years and 
over from 
Cuba, Do-
minican Re-
public, 
Puerto Rico, 
Peru, Vene-
zuela, Mex-
ico , Chin, 
India.  
Sample 
were taking 
from a de-
mentia 
survey 
Not reported  Puerto Rico 
58% 
Peru (71%/ 
in urban; 
84% in rural) 
Others be-
tween 22%-
39% among 
all hyperten-
sive patients  
 Lower blood pressure lev-
els observed in some  
populations were attributed 
to health care factors such 
as detection and blood 
pressure control 
  
 94 
 
 
Study  
 
 
 
Type of 
study  
Setting  Sample 
size 
method 
Blood 
pressure 
method 
Blood 
pressure 
rates 
Type of association  
Poor control  Good control 
Son et al  
2012 (336) 
 
 
Cross sec-
tional survey  
National 
population  
Vietnam  
Population 
aged 25 
years and 
over 
Stratified 
sample  
Omron de-
vice  
10% among 
treated pa-
tients  
 Women  
NA Not applied
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Studies at community services or ambulatory services  
 
 
Study  Type of 
study  
Setting  Sample 
sized 
method   
Blood 
pressure 
method 
Blood 
pressure 
control 
rates 
Type of association 
 
Poor control  
 
Good control 
Lloyd Jones 
et al (205) 
2000 
Cross sec-
tional  
Hypertensive 
patients 
Community 
Mean age 66 
years  
Population 
from the Fram-
ingham Heart 
study 
US 
 
Mercury 
sphygmoma-
nometer 
 
29.% all pa-
tients  
47.8% 
among 
treated pa-
tients 
Older age  
Left ventricular hypertro-
phy 
Obesity   
 
Westheim et 
al  
(315) 
2001 
 
 
Cross sec-
tional  
General prac-
tices  
Norway 
 
Hypertensive 
patients  
Aged 18 years 
and over  
Not reported  26% among 
treated pati-
etns  
Increasing body mass 
index 
Increasing age  
 
Knight et al  
2001(322) 
Cross sec-
tional  
Ambulatory 
services  
US 
 
Used registers 
from antihyper-
tensive patients 
Mean age 65 
years  
 
Not reported  39% among 
treated pa-
tients  
Older age 
Multi-antihypertensive 
prescription  
Poor patient knowledge 
about hypertension  
Reported antihypertensive 
side effects 
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Study 
 
 
Type of 
study 
Setting Sample 
sized 
method  
Blood 
pressure 
method 
Blood 
pressure 
control 
rates 
Type of association  
Poor control  Good control  
Fagard et al  
2002 (385) 
Cross sec-
tional  
 
General prac-
tices  
Belgium 
 
Physicians  
recruited hy-
pertensive men 
aged 55 years 
and over  
Omron 
hem-705  
31% all hy-
pertensive 
patients  
Hypertensive patients at 
higher cardiovascular risk 
 
Jackson  et 
al  
(379) 
2002 
Cross sec-
tional  
Managed 
care/Advance 
physician 
organizations 
 Not men-
tioned 
36% among 
treated pa-
tients  
Diabetes  
Ornstein et  
al (340) 
2004 
Cross sec-
tional  
General prac-
tices US  
 
Hypertensive 
patients aged 
18 years and 
over  
Not men-
tioned  
50% among 
all hyperten-
sive patients  
 Younger below 59 years 
Female 
Visit periodically same 
the practice  
Antihypertensive treat-
ment 
Majernick et 
al (332) 
Cross sec-
tional  
2004  
Family prac-
tices  US 
Hypertensive 
patients on 
treatment visit-
ing primary 
care centres 
Aged 18 years 
and over  
Mercury 
sphygmoma-
nometer  
 
38.8%  
among all 
hypertensive 
patients  
Higher Framingham score  
Female 
Diabetes  
Patient knowledge about 
hypertension  
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Study 
 
 
Type of 
study 
Setting Sample 
sized 
method  
Blood 
pressure 
method 
Blood 
pressure 
control 
rates 
Type of association  
Poor control  Good control  
Hicks  et al  
2004(347) 
Cross sec-
tional  
Community 
health ser-
vices  
 
Used registers 
from hyperten-
sive patients on 
treatment  
Mean age 61.3 
years  
Not reported  36.6% 
among all 
hypertensive 
patients  
Men  
Hispanic 
Patients without insurance  
Intensification of  ther-
apy  
Degli Espo-
siti et al  
2004 
(323) 
 
 
Longitudinal  General prac-
tices Italy  
Practices ac-
cepted invita-
tion recruited 
hypertensive 
patients  
Mean age 64 
years 
 
Automatic 
BP device 
39.5% 
among all 
patients  
Increasing patient age 
Increasing physician age 
Increase in the number of 
antihypertensives 
Previous myocardial in-
farction  
 
 
Mancia  et 
al(324)  
Longitudinal 
study  
 
2005  
Ambulatory 
clinic Italy  
Hypertensive 
patients col-
lected by open 
invitation  
Mean age 61 
years 
 
Omron 705 
CP 
37.5% 
among  all 
patients  
Becoming older  Management offered by 
cardiologist  
Use Monotherapy  
High education level 
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Study  
Type of 
study  
Setting Sample 
sized 
method 
Blood 
pressure 
method 
Blood 
pressure 
control 
rates 
Type of association  
Poor control  Good control  
Roux (372) 
2006 
 
Cross sec-
tional  
Primary care 
centres  
France 
Age 18 years 
an older  
Representative 
sample hyper-
tensive patients 
on treatment  
Mercury or 
aneroid 
sphygmoma-
nometer 
18% among 
all hyperten-
sive patients  
Male  
Increases in age 
Increases in weight  
Increases in heart rate 
Young age 
Female  
King et al  
(350) 
 
 
Cross sec-
tional  
General prac-
tices  
Not referred  
Mean age 55.4 
years 
Not men-
tioned  
Not reported  African American male 
Being from an urban set-
ting  
 
Abaci et al 
(325) 
2006 
Cross sec-
tional  
Primary care 
units Turkey  
Aged 18 years 
and over  
Hypertensive 
patients re-
cruited from 
primary care 
centres. Sam-
ple size was 
defined for 
each centre.  
Mercury 
sphygmoma-
nometer 
30.2% 
among hy-
pertensive 
patients on 
treatment 
Age >=65 years  
Diabetes  
BMI >25 kgr/m² 
Having a cardiovascular 
disease  
Smoking  
Hedblad et 
al (314) 
2006 
Cross sec-
tional  
2006  
Primary health 
care centres 
Skane Swe-
den  
 
Hypertensive 
patients 
Aged 39 years 
and over  
Not reported  22% among 
all hyperten-
sive patients  
Becoming older   
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Study 
 
 
 
 
Type of 
study 
Setting Sample 
sized 
method 
Blood 
pressure 
method 
Blood 
pressure 
control 
rates 
Type of association  
Poor control  Good control  
Senior et al  
2006 (386) 
Survey  General prac-
tices 
New Zeeland  
 
Hypertensive 
patients aged 
80 years and 
over  
Blood pres-
sure meas-
urement 
taken  from 
records 
Target 
140/85 
mmHg 
54% 
(<150/90 
mmHG) and 
31% 
(<149/85 
mmHG) 
 among 
treated hy-
pertensive 
patients 
 Stroke  
Heart  failure  
Hypercholesterolemia  
 
Dennison et 
al (342) 
2007  
 
Cross sec-
tional  
Public and 
private pri-
mary care 
services  
Cape Town 
(South Africa) 
 
 
Hypertensive 
patients of 
black origin  
aged 35 to 65 
years  
Omron M4 
device  
38% among  
all hyperten-
sive patients 
 Taking lower number of 
antihypertensive medi-
cations 
Women  
Higher adherence to 
antihypertensive medi-
cation  
Petrella et al   
2007 
(373) 
 
Longitudinal 
study  
Family prac-
tice clinics  
Canada 
Population 
selected from 
those regis-
tered in general 
practices  
Aged 18 years 
and over  
Aneroid de-
vices  
Mercury 
Sphygmo-
manometer 
Automated 
devices 
 
 
17.3% 
among 
treated pa-
tients  
Overweight patients  Older patients with dia-
betes 
People with two comor-
bidities 
Smokers 
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Study 
 
 
Type of 
study 
Setting Sample 
sized 
method 
Blood 
pressure 
method 
Blood 
pressure 
control 
rates 
Type of association  
Poor control  Good control  
Ma et al  
2008 (326) 
 
 
Cross sec-
tional  
Medical care 
US 
Hypertensive 
patients aged 
18 years and 
over  
Information 
from regis-
ters 
39% among 
treated pa-
tient visits  
Patients aged 75 years 
and older 
Hypertension related –
comorbidities 
 
 
Kim et al   
(344) 
2008 
 
 
Cross sec-
tional  
Primary care 
services  
Korea  
Hypertensive 
patients from 
practices ran-
domly selected  
Standard 
electronic  
sphygmoma-
nometer 
51%  among 
all hyperten-
sive  patients  
Male  
Cardiovascular comorbid-
ity  
Long duration of hyper-
tension  
Unhealthy life style  
 
Rosenberger 
et al  
(341) 
2008 
 
Cross sec-
tional 
 
General prac-
tices North 
Carolina  
Random charts 
from patients 
aged 21 to 84 
years  
Not reported  41% among 
all hyperten-
sive patients  
Being attended by one 
health provider  
Female  
Journath et 
al (333) 
2008 
 
Cross sec-
tional  
Swedish gen-
eral practice 
Hypertensive 
patients regis-
tered in general 
practices  
Mean age 64 
years 
Not  reported  30%  among 
treated hy-
pertensive 
patients 
Women   
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Study  
 
 
 
Type of study  Setting  Sample sized 
method  
Blood pres-
sure method 
Blood pres-
sure control 
rates 
Type of association  
Poor control  Good control  
Varis et al  
(473) 
2009  
Cross sec-
tional  
General prac-
tices  
Finland 
Hypertensive 
patients aged 
18 years and 
over  
Mercury 
sphygmoma-
nometer 
24% all hy-
pertensive 
patients on 
target 
(140/85 mm 
Hg) 
 Being prescribed two or 
more antihypertensive 
drugs 
Buckely et al 
2009 
(380) 
Cross sec-
tional  
Ireland pri-
mary care 
practices 
Hypertensive 
patients on 
treatment  
Mean age 64.7 
years 
Blood pres-
sure records 
from regis-
ters  
48.6% 
among all 
hypertensive 
patients 
without dia-
betes  
Diabetic patients  
Tan et al 
(348) 
2009 
Cross sec-
tional  
Primary care 
services 
Singapore 
Hypertensive 
patients  
Mean age 60 
years  
Omron hem- 
705cp 
37.7% 
among all 
hypertensive 
patients  
Male   
Filippi et al 
(474)  
2009 
Retrospective 
survey  
Controlled  
Italian general 
practice  
Voluntary 
participation  
Hypertensive 
patients  
Mean age 63.5 
years  
Automatic 
BP device 
(Dinamap) 
28% among 
all hyperten-
sive patients 
Low rate patient atten-
dance  
Under-recording blood 
pressure  
 
Ohta et al 
(475) 
2009 
Longitudinal 
study  
54% 
Japan  
Hospital clinic  
Hypertensive 
patients  
Mean 68 years  
Mercury 
sphygmoma-
nometer 
52% and 
68.1% 
among 
younger and 
older  hyper-
tensive pa-
tient 101es-
pecttively 
 Increases in  antihyper-
tensive medication  
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Study  
 
 
 
Type of study  
 
Setting  
Sample sized 
method 
Blood pres-
sure method 
Blood pres-
sure control 
rates 
Type of association  
Poor control  Good control  
Saleheen et 
al (327) 
2010 
Cross sec-
tional  
Pakistan  
Primary care 
health centres 
 
 
Hypertensive 
patients  
Mean age 59 
years  
Not reported  6.4% among 
those on 
treatment  
Become older 
Hypercholesterolemia  
Physical inactivity  
 
Skliros et al  
et al (291) 
Cross sec-
tional  
2012 
Primary 
Health Care  
Nemea Health 
program  
Greek 
Sample size 
defined based 
on census  
Older hyper-
tensive patients  
Mercury 
sphygmoma-
nometer 
49% among 
hypertensive 
patients on 
treatment 
Heavy drinking   
Qvarnstrom 
et al 
2011(328) 
Cross sec-
tional 
2011 
Primary care 
centres 
Swedish  
Hypertensive 
patients aged 
30 years and 
older  
Not reported  27% among 
all hyperten-
sive patients 
Women at older age  Women at younger age 
Brenner et al  
2011 
(286) 
 
 
Cross sec-
tional 
Survey   
Swiss  
General prac-
tice  
Hypertensive 
patients aged 
20 years and 
over 
Practice ran-
domly selected  
 
Not reported  56.9% all  
hypertensive 
patients 
Diabetes 
Nephropathy 
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Study  
 
 
 
Type of study  Setting  Sample sized 
method  
Blood pres-
sure method  
Blood pres-
sure control 
rates  
Type of association  
Poor control  Good control  
Paulsen et al 
(349) 
2011 
Cross sec-
tional  
 
Denmark 
Primary care 
Hypertensive 
patients invited 
to participate  
Mean age 65.9 
years  
Not reported 29.1% 
among all 
hypertensive 
patients  
Diabetes  
Men  
Patients with other car-
diovascular comorbidity  
Listerri et al  
2011 
(381) 
 
 
Cross sec-
tional  
Women  
Primary care 
settings 
Spain  
Hypertensive 
patients  
Sample size 
calculated 
based on heart 
failure preva-
lence  
Mean age 65 
years  
Mercury-
based or 
aneroid 
sphygmoma-
nometer 
29% among 
all hyperten-
sive patients  
Patients being diagnosed 
with hypertension recently 
High cholesterol  
Monotherapy 
HbA1c  
 
Al Saadi 
2011(382) 
Cross sec-
tional  
Primary care 
services  
Oman  
Hypertensive 
patients  
Aged 18 years 
and over  
Not reported  39% among 
all hyperten-
sive patients 
Diabetes  
Renal disease 
 
Labeit  et al 
(287) 
2012 
Cross sec-
tional  
 
Germany 
Primary care 
Services  
Hypertensive 
patients Aged 
18 years and 
old from repre-
sentative pri-
mary care ser-
vices  
Sphygmo-
manometer 
or 
Automated 
validated 
devices.  
20.3% 
among 
treated hy-
pertensive 
patients  
Increasing age 
Obesity 
Coronary heart disease 
Antihypertensive medi-
cation  
Women 
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Study  
 
 
 
Type of study Setting Sample sized 
method 
Blood pres-
sure method  
Blood pres-
sure control 
rates 
Type of association 
Poor control  Good control  
Paulsen et al 
(383) 
2012 
Longitudinal 
study  
Denmark  
General prac-
tices  
Hypertensive 
patients  
Aged between 
25 and 80 
years  
Mercury 
sphygmoma-
nometer or 
home blood 
pressure 
measure-
ment  
33.2% 
among pa-
tients on 
treatment  
Those with diabetes or 
those with diabetes plus 
other cardiovascular dis-
eases 
 
Paulsen et al  
(384) 
2012 
Cross sec-
tional  
Denmark 
General prac-
tices  
Hypertensive 
patients  
Mean age 65.9 
years 
 
Mercury 
sphygmoma-
nometer 
29.1% 
among all 
hypertensive 
patients   
Diabetes  For patients aged 65 
years and over: being 
married/cohabiting 
For patients aged below 
65 years: 
High level of education  
For all presence of car-
diovascular disease 
 Sandonval  
et al 2012 
(292) 
 
 
Cross sec-
tional  
Primary care 
centres  
Chile  
Hypertensive 
patients aged 
20 years and 
over 
 
Multicenter 
cross-sectional 
 
Systematically 
randomized 
sample 
Mercury 
sphygmoma-
nometers 
59.7% 
among all 
hypertensive 
patients 
Diabetes 
 Obesity  
High cholesterol levels  
Smoking  
Presence of stroke, 
heart failure and/or is-
chaemic heart disease 
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Study  
 
 
Type of study  Setting  Sample sized 
method 
Blood pres-
sure method  
Blood pres-
sure control 
rates 
Type of association  
Poor control  Good control  
 
Schaffer et 
al  
2012 
(285) 
 
Cross sec-
tional  
Primary care 
practices  
Swiss  
Hypertensive 
patients aged 
18 years and 
old 
Auscultatory 
or Oscillatory 
method 
54% among 
all hyperten-
sive patients 
Diabetes  
Chronic renal disease  
 
 
Suarez et al  
(374) 
2013 
Longitudinal 
retrospective 
study  
General prac-
tices  
Spain 
Hypertensive 
patients aged 
18 years and 
over  
Aneroid or 
mercury 
sphygmoma-
nometer or a 
validated 
automatic 
device 
NA  Weight gain  
High baseline LDL choles-
terol  
No reduction in fasting 
glucose 
 
No smoking  
Absence of diabetes 
Reduction in cholesterol  
Low baseline cholesterol 
No weight gain  
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Table 9 Factors associated with blood pressure control  
Factors  Good control  Poor control 
Patients factors Reference  Reference 
Age   
Become older  or  
Age >65 years  
(373) (18, 205, 282-
283, 287, 295, 
311-328) 
Younger age (340, 343) (283, 318, 328-
330) 
Ethnicity   
Black  
 
 (283, 313, 329, 
347, 351-352) 
Mexican American   (283, 317, 347) 
Malay ethnicity   (345) 
Sex   
Women  (287, 311, 334, 
336-343) 
(205, 313, 315, 
320, 331-334) 
Men   (290, 312, 316-
317, 344-350) 
Presence of comorbidity    
Obesity  Higher BMI/Overweight  
 
 (205, 282, 287, 
290, 292, 311, 
315, 325, 370-
374) 
Low waist hip ratio (343)  
Presence of other cardiovascular 
comorbidity (Diabetes, left ventricu-
lar hypertrophy, hypercholes-
terolemia) 
(287, 292, 344, 
349, 373, 384-386) 
 
(205, 285-286, 
292, 313, 323, 
325-327, 332, 
344, 349, 372, 
374-384) 
Consumption of other medications  (476) 
The severity of  hypertension  (385) 
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Factors  Good control  Poor control 
Long duration of hypertension   (344) 
Family history of hypertension  (311)  
Being diagnosed recently   (381) 
Multiple antihypertensive medica-
tion  
 (312, 322) 
Few antihypertensive drugs  (342)  
Life style    
Smoking  (295, 369) 
Not smoking (374)  
Diet Lower salt consumption  (317)  
Doing physical activity  (311, 317)   
Unhealthy life style (Physical inac-
tivity) 
 (290, 327, 344, 
346) 
Weight loss  (317)  
Higher adherence to antihyperten-
sive medication  
(342)  
Heavy physical work   (477) 
Heavy drinking   (291) 
Misunderstood prescription   (478) 
Being on antihypertensive  treat-
ment  
(287, 340, 473)  
Socio economic conditions    
Living alone   (375, 479) 
Lack of social support  (479) 
Being married/cohabiting  (384)  
High level of education  (292, 311, 313, 
321, 324, 384) 
 
Being trader (319)  
Poverty income  (313) 
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Factors  Good control  Poor control 
Perception of a good health  (329)  
Poor knowledge about hyperten-
sion  
 (322, 398) 
Physician factors   
Intensification of therapy  (475) (347) 
Clinical inertia   (359, 402, 408, 
480-483) 
Poor adherence to guidelines   (327, 405-406, 
413, 415, 484) 
Lack of continuing education  for 
physician  
 (340, 485) 
Continuing education for physician  (485-486)  
Increasing physician age   (323) 
Health system factors     
Having good access  (317)  
Not visiting regularly a physician   (313, 316, 474) 
Having a regular clinical visit  (317, 329, 340)  
Type of health plan 
Not having an insurance  
(317) (347) 
Being attended by one provider   (341) 
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Key points 
 The percentage of hypertensive individuals who achieved a blood pressure 
level below 140/90 mm Hg is below 50% worldwide 
 The management of hypertensive patients mainly relies on primary care ser-
vices. 
 Within patients receiving care in well developed primary care services  the 
percentages of hypertensive of patients who achieved a target of 140/90 
mmHg ranged from 25% to 42%.  
 In primary care settings, the achievement of a target of 140/90 mmHg de-
pends on individual factors, physician factors and health system factors.  
 The most frequent individual factors are age, race/ethnicity, BMI, adherence 
to pharmacological and non-pharmacological interventions and social condi-
tions.  
 The physician-related factors are mainly related to inertia clinical, physician 
knowledge about the management of hypertension and physician communi-
cation skills. 
 The health system factors include access to health care and performance of 
services.  
 Patient attending regularly health care services seem to have better blood 
pressure control  
 Multiple initiatives have been proposed and implemented in primary care ser-
vices to improve blood pressure control in primary care.  
 Among these initiatives the team based management approach seems to 
produce the better improvement on blood pressure control  
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Chapter 3 Epidemiology of  hypertension in 
England  
 
3.1 General trends  
In England the prevalence of raised blood pressure is assessed through the Health Survey 
for England (HSE) (487). The survey includes individuals over 16 years sampled from the 
general population living in a private house. Since 2003, the survey has defined a hyperten-
sive individual as one who meets at least one the follow criteria: a) having systolic blood 
pressure equal or above 140mm Hg and/or diastolic blood pressure equal or above 90 mm 
Hg with or without taking antihypertensive medication; b) taking medicaments for hyperten-
sion regardless of blood pressure levels. The measurement of blood pressure was taken 
using Omron monitor. Since 2003 the protocol for measuring blood pressure has not been 
changed. To assess blood pressure control four categories of patients have been defined 
(Box 2). 
  
The prevalence of hypertension has slightly changed over the last seven years. The preva-
lence was 30.6% in 2003 and 30.2% in 2010 among those aged 16 years and over (284, 
487). Prevalence increases with age and the highest rates are in those over 55 years. Over-
all, the prevalence is higher in men than women across all age categories. In 2006, mean 
blood pressures were 131.4/74.5 mmHg and 125.7/73.3 mmHg for men and women respec-
tively (488).  
 
Differences in blood pressure levels between racial/ethnic groups in the UK population have 
been reported. In a systematic review of 14 studies conducted between 1966 and 2002, 
Agyemang et al reported that mean systolic and diastolic blood pressure was higher in men 
and women of African descendent compared to those of white origin among population living 
in UK. Compared to white population, the African population had higher prevalence of hyper-
tension (489). Similarly in the analysis of Health Survey for England between 1991 and 
1996, Primatesta et al found that individuals of black origin had higher blood pressure levels 
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than those of white origin among those aged 40 years and over (490). Using data from peo-
ple resident in the West Midlands, Lane et al found that participants of black origin had 
higher prevalence of hypertension than those of Caucasian or South Asian origin (491).  By 
contrast, individuals of South Asian origin tend to have lower blood pressure levels than their 
white counterpart (90).  
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Box 2 Classification of individuals by blood pressure levels in Health Survey 
for England 
Category  Definition  
Normotensive untreated  Systolic blood pressure<140 mmHg and Diastolic blood pres-
sure <90 mmHg, not currently taking medication specifically 
prescribed to treat high blood pressure  
Hypertensive controlled  Systolic blood pressure<140 mmHg and Diastolic blood pres-
sure <90 mmHg, currently taking medication specifically pre-
scribed to treat high blood pressure 
Hypertensive uncontrolled  Systolic blood pressure>=140 mmHg and Diastolic blood pres-
sure >=90 mmHg, currently taking medication specifically pre-
scribed to treat high blood pressure 
Hypertensive untreated  
 
Systolic blood pressure>=140 mmHg and Diastolic blood pres-
sure >=90 mmHg, not currently taking medication specifically 
prescribed to treat high blood pressure 
    Source (487) 
 
3.2 Blood pressure control in England  
 
In England the percentage of hypertensive patients with blood pressure below 140/90 mm 
Hg has increased between 2003 and 2010. An opposite trend has been observed in the per-
centage of untreated patients over the same period (487, 492). In 2010 among those classi-
fied as hypertensive individuals (30.2%), 10% had controlled hypertension, 7.1% had uncon-
trolled hypertension and 12.4% were not being given antihypertensive treatment (487) (Ta-
ble 10).  
 
According to the last published national survey, the proportion of hypertensive patients with 
blood pressure below or at 140/90 mm Hg was 28% in 2006. Among those on antihyperten-
sive treatment the proportion of patients with controlled hypertension rose from 46% in 2003 
to 52% in 2006 (284).  In 2009 that proportion was 58% for men and 50% for women includ-
ing only those aged 35 years and over (493). A sub analysis of the surveys carried out be-
tween 2005 and 2007 revealed that the percentage of hypertensive people on treatment 
varied across the country. Hypertensive patients living in London suffering with others co-
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morbidities are more likely to be on treatment than those living in the rest of the country 
(494).                 
The 2006 survey has not produced blood pressure control rates by ethnic groups or social 
strata (284). In an analysis of 1999 to 2004 Healh Surveys for England, Nazroo did not find 
significant differences in blood pressure control rates between hypertensive individuals be-
long to ethnic minorities (Irish,   Caribbean, Indian, Pakistani, Bangladeshi or Chinese) and 
those of white origin. Caribbean patients were more likely to have controlled blood pressure 
(495). The authors commented that the low response rate found in ethnic minorities may 
bias the results. Other reports have shown that African hypertensive patients were less likely 
to have their blood pressure controlled (496-497). Reductions in ethnic disparities of blood 
pressure control have been published though using a higher target of 159/90 mm Hg (498). 
 
Table 10 Trends in hypertension prevalence and control. 2003 -2010 England  
 
Source HSE  (492) 
Definition of clinical hypertension  
The definitions of hypertension for clinical assessment in primary care are established by 
NICE (Table 11). The definition has been changed mainly due to variation in hypertension 
categories and the methods recommended for the measurement of blood pressure. However 
the level equal to or above 140/90 mm Hg remains as the level used for defining hyperten-
sion in the last clinical guideline (144, 499). The recommendations applied to adults aged 18 
years and over of all patients regardless of race/ethnic origin and sex.  
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Table 11 Classification of blood pressure levels in England hypertension 
guidelines 
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3.3 The blood pressure targets for the management 
of hypertension  
 
The blood pressure targets for the management of hypertensive patients have been estab-
lished in national guidelines since 1993 (Table 12). Blood pressure targets are established 
based on the initial blood pressure and the individual cardiovascular risk assessment. There 
has been a reduction in the level of blood pressure target particularly for those at a higher 
cardiovascular risk. The following section describes the background used to establish the 
recommendations on blood pressure targets in the former guidelines. The review mainly is 
focused on the guidelines orienting the management of hypertensive patients without addi-
tional cardiovascular comorbidity.  
 
3.3.1 The assessment of cardiovascular risk 
 
Current guidelines advised on assessing the absolute cardiovascular risk of cardiovascular 
of the hypertensive patients without cardiovascular complications or target organ damage. 
The first step is to evaluate whether or not the patient has another established cardiovascu-
lar disease. The second is to determine if there are signs of hypertensive damage to target 
organs such as heart, kidneys or retina. Then the assessment of the probability of having a 
cardiovascular event over a long term period usually 10 years is indicated.  The 1999 BHS 
guidelines recommended assessing the risk of coronary heart disease (CHD) based on the 
Framingham risk function. Then patients are classified into a high, middle and low cardio-
vascular risk category dependent upon a score of >= 30%, >= 15% or <15% in the Framing-
ham risk scale respectively. 
 
The 2004 BHS hypertension guidelines and the 2004 hypertension NICE guidelines encour-
aged physicians to calculate the absolute risk of cardiovascular disease (CVD) rather than 
the risk of CHD (174). The change is based on the need for estimating as much as possible 
the total hypertension-related cardiovascular risk present in each hypertensive patient. The 
interventions should aim at preventing hypertensive patients from having any hypertension-
 116 
 
related cardiovascular event not only one in particular. The assessment of the CVD risk was 
again based on the Framingham risk function. A modification is introduced for the assess-
ment of age-related risk. Patients aged 50 years and below were considered as having the 
risk of those aged 49 years and those aged 60 years and over are considering as having the 
risk of those aged 69 years. This modification intends to correct the underestimation of the 
risk in patients at extreme ages, younger and older. Patients with a Framingham risk score 
>=20% were classified as those at high cardiovascular risk.  
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Table 12 Blood pressure targets recommended in England hypertension guidelines between 1999 and 2011 
 1999 BHS 
(500) 
2004 BHS 
(174) 
2004 NICE  
(501) 
2011 NICE 
 (144) 
Patients at low and middle cardiovascular risk  <140/85 mmHg <140/85 mmHg <=140/90 mmHg <140/90 mmHg‡ 
Patients > 80 years 
<150/90 mmHg¥ 
Patients at higher cardiovascular risk  <140/80₁ mmHg <= 130/80₂ mmHg See section 3.3.3 See section 3.3.3 
‡ Clinic blood pressure measurement. Below 135/85 mm Hg using ABPM or HBPM  
¥ Clinic blood pressure measurement. Below 145/85 mm Hg using ABPM or HBPM 
₁Referred to diabetic patients 
₂Referred to patients with diabetes, renal impairment or established cardiovascular diseases 
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The 2011 NICE hypertension guidelines discouraged physicians to use the Framingham risk 
function as the standard score to assess cardiovascular risk (144). That is because the 
Framingham score has the potential to overestimate the cardiovascular risk in UK population 
(146). However the use of Framingham score is upon physician criteria in that the guidelines 
provide recommendations on interpreting the Framingham score in UK population. There are 
also other scores to assess the risk of cardiovascular diseases such as QRISK and AS-
SIGN. However, the NICE guidelines advised on the need for validating these scores. The 
QRISK score has undergone additional validation. Because it is derived from UK data (unlike 
Framingham), it is being used much widely for the measurement of CVD risk in UK primary 
care. The assessment of cardiovascular risk aims to determine the therapeutic interventions 
and blood pressure targets more suitable for each individual (144, 174, 499). The threshold 
to which blood pressure should be lowered is based on the following criteria:  
 
3.3.2 Patients at low and middle cardiovascular risk  
 
The 1999 and 2004 BHS guidelines advised on achieving a level of blood pressure below 
140/85 mm Hg in hypertensive patients without diabetes (174, 502). The recommendation 
required the achievement of both systolic blood pressure below 140 mmHg and diastolic 
blood pressure below 90 mmHg to define the control of blood pressure. The diastolic blood 
pressure target is mainly based on the findings reported in the HOT clinical trial (185). The 
study found that there were no differences in cardiovascular mortality between patients 
achieved diastolic blood pressure below 90 mmHg and those achieved diastolic blood pres-
sure below 85 mm Hg or below 80 mmHg. 93% of the patients achieved diastolic blood 
pressure below 90 mm Hg (185).  The systolic blood pressure target was based on the re-
sults from the VALUE trial (242) and the ASCOTT-LLA trial (503). Both trials reported that 
more than 80% of patients achieved systolic blood pressure below 140 mm Hg. In these 
studies hypertensive patients were mainly at high cardiovascular risk.  
 
The 2004 NICE guidelines recommend a target of or below  140/90 mmHg for all hyperten-
sive patients who are at middle or low cardiovascular risk (501). The target is recommended 
for all hypertensive patients regardless of age, sex and ethnicity. The target is supported by 
the following considerations. The proportion of patients who achieved blood pressure targets 
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ranged from 21% to 80% in the 24 clinical trials referred in the guideline. These trials used 
different blood pressure targets and some of them assessed only the achievement of a dia-
stolic blood pressure target (178, 185, 228-229, 254-255, 504-509). The lack of significant 
differences in cardiovascular mortality between patients randomised to intensive blood pres-
sure control and those to standard blood pressure control. Finally, the statement is mainly 
based on the HOT clinical trial (185). None of the clinical trials aimed to test the 140/90 
mmHg target against other blood pressure target.   
 
The 2011 NICE hypertension guidelines advocate a target blood pressure below 140/90 mm 
Hg for the hypertensive patients aged below 80 years and at low or middle cardiovascular 
risk. This level is the measurement of blood pressure taking in clinical settings. This blood 
pressure level corresponds to a target of 135/85 mm Hg when blood pressure is measured 
by using ABPM or HBPM. The recommendation is grounded in a review of fifteen studies 
(142, 197-198, 200, 218-219, 234, 510-525). The studies are two meta-analysis (142, 524), 
one systematic review (525), six clinical trials (197-198, 200, 510-512), five post hoc analy-
ses (176, 218, 245, 258, 526) and one observational study (259). None of the studies aim to 
compare the 140/90 mmHg blood pressure target with other blood pressure target. The two 
meta-analysis concur on the benefit of reducing systolic and diastolic blood pressure regard-
less of patient age (142, 524) The systematic review assessed the reduction in cardiovascu-
lar risk in hypertensive patients but not the association with lower blood pressure targets 
(525). The six clinical trials differ in the follow up period and patients characteristics. Two 
trials do not have power to detect differences between intensive and standard target (198, 
200). Two trials report a follow up period less than two years (510-511) and one does only 
24 weeks (512). There is no level proposed as a blood pressure target in any of the trials. 
The five post hoc studies agreed on the significant impact of achieving blood pressure levels 
below 140/90 mm Hg. However three of them also report a high incidence of mortality in 
hypertensive patients with coronary disease when they achieved blood pressure levels be-
low 65 mmHg diastolic blood pressure (176, 245, 258). The authors of the guideline con-
cluded that the available evidence cannot prove the use of specific threshold as a blood 
pressure target. Hence they recommend preserving the target established in the 2004 hyper-
tension guidelines.  
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3.3.3 Targets for specific groups   
The 1999 and 2004 BHS guidelines did not establish a specific blood pressure target for 
elderly patients; it did highlight the lack of evidence about prescribing antihypertensive medi-
cation for those with systolic blood pressure levels between 140-150 mmHg and diastolic 
blood pressure below 90 mmHg. For diabetic patients and patients with renal disease a 
blood pressure level less than 130/80 mmHg is the recommended target (174, 502). 
 
The hypertension NICE guidelines do not include recommendations for patients with diabe-
tes or renal diseases because a disease-related guideline is produced for these conditions. 
The 2008 NICE guidelines for diabetes establishes a target of blood pressure below 140/80 
mmHg for all diabetic patients and a target of blood pressure below 130/80 mmHg for those 
at particular risk for example patients with albuminuria (225). The 2008 NICE guideline es-
tablishes a blood pressure target below 140/90 mm Hg with systolic blood pressure between 
120-139 mm Hg for hypertensive patients with chronic kidney disease (CKD). For hyperten-
sive patients with CKD and other conditions such as diabetes a blood pressure target of sys-
tolic blood pressure between 120/129 mmHg and diastolic blood pressure below 80 mmHg 
is recommended (226).  
 
The 2011 hypertension NICE guidelines also added a new blood pressure target for hyper-
tensive patients aged 80 years and over. The guideline recommends a blood pressure target 
below 150/90 mm Hg. The recommendation is mainly based on the meta-analysis of eight 
trials conducted by Bejan-Angoulvant et al (527). The meta-analysis revealed that hyperten-
sive patients with mean age of 83 years on antihypertensive treatment had a higher reduc-
tion in the risk of stroke, heart failure and cardiovascular events compare to those without 
treatment. The finding was observed in the least and lowest blood pressure levels achieved 
by the patients on treatment. However there was not reduction in all cause mortality. That 
may due to differences in patient characteristic between studies producing heterogeneity in 
this outcome. Hence this variability may detract from establishing a conclusive statement 
about the benefit of achieving a blood pressure below 150/90 mmHg.  
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The assessment of blood pressure control in primary care 
Since 2004 the assessment of blood pressure control in primary care in England has been 
based on the Quality and Outcome Framework (OQF). The description of the QOF is pre-
sented in the section 4.4. For hypertension the percentage of patients with blood pressure 
equal to or less than 150/90 mmHg is the criterion of performance (528). The criteria used to 
select the threshold were not well supported in the guidance. However this level was the 
audit standard recommended by the BHS in 1999 (174).  
 
Comparisons of performance between general practices are based on the achievement of 
the QOF indicators. According to Ashworth et al, the blood pressure control has improved 
across all general practices after the introduction of QOF (498). Moreover there has been 
reduction in disparities in blood pressure control between general practices. The last report 
of QOF indicators also showed that nearly 98% of general practices achieved the indicator in 
2012 (529) .  
 
3.4 Factors affecting blood pressure control: evi-
dence from studies carried out in England 
 
In England, associations between different factors and blood pressure control have been 
quantified. For instance adherence to medication may vary over the time. In a study includ-
ing 37643 hypertensive patients, Jones et al found that for patients who were prescribed with 
a new antihypertensive drug, 50% of the initial prescriptions had been modified or discontin-
ued after six months (530). In an analysis of medical records from 21024 hypertensive pa-
tients, Walley et al identified that the rate of using the same first line antihypertensive medi-
cation was 69% in the first year (531). Using information from 109454 hypertensive patients 
registered with the UK General Practice Research Database (GPRD), Burke et al identified 
that the rate of antihypertensive drug discontinuation was 20% and 28.5% over six months 
and one year follow-up period respectively (532). 
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The relevance of sex, age and race/ethnic in blood pressure control has been assessed n 
different studies conducted in general practices. In a study carried out in 16 general prac-
tices located in Wandsworth, London, Millett et al identified that hypertensive patients of 
black origin were less likely to have controlled blood pressure compared to those of white 
origin (496). Similarly, in a study conducted in Lambeth, London, Schofield et al reported that 
hypertensive patients of black origin were less likely to have controlled blood pressure com-
pared to those of white origin (497). In analysis of 41250 patients registered with general 
practices in West Midlands (UK), Sheppard et al did not find differences in antihypertensive 
prescription between sex. They also identified that the percentage of patients who received 
antihypertensive medication increased with age (533). In a study of 4195 hypertensive pa-
tients, Tabenkin et al revealed that there were no differences in the management of hyper-
tension between the sexes (534). In a cross-sectional study conducted in 148 general prac-
tices, Mathur et al identified that hypertensive patients of South Asian origin were more likely 
to have controlled blood pressure compare to those of white origin (535). They also found 
that hypertensive patients with an additional cardiovascular comorbidity were more likely to 
have controlled blood pressure (535). 
 
Inister et al. performed an analysis of 536 hypertensive patients being treated in eight gen-
eral practices to assess the relative importance of patient-factors, physician-factors and ser-
vice performance in blood pressure control (536). They found that being treated with more 
than two antihypertensive drugs was not associated with blood pressure control. Similarly, 
continuity of care as a measurement of the number of clinical visits was not associated with 
blood pressure control (536). In the Whitehall II cohort of men and women aged between 42 
and 63 years, Sabia et al found that healthy behaviours was associated with better systolic 
blood pressure levels  among those being prescribed antihypertensive medication (537).  
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Chapter 4 Primary care 
 
The origin of the term is not completely known but the concept was probably illustrated ini-
tially in the Dawson Report released in the UK in 1920 (538). The report described a pyrami-
dal structure of health care services with three levels of complexity. The first level of com-
plexity led to the origin of primary care.  In 1961 White et al pointed out the concept of the 
ecology of medical care. The review described that the majority of health problems can be 
solved by local health services (539). Since then the concept of primary care has evolved 
further. I will describe the definition of primary care and its impact on the control of chronic 
diseases. A particular reference to the model of primary care in England will be presented.  
 
4.1 Primary care concept  
A definition of primary care was formally established in the Alma- Ata declaration in 1978 
(540). Subsequently, the term has been modified (Box 3). From this historical background 
two terms have emerged: Primary Care (PC) and Primary Health Care (PHC). These terms 
have often been interchangeable depending on the country and the strategy used to deliver 
services at the community level.  
 
Similarities and differences between both terms are presented in box 4. One difference be-
tween PHC and PC is that the former integrates some public health aspects into its defini-
tion. For instance the Alma-Ata declaration and the following WHO reports included activities 
such as improving the potable water supply or basic sanitation as part of the Primary Health 
Care strategy (541). The role of the local community in health decision-making forms a com-
ponent of PHC and also represents another difference (541). These aspects are not clearly 
stated under the definition of PC (542).  
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The concepts are also context-dependent. Within PC, strengthening the role of the family 
doctor or general practitioner has mainly been the predominant strategy to expand health 
services at community level in some high income countries from Europe (440, 543). On the 
other hand, PHC, with its broad approach that includes community participation and envi-
ronmental interventions, has delivered a strategy to develop health services at community 
level in low and some middle income countries (544-545). Moreover, selective primary 
health care, defining a PHC focused on managing particular health conditions in order to use 
resources efficiently, has also been implemented in some of low income counties (546-547). 
 
In essence both PC and PHC aim to provide care for individuals in the context of the family 
and community in which the patient lives. PHC integrates the functions of health policy to 
thus influence the strategies used by PC to deliver care to individuals within a specific popu-
lation (548-549).  
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Box 3 Definitions of Primary Care  
Report  Definition  
Lalonde   
(550) 
 
The report introduced the term of health field which identified four elements that the health popula-
tion status depends upon:  human biology, environment, lifestyle and health care organization. 
Health field incorporated the following criteria: a) the equal importance of the four elements in de-
termining health population status, b) a comprehensive approach in that the cause of any health 
problems should take into account one or all elements, c) measuring the contribution of each ele-
ment in the analysis of any health problem, d) the identification of factors susceptible to intervene. 
There were not specific mentions of the primary care concept but it was implied that there was a 
need for seeking health solutions outside the hospital environment.  
 
Alma-Ata 
(540) 
The term Primary Health Care was defined as “Primary health care is essential health care based 
on practical, scientifically sound and socially acceptable methods and technology made universally 
accessible to individuals and families in the community through their full participation and at a cost 
that the community and country can afford to maintain at every stage of their development in the 
spirit of self-reliance and self-determination. It is the first level of contact of individuals, the family 
and community with the national health system bringing health care as close as possible to where 
people live and work, and constitutes the first element of a continuing health care process”.   
WHO 
(551) 
The report preserved the definition of Primary Health Care established in the Alma-Ata declaration.  
In addition to this, the report defined the essential elements of Primary Health Care. These ele-
ments arose from integrating activities such as the proper use of water and sanitary facilities and 
other related to environment and health technology development into the concept of Primary Health 
Care 
 IOM  
(552) 
 
The document used the term Primary Care as it was established in the 1996 definition.   “Primary 
care is the provision of integrated, accessible health care services by clinicians who 
are accountable for addressing a large majority of personal health care needs, developing a sus-
tained partnership with patients, and practicing in the context of family and community”. 
Barbara 
S.  (553)  
Primary Care is “is that level of a health service system that provides entry into the system for all 
new needs and problems, provides person-focused (nor disease-oriented) care over time, provides 
care for all but very uncommon or unusual conditions, and coordinates or integrates care provide 
elsewhere by others” Primary care connotes conventional primary medical care striving to achieve 
the goals of primary care health care” 
WHO 
(554) 
The report neither did establish a new definition of Primary Health Care nor Primary Care.  The 
document defined what is called “the features of primary care” which including effectiveness and 
safety, person-centred care, comprehensive and integrated responses, continuity of care and longi-
tudinality. 
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4.2 Definition of Primary Care attributes  
The attributes of PC services are described below. I divide these attributes into two catego-
ries; the essential features of primary care services (542) and  attributes added as a result of 
the  progressive changes in clinical practice  (554)   (Box  4). 
 
Essential features of primary care  
The essential features of PC have been postulated by Starfield (542). PC services built on 
these features have improved the health conditions at community level (440, 554-556). The 
definition of each feature is below:  
First contact access: this feature implies two dimensions. One is accessibility meaning that 
individuals can benefit from primary care interventions without financial, geographical, lan-
guage or cultural limitations. The other is the role of PC as the entry point to the health sys-
tem whereby people must use PC for each new health need.  
Longitudinality of care (Long term-person care/continuity of care): it includes the following 
aspects: a) the process of care for each patient is delivered either until the resolution of 
health problem or until a health risk needed a follow-up to be eliminated; b) a person centred 
care approach whereby the solution for each health problem integrates, patient needs, pa-
tient beliefs and patient preferences on treatments.  
Coordinated care: it is the requirement of the system to provide continuity and identify indi-
viduals with conditions which require follow-up. In other words health systems should sys-
tematically record patient information, including all levels of attention, to provide access to 
data regarding patients’ medical history.   
Comprehensive and integrated responses: PC services have the potential to offer to each 
patient an integrated management plans which may include not only drug prescription but 
also health promotion and prevention advice. The final solution for the health need could be 
beyond the primary health care service with which PC services are working.  
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Additional attributes of primary care 
Effectiveness: the capability of solving health problems presented in the referred popula-
tion. 
Quality of care: ability to achieve defined health outcomes which can be measurable  
Safe: medical interventions must be evidence-based regarding patient-values. In addition 
primary care health providers will pursue standards of care that assures high quality and 
safety care. 
 
Box 4 Similarities and differences between Primary Care and Primary Health 
Care 
Attribute  Primary Care Primary Health 
Care 
First entry  point to  the health system (553-554) (540, 551, 554) 
Person-centred care (553-554) (555) 
Long term continuity person care   (552-554)  
Comprehensive  (553-554)  
Essential services and health programs based on local 
epidemiology  
 (540) 
Provided services affordable by each country  (540, 551) 
Universal access (552-553) (540, 554) 
Family doctor approach (552)  
Community participation in establishing health priorities 
and health interventions 
 (540, 551) 
Coordination  (553-554)  
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4.3 Impact of primary care on the management of 
cardiovascular diseases  
 
A positive impact of PC upon the population’s health status has been documented. (440, 
557-559). Thus access to primary care has resulted in lower mortality rates and a higher life 
expectancy for population involved. Moreover available primary care services have also pre-
vented excessive hospitalizations mainly due to the better management of ambulatory pri-
mary care sensitive conditions (556, 560-562). Similarly improvements on health promotion 
such as vaccination, cancer screening, maternity health has been associated with the devel-
opment of primary care (563). These impacts have been achieved regardless of the popula-
tion characteristics such as ethnicity, income, education, urban-rural population dynamics 
and unemployment rates. They have also been reported worldwide.  
 
Similarly the implementation of PC has led to improvements in the control of cardiovascular 
diseases (564-566). Lower mortality rates of heart disease and stroke have been associated 
with improves on the development of PC services (557-559). Advances in the management 
of chronic kidney disease (CKD) have been attained by incorporating PC services into CKD 
control (567-569). The use of patient centred strategies has also improved the management 
of chronic diseases (570). Similarly PC services which have integrated a chronic care model 
have provided better control for those with chronic diseases, particularly diabetes (571-572).   
 
Blood pressure control in primary care   
PC also has a central function in the management of patients with hypertension. The care of 
hypertensive patients is essentially provided in PC settings (573). Well established PC ser-
vices have led to reductions in the number of admissions due to hypertension (441, 574-
575), and increases in the number of hypertensive people having regular blood pressure 
monitoring (576). By contrast hypertensive patients in regions with lack of primary care phy-
sician have an increased probability of having uncontrolled blood pressure (577). Compari-
sons between the management of hypertensive patients provided by GPs and specialists 
have been found not being significantly different (578). Hence the management of blood 
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pressure is currently considered as a measure of performance of primary care services (579-
581).  
 
Despite the significant impact of PC services on the management and prevention of chronic 
diseases, benefits derived from interventions delivered in PC have not been equally distrib-
uted across the population. Both geographical and financial barriers to access PC as well as 
unequal distribution of resources across population account for dominating factors reducing 
the impact of PC (562). On the other hand, individual preferences, life style and low social 
class are the most relevant individual factors that have been reported as conditions which 
detract people from maximally benefiting of PC services (562, 582-583).  
 
4.4 Primary care in England  
 
In England, primary care has been changed continuously along with the transformations in 
the health system (584). I will present the current organization of primary care in England.  
There is no consensus on the definition of primary care.  PC has mainly constituted the 
health services provided by general practices, dental practices, community pharmacies and 
high street optometrist in the settings operating in local areas (585-586). The last reform of 
PC services was performed in 2002 but a new revision of PC services is undertaking since 
2010 (587) . The following features are considered the essential elements of PC in England 
(586, 588): 
First contact care: PC is the first level of contact between citizens and the health system 
regardless of the type of health service they required. Therefore PC is the entry point to the 
system. Patients with accidents and emergencies are excluded from this definition in that 
they can receive their initial care at any level of health system.   
Equity: it means that there is an equal access for equal health needs.  
Access: the service is free at the point of entry to all citizens. 
Location: services are as closer as possible to the citizen residence. 
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Continuity of care: long term care is delivered by general practice for patients suffering 
from the most common conditions. It is intended that the general practitioners working in the 
same practice manage the same patients registered within the practice.   
Registration: almost all citizens are registered with a general practitioner. Currently, the 
registration is taken with general practices.  
 
4.4.1 Organization of Primary care in England 
 
In England PC service -like other NHS services- are funded from general taxation. The Na-
tional Health Service (NHS) provides primary care services for a defined geographical popu-
lation through the Primary Care Trust (PCT) (589). Thus, the  PCT contracts with general 
practices and  private providers to deliver essential primary care services to a defined popu-
lation (590). The PCT pays for the services mainly based on two criteria. One is the annual 
amount of payment associated with each individual registered with a practice (capitation).  
The other criterion is an extra payment linked to a measure of quality of care assessed with 
the parameters defined in the Quality and Outcome Framework (QOF) (591). The QOF ac-
counts for up to 25% of the total payment. Other extra payments are considered when the 
provider offers out of hours care and/or  some additional services (e.g. Local Enhanced Ser-
vices)  (592).  
 
In England there have been 152 primary care trusts (PCT) (565). They have been  the local 
health units responsible for assessing the health needs in an defined population since 2002 
(590). The PCT developed local public health strategies and planed primary care health ser-
vices. The primary care health services are mainly purchased with general practices. PCTs 
can also contract or commissioning independent providers: such as Personal Medical Ser-
vices (PMS), which includes Specialist PMS (SPMS); Primary Care Trust-Led Medical Ser-
vices (PCTMS); Alternative Provider Medical Services (APMS) to provide primary care ser-
vices.  Currently, the PCT structure is changing and they will no longer operate with the 
same functions. Since April 2013, the PCT have been abolished and replaced by clinical 
commissioning groups integrated to local health system (593).  
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The general practice is the health service unit directly responsible to provide citizens with 
primary care services (594-595). The services offered are diagnostic, acute illness, long-
term conditions care, prescribing, referrals and health promotion services. Other services 
may also be offered such as out of hour’s service. Each general practice is composed of one 
or more general practitioners or a group of them working with a primary care health team 
(PHCT) that generally includes practice nurses, managers, administrative staff and health 
care assistants.  
 
The general practitioner has been at the core of the development of PC in England since the 
start of NHS in 1948 (595). The role of the GP has evolved from being medical doctors regu-
lating referrals into medical doctors with formal training in general practice. The training in-
cluded not only clinical education but also health promotion and prevention subjects. A GP 
now also receives training on working with other health professionals and in multi-
disciplinary teams  (596).  
 
The PCHT is an interdisciplinary health group (597). The PC team includes a combination of 
district nurses, health visitors, social and community workers, pharmacists, dentists, opti-
cians, physiotherapists, counsellors among others. It intends to provide care beyond that 
provided by medical doctors (598).  For instance community pharmacists provide patients 
suffering from chronic diseases with their prescription drugs and can also advise patients on 
the use of medication. The pharmacist also gives patient’s advice on health promotion, as-
sesses the prescription against the national protocols and examines potential drug side ef-
fects (599).   
 
Each practice is committed to register clinical data into an electronic medical record system. 
Clinical diseases are codified using the Clinical Term (The Read Codes)  (600).  Data from 
these electronic medical records systems are used in national datasets such as the General 
Practice Research Database (GPRD), QResearch, and the Health Improvement Network 
(THIN) which are available for research purposes. Grouped data sets are also constructed to 
record the QOF indicators and prescribing data. The QOF includes incentives for maintain-
ing registers of patients with chronic diseases such as diabetes or hypertension. The data on 
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patient outcomes is reported to the Quality Management and Assessment System (QMAS) 
(601-602).   
 
The performance of general practices is oriented by national regulations. On the one hand 
clinical guidelines are provided by the National Institute for Health and Clinical Excellence 
(NICE). The guidelines formulate recommendations on how to prescribe drug therapy, use 
health technology and implement preventive interventions. The guidelines are developed by 
multi-disciplinary groups of experts assessing clinical evidence (603). On the other hand, the 
quality of care is assessed according to indicators established in the Quality and Outcomes 
Framework (QOF) (591).  
 
4.4.2 The Quality and Outcome Framework  
 
The Quality and Outcomes Framework (QOF) was an initiative launched in 2004 (591). This 
initiative aimed at improving both health worker satisfaction and the quality of care at primary 
care level (592). Since then the QOF has been a part of the contract between the Depart-
ment of Health and general practices. The participation is voluntary but almost all general 
practices are part of the QOF agreement. The QOF is annually revised so that the 
2011/2012 QOF differs from the original2004/2005  version (604). Thus variations in the in-
dicators and modifications in the formula payments have been made since QOF was first 
introduced in 2004 (595).  
 
The 2011/2012, QOF guidance defines indicators to measure four dimensions of quality, 
called domains. The established domains are clinical domain, organizational domain, patient 
experience domain and additional services domain. Each domain is measured by a set of 
indicators Box 6. The indicators are calculated after excluding patients for whom the indica-
tor is inappropriate (exception reporting). The annual result of the each indicator is translated 
into points. The sum of all points results in a maximum achievable of 1000 points. The final 
financial reward is adjusted for disease local prevalence and the number of patients regis-
tered with the practice (595, 604).  
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The clinical domain represents the majority of the framework. It accounts for 69.7% of the 
total points. It consists of a group of 20 diseases. Disease-related indicators are used to as-
sess the quality of care provided by the practice. The indicators have been modified and 
since 2009 NICE has been contributed to these updates (279). For hypertension, there has 
been a reduction in the number of indicators. The current indicator for blood pressure control 
is the percentage of hypertensive patients having blood pressure equal or less than 150/90 
mm Hg. This indicator was established in 2004 but it is under revision  (605). (Box 5-6). 
 
Box 5 The 2007/2008 hypertension QOF indicators  
Indicator Points  Payment 
thresholds 
Records    
BP 1. The practice can produce a register of patients with es-
tablished hypertension 
 
6  
Ongoing management    
BP 4. The percentage of patients with hypertension in whom 
there is a record of the blood pressure in the previous 9 
months 
 
16 40 – 90% 
BP 5. The percentage of patients with hypertension  
whom the last blood pressure (measured in the previous 9 
months) is 150/90 or less 
 
57 40-70% 
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Box 6 The 2011/201 QOF indicators  
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4.5 Impact of primary care on the management of cardio-
vascular diseases in England 
 
In England there has been a significant reduction in coronary heart disease mortality over 
the last 20 years (606-607). A similar decline has been documented in cardiovascular re-
lated-hospitalizations rates (608). Moreover,  the number of patients with cardiovascular dis-
eases within the control outcomes such as diabetes and hypertension  has continually in-
creased (609). Both population and individual interventions account for these improvements. 
On the one hand, the ban on tobacco advertising (610), comprehensive smoke-free legisla-
tion (611), and voluntary agreements to reduce salt intake (612)  are of the most significant 
population interventions to reduce cardiovascular risk factors. On the other hand improve-
ments on access to treatment are the most significant intervention at individual level (606, 
613). Since the individual interventions are mainly delivered in primary care settings (614), 
these  achievements also reflect the impact of primary care on cardiovascular diseases in  
England  (615-618).   
 
In England different characteristics of primary care have been associated with these im-
provements (617). The introduction of Primary Care Groups,  and then the PCTs, have  led 
to a greater development of community and population based services (619). The model  
provides a comprehensive approach to the provision of care  and the continuity of care par-
ticularly for those suffering from chronic diseases (620). The progressive use of clinical reg-
isters has also been associated with reductions in both total and coronary heart disease 
mortality (615, 621). Finally, the PCTs have provided integral interventions to those suffering 
from chronic diseases (622-623). 
 
Despite these improvements, inequalities in the management of cardiovascular diseases 
across PCTs have been reported (446, 624). Cardiovascular mortality rates and hospitaliza-
tions rates due to chronic diseases have been higher in the most deprived areas than in the 
least deprived areas (608, 625). The introduction of QOF has been associated with reduc-
tions in health inequalities among the PCTs (498, 626-627). However the reasons for these 
discrepancies have not always been linked to PC services. Social determinants such as 
economic deprivation and low education may explain these differences (446, 582-583, 608, 
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628). Recently air pollution and extremes of temperature have been associated with dis-
crepancies in coronary heart disease mortality rates across the country (629). 
 
 
Key points 
 The control of hypertensive patients is mainly carried out at community level.  
 Primary Health Care is the WHO strategy to deliver health services at community 
level. It includes some public health actions.  
 Primary care is the strategy to deliver medical health services at community level.  
 Well established primary care services have been positively associated with better 
health outcomes at population level. 
 Population with good access to primary care services have better control rates of 
chronic cardiovascular diseases.  
 In England primary care is the core of the national health system.  
 England PC covers almost entirely population and it is free access.  
 England PC is delivered through general practices.  
 In England the control of hypertensive patients are mainly relied on primary care 
services.  
 The development of England PC has led to improvements in cardiovascular dis-
eases control. 
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Chapter 5 Aim and objectives  
Justification  
Hypertension is the main cardiovascular risk factor. Nearly 40% of adults aged 25 years and 
over have hypertension worldwide. It accounts for almost 50% of total cardiovascular mortal-
ity worldwide. Despite available interventions to reduce blood pressure, the percentage of 
hypertensive patients with controlled blood pressure is around 25%. Improvements on blood 
pressure control have been observed in developed countries over the last ten years.  
The control of hypertensive patients largely takes place in primary care settings. The defini-
tion of control is based on the achievement a blood pressure target. The interaction between 
patient-related factors, physician-related factors and health system factors determine the 
probability of having controlled blood pressure. The relative contribution of each factor is 
context-dependent.   
Main objective 
To assess the association between patient-related factors, physician related factors and 
health system factors and blood pressure control in hypertensive patients managed in pri-
mary care practices located in Wandsworth, London between 1998 and 2007. 
Objectives 
 To determine differences in the classification of patients with and without controlled hy-
pertension using the National Institute for Health and Care Excellence (NICE) blood 
pressure target and the Quality and Outcome Framework (QOF)  blood pressure target.  
 To estimate the effect of national hypertension guidelines on antihypertensive prescrib-
ing patterns between 1998 and 2007.  
 To estimate the association between patient factors, health provider characteristics and 
blood pressure control. 
 To develop a Bayesian model for the analysis of hypertensive patient data using elec-
tronic medical registers. 
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Chapter 6 Description of  study setting and 
sample characteristics 
 
6.1 Study setting  
The study was carried out in 28 general practices located in Wandsworth, South West Lon-
don (Figure 4). These general practices provide primary care services to the local popula-
tion. Population living in Wandsworth increased from 260380 in 2001 to 307.000 in 2011. 
The population is younger than both London population and England population. In 2011, 
mean age for  Wandsworth population was 34.5 years whereas for London population was 
35.6 years and for England population was 39.4 years (Table 13) (630). Among those aged 
between 16 and 74 years, 37.4% and 39.3% were men in 2001 and 2011 respectively. Be-
tween 2001 and 2011, there was an increase in the percentage of residents aged 33 to 64 
years.  
Figure 4 Wandsworth location in London  
 
 Source www.ons.gov.uk  
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Table 13 Distribution of population resident in Wandsworth by age, 2001 and 
2011 
 
Source (631) 
 
Distribution of Wandsworth population by race/ethnicity 
The definition of ethnicity is a complex concept. According to Bhopal ethnicity is a multidi-
mensional individual characteristic meaning “the group to which people belong, and/or per-
ceived to belong, as a result of certain shared characteristics including geographical and 
ancestral origins, but particularly cultural traditions and languages” (632).  By comparison, 
the term race has been initially associated with biological characteristics (633). However, 
because the high genetic variation within individuals with same race origin (634), race was 
questioned as a measure of sub-population groups (635-636). Consequently, race has 
evolved to include the social background associated with a defined population group (637). 
Hence, currently both terms seem to represent the same concept.  
 
The need for including race/ethnicity in the analysis of population health is because the pat-
terns of some diseases varied between individuals with different ethnic background. For in-
stance, Harper et al reported that individuals of white origin continue having higher life ex-
pectancy than those of black origin between 1983 and 2003 in the US population (638).  
That difference was mainly due to cardiovascular diseases mortality follow by homicide, HIV 
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and infant mortality (638). In the REACH study, which included data from 49602 patients 
registered with 5587 general practices from 44 countries, a significant difference in the 
prevalence of risk factors between the seventh ethnic categories used in the analysis was 
observed (639). Those of black origin had the highest prevalence of hypertension and pa-
tients of South Asian origin had the highest prevalence of diabetes. Whites had the lowest 
prevalence of hypertension and diabetes (639). Therefore race/ethnicity as a variable could 
help to trace populations with particular health risk factors.   
 
The categorization of ethnicity has been controversial. The interaction between genetic 
traits, family ancestry and cultural heritage ancestry to define a specific ethnic group is still 
only partially understood. There are no gene clusters which define a particular race or cul-
tural group (640). For instance, a significant heterogeneity in genetic markers among African 
populations has been described indicating that they did not form a homogenous population 
(641-642). By contrast, strong genetic correlations between some European population and 
African population have been observed (642-644).  African populations living in East Africa 
have been found to be genetically similar to European-Middle Eastern populations (642, 
644). African Caribbean populations also exhibited a diverse genetic ancestry. Populations 
from Barbados had a higher level of West African ancestry than those from Jamaica (645). 
But populations from Jamaica had higher European ancestry than those from Barbados 
(645). Hence, the definition of ethnic groups is beyond genetic patterns and without a spe-
cific genetic pattern defining race/ethnicity.   
 
Similarly differences in morbidity and cultural characteristics among populations closely lo-
cated have been documented. Populations from India, Pakistan, Bangladesh and Sri Lanka, 
commonly named as those of South Asian origin, could differ in some cultural aspects.  For 
example individuals of Bangladeshi origin living in the UK have found having a higher preva-
lence of smoking than those of Pakistani or India origin (646).  Individuals of Indian origin are 
less likely to have coronary heart disease than those of Pakistan and Bangladeshi back-
ground (647). They also differ in the language use and religious beliefs (648-649).  
 
Differences in traditions between African Caribbean and African American populations have 
also been reported. Those of African Caribbean origin seem to have lower adherence to 
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some religious habits than the African American population (650). The English Caribbean 
population had a higher prevalence of smoking than the English African population (651).  
Moreover a wide diversity of eating habits and religious beliefs have been observed among 
the African English population with different African ancestry (652). Therefore, as for South 
Asian population, grouping all people of African descendent into one category has been 
questioned (632, 653). It may detract from understanding mechanisms through race/ethnicity 
influences on health outcomes.  
 
The criteria used for categorizing individuals into race/ethnicity has not totally been standard-
ised worldwide. The 2000 US census established the following categories for race/ethnicity 
white, black/African American including African Caribbean, American Indian/Alaska Native, 
Asian including Chinese, Japanese, Korean, Vietnamese and Asian Indian, and Native Ha-
waiian/other Pacific Islander (654). Others authors suggested using the category Caucasian 
to refer to those of European and West Asian origin. This category also includes the popula-
tion of Indian subcontinent, Middle East and North Africa (655). These categories mainly 
consider the geographical distribution of the population which could have a high genetic cor-
relation (655). By comparison the UK census established categories of South Asian includ-
ing those of Indian, Pakistani or Bangladeshi origin and those of China or other Asian back-
ground in an different category  (631). 
 
Terms used in the current study  
In the UK the ethnic classification is based on that established in the national census con-
ducted by the The Office for National Statistics. The classification is based on self assigna-
tion to previous groups described in the census. A comparison of the classification between 
2001 and 2011 is presented in box 7. According to 2001 census, in Wandsworth white eth-
nicity configures the highest percentage of population (77.9%) and this percentage slightly 
decreased in the 2011 census (71.4%). Population of South Asian origin and black origin 
also increased from 6.9% in 2001 to 10.9% in 2011 and from 9.6% in 2001 to 10.6% in 2011 
respectively. Population of mixed origin increased from 3.35% in 2001 to 5.0% in 2011. Pop-
ulation living in Wandsworth looks less diverse than that living in London in 2011. Of total 
28.6% of residents were other ethnicity different from white in 2001, compare to 49.2% living 
in London (Table 14-15).   
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The assessment of ethnicity is controversial. Currently a self-reported measure based on the 
pre-established census categories has been commonly used (632). The classifications used 
in the current analysis were based on the classifications of ethnicity established in the 2001 
UK census (656). The categories of ethnicity were provided by the patient as a self-report 
and registered by a health worker. I grouped the patients into six race/ethnic categories ac-
cording to the ethnic origin and the numbers of patients in each category registered in the 
data. Because the patients were registered progressively, the samples of ethnic groups dif-
ferent from white were smaller particularly at the beginning of the study period.  Therefore, 
the small numbers make it difficult to quantify significant differences of some outcomes be-
tween subgroups.  
 
I used the main categories established in the 2001 UK census with the following labels 
white, South Asian for those of Indian, Pakistani or Bangladeshi origin, black for those of 
African or Caribbean origin, other Asian origin for those of Chinese, Taiwan or Hong Kong 
origin, other ethnicity for those of Hispanic origin or other ethnic category and unknown for 
those without any register of ethnicity (Table 16) (631). This classification might fail to identi-
fy particular conditions occurring in some ethnic groups such as African Caribbean and Afri-
can British or those of South Asian from India and from Pakistan associated with blood pres-
sure control. However it provides light about how the control of blood pressure could vary 
across the main ethnic categories living in Wandsworth. They were also exposed to similar 
health interventions for improving blood pressure control occurring in the area over the study 
period.  
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Box 7 Race/Ethnicity classification in the 2001 and 2011 England census  
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Table 14 Distribution of population resident in Wandsworth by race/ethnicity, 2001 
    
Source (631) Office for National Statistics.    
Table 15 Distribution of population resident in Wandsworth by race/ethnicity, 2011 
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Source (631) 
Socio economic status in Wandsworth population  
In 2004 the Department of Communities and Local government updated the measurement of 
socio economic conditions. In a commissioned work, an index of deprivation was developed 
by   the Department Social Policy Work at the University of Oxford. This index is used in the 
analysis of the current data.  
 
The index of deprivation is composed of seven domains (Box 8). The assessment of this 
index was performed at Super Output Areas (SOA) regarding population density. Each do-
main is measured by several items and given a score between 0 and 100. A higher score 
reflects higher deprivation conditions. The score is additionally transformed into a rank score 
which ranges from 1 to 500 units. Similarly, higher levels represent higher levels of depriva-
tion (657).  
In 2004, Wandsworth Borough was at 114th rank sore of the most deprived area related to 
the maximal national rank score of 355. None of the SOA was in the 10% most deprived 
nationally. Similarly there was no SOA at the 10% worst rank of the national employment or 
education score distribution. However, 11 SOAs were at 10% worst income domain depriva-
tion (658).   
Box 8  Domains of deprivation index  
Domain of deprivation  Domain weight 
Income deprivation  22.5% 
Employment deprivation  22.5% 
Health deprivation and disability  13.5% 
Education, skills and training deprivation  23.5% 
Barriers to Housing and Services  9.3% 
Living environment deprivation  9.3%  
Crime  9.3%  
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Hypertension prevalence in Wandsworth  
The estimated prevalence of hypertension was 21.8% in 2008 and 22.6% in 2011. Of total 
hypertensive population only 8.3% and 8.8% were registered with general practices in 2008 
and 2011 respectively (659-660). The prevalence is lower than estimated for England 30.2% 
in the last Health Survey for England (284). The percentage of hypertensive patients regis-
tered with general practices was 10.9% and 13.4% in 2008 and 11.1% and 13.6% in 2011 
for London and England respectively (659-660). Then there has been a higher gap between 
the number of hypertensive registered with general practices and the total of hypertensive 
patients in Wandsworth compared to that observed in London and England (660-661). Con-
sidering data using registers in the QOF reports, the prevalence of hypertension was 84.76 
per 1000 habitants lower than observed in London 108.19 and in England 131.33 (662). 
 
6.2 Study design  
Sample population 
 
The data for this study corresponded to hypertensive patients registered with 28 general 
practices. To obtain the data an ethical approval was gained from the Wandsworth local re-
search ethics committee. Each practice gave consent to download the data. All included 
practices had electronic patient records used by general practitioners and other members of 
the primary care health team to register clinical data. The data was extracted from each 
practice computer using an algorithm linking patient information by a patient code. The code 
was an anonymised number which did not allow for identifying the patient. Then the files 
from all practices were merged in a macro data set in which patients were nested within 
each practice. Similarly to patient level data, each practice were given a number which pre-
venting me for identifying the name of the practice. The process was described by Curcin et 
al (663) 
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Patient inclusion criteria 
Individuals aged 18 years and older with hypertensive diagnosis in the registers of the 31st of 
December 2007 formed the included population. The diagnosis was based on the Read 
clinical classification codes (600).  For essential hypertension and/or primary hypertension in 
non-pregnant women the code was G20. Data for all included patients was retrospectively 
and annually retrieved between 1998 and 2007.  
 
Definition of study variables  
Patient level variables  
Information about patient variables was provided by the patient. Blood pressure level was 
recorded once as the last annual measurement registered in data set. The measurement of 
blood pressure was taken using either sphygmomanometer by listening Korotkoff sounds 
(auscultatory method) or an electronic device (oscillatory method). The former was more 
commonly used in years before 2004. The definition of race/ethnicity was based on self-
report taken during the clinic visit and registered based on the 2001 census classification. It 
was grouped in six categories due to the small number in some of those established in the 
referred census. The date of registration was used for identifying the first record of each pa-
tient in the data set. The definitions of all variables are established in table 16. 
  
Practice level variables  
There were two practice level variables. The deprivation index which was based on the prac-
tice post code as the individual data was not linked to the individual post code. The depriva-
tion index was based on the criteria described above and the one reported in 2004 was used 
for the study period. The number of patients registered with each practice was annually re-
corded. There was an annual increased in the number of patients registered with each prac-
tice over the study period.  
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Table 16 Definition of study variables 
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Chapter 7 Differences in the classification of  
patients with controlled hypertension between 
the Quality and Outcome Framework and the 
National Institute for Health and Clinical Excel-
lence blood pressure targets 
 
7.1 Background 
Despite the known limitations of blood pressure targets, these outcomes define the standard 
of care for hypertensive adults. The classification of having controlled pressure relies on a 
target definition. The use of two target definitions for hypertension control in England pro-
vides an opportunity to determine how blood pressure control varies with different targets. I 
analysed information on hypertensive patients managed in primary care to examine  differ-
ences in the classification of patients with controlled hypertension by using two target defini-
tions, one based on the QOF guidance  (664) and other in the  NICE hypertension guideline 
(499, 501).   
Secondary objectives 
1. To describe patient’s characteristics of those with and without controlled blood pres-
sure. 
2. To describe blood pressure levels by patient’s characteristics.  
3. To assess the relationship between patients’s characteristics and having controlled 
blood pressure. 
 
7.2 Methods 
I performed a cross-sectional study using data from hypertensive patients registered with 28 
general practices located in Wandsworth, South London in 2007.  
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Outcome variables  
The classification of hypertensive control patient was based on the former definitions estab-
lished in the 2007/8 QOF and in 2006 NICE guidelines (499). The QOF guidance establishes 
a level of blood pressure equal to or less than 150/90 mm Hg as  the recommended target 
for patients classified into hypertension disease category (528). Additional blood pressure 
targets for patients classified into other cardiovascular disease categories are specified by 
the QOF guidance Box 9 (528).   
 
Box 9 Clinical QOF blood pressure indicators for cardiovascular diseases  
Disease category  Clinical target  
Hypertension (BP)  
 
BP 5. The percentage of patients with hypertension  whom the last 
blood pressure (measured in the previous 9 months) is 150/90 or less 
Diabetes mellitus 
(DM)  
DM 12.The percentage of patients with diabetes in whom the last 
blood pressure is 145/85 or less 
Coronary heart 
disease  (CHD)  
CHD 6. The percentage of patients with coronary heart disease in 
whom the last blood pressure reading (measured in the previous 15 
months) is 150/90 or less 
Stroke STROKE 6. The percentage of patients with a history of  TIA or 
stroke in whom the last blood pressure reading (measured in the pre-
vious 15 months) is 150/90 or less 
Chronic kidney 
disease (CKD) 
CKD 3: The percentage of patients on the CKD register in whom the 
last blood pressure reading, measured in the previous 15 months, is 
140/85 or less 
Reference (528) 
 
This analysis used the definitions of blood pressure targets established in the period-related 
hypertension national guidelines. In 2004, NICE produced guidelines on the management of 
hypertension in adults in England primary care (501). For hypertensive patients without pre-
existing clinical disease a level equal to or below 140/90 mm Hg blood pressure is defined 
as the target of therapy.  In addition, lower blood pressure targets for hypertensive patients 
with diabetes or other cardiovascular disease are established in each NICE disease-related 
guideline (223, 665). The targets established in both the QOF guidance and the NICE guide-
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line applied for hypertensive adults 18 years or over, males and females, and patients of all 
ethnic origin.  
 
Independent variables 
I identified hypertensive patients who had a record of blood pressure in 2007. The indepen-
dent variables were defined as follows: a category of patients with additional cardiovascular 
comorbidity for those with diabetes or coronary heart disease or stroke or atrial fibrillation or 
renal failure or heart failure. Patients with chronic obstructive pulmonary disease, depression 
or asthma were classified as patients with other no cardiovascular comorbidity. Ethnicity 
origin was grouped into white, black, South Asian, Other Asian, other ethnic and unknown. 
The data on treatment was based on drug prescription available over the current year. 
Dependent variables  
 
For each individual the dependent variable was having controlled blood pressure based on 
the NICE target and the QOF target. The NICE target of equal to or below 140/90 mmHg 
and the QOF target equal to or below 150/90 mmHg were use for all hypertensive patients. 
In the analysis of hypertensive patients with diabetes the 2008 NICE target of less than 
140/80 mmHg and the QOF target of less than 145/85 mmHg were used. The 2008 NICE 
target was the recommended audit target for diabetic patients in the 2004 BHS hypertensive 
guidelines.  
  
Statistical methods 
Characteristics of patients were reported as percentages for categorical variables and mean 
with standard deviation for continuous variables. I tested differences in continuous variables 
between different strata using Student’s t-test or analyses of variance (ANOVA) for compari-
sons of three or more groups. Categorical variables were assessed using the Chi-squared 
test. The main outcome was the proportion of patients who achieved blood pressure targets 
as defined  in both QOF and NICE guidelines (501, 528). The percentage was reported as 
the number of controlled patients divided by the total number of hypertensive patients in-
cluded in the analysis. We additionally stratified the percentage of patients with controlled 
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blood pressure by age, sex, ethnicity, antihypertensive prescribing and the presence of car-
diovascular comorbidity.  
 
I used a multiple logistic regression to assess the relationship between patient characteris-
tics and the odds of being classified as a patient with controlled hypertension (PCH). A sepa-
rate logistic model for each target definition was performed.  The patient characteristics in-
cluded in each model were based on the following criteria: 1) those which have been previ-
ously shown to influence blood pressure levels such age, sex and ethnicity (34, 73, 143, 
666). We stratified age into three groups younger 17 -44 years, middle age 15 – 64 years 
and older 65 years and over. 2) Those variables which are used in the guidelines to classify 
patients at high cardiovascular risk as lower targets are established for these patients. Pa-
tients with at least one of the following clinical conditions diabetes, renal failure, stroke, heart 
failure, atrial fibrillation and coronary heart disease were classified as patients with cardio-
vascular comorbidity (501) 3) Those which directly modify blood pressure levels such as 
number of prescribed drugs. I grouped patients into being or not being prescribed antihyper-
tensive medication (140) 4) Those which could modify blood pressure levels and/or drug 
prescription such as the presence of other comorbidities, patients with at least one of the 
following conditions COPD, depression or asthma were classified as patients with other co-
morbidity. The standard errors were adjusting for the cluster of 28 practices to take into ac-
count intragroup correlation. In the model the main explicatory variable was sex. I assessed 
whether or not the probability of being with controlled hypertension varies between the sexes 
across the age categories by including a term for interaction. A logistic model including only 
hypertensive patients with diabetes was also performed.  
The data was analysed using STATA version 11 (Stata Corporation, College Station, TX, 
USA). 
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7.3 Results 
 
In 2007, 17252 hypertensive patients aged 17 years and over were registered with 28 gen-
eral practices. Of these 15751 (91.4%) with a valid record of blood pressure were included in 
the analysis. 8433 (53.5%) were of white origin, 8753 (56%) were female, and 5985 (38%) 
had at least an additional cardiovascular comorbidity. Diabetes was the most frequent dis-
ease comorbidity followed by coronary heart disease 1816 (11.5%), stroke 1141 (7.3%), 
atrial fibrillation 753 (4.7%), renal failure 671 (4.2%) and heart failure 395 (2.5%).  3977 
(25.2%) patients had other comorbidities such as depression 2367 (15.0%), chronic obstruc-
tive pulmonary disease (COPD) 2054 (13.0%) and asthma 1646 (10.4%).  1608 (10%) of 
patients were not prescribed antihypertensive medication and 9103 (57.8%) were prescribed 
more than two antihypertensive drugs. Patients with cardiovascular comorbidity were older 
and more likely to be males than those without cardiovascular comorbidity. Patients with 
cardiovascular comorbidity were more likely to be on antihypertensive therapy than those 
without comorbidity (Table 17).   
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Table 17 Characteristics of hypertensive patients, 2007 
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95.5% had a record of race/ethnicity. Patient’s characteristics vary between race/ethnicity 
groups (Table 17). Patients of black origin were younger and predominantly female in com-
parison to patients with others ethnic origin. South Asian and Other Asian patients were 
more likely to have diabetes and renal failure. Those of white origin had the highest preva-
lence of stroke. Patients with unidentified race/ethnicity were less likely to have other cardi-
ovascular comorbidity and not being prescribed antihypertensive medication,  
 
Practices differed in the patient’s characteristics. (Figure 5) The number of hypertensive pa-
tients registered with each practice ranged from 114 to 1096. The youngest population was 
in the practice number 5. The highest percent of females was in the practice number 11, 71 
(62.3%). White was the most frequent race/ethnicity in all practices except for practices 5, 9, 
22, 23. In practices 5 and 23 the highest race/ethnicity group was South Asian with 
111(33.4%) and 472 (40.3) respectively.  In practice 9 and 22 was Black with 260 (45.9%) 
and 64 (45.4%) respectively. The practice 8 had the highest percentage of patients without 
record of race/ethnicity, 369 (54.8%). In most practices the percentage of patients without 
antihypertensive medication was nearly 10% or below with the exception of practice 12, 71 
(27.7%). Practices are mainly located in areas with median deprivation index of 21.3. The 
practice 2 is located in the wealthiest area, deprivation index 8.1 and the practice 17 in the 
less wealthy, deprivation index 38.5.  
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Figure 5 Distribution of patients by race/ethnicity in each practice, 2007 
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Blood pressure levels  
For all included hypertensive patients mean systolic blood pressure and mean diastolic 
blood pressure were 137.8 mmHg (sd 16.3) (95% CI 137.5 – 138.0) and 79.8 mmHg (sd 
10.7) (79.6 – 79.9), respectively.  Of total patients 63.2% had systolic blood pressure equal 
to or below 140 mmHg and 88.6% had diastolic blood pressure equal to or below 90 mmHg. 
Patients aged between 17-44.9 years had lower mean systolic blood pressure 134.8 mmHg 
(sd16.7) (95% CI 133.9 – 135.6) than patients aged 45 – 64.9 years 137.0 mmHg (sd15.7) 
(95% CI 136.6 – 137.4) and patients aged 65 years and over 138.8  mmHg (sd 16.5) (95% 
CI 138.5 – 139.1). Conversely, patients aged 65 years and over had  the lowest mean dia-
stolic blood pressure 76.3 mmHg (sd 9.9) (95% CI 76.0 – 76.5), of whom almost 40% had 
diastolic blood pressure between 70 mmHg and 80 mmHg. Hence, whereas diastolic blood 
pressure levels decreased with age, systolic blood pressure levels rose with age (Figure 6-
7). 
Figure 6 Distribution of systolic blood pressure mmHg by age, 2007 N=15761 
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Figure 7 Distribution of diastolic blood pressure mmHg by age, 2007 N=15761 
 
 
 
Men aged 65 years and over had lower mean diastolic blood pressure 76.1 mmHg  sd (10.2) 
95% CI 75.7 – 76.4) compared to those aged 45 to 64.9 years 83.8 mmHg sd (10.2) (95% CI  
83.4 – 84.2) and those aged 17-44 years 86.5 sd (10.8) mmHg (95% CI 85.7 – 87.3) 
(P<0.0001). By contrast, there was not a significant difference in mean systolic blood pres-
sure between age groups. Globally, mean systolic blood pressure was 138.2 mmHg (sd 
16.49) (95% CI 137.8 – 138.5).  Regardless of age group systolic and diastolic blood pres-
sure levels were lower in those with cardiovascular comorbidity. The overall differences in 
mean systolic and diastolic blood pressure were 4.6 mmHg and 6.3 mmHg between both 
groups respectively. (Figure 8 –Table 18)  
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Figure 8 Distribution of systolic and diastolic blood pressure for men, 2007 
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Table 18 Comparison of mean systolic blood pressure and mean diastolic 
blood pressure mmHg in men by age and cardiovascular comorbidity, 2007  
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For women, those aged 65 years and over had the lowest diastolic blood pressure with the 
highest systolic blood pressure. Women with additional cardiovascular comorbidity had lower 
blood pressure levels than those without cardiovascular comorbidity. Thus, those with an 
additional cardiovascular comorbidity had 4.6 mm Hg lower diastolic blood pressure and 0.9 
mm Hg lower systolic blood pressure than those without additional cardiovascular comorbid-
ity. However neither mean systolic blood pressure nor mean diastolic blood pressure were 
different between women with and without cardiovascular comorbidity aged 17 to 44 years. 
That may be due to the small number of patients in these patient groups (Figure 9, Table 
19).  
 
Figure 9 Distribution of systolic and diastolic blood pressure mmHg for 
women, 2007 
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Table 19 Comparison of mean systolic blood pressure and mean diastolic 
blood pressure mmHg in women by age and cardiovascular comorbidity, 2007 
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Differences in blood pressure levels between men of different race/ethnic origin were ob-
served. Black patients aged 17 to 44 years and those aged 45 to 64.9 years had the highest 
systolic blood pressure levels, 143.3 mmHg (sd 16.2) and 141.3 mmHg (sd 16.4) respec-
tively. The lowest level of systolic blood pressure was observed in men of South Asian ori-
gin, mean systolic blood pressure 134.6 (sd 17.1) mmHg. Among patients aged 65 years 
and older there were significant differences in diastolic blood pressure between all 
race/ethnic groups. Again those of south Asian origin had the lowest pressure levels with 
mean diastolic blood pressure of 77.7 (sd 10.6) mmHg (Tables 20-21).  
 
Women of South Asian origin and other Asian origin had the lowest systolic blood pressure 
levels, 135.6 mmHg (sd 17.9) and 135.0 mmHg (sd 16.7) respectively. Among those women 
aged 17 to 44 years without cardiovascular comorbidity there were significant differences in 
systolic blood pressure between race/ethnic groups. Thus women of black origin had the 
highest level of systolic blood pressure 133.4 mmHg (sd 16.2). The analysis did not reveal 
significant variations in systolic blood pressure across other age groups between ethnic 
groups. On the contrary, higher variations were found in diastolic blood pressure across age 
groups except for those aged 17 to 44 years. Consistently higher diastolic blood pressure 
was observed in women of black origin, mean diastolic blood pressure 81.3 mmHg (sd 10.2) 
and lower diastolic blood pressure levels in those of South Asian origin, mean diastolic blood 
pressure 78.2 mmHg (sd 10.4). (Tables 22-23)   
 
 
 
 
 
  
 164 
 
Table 20 Comparison of systolic blood pressure mmHg for men by race/ethnicity and presence of cardiovascular comor-
bidity, 2007 
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Table 21 Comparison of diastolic blood pressure mmHg for men by race/ethnicity and presence of cardiovascular comor-
bidity, 2007 
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Table 22 Comparison of systolic blood pressure mmHg for women by race/ethnicity and presence of cardiovascular co-
morbidity, 2007 
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Table 23 Comparison of diastolic blood pressure mmHg for women by race/ethnicity and presence of cardiovascular co-
morbidity, 2007 
 
 168 
 
Blood pressure control  
Overall 12536 (79.5%) and 9568 (60.7%) of patients were classified as a PCH using the 
QOF and NICE target respectively. (Figure 10-11, Table 25) Regardless of the target, the 
percentage of men with controlled hypertension increase with age. Thus men aged 65 years 
and over had the highest percentage of those with controlled hypertension, 83.3% using the 
QOF target and 61.1% using the NICE target. The percentage of women with controlled hy-
pertension rose with age using the QOF target but decreased using the NICE target. Thus 
the percentage of women aged 65 years and over with controlled hypertension was 81.1% 
and 58.2% using the QOF target and the NICE target respectively. Men aged below 65 
years had lower blood pressure control rates than women at same age but men aged 65 
years and over had higher blood control than women at similar age.  Between race/ethnic 
groups, the highest percentage of percentage of PCHs was in those of South Asian origin, 
1184 (82.2%) and 990 (68.8%) using the QOF target and the NICE target respectively.  
Figure 10 Distribution of hypertensive patients by blood pressure levels 
 
The classification of hypertensive patients is plotted according by the target definitions. The  left verti-
cal line represents the  systolic blood pressure target of 140 mmHg recommended by NICE guidelines  
and the right the level of 150 mmHg recommended by the QOF guidance The horizontal line is at 90 
mmHg diastolic blood pressure. 1. Patients with controlled hypertension 2. Patients with uncontrolled 
hypertension due to higher systolic blood pressure levels.  3. Patients with uncontrolled hypertension 
due to both higher systolic and diastolic blood pressure levels. 4. Patients with uncontrolled hyperten-
sion due to higher diastolic blood pressure levels. 
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Table 24 Cross-tabulation between NICE and QOF targets 
NICE target  QOF target Total  
 No  Yes   
No  3225 2698  6193 
Yes  0 9568  9568 
Total  3225 12536 15761 
Fisher´s exact <0.0001 
 
The comparison between the QOF and NICE targets showed the percentage of patients 
classified as having controlled blood pressure is significantly different. There was one cate-
gory with zero frequencies because it is not possible to be classified as patient with con-
trolled blood pressure by the NICE target but not by the QOF target simultaneity. The QOF 
target thresholds include those of the NICE target (Table 24).  
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Table 25 Percentages of patients with controlled hypertension by age, sex and 
race/ethnicity  
 
 
 
 
 
 
 
QOF target NICE  target
% (number) p value % (number) p value 
Male <0.0001 0.001
17 - 44 yr 466 (66.9) 377 (54.1)
45 - 64 yr 2154 (74.5) 1691 (58.5)
>= 65 yr 2850 (83.3) 2092 (61.1)
Female <0.0001 <0.0001
17 - 44 yr 589 (75.0) 543 (69.2)
45 - 64 yr 2578 (80.5) 2093 (65.4)
>= 65 yr 3899 (81.8) 2772 (58.2)
Ethnic group  0.016 <0.0001
White 6740 (79.9) 5013 (59.5)
Black 2824 (78.2) 2187 (60.6)
South Asian 1184 (82.2) 990 (68.8)
Other Asian 442 (79.8) 381 (68.8)
Other ethnicity 543 (79.0) 407 (59.2)
Unknown 803 (77.4) 590 (56.9)
Overall 12536 (79.5) 9568 (60.7) 
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Figure 11 Distribution of patients with controlled hypertension by sex and age 
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Whereas the percentages of PCH with additional cardiovascular comorbidity were 4955 
(82.8%) and 3893 (65.1%), the percentages of PCH without cardiovascular comorbidity were 
7581 (77.6%) and 5675 (58.1%) using the QOF target and the NICE target (p<0.0001), re-
spectively. The percentage of women aged 65 years and over with controlled hypertension 
was similar between those with and without cardiovascular comorbidity using the QOF target 
82.3% and 81.4% respectively. In contrast, this percentage was higher in women with car-
diovascular comorbidity than in those without cardiovascular comorbidity using the NICE 
target, 61.3% vs. 55.9% (Table 26, Figure 12).   
 
 
Table 26 Comparison of patients with controlled hypertension between those 
with and without cardiovascular comorbidity¥ 
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Figure 12 Distribution of patients with controlled hypertension by 
race/ethnicity  
 
 
The assessment of blood pressure control varied across the 28 practices with the target 
used. Almost all practices, 26 practices (92.8%) reported having more than 70% of patients 
with controlled hypertension by using the QOF target. On the contrary, only 5 practices 
(14.3%) had more than 70% of patients classified as a PCH by using the NICE target (Figure 
8). Of these 4 practices had the higher percentages of patients of south Asian origin (prac-
tice 5 (33.4%), practice 22 (10%), practice 25 (24.1%) and practice 26 (25.4%)) compared to 
what observed in all practices. Practice 22 had the highest percentage of black patients 
(45.4%) and also the highest percentage of patients with an additional cardiovascular co-
morbidity (51.7%). The practices 14 and 15 had the lowest proportion of PCHs. Patients of 
white origin represent the highest percentage of all registered patients with these practices, 
69.2% and 64.1% respectively (Figure 13). 
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Figure 13 Percentage of hypertensive patients with controlled blood pressure 
by practice 
  
 
Using the QOF target there were no significant differences in the proportion of PCHs be-
tween practices in the least deprived and the most deprived areas. By contrast, using the 
NICE target practices located at the least deprived areas had lower percentage of patients 
with blood pressure controlled compared to those located at the most deprived areas (57.1 
vs 61.6%). Except for two practices (practice 22 and practice 23), the practices located at 
the least deprived had a higher percentage of hypertensive patients without additional car-
diovascular comorbidity than those located at the most deprived areas (Figure 14-15). The 
reported differences in blood pressure control also were observed when only patients with-
out cardiovascular comorbidity were compared. Patients registered with practices located at 
least deprived areas were more likely to be younger, male and belonging to other ethnicity 
different from white.  
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Figure 14 Distribution of patients with controlled hypertension by deprivation index  
 
 
Figure 15 Distribution of patient with and without cardiovascular comorbidity by dep-
rivation index 
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Variations in the odds ratio of being classified as a PCH by target 
definition in all patients included  
 
 The QOF target model  
Overall men were less likely to be classified as a PCH (OR 0.64 95% CI 0.52 – 0.81) com-
pared to women using the QOF target of 150/90 mm Hg. However men aged 45–64 years 
and those aged 65 years and over were more likely to be classified as a PCH (OR 1.34 
95%  CI 1.08 – 1.65) and (OR 2.15 95% CI 1.61 – 2.87) respectively related to men and 
women aged 17 to  44 years. A similar pattern was observed in women. There were no 
significant differences in the odds of being classified as a PCH between hypertensive pa-
tients of different origin. Patient with an additional cardiovascular comorbidity had a higher 
odds of being classified as a PCH (OR 1.25 95% CI 1.15 – 1.36) in comparison to those 
without an additional cardiovascular comorbidity (Table 27). 
 
The NICE target model  
Similar to what observed in the QOF target model, by using the NICE target of 140/90 mm 
Hg men were less likely to be classified as a PCH  (OR 0.50 95% CI 0.41 – 0.62 ).  How-
ever men at the age of 45 to 65 years and 65 years and over were more likely to be classi-
fied as a PCH (OR 1.31 95% CI 1.08 – 1.58) and (OR 1.61 95% CI 1.26 – 2.06) respec-
tively compared to women and men aged 17 to 44 years. Conversely women were less 
likely to be classified as a PCH with increases in age. Thus those aged 65 years and over 
were less likely to be classified as a PCH (OR 0.77 95% CI 0.60 – 0.99). Patients of South 
Asian origin and other Asian origin were more likely to be classified as a PCH (OR 1.36 
95% CI 1.23 – 1.57) and (OR 1.39 95% CI 1.16 – 1.68) respectively compared to those of 
white race/ethnicity. Those with an additional comorbidity were also more likely to have 
controlled blood pressure (OR 1.33 95%CI 1.24 – 1.42) (Table 27). 
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Interaction effect 
The probability of being classified as a PCH varied between men and women across age 
groups. By using the QOF target, men aged 65 years and over had almost equal probabil-
ity of being classified as a PCH as women, nearly 80%. However, men aged between 17 
and 44 years had a lower probability of being classified as a HCP than women, 72% vs. 
80.0%.  Similar findings were also produced by the NICE target model but with lower 
probabilities of being classified as a HCP (Figure 16).   
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Table 27 Odds ratio of patient characteristics associated with being classi-
fied as a patient with controlled hypertension 
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Figure 16 Variation in the probability of being classified as patient with con-
trolled blood pressure* 
 
*Interaction effect 
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Blood pressure control in hypertensive patients with diabetes  
Of 3360 patients with both diabetes and hypertension, 1318 (39.2) and 2373 (66.9) were 
classified as patients with controlled blood pressure by the NICE target of less than 140/80 
mmHg and the QOF target of equal to or less than 145/85 mmHg respectively. Regardless 
of the target, higher percentages of patients with controlled blood pressure were present in 
those aged 45 years and over. An exception was observed in females where I did not find 
differences in the percentages between age groups when the NICE target was used. 
There were no significant differences in the percentages of blood pressure control be-
tween race/ethnic groups (Table 28).  
By using the NICE target, 473 (44.9%) and 845 (36.6%) diabetic patients with hyperten-
sion and other cardiovascular comorbidity and without an additional comorbidity had con-
trolled blood pressure, respectively (p<0.001). Higher proportions of patients with con-
trolled blood pressure were observed in men aged 65 years and over and in those of 
South Asian and other Asian origin. Comparisons of the percentage of those with con-
trolled blood pressure across sex, age categories and each ethnic group did not produce 
significant differences; except for male aged 45 to 65 years, whites and those of South 
Asian origin with an additional comorbidity who had higher percentages of those with con-
trolled blood pressure than their counterparts without comorbidity.  By using the QOF tar-
get, there were not significant differences in the percentages across age, sex and ethnic 
groups (Table 29).   
 
The NICE logistic model including all diabetic patients with hypertension showed that for 
one year increase in age there was an increase in the risk of having controlled blood pres-
sure OR 1.01 (95% CI 1.00 – 1.02). Compared to whites, those of other Asian origin were 
more likely to have controlled blood pressure OR 1.59 (95% CI 1.09 – 2.29). Having an 
additional cardiovascular comorbidity was positively associated with the control of blood 
pressure OR 1.19 (95% CI 1.05 – 1.37). In the model using the QOF target, none of the 
included variables were significant associated with having controlled blood pressure (Table 
30).  
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When only patients with hypertension and diabetes were included in the NICE logistic 
model, again being older was significantly associated with having controlled blood pres-
sure OR 1.02 (1.00 – 1.04). Those of other Asian origin were more likely to have controlled 
pressure related than whites OR 1.84 (95% CI 1.29 – 2.63). In the model using the QOF 
target, patients of other Asian origin were also more likely to have controlled blood pres-
sure compared to whites OR 1.55 (95% CI 1.03 – 2.33) (Table 31).  
 
Globally the sample of diabetic patients becomes smaller particularly in some patient 
groups. For instance, the number of hypertensive patients with diabetes aged 17 to 44 
years is 142 but those aged 65 years and over is 1973. This distribution may limit the abil-
ity to make inferences about the results. However, the QOF targets consistently produced 
a higher percentage of hypertensive patients with diabetes with controlled blood pressure 
than that produced by the NICE target. It seems that the achievement of lower blood pres-
sure targets was not completely satisfactory. Becoming older and those of other Asian 
origin were patient characteristics positively associated with having controlled blood pres-
sure. However, the results should be interpreted cautiously because of the limitations of 
the sample size.   
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Table 28 Percentage of diabetic patients with controlled blood pressure by 
age, sex and race/ethnicity (N=3360) 
 
  
QOF target NICE target
number (%) p value number (%) p value 
Male <0.0001 <0.0001
17-44 years 40 (53.3) 19 (25.3)
45 - 64 years 412 (63.3) 204 (31.2)
>= 65 years 709 (74.9) 441 (46.2)
Female 0.006 0.109
17-44 years 38 (56.7) 20 (29.9)
45 - 64 years 416 (70.4) 218 (36.9) 
>= 65 years 758 (73.8) 416 (40.5)
Ehnic group 0.062 0.059
White 1016  (72.1) 570 (40.5) 
Black 675 (68.6) 349 (35.5) 
South Asian 391 (72.4) 234 (43.3)
Other Asian 134 (74.0) 89 (49.2)
Other 106  (63.1) 52 (30.9)
Unknown 51 (66.2) 24 (31.2)
Overalll 2373  (70.6) 1318 (39.2)
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Table 29 Comparison of diabetic patients with controlled hypertension be-
tween those with and without cardiovascular comorbidity N(3360) 
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Table 3 with controlled hypertension for all diabetic patients (N 3360) 
 
Table 30 Odds ratio of patient characteristics associated with being classified as 
a patient with controlled hypertension for all diabetic patients (N 3360) 
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Table 31 Odds ratio of patient characteristics associated with being classi-
fied as a patient with controlled hypertension for all diabetic patients without 
cardiovascular comorbidity (N=2308) 
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7.4 Discussion 
 
In 28 general practices with 15761 hypertensive patients differences in the proportion of 
PCHs were quantified when different targets were used. The use of the 150/90 mm Hg 
QOF target produced a higher proportion of PCHs, overall 79.5%. In comparison, the pro-
portion of patients with controlled hypertension was 60.7% using the NICE target. There 
were 26 (93%) of practices with more than 70% of their patients with controlled hyperten-
sion by using the QOF. In contrast when the NICE target is used, only 4 (14.2%) of prac-
tices had more than 70% patients with controlled hypertension.  
 
The difference in the proportions of patients with controlled hypertension between both 
blood pressure targets can be explained by variations in systolic blood pressure levels 
among hypertensive patients because the diastolic blood pressure threshold was the same 
for both targets. Then the lower proportions of PCHs observed by using the NICE target 
may be attributed to patients having systolic blood pressure levels above the NICE thresh-
old. Reductions in systolic blood pressure levels have been less well achieved than reduc-
tions in diastolic blood pressure levels even in controlled clinical trials (214, 667). There-
fore despite improvements in blood pressure control, it seems that higher systolic blood 
pressure levels still account for most cases of uncontrolled hypertensive patients (668). 
That occurring particularly in adults over 50 year because systolic blood pressure continu-
ally increased with age and the opposite trend is observed in diastolic blood pressure (73).   
 
On overall women had mean systolic blood pressure 137.4 mmHg (sd 16.2). Women aged 
17 to 44 years had the lowest systolic blood pressure levels, mean systolic blood pressure 
131.5 (sd 16.2) mmHg. Of note, mean systolic blood pressure 139.5 mmHg (sd16.4) ob-
served in those aged 65 years and over was comparable to that observed in some clinical 
trials. For instance, results from individual trials such as JATOS and VALISH illustrated 
that hypertensive patients aged over 70 years were able to achieve mean systolic blood 
pressure of 135.9 mmHg and 135.6 mmHg respectively without excess in side effects 
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(198, 200). It appears that blood pressure reductions are correlated with baseline blood 
pressure so that more intensive approach may be required to those with higher blood lev-
els (173). Then the current results suggested that high reduction in systolic blood pressure 
is possible to achieve in the daily clinical practice.  
 
Systolic blood pressure was similar in men at different age groups; overall mean systolic 
blood 138.2 (16.4) mmHg. There were no differences in systolic blood pressure between 
age groups. Similar to what observed in women, there seems that these levels were in the 
range of what observed in clinical trials (139) and in the last Health survey for England. 
The survey revealed that men had a mean systolic blood pressure of 130.8/74.2 mmHg 
(284). The current results showed that men aged 65 years and over had lower blood pres-
sure levels than that those observed in women at same age. Early reports suggested a 
differential lowering blood pressure effect of antihypertensive drugs in women (669). How-
ever, Turnbull et al. in a meta-analysis of 31 clinical trials did not find differences in blood 
pressure reductions between men and women neither in the hypertension-related cardio-
vascular risk reduction across clinical trials (670). The analysis used individual clinical data 
and the follow up period was comparable between studies (670). Hence the observed dif-
ferences in blood pressure levels between men and women could be explained by other 
factors different from sex, age and antihypertensive drug therapy effect.  
 
Comparisons of blood pressure between ethnic groups revealed that for men and women 
blood pressure levels were lower in patients of South Asian origin. In an analysis of 12 
studies, Agyemang et al reported that population of South Asian origin living in England 
had lower blood pressure levels than those observed in the general population (90). 
Women had lower blood pressure levels than men (90). Similarly, In analysis of 99683 
patients from 148 practices in east London, Mathur et al found that hypertensive patients 
of South Asian origin had lower blood pressure levels compared to that observed in pa-
tients of white and black origin (535). They also had a higher prevalence of other cardio-
vascular comorbidities such diabetes.  Hence it seems that the observed lower blood 
pressure levels may be due to both the biological conditions presented in this population 
and the interventions they received.  
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Patients of black origin had similar blood pressure levels to those observed in the white 
population. Thus 78.2% and 60% of black patients were classified as a PCH using the 
QOF target and the NICE target respectively. In a study conducted  among 16613 hyper-
tensive patients from general practice located in South London, Ashworth et al reported 
that 77.0% of black patients had controlled hypertension with  a mean systolic blood pres-
sure of 138.2 mmHg (497). Similarly in an analysis of data from the 2004 Health Survey for 
England, Nazroo et al did not find differences in the risk of having controlled blood pres-
sure between whites and other ethnic groups (495). By contrast, people of African origin 
living in other countries have been found to have higher blood pressure levels that those of 
white origin. In the NHANES surveys carried out between 1988 and 2008, Egan et al found 
that African American people had a higher prevalence of hypertension with lower blood 
pressure control rates than the white people (283). Similarly, in a survey conducted in 
Netherlands, Agyemang reported that people of African origin were less likely to have con-
trolled blood pressure than the white population (671).  
 
The reasons for these differences could be a lower baseline blood pressure levels in the 
African British population. In a review of population surveys carried out in the UK and the 
Netherlands, Agyemang et al found that Dutch African people had higher blood pressure 
levels than African British. Differences in access to treatment may account for these differ-
ences between countries. In that, the review showed that African British people were more 
likely to receive treatment and to have controlled blood pressure (671). The hypertensive 
patients of the current study came from those who had periodically been treated by health 
services. Those patients have been found to have better blood pressure control than hy-
pertensive individuals included in national surveys. Being treated by a multidisciplinary 
team and access to treatment are factors which may contribute to the high proportion of 
black patients with controlled hypertension (672). Moreover reductions in the discrepan-
cies of blood pressure control rates between patients of different ethnic origin have been 
reported in patients exposed to health care over a long follow-up period (672). Then black 
patients under appropriate treatment are able to attain similar reductions in blood pressure 
levels to those observed in patients of other ethnic origin (143, 673). Differences in life 
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style such as exercise and diet between black populations living in different countries 
could also explain the differences in blood pressure control rates (674). Globally, it seems 
that people of African origin living in the UK are more physically active than those living in 
Netherlands (674-675).  
 
For men and women systolic and diastolic blood pressure levels were lower in hyperten-
sive patients with an additional cardiovascular than those observed in hypertensive pa-
tients without an additional cardiovascular comorbidity. The most frequently associated 
comorbidity was diabetes. The lower blood pressure targets for these patients established 
in the hypertension guidelines may contribute to this finding (174). Early clinical studies 
showing the benefit of lowering blood pressure below 140/90 mmHg in hypertensive pa-
tients with additional comorbidity such as diabetes also may influence the use of lower 
blood pressure targets (201). In English primary care, Meran et al also documented im-
provements in blood pressure control in patients with kidney chronic disease associated 
with the implementation of the NICE guidelines for the management of chronic kidney dis-
ease (569). Similarly in the analysis of diabetic patients from the US 1999 -2010 NHANES 
Wong et al reported improvements in the management of blood pressure in this patient 
group over the period (676). Hence, it seems that the lower blood pressure threshold es-
tablished in the guidelines has influenced the management of hypertensive patients in pri-
mary care.  
 
The higher blood pressure levels observed in patients without cardiovascular comorbidity 
could be related to the lack of evidence supporting the benefit of using lower targets for 
this patient group. The recommended targets are mainly based on blood pressure levels 
achieved by patients included in clinical trials. However these patients have been mainly at 
high cardiovascular risk (677-678). Analysis from subgroups of patients included in clinical 
trials have shown that using lower targets in hypertensive patients at low cardiovascular 
risk could result in higher reductions in the hypertension-related cardiovascular risk (210, 
262, 679). Moreover an excess of cardiovascular risk is still present at the level of the cur-
rent blood pressure target as the hypertension-related cardiovascular risk has been ob-
served at levels up to 115/75 mmHg blood pressure (7, 680). People with these blood 
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pressure levels could also account for the major burden of hypertension at population level 
(681). Hence, despite not having a clinical trial supporting a defined lower blood pressure 
target for patients at low or middle cardiovascular risk, there is no a clear reason for not 
attempting lower blood pressure levels in this patient group. 
 
Blood pressure control  
The percentage of patients with controlled blood pressure equal to or below 140/90 mmHg 
was 60.5%. Overall 50% of patients without cardiovascular disease had blood pressure 
levels below 140/90 mm Hg. Data from the Health Survey for England showed that blood 
pressure rates have been improved in England since 2002 (284, 682). The 2006 Health 
Survey for England showed that on overall 28% of hypertensive patients have blood pres-
sure levels below 140/90 mm HG. Similarly to my results, the percentage of women with 
controlled hypertension tended to decreased with age. For men there were not significant 
variations across age categories (284). The fact that the population included in the current 
study were managing in primary care settings could be explained the higher percentage of 
PCHs compared to that reported by the national survey. The survey sampled civil popula-
tion having or not having care in primary care settings.  
The percentage of hypertensive patients with blood pressure levels equal to or below 
150/90 mmHg was 79.5%. The percentage tended to increase with age in both sexes. This 
may be because diastolic blood pressure levels were higher in those at younger age than 
in those at older age. Systolic blood pressure had less variation across age groups, par-
ticular in men. In a cohort of 470725 hypertensive patients, Serumaga et al reported that 
nearly 70% achieved blood pressure levels <= 150/90 mmHg during a  seven years follow 
up period (683). This target was established as the audit threshold for the management of 
hypertensive patients in a clinical practice in the 2004 BHS hypertension guidelines (174). 
However using this target may leave patients classified as patients with controlled hyper-
tension but with an excess of cardiovascular risk potentially intervened. That is because 
reductions in systolic blood pressure below 150 mmHg are feasible attained with a subse-
quent reduction in hypertension-related risk (7, 140). Therefore, The classification of hy-
pertensive patients as those with controlled or uncontrolled hypertension based on this 
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target could fail to provide accurate information on the long-term blood pressure control 
needed to achieve the maximal cardiovascular risk reduction for each patient (171, 684). 
 
Regardless of the target used higher proportions of blood pressure control were identified 
in those of South Asian origin, overall 82.2% with the QOF target and 68.8% with the NICE 
target. That may be expected due to the lower blood pressure levels observed in these 
population (90). In study carried out in South east London, Ashworth et al found that pa-
tients of South Asian origin had higher rates of blood pressure control and also had more  
additional cardiovascular comorbidity (497). The percentage of black PCHs was similar to 
what observed in white population. Thus 78.2% and 60.6% of patients of black origin were 
classified as a HCP using the QOF target and NICE target respectively. Similarly Ashworth 
P et al reported that by using the QOF target 77.8% of Black patients had controlled blood 
pressure with a mean systolic blood pressure of 137.8 mmHg. In the analysis of data from 
the 2004 Health Survey for England, Nazroo et al also did not find differences in blood 
pressure control rates between patients of different race/ethnic origin (495). However, they 
acknowledged that this finding may be due to the small sample size in some ethnic 
groups.                                                                                                                       
In both target distributions the percentage of hypertensive patients with controlled blood 
pressure was higher in those with an additional cardiovascular comorbidity compared to 
that in those without additional cardiovascular comorbidity. In an analysis of 148 practices 
located in east London, Mathur et al found that patients with multicomorbidity were more 
likely to achieve blood pressure targets than those with only one comorbidity  (535). Simi-
larly Laverty et al reported better improvement in blood pressure control in patients with 
cardiovascular comorbidity compared to those without cardiovascular comorbidity over a 
period of 10 years (609). Reassuring the management of hypertensive patients at high 
cardiovascular risk such those with an additional cardiovascular comorbidity has been im-
proved in England.    
 
The probability of achieving either the QOF target or the NICE target was lower for men. 
However the probability varied between sexes across age groups. Thus women aged 17 
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to 44 years and men over 65 years had the highest probability of being with controlled hy-
pertension. Differences in blood pressure control between men and women have been 
inconsistent between different studies. Falascheti et al did not report significant differences 
in blood pressure control between men and women on hypertensive treatment in the 
Health survey for England (284). In the analysis of NHANES 1999-2004,  Ong et al re-
ported that  men and women had similar blood pressure control rates (685). However in a 
cross sectional analysis of the NHANES 1999 – 2004, Gu et al revealed that women were 
less likely to achieve blood pressure control than men (320). In a cohort of 288916 patients 
with incident hypertension Daugherty et al analysed gender differences in blood pressure 
control (274). They  found that hypertensive younger men with or without cardiovascular 
comorbidity had lower blood pressure rates than women but older men had higher blood 
pressure control rates than women (274). The reasons for those differences have not been 
clarified. The well-known differences in age-related blood pressure levels between sexes 
could play a role in the probability of achieving a specific target (38, 73, 686). Other expla-
nations may be related to differences in blood pressure response to therapy between 
males and females. However evidence from two meta-analyses on differences in the effect 
of antihypertensive drug therapy between sexes did not revealed significant variations in 
blood pressure reductions between women and men (670, 687). Also, differences in life-
style and behaviour could account for this effect (688). Therefore more exploration on the 
contribution of sex and age in the probability of having controlled hypertension may be 
needed.  
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The assessment of blood pressure control in practices 
Using the QOF target produced slight differences in the proportion of PCHs between prac-
tices. 95% of the practices had more than 70% of hypertensive patients with blood pres-
sure equal or below 150/90 mmHg. In an analysis of more than 2000 practices in England, 
Ashworth et al found that slight differences in the percentages of patients with blood pres-
sure equal to or below 150/90 mmHg after the introduction of the QOF (498). Similarly in 
sample of 303 patients, Hammouche et al reported that there were no differences in blood 
pressure control between patients in the least and most deprived areas using the QOF 
target (689). The 2008 and subsequently reports of the QOF indicators revealed that more 
than 90% of the registered practices had nearly 90% of hypertensive patients with blood 
pressure levels below 150/90 mm Hg. The report also showed a reduction in inequalities of 
blood pressure control between practices located at different socio-economic strata (529).  
 
Using the NICE target, practices located in the least deprived areas had a lower percent-
age of patients with controlled blood pressure than those located at the most deprived ar-
eas. This finding may differ from others reports shown that practices working at the most 
deprived areas had lower quality of care (608). However reductions in inequalities of care 
between socio-economic strata have been observed in England and also in Wandsworth 
(690-693). Therefore other factors different from socio-economic status may explain this 
finding. Population characteristics could account for that difference because patients regis-
tered with these practices were more likely to be younger, of other ethnic origin different 
from white and without cardiovascular comorbidity. Patients of black origin may have low 
adherence to antihypertensive interventions (464). Differences in dietary habits have been 
found between ethnic groups (466). South Asian people have been found to experience 
more psychosocial adversity than whites in the UK (694). That may result in additional 
cardiovascular risk (648, 694). They also tended to have lower physical activity (695).  
Consequently, the care provided by the practices may need a complementary approach 
taking into account the cultural background of its population.  
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The QOF indicators used for the assessment of blood pressure control in primary care 
may need revision. The small variations in blood pressure control rates between practices 
using the QOF target suggest that the QOF target may not able to capture differences in 
blood pressure control rates between general practices. That could be attributed to the 
higher blood pressure threshold used as a target. A reduction in blood pressure levels has 
been observed in the UK according to the Health Survey for England. In 2006, overall 
mean blood pressures was 127.3/73.3 mmHg suggesting that most of the population have 
blood pressure levels below the QOF target (284). Hence the threshold may need  a revi-
sion and  in fact a consultation is ongoing to replace the current blood pressure level of 
150/90 mmHg with 140/90 mmHg (605) 
 
Lester H and Campbell S propose that one the characteristics of QOF indicators is the 
capability of detecting variations in quality of care (279).  Additionally, it has been argued 
that the QOF indicator may detract attention from improving reductions in hypertension 
cardiovascular risk for all hypertensive patients (696). Then the QOF indicator may be 
suitable as a proxy measured of the blood pressure control but more stringent measured 
may be needed. Moreover, Millet et al have proposed to develop targets regarding local 
and populations’ characteristics. The development of local operational definitions of blood 
pressure control could improve the monitoring of the hypertension-related cardiovascular 
risk for all hypertensive patients at community level (697). 
 
7.5 Strengths and weaknesses of the study 
I have illustrated the utility of medical registers to assess the implications of two definitions 
of blood pressure control. As the conditions and patients included in clinical trials usually 
differ from those in routine clinical practice, information collected in that routine practice is 
an important resource to explain the discrepancies between both contexts. Moreover, the 
register included a large proportion of patients from ethnic minorities and women groups 
who are often under-represented in clinical trials (670, 698).   
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The study does however several limitations. In line with observational studies, findings 
from this analysis may not always be generalised to patients with hypertension in other 
settings.  The associations explored are only limited to the variables available in routine 
clinical data. The proportions of patients who achieved the blood pressure targets were 
derived from one blood pressure measurement. They could be overestimated or underes-
timated the number of PCH due to the variability of blood pressure levels (699-700). How-
ever, our findings  such the proportion of patients classified a PCH was consistent with 
other studies analysing  QOF data (498).  
 
7.6 Conclusion  
 
I illustrated to what extent using targets can modify the concept of blood pressure control. 
The QOF target of 150/90 mm Hg  produced higher blood pressure control rates than the 
NICE target of 140/90 mm Hg. Regardless of the target men over 65 years and over were 
more likely to be classified a patient with controlled hypertension.  Hypertensive patients 
with an additional cardiovascular comorbidity also were more likely to be classified as a 
patient with controlled hypertension. That may due to the lower blood targets established 
in the national guidelines for the management of these patients. The observed differences 
in blood pressure levels between age, sex and ethnic origin may suggest the need for age, 
gender and ethnic orientation for the management of hypertensive patients in primary 
care.    
 
The use of a target of 150/90 mm Hg may not accurately reveal differences in blood pres-
sure control between general practices. In England there has been a constant reduction in 
blood pressure levels since 2000 so that a more stringent target may be needed. An ap-
proach using local blood pressure targets for geographical areas may contribute to im-
prove blood pressure control in primary care.   
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Key points 
 In England  the 2004, 2006 and 2011 hypertension NICE recommend a blood 
pressure target equal or below 140/90 mmHg for hypertensive patients without 
cardiovascular comorbidity.  
 In England the assessment of blood pressure control in primary care is based on 
the QOF indicators.  
 The percentage of hypertensive patients with blood pressure equal to or below 
150/90 mmHg is the QOF indicator for the assessment of blood pressure control in 
primary care.  
 In 2007 among 15761 hypertensive patients registered with 28 practices located at 
Wandworth, on overall 60.5% and 79.5% of patients were classified as patients 
with controlled hypertension by using the NICE target of 140/90 mmHg and the 
QOF target of 150/90 mmHg respectively. 
 Regardless of the target used, men aged 65 years and over with additional cardio-
vascular comorbidity were more likely to have controlled hypertension.   
 On overall, younger women were more likely to have controlled hypertension but 
the probability of having controlled hypertension decreased with age.  
 Patients of South Asian origin had lower blood pressure levels than patients of 
other race/ethnic origin.  
 Younger black patients had the highest levels of blood pressure 
 By using the 150/90 mmHg target there were no differences in the percentage of 
patients with controlled hypertension between general practices. 
 By using the 140/90 mmHg target the percentage of patients with controlled hyper-
tension varied between practices.  
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Chapter 8 Impact of  ethnic-specific guide-
lines for antihypertensive prescribing in pri-
mary care in England: longitudinal study 
 
Providing hypertensive patients with appropriate drug therapy is essential for achieving 
blood pressure control. The reductions in blood pressure obtained from taking antihyper-
tensive drugs lead to a lower risk of stroke and coronary events (139, 701).  However, in-
appropriate management of hypertensive patients is recognized as one of the most impor-
tant causes of poor blood pressure control (45, 702). The percentage of clinical visits in 
which physicians have not intensified the antihypertensive treatment for hypertensive pa-
tients with high blood pressure levels may vary between 20% and 45% (402, 404-406). 
Guidelines have been produced to summarize information on the management of hyper-
tensive patients and help physicians to choose therapeutic treatment (13, 144, 703-705).  
This chapter explores the impact of the England national hypertension guidelines on drug 
therapy prescription.  
 
8.1 Guidelines for the management of hyperten-
sion   
 
The definition of clinical practice guidelines promulgated by the Institute of Medicine in 
1992 was recently updated as “Clinical practice guidelines are statements that include 
recommendations intended to optimize patient care that are informed by a systematic re-
view of evidence and an assessment of the benefits and harms of alternative care options” 
(706-707). Thus clinical recommendations established in these guidelines should be evi-
dence-based, prepared by a multidisciplinary team and taken into account the patient´s 
preferences on treatment (706-708). The guidelines for the management of hypertension 
establish recommendations on the definition of hypertension, the use of antihypertensive 
drugs, the targets for blood pressure control and the non-pharmacological aspects on the 
management of hypertension (13, 144, 703-705). Since 1978, when the first WHO hyper-
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tension report was launched (709) hypertension guidelines have proliferated worldwide. 
The current guidelines diverge in topics such as blood pressure thresholds to initiate ther-
apy, the first line drug therapy recommendations and/or blood pressure targets for hyper-
tensive patients on treatment (710-711).   
 
 
Impact of hypertension guidelines  
Evidence from interventional studies had shed light on the positive impact of implementing 
hypertension guidelines on the management of hypertension. In a longitudinal study con-
ducted in an Italian primary care, Grandi et al tested the effect of training 588 general prac-
titioners on the use hypertension guidelines. After nine months follow-up period, the rate of 
blood pressure control increased from 33.4% to 52.7% (712).  This improvement was attri-
buted to the use of guidelines because there were no others interventions occurring in the 
settings. Similar findings were revealed by Avanzini et al in a cohort study. They showed 
that whereas there was an increase in antihypertensive prescribing and lower blood pres-
sure levels among hypertensive patients being treated in the intervened clinical settings, 
there were no significant variations in these outcomes among hypertensive patients being 
managed in clinical settings where hypertension guidelines were not implemented (713). 
The additional input of this study relied on the participation of general practitioners in the 
preparation of the guidelines. In a case-control study among patients being managed in 
private and public primary care,  Allaire et al found that a continuing medical education 
program on using hypertension guidelines were associated with higher reductions in blood 
pressure levels (714). 
 
The impact of hypertension guidelines on the management of hypertension has however 
been variable (473, 715-716). On the one hand, using hypertension guidelines has not 
always produced improvements on the management of hypertensive patients (451, 455, 
473, 717-718). In Finland, there was no a significant increase in the percentage of patients 
with controlled hypertension after the introduction of the national guidelines (473), although 
the hypertension guidelines have been highly adopted (719).  Also changes in prescribing 
patterns were not found after the introduction of the Finish guidelines (716). That observa-
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tion may have been due to differences in the implementation of the Finnish hypertension 
guidelines across general practices (720). On the other hand, structured programs intro-
ducing hypertension guidelines have produced improvements on blood pressure control 
(280, 721-722). The implementation of the Canadian Hypertension Education Program, 
incorporating evidence-based hypertension guidelines, has produced an increase in both 
the percentage of patients with controlled hypertension and the percentage of hyperten-
sive patients under hypertensive treatment (723-724). Similarly experiences from China, 
Japan and Catalonia also documented the positive impact of introducing national guide-
lines (451, 721, 725). Reductions in the number of patients without treatment also account 
for the positive results derived from the introduction of the guidelines. Additional, physi-
cians aware of hypertension guidelines are more likely to use lower thresholds of blood 
pressure for the management of hypertensive patients (409). By contrast lower adherence 
to guideline recommendations could led to poor pressure control (726).  
 
The inconsistencies in the impact of hypertension guidelines on blood pressure control 
have been attributed to different causes. The mentioned physician-related factors, patient-
related conditions and the guideline implementation procedures may determine the effec-
tiveness of the guidelines in clinical practice. Patient-related conditions are those which 
are impediments to the use of the recommendations established in the guidelines, for in-
stance, having a terminal disease or intolerance to medications (727).  The failures of the 
diffusion process may detract health workers from being aware of the local hypertension 
guidelines (715). Then poor adherence to established recommendations could be ob-
served. In contrast providing physicians with continual education may improve the use of 
the guidelines (728-731). Similarly the use of computer-based clinical guidelines reminder 
systems has resulted in higher levels of adherence to the guideline-based recommenda-
tions (732). Hence, it seems that the effectiveness of guidelines is highly dependent on the 
methods used to implement and disseminate them among the potential users (451, 733-
734). Additionally, a multidisciplinary approach including strategies targeting patient´s be-
haviors may be needed to improve blood pressure control (735). 
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Guidelines are also tools to standardize the care of hypertensive patients at the primary 
care level (736-737). Observational studies have shown differences in the management of 
hypertension between localities in one geographical area (413). The percentage of hyper-
tensive patients on drug therapy prescriptions varies even though they are managed under 
similar organizational health conditions. Hence, recommendations established in the 
guidelines have been used as criteria to measure the quality of care offered to hyperten-
sive patients in primary care settings  (738).  
 
8.2 England guidelines for the management of 
hypertension in primary care 
 
This section describes a summary of the antihypertensive drug treatments established in 
the English hypertensive guidelines. The topics related to hypertension definitions and 
blood pressure targets were described in chapter 3.  Since 1993, when the first guidelines 
were published, modifications in drug therapy prescription have been produced (739). The 
British Hypertension Society (BHS) produced guidelines for the management of hyperten-
sion as an independent institution until 2004 afterwards the BHS has been part of the 
committee working with NICE to elaborate the national guidelines. The summary of 
changes is presented below (Table 32). 
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Table 32 Variations in antihypertensive therapy recommendations established in England hypertension guide-
lines 
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In essence the evolution of the guidelines has been towards providing hypertensive pa-
tients with treatment based on their characteristics. Since 2004 three patient groups have 
been considered by the national guidelines in England:  patients under 55 years, patients 
aged 55 years and over and black patients of any age (740). The 2011 NICE guidelines 
called the latter group as Black person of African or Caribbean family origin of any age 
(144). The groups were based on the varying role of the renin-angiotensin system in the 
genesis of hypertension. Younger patients exhibit higher plasma renin activity (PRA) asso-
ciated with high blood pressure but black patients and older patients have lower PRA (741-
742). Patients with low PRA also have volume excess and those with high PRA exhibit 
high arteriolar vasoconstriction  (743). Some studies revealed that ACEI and angiotensin 
receptor blockers (ARB) are associated with attaining lower blood pressure levels in pa-
tients with high PRA (744-746). In comparison, diuretics such as hydrochlorothiazide pro-
duce lower blood pressure levels in those with low PRA (747-748).  However the cut-off 
age defining the variation in the role of PRA has been less well-established. Whereas a 
meta-analysis of 35 trials  did not find differences in blood pressure reductions between 
antihypertensive drug class for patients aged 65 years and over compared with those be-
low 55 years (142, 749-750), other clinical trials showed that in comparison with calcium 
channels blockers and diuretics, beta-blockers and  ACEI produce significantly higher 
blood pressure reductions in younger patients of Caucasian origin (751-752).  
 
The recommendations on the use of beta blockers and diuretics have also changed over 
time. Beta blockers were recommended as a first line treatment in the 1993, 1999 and 
2004 BHS guidelines (500, 739, 753) but were downgraded in the 2006 NICE guidelines. 
The reported association between a long-term use of beta blockers and increases in the 
risk of diabetes may explain the change in the recommendation (754). Additionally some 
meta-analyses reported that comparing with other blood pressure lowering drugs beta 
blockers may have less efficacy in preventing stroke and other adverse cardiovascular 
outcomes (755-757). However, this observation has been questioned as the results may 
have varied including clinical trials with patients with different characteristics (139, 142). 
Diuretics were discouraged as a first line therapy for patients aged 55 years and older and 
black patients in the 2011 NICE guidelines (NICE). The decision was based on the as-
sumption that diuretics are less effective in reducing cardiovascular events than calcium 
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channels blockers (240). This result has not always been replicated by other clinical stu-
dies comparing diuretics against calcium channel blocker (228, 504).  
 
8.2.1 Impact of hypertension guidelines on the manage-
ment of hypertension in England  
 
The Health Survey for England reported that the proportion of hypertensive patients on 
treatment has increased from 48% in 2003 to 54% in 2006 (284). The surveys suggested 
that the guidelines may have had an impact on that change. I searched for studies assess-
ing the impact of the England guidelines on drug therapy prescribing between 1999 and 
2012 using MEDLINE and PUBMED sources (Table 33). 
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Table 33 Studies conducted in England showing the use of therapeutic rec-
ommendations established in the time-related hypertension guidelines be-
tween 1999 and 2012 
Year  Type study  Results related to drug therapy prescrip-
tion  
2003 (531) Longitudinal 
study 
55% of patients were prescribed with diuretic 
or beta-blocker monotherapy. The recommen-
dation established in the guideline.  
2007 (758)  
 
Cross sec-
tional survey  
62% of GPs reported not choosing the recom-
mend drug despite being aware of the guide-
line. Between 12% and 25% of GPs considered 
that there are differences in the lowering pres-
sure effect between antihypertensive drugs 
though the guideline postulated the opposite 
statement.  
2011  (759) Cohort 
study hyper-
tensive pa-
tients with 
stroke  
Between 1997 and 2006 the proportion of pa-
tients prescribed with guideline drug recom-
mendations increased from 24% to 37%. Over-
all 31%.  Using the recommended treatment 
was associated with lower recurrence of 
stroke. 
2010 (760) 
 
 
Analysis of 
the electron-
ic Prescrib-
ing Analysis 
Cost Tool 
system 
After the 2006 NICE hypertension guidelines 
there has been an increase in the number of 
younger<55 years prescribed with ACEI. The 
usage of calcium channels blockers also in-
creased.   There was a reduction in beta-
blocker use.  
2012(761) Cross sec-
tional study 
44% of hypertensive patients were prescribed 
with the guideline recommended treatment.  
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In England there have been few studies assessing the impact of the guidelines on drug 
therapy prescribing. The studies mainly assessed adherence to the time-related guidelines 
(531, 758, 761).  None of the studies reported a level of adherence higher than 60% to the 
recommendation established in the time-related guidelines One study described the pre-
scribing patterns over the period but it did not quantify the impact of the guidelines in the 
reported trend (759). This study also found that less than 50% of hypertensive patients 
were prescribed the recommended treatment (759). 
 
To sum up, hypertension guidelines aim to improve blood control. The association be-
tween the introduction of the guidelines and blood pressure control varied across different 
studies. Because drug therapy prescribing is more likely to be influenced by the recom-
mendations established in time-related guidelines, it has been used as indicator to meas-
ure the impact of the guidelines on the management of blood pressure. Generally low 
rates of physician adherence to drug therapy recommendations have been reported 
worldwide. 
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8.3 Study 
 
Background  
In England few studies have explored the association between antihypertensive drug pre-
scribing and the implementation of the hypertension guidelines. I conducted a longitudinal 
study to explore the variations in antihypertensive drug prescribing in a cohort of hyperten-
sive patients from the Wandsworth database. The cohort is formed of hypertensive pa-
tients who were registered with 28 general practices in Wandsworth from 1998 to 2007. 
Because the recommendations established in the guidelines are based on studies already 
published, I also aimed to assess the impact of the ethnic-specific recommendations intro-
duced by the 2004 BHS guidelines and incorporated in the 2006 NICE guidelines on the 
first line recommended treatment prescribe  by general practitioners over this period. 
Secondary objectives 
1. To describe  variation in drug therapy prescribing  between 1998 and 2007 among 
hypertensive patients managed in primary care 
2. To determine variations in drug class monotherapy prescribing over the study pe-
riod. 
3. To describe variations in the recommended monotherapy drug prescribing across 
NICE patient groups over the study period. 
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8.3.1 Methods  
 
I performed a retrospective longitudinal study to assess variations in antihypertensive pre-
scribing among hypertensive patients treated in primary care between 1998 and 2007. For 
this analysis all hypertensive patients aged 17 years and over forming the retrospective 
cohort were included. The data contained information on the prescription of the following 
antihypertensive drug class: angiotensin converting enzyme inhibitors (ACEI), beta-
blockers (BB), calcium channel blockers (CCB), and diuretics (DD). The drug prescription 
was recorded once each year for each patient as 0 for not prescribed and 1 for prescribed. 
Patients who had other additional cardiovascular comorbidity such as diabetes mellitus, 
coronary heart disease, stroke, atrial fibrillation, renal failure and heart failure were classi-
fied as a patient with an additional cardiovascular comorbidity.  
 
I used the 2006 NICE first line antihypertensive recommendation as the reference to as-
sess the use of the recommendations established in the guidelines (499) (Box 10).  I quan-
tified variations in drug prescription across the 3 main groups established in the 2006 
NICE guidelines such as  black for patients at all ages with black ethnicity, younger non-
black for patients below 55 years with other ethnic origin different from black  and older 
non-black for patients over 55 years with other ethnic origin different from black.  
 
To examine variations in antihypertensive prescribing over the study period, I measured 
the following annual percentages a) the percentage of patients on antihypertensive treat-
ment as the number of patients being prescribed no antihypertensive drug, one antihyper-
tensive drug and two or more antihypertensive drugs over the total number of patients in 
each NICE patient group; b) the percentage of patients on ACEI, BB, CCB and DD mono-
therapy as number of patients prescribed each class drug over the number of patients on 
monotherapy in each NICE patient group; c) the annual percentage of patients on the rec-
ommended monotherapy as the number of patients prescribed the recommended mono-
therapy over the total number of patients on monotherapy in each NICE patient group. 
Because the recommendations established in the 2006 NICE guidelines applied to hyper-
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tensive patients aged 18 years and over without other cardiovascular comorbidity, I in-
cluded only this hypertensive patient category to calculate the last two percentages (Box 
11).  
Box 10 First line monotherapy treatment established in the 2006 NICE hyper-
tension guidelines  
NICE group Younger than 55 years  55 years or older or Black 
at any age 
First line monotherapy 
treatment  
Angiotensin converting en-
zyme inhibitors (ACEI) 
Calcium antagonist blockers 
(CCB)  or diuretics (DD) 
 
 
Box 11 Definition of the outcomes  
 
Outcome Description  
Annual percentage of  pa-
tients on antihypertensive 
treatment  
Number of patients being prescribed no drug, one drug, two or 
more drugs by the total number of patients in each NICE 
group*100 
Annual percentage of patients 
without other cardiovascular 
comorbidity  on ACEI, BB, 
CCB and DD monotherapy 
Number of patients prescribed each drug class as monothera-
py by the number of patients on monotherapy in each NICE 
group*100. 
Annual percentage of patients 
without other cardiovascular 
comorbidity   on the first line 
NICE recommended mono-
therapy   
Number of patients prescribed the first line recommended mo-
notherapy by the total number of patients on monotherapy in 
each NICE group*100   
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Statistical methods 
The characteristics of patients were presented as mean values or percentages where ap-
propriate. The analysis of the outcomes was separately conducted for all registered pa-
tients and newly registered patients.  
Unadjusted trend analysis for the percentage of hypertensive patients being prescribed  
antihypertensive treatment, the percentage of those on antihypertensive drug class and 
the percentage of those on the first line NICE recommended monotherapy between 1998 
and 2007 was performed using the chi-Squared Stata test for trend assessment. The anal-
ysis was separately conducted for newly registered patients and all registered patients 
(762).  
 
Models for all included patients 
Variations in drug class monotherapy prescribing were assessed using generalized esti-
mating equation (GEE) regression models. The models were selected to take into account 
the potential correlation among drug prescriptions for each individual over the time (763-
764). Because the GEE models estimate variations in the outcomes at group level, they 
allow to measure the impact of interventions on subgroups exposed to an intervention over 
time (765). Models were performed separately for all registered patients in each NICE pa-
tient group. Only patients without cardiovascular comorbidity were included in this analysis 
as the NICE recommendations applied to this patient group.  
The GEE models were run using logit function to measure variation in the odds of being 
prescribing each antihypertensive drug class as a monotherapy over the period. The mod-
els were adjusted for the introduction of the BHS and NICE guidelines. The effect of the 
NICE guideline was measured by including a dummy variable with levels 0 and 1 
representing the before (1998-2005 years) and after (2006-2007 years) periods respec-
tively. Similarly, for the introduction of BHS guideline in 2004 a value of 0 was assigned for 
years between 1998 and 2003 and 1 for 2004 and afterwards.  
A logistic regression (population-average logistic regression GEE) was performed to as-
sess the variation in the odds ratio of being prescribed the first line NICE recommended 
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treatment over the study period. The models take into account the correlation occurring in 
repeated measurements over time (766-768). For this model, the binary outcome variable 
was the prescription of the first line recommended monotherapy for each hypertensive 
patient regarding the NICE guideline recommendation. I adjusted the model for the inclu-
sion of NICE and BHS guidelines as I did in the GEE models. The variation of the recom-
mended prescription in time was assessed by including year as a continuous variable. The 
model was adjusted for sex using a dummy variable. An interaction term between the 
NICE introduction and each NICE patient group was also included.  
 
Models for newly registered patients  
Data from the newly registered hypertensive patients is independent because the patient is 
registered with the data only once over the period. For these patients a logistic regression 
was run to test variation in the odds of being prescribing each antihypertensive drug class 
as monotherapy. The analysis was performed without divided patients into NICE patient 
groups because the small number of individuals in some groups. The models were ad-
justed for the inclusion of BHS and NICE guidelines as I did for the GEE models.  
 
A logistic regression model with standard errors adjusted for practice clustering was per-
formed to assess the variation in the odds ratio of being prescribed the first line recom-
mended treatment over the period (768). The model included the explanatory variables as 
I did in the logistic model for all included patients 
The statistical model  
The mathematical formulation was 
 
                               
The     was the term used to adjust for the baseline trend of Odds ratio  prescribing so 
that the other variations in the trend prescribing could be attributed to the introduction of 
whichever guidelines. 
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     represents the coefficient for the introduction of the BHS guidelines 
     represents the coefficient for the introduction of the NICE guidelines 
The data was analyzed using STATA version 11 (Stata Corporation, College Station, TX, 
USA).  
 
8.3.2 Results 
 
17245 hypertensive patients registered in 2007 formed the retrospective cohort. Among 
them 9510 (55.4%) were female, 9085 (68.29%)  White, and 10179 (50.2%) were 55 years 
and over. The frequency of associated cardiovascular comorbidities was diabetes in 3519 
(20.4%), coronary heart disease in 1889 (10.9%), stroke in 1212 (7.0%), atrial fibrillation in 
793 (4.6%), renal failure in 707 (4.1%) and heart failure in 412 (2.4%). The presence of 
other cardiovascular comorbidity was higher in older non-black patients than in others 
NICE patient groups (Table 34). 
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Table 34  Patients characteristics by NICE patient groups, 2007 
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Intensity of treatment  
All hypertensive patients 
Between 1998 and 2007, there was an increase in the percentage of patients who were 
prescribed antihypertensive medication. Thus the percentage of patients not being pre-
scribed antihypertensive medication decreased from 49.0% in 1998 to 14.8% in 2007 
(p<0.0001 for annual trend). By contrast, the percentage of patients being prescribed two 
or more antihypertensive medication increased from 21.2% in 1998 to 54.7 in 2007 
(p<0.0001 for annual trend). The percentage of patients on antihypertensive monotherapy 
slightly changed though significantly over the period (Table 35 Figure 17).   
Figure 17 Variation in the proportion of all include patients on antihyperten-
sive treatment, between 1998 and 2007 
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Table 35 Variation in percentages of all hypertensive patients on antihyper-
tensive treatment between 1998 and 2007  
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Over the study period the percentage of black patients on antihypertensive treatment also 
increased. The percentage of black patients without antihypertensive medication de-
creased from 48.6% in 1998 to 13.5% in 2007 (p<0.0001 for annual trend). A constant 
increase in the percentage of black patients being prescribed two or more antihypertensive 
drugs was observed from 25.7% in 1998 to 58.1% in 2007 (p<0.0001 for annual trend). 
There was no a significant variation in the percentage of black patients on antihypertensive 
monotherapy (Table 35, Figure 18). 
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Figure 18   Variation in the proportion of all patients on antihypertensive 
treatment by NICE groups between 1998 and 2007 
   
Black patients Younger non-black patients Older non-black patients 95% CI
Percentage: number of patients on  monotherapy /total of patients  on monotherapy  in each  patient group by drug classes
Vertical line indicated the introduction year of  the BHS and NICE guidelines
*Patients without one of the follow diseases coronary heart disease, diabetes mellitus, heart failure, atrial fibrillation, stroke or renal failure
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Similarly, the percentage of younger non-black patients on antihypertensive medication 
increased between 1997 and 2008. Thus, the percentage of younger non-black patients 
without antihypertensive medication decreased from 60.8% in 1998 to 31.7% in 2007 
(p<0.0001 for annual trend). By comparison, there were an increase in the percentages of 
younger non-black patients being prescribed one antihypertensive drug and two drugs, 
from 25.9% to 32.5% and from 13.2% to 35.9% (p=0.003 and p<0.0001 for annual trend) 
respectively. (Table 35 Figure 18) 
 
From 1998 to 2007 for older non-black patients the variation in antihypertensive prescrib-
ing changed as follows: the percentage of those not being prescribed antihypertensive 
medication decreased from 45.8% in 1998 to 10.0% in 2007 (p<0.0001 for annual trend), 
the percentage of patients on two or more antihypertensive drugs increased from 22.5% in 
1998 to 59.2% in 2007 (p<0.0001). The percentage of patients being prescribed one anti-
hypertensive varied from 31.7% in 1997 to 30.9% in 2008 (p<0.0001). Although the per-
centage were similar, a trend tend to reduce the percentage of patients on monotherapy 
prescribing was observed (Table 35 Figure 18). 
 
Over the period hypertensive patients with another cardiovascular comorbidity were more 
likely to receive more antihypertensive medication in comparison with those without other 
cardiovascular comorbidity. However there was an increase in the percentage of patients 
being prescribed antihypertensive medication for both groups.  For patients registered as 
having cardiovascular comorbidities the percentage of those without antihypertensive me-
dication decreased from  43.0% in 1998  to 5.9% in 2007 (p<0.0001 for annual trend) and 
the percentage of those being prescribed two or more medication increased from 30.3% in 
1998 to 69.9% in 2007 (p<0.0001 for annual trend). There was small but statistical signifi-
cant reduction in the percentage of patient on antihypertensive monotherapy prescription 
from 26.7% 1998 to 24.2% in 2007 (p<0.0001 for annual trend) (Table 36 Figure 19). 
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Figure 19 Variation in the proportion of all patients on antihypertensive 
treatment by presence of cardiovascular comorbidity between 1998 an 2007 
 
 
 
No comorbidity With comorbidity 95% CI
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Table 36 Variation in percentages of all hypertensive patients on antihypertensive 
treatment by presence of cardiovascular comorbidity between 1998 and 2007  
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Newly hypertensive registered patients  
As for all registered patients, the percentages of newly registered patients being pre-
scribed antihypertensive medication increased over the study period. Thus, an overall the 
percentage of newly registered patients without antihypertensive medication decreased 
from 49.6% to 18.4% (p<0.0001 for annual variation). Both the percentage of newly regis-
tered patient on one antihypertensive drug and on two or more medication increased from 
30.8%  to 47.8% and from 19.7% to 33.8% respectively over the study period (p<0.0001 
annual trend for both). (Table 37 Figure 20) 
 
From 1998 to 2007 the variation in antihypertensive prescribing for black patients 
changed; the percentage of those not being prescribed antihypertensive drug dropped 
from 46.5% to 17.9% (p<0.0001 annual trend), the percentage of those on one antihyper-
tensive increased from 29.7% to 45.2% (p=0.0001 for annual trend) and the percentage of 
those on two or more antihypertensive medication increased from 23.9% to 36.9% 
(p=0.0087 for annual trend).  
 
Over the study period the prescribing patterns significantly changed for newly registered 
younger non-black patients. A significant reduction in the percentage of those not being 
prescribed medication was present from 62.1% in 1998 to 27.0% in 2007 (p<0.0001 for 
annual trend). The percentage of patients prescribed two or more antihypertensive drugs 
increased from 10.9% to 24.8% (p<0.0001 for annual trend).  
Similar variations were observed in newly registered older non-black patients. In 1998, 
42.8% of them were not prescribed any antihypertensive drugs, with 33.7% were pre-
scribed only one antihypertensive, and 23.5% prescribed two or more antihypertensive 
medications. In 2007 by contrast, only 11.2% of newly registered older non-black hyper-
tensive patients were not prescribed any antihypertensive medications, 48.6% were pre-
scribed one antihypertensive and 40.2% were prescribed two or more antihypertensive 
medications. These variations were statistically significant over the period (p<0.0001 for 
annual trend for all).  
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Table 37 Variation in percentages of newly* registered hypertensive patients 
on antihypertensive treatment between 1998 and 2007 
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Figure 20 Variations in the percentage on antihypertensive treatment in 
newly registered patients between 1998 an 2007 
 
 
Black patients Younger non-black
Older non-black
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Newly hypertensive patients with additional cardiovascular comorbidity were more likely to 
be on antihypertensive treatment over the period. For this group, there was a decrease in 
the percentage of those not having antihypertensive drug from 36.2% in 1998 to 6.4% in 
2007 (p<0.0001). Consequently the percentage of those on two or more drugs significantly 
increased from 29.5% to 55.9% (p<0.0001) over the period. However there was no a sig-
nificant variation in the percentage of those prescribed one antihypertensive medication. In 
comparison, the percentage of hypertensive patients without cardiovascular comorbidity 
prescribed with one antihypertensive treatment significantly increased from 29.8 in 1998 to 
50.1% in 2007 (p<0.0001 for annual trend) (Table 38 Figure 5). 
 
Table 38 Variation in the percentage of newly* hypertensive patients on anti-
hypertensive treatment by comorbidity between 1998 and 2007 
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Figure 21 Variation in the percentage of newly registered patients on anti-
hypertensive treatment by comorbidity  
 
  
No comorbidity With comorbidity
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Summary intensity of treatment 
To sum up from 1997 to 2008 there was an increase in the percentage of patients on anti-
hypertensive treatment. The increase was observed in both newly and all hypertensive 
patients registered with general practices. The greatest increased was observed in young-
er non-black patients. Patients with additional cardiovascular comorbidity were more likely 
to receive more than one hypertensive medication.  
 
Variations in antihypertensive drug class monotherapy prescrib-
ing among patients without cardiovascular comorbidity  
All patients  
ACEI  
Between 1998 and 2007, the use of ACEI monotherapy varied as follows: in younger non-
black patients from 25.3% to 52.3% (p<0.0001 for annual trend), in older non-black pa-
tients from 16.9% in 1998 to 32.6% (p<0.0001 for annual trend) and in black patients from 
9.6% to 11.7% (p=0.2106 for annual trend). The GEE models revealed that for younger 
non-black patients and older no-black patients, the introduction of the NICE guidelines was 
associated with an additional increase in ACEI prescribing odds ratio 1.2 (95% CI 1.07 – 
1.34) (p < 0.0001) and odds ratio 1.07 (95% CI 1.01 – 1.14) (p<0.0001) respectively. For 
black patients, there was no a significant change odds ratio 1.06 (95% CI 0.93-1.22) 
(p=0.370).  Over the period, younger non-black patients were more likely to be on ACEI 
monotherapy and an additional increase in its prescription for this NICE patient group was 
observed after the introduction of the NICE guidelines (Figure 22 Table 39-40).  
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Beta blockers 
During 1998-2007, there has been a reduction in the use of beta blockers as monotherapy 
for all NICE patient groups. The percentage of younger non-black patients on beta blocker 
monotherapy decreased from 33.9% to 12.3%, (p<0.0001 for annual trend); from 25.8% to 
11.1% in older non-black patients, (p<0.0001 for annual trend) and from 22.4% to 5.6%, 
(p<0.0001 for annual trend) in black patients. The GEE models also showed that the intro-
duction of NICE guidelines was associated with an additional reduction in the beta-
blockers prescribing, with odds ratio 0.56 (95% CI 0.44 – 0.70) (p=0.003), 0.52 (95% CI 
0.42 – 0.65) (p< 0.0001) and 0.88 (95% CI 0.81 - .094) (p<0.001) for black patients, 
younger non-black patients and older non-black patients respectively.    
 
Calcium channel blockers 
There was a significant increase in the percentage of black patients on CCB monotherapy 
from 46.6% in 1998 to 58.3% in 2007 (p=0.0001 for annual trend). The percentage slightly 
changed from 22.5% in 1998 and 23.4% in 2007 in younger non-black (p =0.096 for an-
nual trend) and from 22.7% to 30.5% (p=0.0144) for annual trend) in older non-black pa-
tients. There was a significant contribution of the NICE guidelines to the use of CCB as 
obtained from the GEE models. Thus, the odds ratio associated with the introduction of the 
NICE guidelines was 1.20 (95% CI 1.08 – 1.32) (p<0.0001), 1.17 (95% CI 1.02 – 1.35) 
(p=0.023) and 1.07 (1.01 – 1.13) (p=0.001) for black patients, younger non-black patients 
and older non-black patients respectively.  
 
Diuretics 
The percentage of black patients on DD monotherapy was 21.4% in 1998 and 24.4% in 
2007 (p=0.0124 for annual trend). There were fluctuations in the trend over period with a 
slightly increase in the percentage in 2005. The percentage changed from 18.3% to 11.9% 
(p=0.010 for annual trend) in younger non-black patients and from 29.6% to 25.9% 
(p=0.0419 for annual trend) in older non-black patients. The GEE models showed that the 
introduction of the NICE guidelines led to an additional reduction in the use of diuretics, 
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odds ratio 0.74 (95% CI 0.62 – 0.87) (p=0.001), 0.70 (95% CI 0.62 – 0.80) (p<0.001) and 
0.92 (95% CI 0.87 – 0.97) (p=0.007) for black patients, younger non-black patients, and 
older non-black patients respectively.  
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Table 39 Variation in percentages of all antihypertensive patients on anti-
hypertensive drug monotherapy between 1998 and 2007 
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Figure 22 Variation in the percentage hypertensive patients on drug mono-
therapy class from 1998 to 2007 
  
Black patients Younger non-black patients Older non-black patients 95% CI 
Percentage: number of patients on monotherapy/total patientsts on monotherapy in each group drug category 
Vertical line indicated the introduction year of the BHS and NICE guidelines 
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Table 40 Variation in the odds of being prescribed antihypertensive drug 
class in each NICE patient group between 1998 and 2007
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Newly registered patients  
 
ACEI  
Over the period ACEI was the most common antihypertensive prescribed as monotherapy 
among the newly registered hypertensive patients. The use increased from 14.7%   to 
37.5% (p<0.0001 for annual variation). The percentage in use started changing after the 
introduction of the 2004 BHS guideline. The logistic model showed an additional increase 
in the use of was observed after the introduction of NICE guidelines, odds ratio 1.61 (95% 
CI 1.29 – 2.01) (p<0.0001). The observed increase in use was mainly due variations oc-
curring at the end of the 10 year period (Figure 23, Table 41-42). 
.   
Beta blockers 
Between 1998 and 2007 the usage of beta blockers as monotherapy has significantly 
dropped from 27.3% to 5.2% (p<0.0001) among newly registered hypertensive patients. 
An additional decrease was observed in the period after the introduction of the NICE 
guidelines, odds ratio 0.36 (95% CI 0.26 – 0.52) (p<0.0001) (Figure 23, Table 41-42). 
 
Calcium channels blockers  
From 1998 to 2007 the percentage of newly registered patients on CCB monotherapy in-
creased from 25.0% to 45.2% (p<0.0001 for annual trend). Between 1998 and 2003 the 
use remained stable. Then a sharply rise in use was observed coincident with the introduc-
tion of the 2004 BHS guidelines. Finally after the introduction of the NICE guidelines, there 
was an additional increase in the prescribing of CCB as monotherapy, odds ratio 2.93 
(95% CI 2.36 – 3.65) (p<0.0001). The overall increase in CCB use was mainly produced 
by the growth observed at the end of the period (Figure 23, Table 41-42) 
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Diuretics 
The prescribing of diuretics as monotherapy declined from 32.9% to 12.1% (p<0.0001) 
annual trend). The percentage of newly registered on DD monotherapy remained nearly 
stable from 1998 to 2004. Afterwards the percentage steeply declined which as associated 
with the introduction of the NICE guidelines. Thus, the odds ratio of being prescribed DD 
was OR 0.27 (95% CI 0.22 – 034) (p<0.001) after the introduction of the NICE guidelines. 
The decline in the use of diuretics was mainly marked at the end of the period. 
 
Summary monotherapy drug class prescribing  
 
To summarize from 1998 to 2007 the most noticeable variation in drug class prescribing 
has been the decline in the use of the beta blocker as monotherapy in all NICE patient 
groups. ACEI has been the most frequently antihypertensive prescribed as monotherapy 
mainly for younger non-black and older non-black. CCB has been the most common mo-
notherapy used for black patients. After the introduction of the NICE guidelines the follow-
ing variations in drug class monotherapy were quantified: a significant increase in the ACE 
use in younger non-black and older, an additional decrease in the usage of BB in all NICE 
groups, a higher use in CCB in all NICE groups and additional decrease in the use of DD.  
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Table 41 Variation in the percentage of newly* registered patients on drug 
monotherapy class between 1998 and 2007 
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Figure 23 Variation in the percentage of newly registered hypertensive pa-
tients on drug monotherapy class between 1998 and 2007 
ACEI Beta blockers
CCB Diuretic
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Table 42 Variations in the odds ratio of being prescribed antihypertensive drug monotherapy class for newly reg-
istered hypertensive patients between 1998 and 2007 
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Variations in the odds ratio of being prescribed with the first 
line NICE recommended monotherapy  
 
All patients without cardiovascular comorbidity 
  
Between 1998 and 2007, the percentage of patients prescribed with recommended 
monotherapy changed from 52.1% to 61.2% (p<0.0001 for annual trend). For black 
patients the increase was from 67.9% to 82.6% (p<0.0001 for annual trend). Between 
1998 and 2004 the percentage of black on first recommended monotherapy stayed at 
nearly same level. After 2004 a constant increased was observed. 
 
The percentage of younger non black patients on recommended treatment increased 
from 25.3% to 52.3% (p<0.0001 for annual trend) over the study period. From 1998 to 
2004 the percentage leveled off and then constantly increased. This has been the 
highest increase in the first line monotherapy among all NICE patient groups over the 
period (Figure 24 Table 43).   
 
For older non-black patients the percentage of hypertensive patients on recommended 
treatment varied from 57.3% to 56.3% (p=0.7645 for annual trend).The percentage 
almost remained stable over the period and it has not been influenced by the introduc-
tion of the guidelines.    
 
The logistic model revealed that after the introduction the NICE guidelines (2006- 2007) 
there was an increase in the use of the first line NICE recommended monotherapy (OR 
1.19, 95% CI 1.08 – 1.32) compared with the period before (2000 – 2005). An increase 
in the use of first line recommended monotherapy in younger non-black patients was 
also observed (OR 1.23, 95% CI 1.07 – 1.41) compared to the first line monotherapy 
offered to black patients.  In contrast, older non-black patients were less likely to be 
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prescribed the first line recommended monotherapy in comparison with black patients, 
(OR 0.76, 95% CI 0.68 – 0.84). On overall black patients were significantly more likely 
to be prescribed the first line recommended monotherapy than younger non-black (OR 
0.21, 95% CI 0.17 – 0.25) and older non-black patients (OR 0.45, 95% CI 0.39 – 0.52) 
respectively over the study period.  (Table 44 Figure 24)   
 
Newly registered patients without cardiovascular comorbidity  
Overall the percentage of newly registered patients being prescribed the first line rec-
ommended treatment increased from 52.3% in 1998 to 66.1% in 2007 (p<0.0001 for 
annual trend). The percentage remained nearly stable up to 2004 and afterwards 
sharply increased and leveled off at the end of the period (Table 43).   
For newly registered black patients the percentage of patients of patients on the rec-
ommended treatment increased from 73.6% in 1998 to 86.1% in 2007   (p=0.0812 for 
annual trend). Although there was an increase in the percentage, the variations over 
the period prevented from configuring a defined trend over the period. Between 1998 
and 2003 the percentage remained constant and plummeted in 2004. The fallen coin-
cided with a decrease in the use of CCB monotherapy at the same year. After that a 
continual increase was observed (Table 43, Figure 23).  
 
The greatest increase in the percentage of patients on the first line recommended 
treatment was observed in younger non-black patients. Thus in 1998 the percentage 
was 19.2% following with a period of fluctuations up to 2004. After 2004, the percen-
tage sharply increased reaching a peak of 57.4% by 2007 (p<0.0001 for annual trend) 
(Table 43). 
 
There was a slight variation of older non-black patients on the first recommended 
treatment over the study period. The percentage changed from 62.8% in 1998 to 
65.0% (p=0.0366). The percentage fluctuated over the period without demarking a 
constant pattern.  
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The logistic model showed that there was a significant variation in the use of the first 
line recommended treatment after the introduction of the 2006 NICE guidelines, overall 
(OR 1.74 95% CI 1.31- 2.34). Younger non-black patients were more likely to be on the 
first line recommended treatment (OR 1.83 95% CI 1.15 – 2.93) in comparison with 
black patients.  
By contrast, after the introduction of NICE guidelines older non-black patients were less 
likely to be prescribed with the recommended first line treatment (OR 0.59 CI 95% 0.38 
– 0.92) in relation to black patients. Over the period younger non-black patients and 
older non-black patients were less likely to have the first line recommended treatment 
compared to black patients, (OR 0.11 95% CI 0.07 – 0.18) and (OR 0.54 95% CI 0.36 – 
0.94) respectively (Table 44).  
 
Table 43 Variation in the percentage of hypertensive on first line mono-
therapy recommended treatment between 1998 an 2007  
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Figure 24 Variation in the percentage of hypertensive patients on the first 
line monotherapy recommended treatment between 1998 and 2007 
 
 
All patients Black patients
Younger non-black patients Older non-black patients
The graphs included only hypertensive patients without other cardiovascular comorbidity
Percentage: patients on monotherapy/total patients on monotherapy by each NICE patients group*100
 
 
 
 
 240 
 
 
 
Table 44 Variation in the odds of being prescribed the first line NICE rec-
ommended monotherapy between 1997 and 2008 
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8.3.3 Discussion  
 
For the hypertensive patients registered with 28 general practices in Wandsworth, there 
have been major changes in antihypertensive prescribing between 1998 and 2007. Over this 
period, an annual decrease in the percentage of all hypertensive patients with no medication 
was observed. Hypertensive patients having an additional cardiovascular comorbidity were 
more likely to receive more antihypertensive drugs. Overall the percentage of hypertensive 
patients without additional cardiovascular comorbidity being prescribed the first line NICE 
recommended treatment slightly increased over the period. Black patients without any cardi-
ovascular comorbidity were more likely to receive the first line NICE recommended treatment 
than younger non-black patients and older non-black patients. The percentage of black pa-
tients being prescribed the first line treatment also increased over time. Similarly the percen-
tage of younger non-black patients without a cardiovascular comorbidity being prescribed 
the first line NICE recommended treatment significantly increased over the period. For all 
NICE patient groups there has been a reduction in the use of beta-blockers and diuretics as 
monotherapy. These prescribing patterns suggested that some recommendations estab-
lished in the 2004 BHS guidelines and the 2006 NICE guidelines were already in used by 
general practitioners. However, the introduction of the 2006 NICE guidelines significantly 
increased the use of the first line recommended monotherapy in younger non-black patients. 
The 2006 NICE guidelines also significantly contribute to the observed reduction in the use 
of beta-blockers use as monotherapy.  
 
Intensity of treatment   
Globally the use of antihypertensive medication increased over the period. Thus the percen-
tage of patients not being prescribed antihypertensive medication decreased from 49.0% in 
1998 to 14.8% in 2007. Increases in the number of hypertensive patients on treatment have 
been reported by the Health survey for England over same period (284, 492). These trends 
were observed for all NICE patient groups but patients with an additional cardiovascular 
comorbidity were more likely to receive more than one antihypertensive drug. Hypertension 
guidelines advised that hypertensive patients may need more than one hypertensive drugs 
to lower blood pressure (13, 144, 184, 501). A sub-analysis from the Health survey for Eng-
land found a similar trend in prescribing for hypertensive patients with additional comorbidity 
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(494). These observations may also be related to the lower recommended blood  pressure 
targets recommended for these patients (225-226). Then these results provide evidence that 
general practitioners have continuously intensified the treatment offered to hypertensive pa-
tients over the study period in Wandsworth.  
Patterns of each class drug as monotherapy 
 
For all NICE patient groups the use of beta-blockers decreased over the period.  This reduc-
tion may be due to the growing evidence that beta blockers might be less effective at reduc-
ing both blood pressure and some cardiovascular outcomes (755), as well as being asso-
ciated with new onset diabetes (769). Additionally, there have been differences in the per-
centage of hypertensive patients on beta-blockers monotherapy between the three NICE 
patient groups, with the lowest percentage amongst black patients. These differences may 
be due to the effect of the recommendations established in the national guidelines published 
before 2004 (265). A decline in the use of BB has also been observed elsewhere. In analysis 
of the Taiwan National Health Insurance, Chou et al documented that between 1997 and 
2004 the ratio of BB prescribing per patient significantly dropped from 0.408 to 0.303 (770). 
The introduction of the NICE guidelines intensified the drop of beta-blocker usage in all NICE 
patient groups. A similar pattern was documented by the national report of antihypertensive 
prescribing published by NICE  (760).  
 
A reduction in the use of diuretics was observed over the study period.  For all NICE patient 
groups diuretics were less frequently prescribed as monotherapy than other antihypertensive 
drugs. The low rates of prescribing were not completely in concordance with the former 
guidelines available over the period. Whereas the 1999 BHS guidelines and the 2004 NICE 
guidelines recommended diuretics as the first line antihypertensive treatment for all patients, 
the 2004 BHS guidelines and the 2006 NICE guidelines established diuretics as first line for 
black patients and older non-black patients (223, 265, 501). A lower use of diuretics has also 
been reported by Fumaga et al in the USA (771). Although it has not been consistently dem-
onstrated (228, 504, 772), the observed underuse may be due to the reports that have 
shown that diuretics may be inferior to amlodipine in reducing hypertension-related cardi-
ovascular events (240). The potential side effects associated with diuretics such as new-
onset diabetes and renal toxicity may also explain the lower usage (504, 773-775).  
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A rise in the ACEI use was observed in younger non-black patients and older-non black pa-
tients. For both groups the percentage of patients on ACEI monotherapy has increased an-
nually over the period. Since, the early 2000s ACEI have been promoted as first line mono-
therapy particularly for those patients with higher activity PAR renin (231, 776-777). Howev-
er, only in 2004 ACEIs were introduced as the first line recommendation for younger non-
black patient (223). Even though there may be differences upon  hypertension-related mor-
bidity and mortality between the drug class categories (139), other long term benefits have 
been associated with ACEI use such as preventing from developing type 2 diabetes mellitus 
(238, 778-779). A similar pattern in ACEI was also found in the Health Survey for England 
(284). An additional increase in the ACEI use for younger non-black patients was observed 
after the introduction of the NICE guidelines. These observations provided additional evi-
dence of the influence of the guidelines in the prescribing of antihypertensive drug class in 
primary care.       
 
Calcium channels blockers were mainly used in black patients over the entire period. Thus 
the percentage of black patients on CCB monotherapy was nearly three times higher than 
that observed in younger non-black patient and older non-black patients. Although the BHS 
guidelines only introduced distinct prescribing advice for black patients in 2004 (223), pre-
vious evidence showing that antihypertensive drugs differ in their effect upon the lowering of 
blood pressure in black patients may account for this trend (746, 780). Additionally, a signifi-
cant impact of the 2006 NICE guidelines was quantified as imposing an additional increase 
upon the percentage of black patients on CCB monotherapy. By contrary the percentage of 
older non-black on CCB monotherapy did not significantly vary over the period.  Neither the 
2004 BHS guidelines nor the 2006 NICE guidelines significantly modified the observed pre-
scribing pattern of this group.  
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Impact of the guidelines  
 
The major impact of the guidelines was observed in the use of some antihypertensive drug 
class. Thus, the guidelines result in an increased use of ACEI for younger non-black and 
decreased use of BB for all NICE patient groups. The contribution of the guidelines to the 
improvements in the management of hypertension has been less explored. Toschke et al 
reported an increase of 31% in use of antihypertensive prescribing after the introduction of 
the former BHS  guidelines (759). An increase in antihypertensive prescribing has been re-
ported by the Health Survey for England though the impact of the guideline has not been 
well measured (284). Others authors reported adherence to the recommendations estab-
lished in the guidelines (761) However, the current results have also consistent with im-
provements in the management of stroke in the UK (781). Although this evidence may sup-
port the value of the guidelines in the management of hypertension, there seems that the 
increase in antihypertensive usage may also occur as a result of the continuity of care in 
primary care settings.  
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Black patients had already been prescribed the first line monotherapy established in the 
2004 BHS guidelines and the 2006 NICE guidelines even before they were launched. Thus 
nearly 67.9% of them received calcium channels blockers or diuretics as monotherapy in 
1998. Moreover the use of CCB was higher than the use of diuretics. That prescribing pat-
tern has not been in concordance with the recommendations established before 2004 as 
initiating diuretic or beta-blockers had been advised for all hypertensive patients. Then, this 
prescribing pattern may be mainly due to general practitioner´s criteria on drug selection. As 
mentioned, reports on black hypertensive patients reacting differently to antihypertensive 
drugs have been produced before the introduction of guidelines (746). Hence, general practi-
tioners could have been aware of the benefits of providing black patients with a different first 
line treatment. The results also showed that general practitioners are more in favor of using 
CCB than diuretic as monotherapy for black patients. Moreover the introduction of the ethnic 
algorithm in the 2006 NICE guidelines significantly increased the risk of having being pre-
scribed CCB in black patients. This did not happen when the same algorithm was published 
in the 2004 BHS guidelines.  
 
Younger non-black patients had the highest variation in the monotherapy prescription. Thus, 
this group experienced the greatest reduction in the number of patients without medication 
and the highest variation in the type of antihypertensive monotherapy being prescribed. 
From 1998 to 2004 there was not a specific age-drug recommendation in the national hyper-
tension guidelines (265). However the data showed that younger non-black patients were 
more likely to receive ACEI and beta-blockers in the years before 2004. Afterwards the per-
centage of younger non-black patients on ACEI monotherapy increased.  Thus, it seems that 
general practitioners’ preference towards the use of ACEI for this patient group may have 
been adopted a long time ago. Two clinical trials carried on a Caucasian population may 
support this selection (751-752). However this observation has not been replicated by others 
authors (142). The potential lower side effects associated with long term ACEI use, in com-
parison to those on diuretics and beta-blockers could influence this criteria selection in 
younger non-black patients (779, 782). The 2006 NICE guidelines positively impact the ACEI 
prescribing trend though only around 50% of this NICE patient group received ACEI as mo-
notherapy at the end of the study period. 
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Older non-black patients had the lowest variation in the monotherapy prescription over the 
period. The prescription offered to them was mainly CCB, diuretics and ACEI. At the end of 
the period there has been a reduction in diuretic use with an increase in ACEI use. Neither 
CCB nor ACEI were the first line recommendation established in the guidelines published 
before 2004 (502, 739). Subsequently, the 2004 BHS guidelines and the 2006 NICE guide-
lines recommended CCB or diuretic as the first line monotherapy for this patient group (174, 
499).  The prescription for older non-black patients may be affected by other considerations 
that could not be accounted for by the guidelines. Side effects, taking other medications or 
the presence of other non-cardiovascular comorbidities may explain the gap between the 
registered prescribing patterns and the recommendations established in the guidelines.  
 
I found that in 2007 on average 61.2% of hypertensive patients were on the monotherapy 
prescription standard established in the 2006 NICE guidelines. The percentage was similar 
to what reported in other studies carried out in the UK general practices (761).  The level of 
adherence has been variable in the international context (414, 783). It seems that the intro-
duction of the hypertension guidelines in a national program has the potential of changing 
antihypertensive prescribing patterns among physicians (414, 784-785). On average, there 
was an increase in the use of the recommended monotherapy after the introduction of the 
2006 NICE guidelines. However this mainly affected younger non-black patients. Physicians 
seem to adhere less to hypertension guidelines when prescribing antihypertensives to older 
patients (786-787). The presence of other comorbidities, the use of other medications and 
the potential higher prevalence of side effects may detract physicians using medications 
recommended in the guidelines (411).  
 
Heneghan et al carried out a survey aimed at evaluating awareness, agreement, adoption 
and adherence to the 2004 BHS and 2006 NICE hypertension guidelines among 800 GPs in 
the UK (758). They found that 62% of GPs did not adhere to the guideline recommendations. 
The survey was sent by the doctors.net.uk website on 10-14 May in 2006. The rate of re-
sponse was only 50.1% (401 GPs) and their geographic location was not mentioned. The 
authors stated that this GP population was similar to the all English GP population but with a 
lower representation of GP partner status. However some considerations should be taken 
into account about the generalization of these results. The sample seems small as 32111 full 
time-equivalent GPs were reported in the UK in 2009 (586). It might not represent all GPs 
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because the method of calculating the sample size was not mentioned in the study.  Addi-
tionally the results may be biased because the participation was voluntary with 50% re-
sponse rate. There was no description of non-responders (788).  Therefore the use of the 
recommendations may be underestimated. 
 
Globally, the observed drug class patterns were more influenced by the 2006 NICE guide-
lines rather than by the 2004 BHS guidelines. There may be some potential explanations for 
this finding. The BHS provides recommendations as an academic institution but it does not 
have a regulatory basis. By contrast NICE, an official NHS organization and health care, 
demands health providers following its guidance. Moreover the recommendations estab-
lished in the NICE guidelines have been integrated into the standards of care promulgated 
by QOF (279). The NICE guidelines aim not only to improve quality of care but also to re-
duce the variation in care across general practices. Hence it seems that integrating clinical 
guidelines into health policy improves the effectiveness of the established recommendations.  
 
8.3.4 Strength and Limitations   
 
The most important strength of this study is the comparison of trends in the management of 
hypertension across patient groups established since 2004 in the BHS guidelines. The report 
estimated the impact of national guidelines in antihypertensive drug prescribing in a cohort of 
patients registered with 28 general practices in England. Therefore I can estimate the tem-
poral variations in antihypertensive prescribing patterns and how long prescribing patterns 
remain over a long term period. Other reports have also quantified the percentage of hyper-
tensive patients on the NICE recommended treatment (761). But they did neither quantify 
how much variation there was before and after the introduction of the guidelines (531, 761) 
nor they could assess variations across ethnic groups (759). Hence the current analyses 
provide new evidence on how antihypertensive prescribing varied with patient characteristics 
and quantify the impact of the guidelines on these variations 
I was only able to examine the impact of the 2006 NICE guidelines over an 18 months period 
because the guidelines were launched between April and June 2006. Therefore the ob-
served impact may only reflect a short term effect. However the observed prescribing pattern  
is consistent to the prescribing trend reported in the National implementation uptake report 
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for the management of hypertension (760). The validity of the association also could en-
hanced by the GEE models as they allow making comparison between short time periods 
(764, 789). The study was based on hypertensive patients registered with general practices 
in a specific area of London.  
 
Other limitations of the present study rare the lack of information on the criteria used by the 
general practitioner to choose the antihypertensive medication for an individual patient. 
Therefore I cannot provide reasons for the differences between the guideline recommenda-
tions and some of the reported trends. Additionally, the patients included in the register may 
be different from all hypertensive patients as the data came from general practices located in 
a specific area in London. Hence our results may not be generalized to other population but 
the findings are in the line with the current trend in antihypertensive drug prescription re-
ported by other authors (284, 761).  
 
8.3.5 Conclusion  
 
The introduction of a treatment algorithm incorporating patient age and ethnicity established 
in the 2006 NICE hypertension guidance was associated with significant changes in the an-
tihypertensive prescribing pattern observed in the general practices in Wandsworth.  The 
findings suggest that the guidelines had the greatest impact on prescribing for younger non-
black patients. The smaller change in the recommended prescribing among black patients 
may be due to higher levels of appropriate prescribing in this group at baseline. Similarly a 
weaker influence of the guidelines upon the treatment offered to older non-black patients 
was observed. The use of beta-blockers as a monotherapy decreased over the period but an 
additional use reduction was associated with the introduction of the guidelines. The findings 
therefore suggest that the ethnic specific recommendations established in the national clini-
cal guidelines influence antihypertensive prescribing in primary care but that the impact of 
these guidelines can vary in the different patient groups 
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Implications  
The use of national hypertension guidelines has the potential of influencing antihypertensive 
prescribing patterns in general practice. However general practitioner criteria on antihyper-
tensive choice selection may be beyond the criteria established in the guidelines. Therapeu-
tic recommendations from well evidenced based studies may be more likely to influence a 
general practitioner’s practice than those based on less evidence-graded studies. Therefore 
the impact of the recommendations established in the guidelines unevenly affect drugs pre-
scribing across different age-ethnic patient groups.  
 
The findings of the study revealed that around 50% of patients received the recommended 
treatment at the end of the period. In particular older non black patients were less likely to be 
on their first line recommended treatment. Additional exploration may be needed to assess 
the implications of this discrepancy. The recommendations established in the guidelines 
could consider data not only from clinical trials but also data from current clinical practice.  
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Key points  
 To provide hypertensive patients with appropriate antihypertensive medication is es-
sential for the management of hypertension.  
 Guidelines on the management of hypertension guidelines have been proliferated to 
help physicians with antihypertensive drug choices.   
 Poor physician adherence to drug prescribing recommendations established in the 
guidelines has been reported worldwide. 
 In 2006 the NICE hypertension guidelines incorporated the ethnic algorithm proposed 
by the 2004 BHS guidelines to guide the first line treatment.  
 In 28 general practices located in Wandsworth, London, there have been major 
changes in antihypertensive prescribing between 1998 and 2007. 
 Over this period there was a reduction in the percentage of all hypertensive patients 
without antihypertensive medication.  
 Black patients without a cardiovascular comorbidity were more likely to receive the 
first line NICE recommended treatment. 
 For younger non-black patients without a cardiovascular comorbidity the risk of being 
prescribed the first line NICE recommendation significantly increased after the intro-
duction of the 2006 NICE guidelines. 
 Older non-black patients without a cardiovascular comorbidity were less likely to re-
ceive the first line recommended treatment over the period. 
 The use of beta-blockers as a monotherapy significantly decreased over the period 
 The introduction of 2006 NICE guidelines was associated with an additional reduction 
in the prescription of BB. 
 On average, at the end of the period, nearly 50% of patients received the first line 
recommended treatment.  
 General practitioners’ choices in selecting antihypertensive medication may not al-
ways be based on the criteria established in the guidelines, particularly in older non-
black patients.  
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Chapter 9 A Bayesian model for the assess-
ment of  factors affecting blood pressure con-
trol in a retrospective cohort of  hypertensive 
patients  
 
Background  
 
From the review presented in the chapter five I considered the following statements. The 
studies assessing factors affecting blood pressure control showed that achieving a blood 
pressure target is a complex health outcome. It depends upon the interaction between pa-
tient-factors, physician factors and the performance of health services essentially within pri-
mary care. The relationship between these factors and blood pressure control varied across 
the studies and sometimes was contradictory.  
 
Studies conducted in primary care services risk overestimating or underestimating the asso-
ciations as sampling may result in choice of those patients more recurrent visitors or more 
adherent to recommendations. The scope for generalizing the associations outside the study 
context may be limited due to differences in patient characteristics, physician’s performance 
and the conditions of the health system across the referred populations. Therefore, the re-
ported associations may be context-dependent. 
 
 The studies reported associations between factors and blood pressure control mainly from 
cross sectional studies using a logistic regression models in a Frequentist framework. These 
associations are highly dependent on the frequency of variable presented in each popula-
tion. They also cannot assess into account the variation on the outcome over time as the 
outcome is measured once at time point. These studies can neither assess the potential lag 
time effect of some variables on blood pressure control. Although some studies took sam-
ples including patients nested into practices, the effect of general practices in a multilevel 
analysis has not regularly been taken into account. To consider the mentioned aspects on 
blood pressure control, I assessed factors affecting blood control in a retrospective cohort of 
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hypertensive patients being treated in 28 general practices from 1998 to 2007. The contribu-
tion of individual factors, physician factors and health service factors on having controlled 
blood pressure was assessed using a survival model in a Bayesian Framework. The ration-
ale for using this approach is explained below.  
Secondary objectives 
1. To describe variations in blood pressure control among  patient cohort between 1998 
and 2007 
2. To compare the contribution of study factors in different subpopulations of hyperten-
sive patients.  
 
 
9.1 The Bayesian framework  
 
The Bayesian statistical approach relies on the fact that the probability of an event depends 
on i) its historical tendency, called the prior belief and ii) the information about the event oc-
currence obtained from the current data (790). Combining both sources under Bayes theo-
rem gives the final probability of the event, called posterior probability (790).  (Figure 25) 
Bayes theorem  
Bayes theorem established the probability of an event occurrence conditioned on other 
event occurrence  (790) 
Mathematical formulation:  
Given two events A and B, the probability (p) of A conditioned on B   is  
                            
          
       
     
 
 
Given the standard probability rules for mutually and exclusive events  
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Then based on the above, Bayes theorem establishes that 
        
            
              
  
 
For example: If we are interested in estimating the distribution of β (parameter of interest of 
a binomial outcome) from a dataset (D), we calculated it based on the following  
 
P (β):  The prior probability  
D:  information from data 
        
             
             
 
 
 Or  
 
                
                         
                          
 
 
Where the posterior is the posterior distribution of the parameter conditioned on data. It 
gives the updated information of the parameter.  
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Figure 25 The Bayesian framework 
 
 
9.1.1 Bayesian statistical inference  
 
Statistical analyses are frequently used to make inferences on unknown parameters. The 
estimated parameters allow us to assess hypotheses, to generalize results outside the data 
or to uncover process occurring in the data (791). In a Bayesian framework the unknown 
parameters are estimated using the data collected, the prior distribution and the model. The 
final result is the posterior distribution of the parameter. 
 
The prior distribution  
In a Bayesian framework all the parameters have a probability distribution. They are a ran-
dom variable rather than a fixed quantity, as seen in the frequentist framework. This distribu-
tion should be defined before conducting a study analysis therefore it is called the prior dis-
tribution. The selection of the prior distributions could be based on previous studies, per-
sonal opinion, expert’s opinion or other data (791).  
 255 
 
 
The prior distributions represent the knowledge or our beliefs about the parameters before 
conducting the current experiment and they can be non-informative or informative (792). The 
former are used when little or no information is known: one of the most common non-
informative prior distributions is a uniform prior which gives equal probability to any potential 
value of the parameter. The latter are used when there is information available on the pa-
rameters from previous studies, personal or expert opinion: normal, gamma or binomial dis-
tribution are typically used (790).  
 
The posterior distribution  
After combining the data and the model, the Bayesian analysis produces a posterior distribu-
tion of the parameters. Thus the mean, median, percentiles, standard deviation and standard 
error of the distribution are provided. Based on boundaries of percentiles for the parameter, 
a credible interval is calculated. 95% credible interval is based on the 2.5% and 97.5% per-
centile value of the posterior distribution. The credible interval corresponds loosely to the 
frequentist confidence interval but with a different interpretation. It  tells that there is a 95% 
probability that the value of the parameter occurs within  the estimated 95% boundaries 
(790). 
 
9.2 The rationale of using a Bayesian approach in 
the current analysis 
 
The present study used a retrospective cohort of hypertensive patients managed in primary 
care services. The data was collected by registering information on clinical evaluations of 
hypertensive patients taking during routine clinical visits. The data has a natural hierarchical 
structure with patients nested within practices and also with multiple outcomes for each pa-
tient. I selected the Bayesian approach to analyse the data based on the following reasons:   
1) Clinical trials and random-sample observational studies have been the traditional 
source of evidence in health research (793). As these studies produce inferences 
based on the calculation of sample size, the use of the Frequentist framework has 
rendered acceptable results (794). However, nowadays observational studies from 
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data collected in clinical settings have been shown to be a tool to  provide evidence 
about  interventions and quality of care taking in daily clinical practice (601). The 
analysis of that data may require a different approach because its origin is not sam-
ple size based-collected and the exposure to interventions is not usually randomly al-
located (794).  Therefore using a Frequentist framework in the analysis of that obser-
vational data has been questioned (790). A Bayesian approach, which is not highly 
dependent on sample size, could be a more suitable method to understand the rela-
tionships between variables present in the data (790, 795). 
 
2) The data from health services is periodically collected regarding patient´s atten-
dance. Consequently, there may be some variables with low frequency of observa-
tions. By using the Frequentist approach, information from spare data is commonly 
discarded because it may result in non-significant associations(796). That is due to 
the frequency of the variable being one of the conditions affecting the significance of 
the associations. Therefore the analysis may be biased towards highly represented 
variables even though they may not be clinical or social determinants of the outcome. 
By comparison in the Bayesian approach, those variables with lower frequency are 
integrated into the analysis equally to those with higher frequencies (797). 
 
3) The data has patients nested within general practices.  This data is also called hier-
archical data (798). The analysis of this data structure should require some consid-
erations. Firstly, patients within each practice are supposed to receive similar health 
care so that they would have a similar probability of achieving an expected outcome 
(799). In other words, the health outcome for individuals clustered within practices is 
considered to be correlated. A statistical analysis which ignores this correlation could 
produce inaccurate results. Secondly, there is variability in the outcome between 
practices. For multivariate models, the number of groups needed to estimate this 
variability is an area of controversy (800-801). Thirdly, the practice´s characteristics 
may contribute differently to the outcome. Using dummy variables for grouping prac-
tices without including practice´s variables could limit the assessment of this contribu-
tion (799).  
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The data also has patients from whom multiples observations of the outcome have been 
collected. For each patient, the measurements of the outcome recorded at various times are 
dependent (791). Particularly, the measurement of blood pressure levels would be consid-
ered correlated over the time (8, 802).  Therefore the data is a complex structure with two 
sources of random effects: one comes from the repeated measurement of the outcome for 
each patient and the other comes from the patients clustered into practices. 
 
In the Frequentist approach, the probability of the estimators is one that can be replicated in 
a long run of estimations (790).Thus if a study is repeated one hundred times under similar 
conditions, 95% of these new studies should produce a confidence interval containing the 
true value of the parameter (790). However when data is routinely collected health services, 
the replication of the conditions occurring in these services may be unlikely. Because these 
conditions may be unique, the assessment of the probability presented in the data could be 
of more interest rather than the assessment based on multiple replications. Using the Bayes-
ian framework we can directly determine the probability of the estimated parameter. Thus 
the 95% credible interval expresses the distribution of the values for the parameter. There-
fore, it expresses the amount of  uncertainty presents in the data given some priors and a 
selected model (790). 
 
9.2.1 Potential limitations on using a Bayesian framework 
 
The definition of the prior distributions has been one of the most questionable aspects of the 
Bayesian analysis (803). The prior distributions reflect information other than that  presented 
in the data (794).  They should be as close as possible to the knowledge available on the 
parameter of interest (790). That knowledge is not always achievable so the selection of the 
priors may rely on the researcher’s expertise. Therefore, a Bayesian analysis has been con-
sidered a subjective method (803). However  strategies such as the use of previous reported 
priors, the use of broad priors,  the comparison of different priors and the analysis of different 
levels of adjustment in the models allow the credibility of  selected priors to be assessed  
(794). 
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Later, Bayesian analysis has been categorized as objective and subjective (792).The objec-
tive uses non informative priors and the subjective uses informative priors (792). The use of 
informative priors introduces information for the parameter which could influence the poste-
rior distribution and the statistical inference. Some authors argued that the use of these pri-
ors may modify the information contained in the data and the results would mainly reflect the 
research´s opinions. However, the choice of the priors  should not be arbitrary and based on 
the expected relationship between variables and outcome (794). By comparison, using non-
informative priors the results are typically data driven and similar to the ones obtained using 
the Frequentist framework  (804).  
 
As occurred in the Frequentist framework, in the Bayesian framework the estimation of the 
probability depends on the model used (790). These models are intended to explain the in-
formation contained in the data. Their configuration should be  based on the following as-
pects: the focus of the study, the aim of the model (prediction, classification or exploratory 
models), the parsimony of the model and a balance between bias and variance (805). Re-
gardless of the statistical framework, the use of these criteria relies on the researcher. Con-
sequently, the model selection afflicts Frequentist and Bayesian methods in a similar way. 
The variable selection may rely not only on its statistical significance but also on its clinical or 
contextual significance. Because of these conditions, the statistical models may be approxi-
mations to the real world.  
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9.2 Methods 
Patient characteristics were described as mean or percentage for continuous or binomial 
variables respectively. Comparisons of blood pressure means were performed using ANOVA 
test.  
9.2.1 The Data  
 
For each hypertensive patient I identified the annual measurement of blood pressure over 
from 1998 to 2007. Hypertensive patients with a blood pressure equal to or below 140/90 
mm Hg were classified as those with controlled hypertension; those with blood pressures 
above this level were considered as having uncontrolled hypertension. The data had patients 
who entered the register at different times over the study period. For the majority of patients 
having a controlled blood pressure was a recurrent event (see descriptive results). Because 
patients with variations in their blood pressure control status were the most frequent group, a 
cohort with this group was used for the assessment of factors affecting blood pressure con-
trol over the study period. 
 
9.2.2 The model 
9.2.2.1 General considerations  
 
The assessment of blood control required some considerations.  Repeated measurements of 
blood pressure are known to be correlated (8).  The probability of having controlled blood 
pressure is depending on the basal blood pressure levels at starting therapy (210). Blood 
pressure has an intrinsic variability so that one blood pressure measurement may not reflect 
the true blood pressure value (8). Blood pressure measurement taking close to periods after 
initiating therapy could not reflect real variations in blood pressure levels (806). Hypertensive 
patients could change their blood pressure control status even in short time periods of three 
months (807). 
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Currently, the aim of the management of blood pressure is to achieve a target. Then, for a 
hypertensive patient having controlled pressure is a binary outcome. It can be interpreted as 
having or not an event over a defined period of time. Because of the variability in blood pres-
sure control status, it can be considered as a recurrent event. Time periods in which patients 
have a recurrent outcome are related to each other over a follow-up period  (791). Addition-
ally, hypertensive patients being treated within the same practice are more likely to have a 
similar outcome. Hence I selected a survival parametric model for recurrent events to assess 
factors affecting blood pressure control in the hypertensive patient cohort over a ten year 
period.  In the model, the outcome is the event time (time periods) of having controlled blood 
pressure as function of set covariates. 
 
Factors affected blood pressure control are classified into individual factors, physician-
related factors and health system factors (289). As mentioned in chapter 2, the contribution 
of these factors varied across studies. I developed a model which included all the potential 
factors related to blood pressure control presented in the data.  The outcome was measured 
at patient level and the factors were classified as follows: 1) Individual factors included age, 
sex, race/ethnicity, presence of cardiovascular comorbidity, presence of non-cardiovascular 
comorbidity and smoking. 2) Factors related of physician performance included being pre-
scribed antihypertensive medication in one of the models. I also assessed the use of the 
recommended antihypertensive treatment established in the 2006 NICE guidelines (499). A 
variable indicated whether or not a patient has been prescribed antihypertensive medication 
based on the algorithm established in the 2006 NICE guidelines was used in the model. The 
variable described the use of the first, second or third line antihypertensive prescription as it 
was established in the guideline. I used this treatment recommendation because the rec-
ommended algorithm was promoted in the 2004 British Hypertension Society guidelines 
(174). Also some recommendations were already published before 2004, for instance the 
differential hypertensive treatment for patients of black origin (504). 3) Factors related to 
practice services included the number of hypertensive patients registered in each practice. 
Because socio economic status was based on deprivation index of the area at which each 
practice was located, this factor was assessed as a practice characteristic. The performance 
of service was indirectly measured as the individual characteristic of being registered before 
or after the introduction of QOF.  
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9.2.2.2 Statistical formulation for the model 
 
 Definition of period times 
The time periods started from the year in which the patient was registered.  The calculation 
of the time period in which each patient had controlled blood pressure was based on the gap 
time formulation (808) Thus, for each patient, all time periods with equal blood pressure 
status were added when they appeared consecutively over year calendar. But, when a varia-
tion in the blood pressure control status appeared, a new time sequence was performed 
(see Figure 26).  
 
Figure 26 Illustration of the time calculation 
 
CBP Controlled blood pressure 
UCBP Uncontrolled blood pressure  
 
 
 
  
Patient A CBP CBP UCBP UCBP CBP CBP CBP CBP UCBP UCBP
Event recurrent time
Event censored time
Patient B UCBP UCBP CBP CBP CBP UCBP
Event recurrent time
1
Event censored time
1 2 3 4 5 6 7 8 9 10
Year 
2
4
2
2
4
2
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The frailty survival hierarchical model  
The descriptive analysis showed that blood pressure levels decreased over the period.  
Then it seems that the risk of having controlled pressure increased over the period. There-
fore I selected a Weibull distribution to model the hazard risk of having controlled blood 
pressure. The Weibull distribution allows modelling time events whose probability tends to 
monotonically increase over a period of time  (809).   
 
 The Weibull distribution for the event recurrent times is formulated as follows  
             
   
  (1.1) 
The hazard function is  
              (1.2) 
The correlation between time periods was measured using a frailty term in the model. The 
frailty term allows for taking into account random effects due to the multiple recurrence times 
of the same event in one individual (809). The term also accounts for other sources of vari-
ability due to differences in experiencing the outcome between individuals  (809).  
Using a Bayesian framework a parametric hierarchical survival frailty model for the hazard 
risk of having controlled blood pressure was formulated. The model is hierarchical with two 
levels. The first level is given by patients having repeated event times. The second level was 
formed by patients clustered with general practices. The model was formulated as follows: 
General formulation:  
                                  (1.3) 
Level one individual  
                                                        
                 
                                                               
Level two individual nested within practices  
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Where i = 1..... N patients; j = each individual measurement of outcome; z = 1...28 practices   
  is the regression coefficient for each variable included in the model. The variables were 
labelled as described in the chapter 6. The value of the variables was the first measurement 
registered in the dataset. For this model an additional variable (QOF) was included to take 
into account the potential effect of QOF on the outcome. It was a binomial variable named as 
0 for those individuals with a first record registered before 2004 and 1 otherwise. The depri-
vation index was categorized into tertiles of the distribution. The number of individuals regis-
tered with practice was taken from that registered in 1998 and it was categorized in tertiles of 
the distribution.  
     is the frailty term which accounts for random effects derived from individuals with multi-
ple measurements and nested within practices. The random effects are assumed to have a 
normal distribution with a mean      and    
  variance depending on the effect of patients 
nested within practices.    depends on the effects on individuals nested within practices.     
is the coefficient for practice effect with a mean      depending on practice characteristics  
and     common variance for all practices.    is the  intercept for practice effect. The code 
for the model is in the appendix.  
The representation of the model is shown below using the directed acyclic graph (DAG)  
(810). The graph illustrates the relationship between all quantities or nodes included in the 
model (variables and outcomes) which are in rectangular or elliptical shape. The rectangular 
nodes represent those nodes which are constants and the elliptical nodes those which rep-
resent either stochastic quantities or functional relationship. The single-edged arrows indi-
cate a stochastic relational and the double edged arrows the functional relationship between 
two nodes respectively. The repeated structures such as j, for individuals, and nested struc-
tures such z, for practices, are represented by plates. The DAG shows the contribution of the 
coefficients to the outcome. It also illustrates how the frailty term    was formed (Figure 27). 
The code for the model is presented in appendix C. 
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Figure 27 Directed acyclic graph (DAG) for describing the frailty survival Bayesian model 
Where: 
Alfa = intercept for practices  
Praclist: Number of individuals 
registered wIth each practice 
Depriv: deprivation index  
Eth: race/ethnicity 
Cco: cardiovascular comorbidity 
Nocc: no cardiovascular comor-
bidity  
Cho: cholesterol 
BMI Body mass index 
Tto: Antihypertensive treatment  
QOF Quality and Outcome 
Framework 
 
 
 
 
 e 
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The prior distributions 
Prior specification on the shape parameter (S) 
The prior distribution for the shape parameter was defined as a Gamma (1, 0.01). This 
distribution was chosen considering that the hazard risk follows a positive distribution and 
may increase over the time (809).   
 
Prior specification on coefficients  
The regression coefficients were given a normal distribution with zero mean and variance 
0.001.  This is non-informative prior but with a large variance  to reduce the influence of 
the prior distribution on the data (811).    
 
The frailty term  
 The frailty term was the random effects of the model. The random effects are assumed to 
have a normal distribution with mean and variance for individuals nested within practices.  
A gamma distribution with mean 0.5 and 0.5 variance was used for the precision of the 
individuals nested into practices. A gamma distribution with mean 1 and variance 0.5 was 
given for the overall precision of practices. Comparisons of gamma distributions for vari-
ance were performed. The gamma distribution with these informative priors was selected 
because the number of units in each hierarchical level is variable. For instance one indi-
vidual can have only two measurements of blood pressure. Similarly the number of indi-
viduals within each practice is below ten in some models. Under these conditions the use 
of non informative priors may led to a miscalibration of the posterior distribution (811-812). 
I also observed that the models did not convergence using gamma distributions with mean 
0.0001 and variance 0.0001 for variance of individuals nested within practices.  
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Censored data 
The data has right censored, left censored and interval censored observations. For in-
stance a patient could be registered with blood pressure control (outcome) but the time 
period before the outcome is unknown. Also, a patient could have uncontrolled blood pres-
sure in the first observation and have controlled pressure in the second observation but 
the second observation could be taken there years after. The parametric model deals with 
both of these censored observations (809).   
 
9.2.3 Data Processing  
Formatting the data for WinBUGS 
 
The data was analysed using WinBUGS software. WinBUGS is a program for carrying out 
Bayesian analysis developed between Medical Research Council Biostatistics Unit,   
Cambridge and Imperial College School of Medicine at St Mary's, London (810).  Win-
BUGS performs the statistical analysis using Markov chain Monte Carlo (MCMC). Thus 
from each iteration, a new value for each unobserved stochastic node is taken. The value 
came from the conditional distribution formed by models parameters and data (810). 
   
The data was originally recorded en excel files linked by the patient´s code. Then it was 
transferred into STATA format. I converted the data from STATA format to WinBUGS for-
mat using the commands provided by Thompson et al (813). In WIinBUGS, the data was 
set up a rectangular format. Three data sets were configured as one set for variables re-
lated to individuals, one for practice code and one for variables related to practices. The 
individuals were nested into practices.  
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Convergence of the parameters and model choice 
 
The assessment of the model was carried out for the parameters and the model. For the 
parameters looked at the convergence based on the patterns of time series, the autocorre-
lation and the Gelman Rubin test (814).  All of them are graphic test provided by the as-
sessment tool. The Gelman Rubin test assesses convergence for the parameters. For the 
model choice, the assessment of the models was based on the Deviance Information Cri-
terion (DIC) (810, 815).   
 
9.3 Results 
 
Baseline patient characteristics 
 
Of 17242 patients registered in the dataset, 11373 were selected for the survival analysis. 
(Figure 28) These patients had more than one blood pressure measurement and variation 
in the blood control status.  The mean age of selected group was 60.5 (12.8 sd) years.  
6459 (56.8%) were female and 6610 (53.7%) were white. 3044 (26.7) had an additional 
cardiovascular comorbidity. Of them, 1635 (14.4%) had diabetes, 919 (8%) had coronary 
heart disease, 11 (0.9%) had heart failure, 226 (2.3%) had atrial fibrillation,211 (1.9%) had 
chronic renal disease and 558 (4.9%) had stroke. Among those with other non-
cardiovascular comorbidity, 947 (45.9%) had asthma, 1109 (9.8%) had depression, 1093 
(9.6%) had chronic obstructive pulmonary disease (COPD).  BMI, cholesterol levels and 
smoking status were recorded at different times over the follow-up period. The first record 
of these variables was used. Patients without variation in the blood pressure status and 
those with only one blood pressure measurement tend to be younger and with less cardio-
vascular comorbidity than those included in the cohort group (Table 45). 
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Among those included in the survival analysis, the median of blood pressure records was 
6 ranging from 2 to 10. The median follow up period was seven years ranging from 1 to 10. 
For those without variation in the blood pressure status, the median was 2 ranging from 2 
to 10 (Figure 29-30).  
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Figure 28 Cohort profile 
 
 
 
*Patients configuring the cohort group 
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Figure 29 Distribution of patients include in the survival cohort by number of 
blood pressure records over the 10 years period 
 
 
Figure 30 Distribution of patients by number of blood pressure records for 
those without variation in blood pressure control  
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Table 45 Baseline patient characteristics  
Patient characteristics 
Those with more than one 
blood pressure measure-
ment and variation in blood 
pressure control  
(N=11373) 
Those  with more than one 
blood pressure measure-
ment and without variation 
in blood pressure control  
(N=3900) 
Those with one  blood 
pressure measure-
ment 
 
(N=1820) 
Age mean (sd)  60.5 (12.8)  57.6 (14.6)  55.1 (15.9)  
    
Male number (%) 4919 (43.2)  1816  (46.6)  931  (51.5)  
    
Body index mass mean  weight/cm²(sd)  28.5 (5.6)§§ 28.6 (6.1) ¥¥ 28.5 (5.8) ** 
    
Cholesterol mmol mean (sd)  5.5 (1.01) § 5.4 (1.0)¥ 5.5 (1.02) *** 
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Patient characteristics  (N=11373)  (N=3900) (N=1820) 
Ethnicity number (%)     
White  6610  (53.7)  2006 (51.4)  910 (50.0) 
Black 2679 (23.6)  827  (21.2)  399 |(21.9)  
South Asian  988 (8.7)  401 (10.3)  157  (8.6)  
Other Asian  355 (3.1)  161 (4.1)  75 (4.1)  
Other ethnicity  471 (4.1)  193 (4.9)  97  (5.3)  
Unknown  770 (6.8)  312  (8.0)  182 (10.0)  
    
Presence of cardiovascular comorbidity 
number‡ (%)  
3044 (26.7)  985 (25.3) 385 (21.2)  
    
Presence of other cardiovascular co-
morbidity number ‡‡ (%)  
2060 (18.1)  753 (19.3) 318  (17.5)  
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Patient characteristics  (N=11373)  (N=3900) (N=1820) 
Patients on antihypertensive treatment 
number (%) 
9215 (81.0)  2998 (76.8)  1350 (74.2) 
    
Systolic blood pressure mm Hg  mean 
(sd) 
146.8 (17.3) 140.7 (21.1) 142.4 (19.1)  
Diastolic blood pressure mm Hg mean 
(sd)  
85.9 (10.7) 83.5 (11.2)  84.8 (11.7)  
*Baseline patient characteristics referred to those characteristics recorded with the first record of each patient 
**Recorded for 1262 (69.4%) patients  
***Recorded for 1004 (55.1%) patients  
¥ Recorded for 3224 (82.7%) patients  
¥¥ Recorded for3380 (86.7%) patients  
§Recorded for 10482 (92.2%) patients  
§§ Recorded for 10407 (91.5%) patients  
‡Patients with at least one of the follow disease: coronary heart disease, diabetes mellitus, heart failure, atrial fibrillation, stroke or renal failure 
‡‡Patients with at least one of the follow disease:  depression, asthma or chronic pulmonary disease (COPD) 
Sd standard deviation 
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Blood pressure levels 
On overall, mean systolic blood pressure was 146.8 (sd17.3) at first entry. Mean systolic 
blood pressure levels at the first record was lower for those patients registered after 2002 
(p<0.0001). Mean diastolic blood pressure at first entry was 85.9 (sd 10.7). Although there 
were differences in mean diastolic blood pressure at first entry over the years, the differ-
ences were less significant than those observed for systolic blood pressure. (p=0.006). By 
comparison there was a significant reduction in systolic and diastolic blood pressure levels 
over the study period. Mean systolic blood pressure was 148.5 mm Hg (sd) in the first year 
observation and 137.4 mg (sd 14.8) in the last year (10th) (p<0.0001). Similarly, mean dia-
stolic blood pressure was 85.9 (10.3) mm Hg at first year registration and 78.9 mm Hg 
(10.1) in the last year observation (p<0.0001). The percentage of hypertensive patients 
with controlled blood pressure increased from 37% in 1998 to 62.4% in 2007 over ten 
years period (Figure 31-34). 
 
Figure 31 Mean systolic blood pressure at first record in the cohort group 
(N11373) 
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Figure 32 Mean diastolic blood pressure at first record in the cohort group 
(N=11373) 
 
 
Figure 33  Annual mean systolic blood pressure in the cohort group (N=11373) 
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Figure 34 Annual mean diastolic blood pressure in the cohort group (N=11373) 
 
Hierarchical survival frailty model  
Five models are presented including different sample size from the data.   
Models 1 and 2  
Model 1 was performed using the total of included patients, 11373. BMI, cholesterol levels 
and smoking variables were excluded. The model was running up to 8350 iterations and 
the first 1330 were discharged. The total time was 27 hours. Model 2 included those pa-
tients who had no missing data in the variables used in the analysis. The posterior estima-
tors were taken after running 17000 iterations. The first 1000 chains were discharged. The 
total time for running this model was 56 hours. For both models a high correlation was 
observed for the beta parameter of treatment. The correlation was corrected after using a 
lag of ten iterations. 
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The models produced similar results. For one year increase in age, there was a reduction 
in the risk of having controlled pressure over the study period. One year increase in age 
was associated with a reduction in the risk of having controlled blood pressure, posterior 
hazard ratio 0.99, (95% credible interval 0.99 - 0.99).  There was no significant association 
between sex and the risk of having controlled blood pressure. Compared to patients of 
white origin, those of other ethnic origin were more likely to have controlled pressure over 
the period, hazard ratio 1.09 (95% credible interval 1.0 -1.19). Although there were no sig-
nificant differences, patients of black origin tended to have uncontrolled blood pressure 
over the period (Figure 35). Neither having an additional non cardiovascular comorbidity, 
nor having an additional cardiovascular comorbidity had a significant effect on the risk of 
having controlled hypertension. Increases in BMI tended to reduce the risk of having con-
trolled pressure even though the estimators did not achieve significance. For those with 
overweight blood pressure control seems to improve but the credible interval has a long 
distribution. Then, this observation may change including a higher number of patients in 
this category (Figure 36). Higher levels in cholesterol were significantly associated with a 
reduction in the risk of having controlled blood pressure. For those patients with very high 
levels of cholesterol (over 6.1 mmol/L), the hazard risk was 0.94 (95% credible interval 
0.91 – 0.98). The risk of having controlled blood pressure did not vary by smoking status.  
In model 1 being prescribed antihypertensive medication was negatively associated with 
having controlled blood pressure. However in model 2 this association disappeared after 
adjustment for BMI, cholesterol levels and smoking status (Table 46-47). 
 
The risk of having controlled blood pressure was higher for patients registered after the 
introduction of QOF,  hazard ratio 1.87 (95% credible interval 1.74- 2.00)  and hazard ratio 
2.05 (95% credible interval 1.94 – 2.16) in model 1 and model 1 respectively. That asso-
ciation was observed in both models. There was no variation in the individual hazard risk 
of having controlled pressure among practices with different number of registered patients 
or located in areas with different deprivation index. The distribution of random effects was 
similar across the practices (Figure 37).  
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Table 46 Posterior hazard ratio associated with associated with variables in-
cluded in the model 1 (N=11373)  
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Table 47 Posterior hazard ratio associated with variables included in the 
model 2 (N=9679) 
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Figure 35  Box plot of the hazard ratio for having controlled blood pressure by race/ethnic Models 1 and 2 
Population Model 1        Population Model 2 
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Model 3  
For this model I included only patients without cardiovascular comorbidity to test the effect 
of being prescribed the 2006 NICE treatment at first entry on having controlled blood pres-
sure over the period. The model was running using a lag of ten iterations to reduce the 
autocorrelation in the parameter for the intercept. The model was run up to 11000 itera-
tions. The first 1000 iterations were discharged. The total time for running this model was 
22 hours. (Table 48) 
Similar to what observed in models 1 and 2, a year increase in age was associated with a 
reduction in the risk of having controlled blood pressure, 0.99 hazard risk (95% credible 
interval 0.99 – 0.99). The association between sex and having controlled blood pressure 
was no significant. Compared to patients of white origin, those of South Asian origin were 
more likely to have controlled blood pressure, 1.05 hazard ratio (95% credible interval 
1.003 – 1.09) (Figure 38).  Although the association was no statistical significant, patients 
of black origin tended to have uncontrolled blood pressure over the period.  The presence 
of other non-cardiovascular comorbidity and smoking did not significantly modify the risk of 
having controlled blood pressure. There was a negative association between increases in 
body index mass and having controlled blood pressure. This association was significant for 
those in the category obesity I, 0.93 hazard ratio (95% credible interval 0.88 – 0.99). The 
association between cholesterol levels and having controlled blood pressure was not sig-
nificant. Similarly there was no significant association between smoking and having con-
trolled blood pressure. Being prescribed the 2006 NICE recommended treatment was not 
significantly associated with having controlled blood pressure. However there was a trend 
showing a positive association between being on NICE treatment and having controlled 
blood pressure.  
Patients registered with the practices after the introduction of QOF were more likely to 
have controlled blood pressure, 2.06 hazard ratio (95% credible interval 1.93 – 2.19). As 
occurred in models 1 and 2, the distribution of random effects was similar between prac-
tices (Figure 37).  
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Table 48 Posterior hazard ratio associated with variables include the model 3 
(N = 6947) 
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Figure 36 Distribution of hazard ratio associated with BMI in population from models 2 and 3  
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Figure 37 Box plot of mean for random effects in 28 practices Models 2 and 3  
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Figure 38 Box plot of hazard ratio for having controlled blood pressure by race/ethnic. Models 3, 4 and 5 
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Model 4    
For this model, I included only those who received antihypertensive treatment at first entry.  
The model was run use a lag of ten iterations to reduce the autocorrelation in the parame-
ter for the intercept. The model was run up to 8700 iterations and the first 1000 were dis-
charged. The total time was 29 hours.  
Similar to the previous models, age was negatively associated with the risk of having con-
trolled blood pressure, 0.99 hazard ratio (95% credible interval 0.99 – 0.99). There was not 
significant association between sex, the presence of other cardiovascular and non-
cardiovascular comorbidities and having controlled blood pressure. Being registered after 
the introduction of QOF was positively associated with having controlled blood pressure 
2.09 hazard ratio (95% credible interval 1.97 – 2.21). Compared to white, the risk of having 
controlled blood pressure was higher in those patients with unknown race/ethnic origin, 
1.23 hazard risk (95% credible interval 1.02 – 1.25). None of the included practice charac-
teristics were significantly associated with variation in the individual risk.  (Table 49, Figure 
38-40) 
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Table 49 Posterior hazard ratio of patient characteristics included in the 
model 4(N=7885)  
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Figure 39 Distribution of posterior hazard ratio by body mass index. Models 4 and 5  
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Figure 40 Box plot of mean for the random effects in 28 practices. Models 4 and 5 
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Model 5  
 
For this model I included only those who were not prescribed antihypertensive treatment at 
first entry. The posterior estimators were taken after running 11000 iterations. The first 
1000 were discharged. The model was run used a lag of 10 iterations. A high autocorrela-
tion in the parameter for the intercept was observed. The total time was 15 hours.  
 
The findings were similar to those described above. Age was negatively associated with 
having controlled blood pressure 0.99 hazard ratio (95% credible interval 0.99 – 0.99). 
There were no significant association between sex, having other cardiovascular or no car-
diovascular comorbidity or smoking and having controlled blood pressure. There was a 
negative association between body index mass and having controlled pressure.  The as-
sociation was significant for those with obesity grade III 0.77 hazard ratio (95% credible 
interval 0.61 – 0.97) respectively.  There was also a negative association between choles-
terol and having controlled blood pressure. Those with very high cholesterol had a lower 
risk of having controlled blood pressure 0.89 hazard ratio (credible interval 95% 0.79- 
0.99). The risk of having controlled pressure was similar between patients of different eth-
nic groups. (Table 50, Figures 38-40) 
Patients registered after the introduction of QOF were more likely to have controlled blood 
pressure with a 1.99 hazard ratio (95% credible interval 1.72 – 2.28). As it was observed in 
the previous models, the distribution of the random effects was similar across the prac-
tices.  
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Table 50 Posterior hazard ratio associated with variables included in the 
model 5 (N=1794)  
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Sensitivity analysis for hierarchical priors   
 
I compared the posteriors estimators of the age coefficient produced by a gamma distribu-
tion (0.0001, 0.0001) and gamma distribution (1, 0.5) for the precision of the practices. The 
analysis was performed using the population included in the model 2.  
      
 
Figure 41 Beta coefficient of age for a gamma (0.0001, 0.0001) prior distribution 
 
Figure 42 Beta coefficient of age for a gamma (1, 05) prior distribution 
 
As it can be seen in figure 41 and figure 42 the posterior distribution of the beta coefficient 
for age is similar regardless of the prior distribution used for the precision. In other words, 
the result has not markedly been affected by the variation in the priors used for the precision.  
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9.4 The Frequentist model  
 
To compare the results from the Bayesian framework, a parametric frailty shared survival 
model was also performed in a Frequentist framework. The comparison was based on the 
model 2. This model used a population that had no missing values in all variables included in 
the analysis. The model was run using the streg function provided by the STATA Corpora-
tion v. 11 statistical program.   
The model 
In this frequentist framework, the model was formed by two components. The first one was 
based on the individual`s characteristics and aimed to model the potential heterogeneity 
occurring among individuals with multiples measurements of the outcome. This is the frailty 
component for the heterogeneity among individuals. The second one represented the vari-
ability between patients nested into practices.  This component was setting using the prac-
tice code which is called the shared frailty model (816). The shared frailty was assumed to 
have a gamma distribution. The time calculation was performed using the Anderson and Gill 
model for  STATA  (817-818). Thus, sequentially from the year of the registration to one 
event a one period time was counted and from this one event to next one another time event 
until completing all follow-up periods. An example is shown below (Table 5): 
Table 51 Time calculation for the Frequentist model 
Patient  Initial time  Time  Event 
A  0  3 1 
A 3 5 0 
A 4 6 1 
A 6 10 0 
B 0 7 0 
B 7 9 1 
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Explanation  
Patient A had the event 1 in his three initial follow-up periods, then two periods with event 0, 
the following two with event 1 and the final four periods with event 0.  
Patient B had the event 0 in his seven initial periods and then two periods with event 1.  
 
A Weibull distribution was used for the model with the following mathematical formulation   
                            
    
 
Where h is the hazard ratio for each j individual into the each practice i. The hazard ratio is 
multiplied by the shared frailty  .    is the coefficient of     variables and   is the shape of 
the model.  
 
Results 
The results are shown in the table 6. Increase in age was associated with a reduction in the 
risk of having controlled blood pressure, hazard ratio (HR) 0.98 (95% CI 0.98 – 0.99). 
Women were less likely to have controlled blood pressure over the period HR 0.89 (95% CI 
0.84 – 0.96). Compared with white patients, those of other Asian origin, other ethnic origin 
and those of unknown origin were more likely to have controlled pressure with HR 1.33 (95% 
CI 1.11 – 1.59), 1.23 (95% CI 1.05 – 1.44) and 1.26 (95% CI 1.06 – 1.49) respectively. There 
were no significant differences in the risk of having controlled pressure between withes and 
those of black origin or South Asian origin. Those having an additional cardiovascular co-
morbidity were more likely to have controlled pressure HR 1.13 (95% CI 1.05 – 1.21). Simi-
larly those with an additional no cardiovascular comorbidity were less likely to have con-
trolled blood pressure 1.09 (95% CI 1.01 – 1.19). Obesity grade I and Obesity grade III re-
duced the risk of having controlled blood pressure HR 0.88 (95% CI 0.80 – 0.97) and HR 
0.75 (95% CI 0.63 - 0.91) respectively. Patients registered after the introduction of QOF 
were more likely to have controlled blood pressure related to those who were registered in 
the previous period HR 1.90 (95% CI 1.73 – 2.09) (Table 52). 
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Table 52  Hazard ratio associated with factors affecting blood pressure control 
in the Frequentist model 2 (N=9679) 
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9.5 Discussion  
 
In the included cohort of hypertensive patients managed in 28 general practices, the control 
of blood pressure was improved over the 10 years study period. Thus there has been a re-
duction in both diastolic and systolic blood pressure over the period. The individual baseline 
characteristics negatively associated with controlled blood pressure were one year increase 
in age, BMI and high levels of cholesterol. Compared to patients of white origin, patients of 
black origin tended to have uncontrolled blood pressure  and those of South Asian origin 
tended to have controlled blood pressure over the period. Those registered after the intro-
duction of QOF were more likely to have controlled blood pressure.  
Over the study period there have been improvements in blood pressure control, the percent-
age of patients with controlled hypertension increased from 37.0% to 62.4%. Patients in-
cluded in this cohort had four median visits over the study period. In an analysis of  blood 
pressure records from 236467 hypertensive patients, Carey et al observed a decrease in the 
number of blood pressure records below 150/90 mm Hg from 2000 to 2005 (699).  The ob-
served reductions in blood pressure may reflect the impact of continuity of care in blood 
pressure control. Hypertensive patients included in the analysis were benefit from continuity 
in their health care. The available information over 10 year period and being contact with the 
same health provider are essential features of continuity of care in primary care (819).  Wat-
son et al reported the benefit of the continuity of care in a clinical trial. Patients randomized 
to the group managed by same health provider over the study period had fewer hospitaliza-
tions and patients referred being more satisfactory with the services (820). Howard et al 
showed that hypertensive patients with access to same health provider had better blood 
pressure control than those who did not have the same health provider over the study period 
(821).  In a cross-sectional study, He et al also identified that those who refereed have been 
treated by the same health provider were more likely to have controlled blood pressure than 
those who have received treatment for a different provider (317). Bolen et al also found that 
hypertensive patients were more likely to receive an additional therapy when they regular 
visit the same health provider (822). Although there have been other national initiatives such 
as salt reduction to improve blood pressure control, its impact could have been modest 
(612). Since the current variations in blood pressure control may reflect the impact of having 
periodical contacts with the same provider.   
 297 
 
 
The blood pressure status varied across the period. Thus, 65% of the total patients regis-
tered with dataset had periods controlled blood pressure and periods without controlled 
blood pressure. It is known that blood pressure levels had both random variability and sys-
tematic variability (8, 823).  For hypertensive patients on hypertensive treatment the variabil-
ity increases over the period. Keenan et al demonstrated that increases in blood pressure 
identified in periods closer to initiating therapy could be false positive increases (806). Ma-
botuwana et al also documented this variability in an analysis of records from hypertensive 
patients being treated in general practices (807). They found that 31% of the included hyper-
tensive patients did not have controlled blood pressure over three months period (807).  The 
variations in blood control status observed in the current cohort also concur with these find-
ings.  
 
Patients registered after the introduction of QOF were more likely to have controlled pres-
sure. The association was significant accounting for all individual variables contained in the 
register and the number of patients registered at the beginning of the period in each practice 
and the deprivation index. The association between the introduction of QOF and blood pres-
sure control has been controversial. In an analysis of 470725 hypertensive patients, Seru-
maga et al did not find differences in blood pressure rates after the introduction of QOF in a 
study using interrupted time series. They used a target of 150/90 mm Hg blood pressure to 
assess variations in blood pressure control. Although this target is the one established in the 
QOF guidance for the assessment of the performance of general practices, it could have low 
sensitivity to capture differences in blood pressure control (683). However, Ashworth et al 
reported that improvements in blood pressure control and monitoring have been observed 
after the introduction of QOF. This analysis was performed using aggregated data at practice 
level (498). In a longitudinal analysis using data from 35 practices located in Northern Cali-
fornia, Lester et al documented that the rate of blood pressure control continually improved 
in periods in which financial incentives were attached to the achievement of targets. They 
could not associate the variation in the rate of blood pressure control with the introduction of 
the payment system (824).  
 
In the studies mentioned above the impact of QOF on blood pressure control was based on 
aggregated indicators taking from practice records. By comparison, the current analysis was 
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done using the individual records. The assessment of the QOF introduction was performed 
by using a variable identifying whether or not the patient was registered before or after the 
introduction of QOF. The variable intended to compare those who were exposed to the inter-
vention with those who were not at first entry. The positive effect associated with being regis-
tered after the introduction of QOF means that those patients had more periods with control 
blood pressure. The association is not explained by having lower blood pressure at first entry 
as the model account for the individual basal risk. The association could be considered due 
to an effect of the longer observation time for those registered before the introduction of 
QOF. However patients were registered consecutively over the study period and the median 
observation time was four years. The association also seems to be strength as it was based 
on the total available blood pressure measurement rather than one estimation point in time.  
 
This patient cohort was also exposed to the use of national guidelines for the management 
of hypertension. I did not find a significant association between being prescribed antihyper-
tensive treatment at first entry and having controlled blood pressure over the period.  How-
ever the use of 2006 NICE recommended treatment at first entry seems to have a positive 
association with having controlled blood pressure. The posterior distribution of the associ-
ated hazard ratio associated with the variable of using the recommended treatment tended 
to be towards positive values.  Moreover those who were prescribed a different medication 
tended to have uncontrolled blood pressure. The assessment of the recommended therapy 
was done for all included patients regardless of the year entry because the recommended 
treatment was already known before the introduction of the guidance (223).  In primary care 
settings, others authors have also observed that patients prescribed antihypertensive medi-
cation did not always achieve blood pressure targets (314, 397). That could be due to fact 
that hypertensive patients frequently stopped using antihypertensive medication even in 
clinical trials (296-297).  Therefore the described association could change if information 
about adherence is considered in the analysis. Although the efficacy of antihypertensive 
therapy for the management of high blood pressure control is unquestionable (142), these 
observations give light on the fact in primary care settings improvements in blood pressure 
control go beyond prescribing antihypertensive drug. They also suggested a possible posi-
tive impact of using age-ethnic oriented prescribing on blood pressure control.  
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I found that for each year increase in age, there has been a reduction of 0.01% in the hazard 
risk of having controlled blood pressure. In primary care settings the association between 
age and poor blood pressure control has been recognized (205, 287, 289). This association 
has been independent from social, education or other health service conditions. The reasons 
for that association have not been completely elucidated.  The well-established increase in 
systolic blood pressure with age may account for some the association (73).  This increase 
has been attributed to reductions in elasticity and compliance of the central and peripheral 
vessel with age (825). This variation occurs regardless of sex and race/ethnic origin (826). 
Even under controlled conditions, reductions in systolic blood pressure are less achievable 
than reductions in diastolic blood pressure (214).  Therefore the achievability of lower sys-
tolic blood pressure levels in elderly hypertensive patients has been a matter of controversy. 
However, results from the JATOS study revealed that blood pressure levels below 140/90 
mm Hg are possible to obtain in patients aged 65 years and over. In the study 65% of hyper-
tensive patients achieved his target among those to who the target was applied (198). Reas-
suring aging is a significant factor for having uncontrolled pressure. The limitations in modify-
ing the established changes in vascular vessel could account for this association.  
 
A negative association between increases in BMI and having controlled blood pressure was 
observed. The association was significant particularly in those who were not prescribed 
medication at first entry. Obesity have been recognised as a risk factor for having uncon-
trolled blood pressure (287, 827). The association relies on the positive relationship between 
increases in weight and blood pressure levels (118, 120, 828). Lowering weight leads to re-
ductions in blood pressure (154, 156). However for hypertensive patients undertaken in pri-
mary care, reductions in body index mass have not been well attained (156).  Low adher-
ence to lowering weight interventions account for  the most frequently reason (158). The 
impact of obesity on blood pressure control has not been quantified but it is known that body 
index mass over 22.5 kg/m² is risk for vascular mortality (829). There is a potential for im-
proving blood pressure control by lowering BMI   
 
Compared to hypertensive patients of white origin, patients of other ethnic group were more 
likely to have controlled blood pressure adjusted for BMI, cholesterol, smoking, age, sex, the 
presence of other cardiovascular comorbidity and non cardiovascular comorbidity and prac-
tice characteristics. Patients of black origin tended to have uncontrolled blood pressure and 
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those of Asian origin tended to have controlled blood pressure over the period. Hence there 
seems that under similar conditions of care, the differences in blood pressure control be-
tween ethnic groups tended to disappear. Howard et al revealed that there were not differ-
ences in blood pressures control rates among patient of different ethnic origins when they 
have been attending by the same provider under similar conditions (821).  Rehman et al also 
revealed that hypertensive patients of black origin being treated in the Department of Veter-
ans Affairs (VA) services had better blood pressure control than those in non-VA services 
(360). In the analysis of Health Survey for England, Nazroo et al revealed that differences in 
blood pressure control between patients of white origin and those of other ethnic origin are 
minimal (495). However, patients of black origin have been found less likely to achieve the 
target of 140/90 mm Hg in reports from some general practices in London (496-497).  There 
seems that despite biological, social or behaviour conditions present among patients of dif-
ferent ethnic origin, primary care services have the potential to reduce differences in blood 
pressure control between ethnic groups.    
 
There were not significant associations between the presence of other cardiovascular and 
non-cardiovascular comorbidities and blood pressure control over the period. However I did 
not disintegrate the effect of any particular disease due to the small numbers in each group 
to make comparisons across the period. However the impact of other comorbidities such as 
depression on blood pressure control has varied across different studies (377). 
 
Comparison between the Frequentist and Bayesian models 
 
The results of the Frequentist model 2 look similar for all variables to those produced by the 
Bayesian model 2. The only differences were for the coefficients associated with patients of 
other Asian group, unknown ethnicity, having an additional cardiovascular comorbidity and 
having an additional no cardiovascular comorbidity. All of them were significant and posi-
tively associated with having controlled blood pressure.  By contrast, in the Bayesian model 
2 these coefficients were not significantly associated with the probability of having controlled 
blood pressure. However the directionality of the association was similar except for the coef-
ficient of having an additional cardiovascular comorbidity variable. An explanation for these 
differences will be addressed below.  
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I aimed to develop a Frequentist model as comparable as possible to the Bayesian model. 
However some considerations are addressed to explain the reasons for the mentioned dis-
crepancies and support the potential benefit of using a Bayesian approach in the analysis of 
the current data.  
Firstly the Frequentist formulation does not completely account for the hierarchical structure 
of the data. The formulation included a dummy variable indicating to which practice each 
patient belonged.  However this formulation did not allow for including the practice variables 
in the practice level model. And the practice-level variables such as deprivation index and 
practice list were assigned as a dummy variable for each individual. Therefore the variability 
of the practices due to practice level characteristics is not taken into account by the model. 
In other words, the random effects due to between practice variability due to practice charac-
teristics are not measured in the model. As a consequence the standard errors of the model 
may be inaccurate (798-799).  
The frequentist model did not provide the estimations of the parameters associated with 
practice level. Although it accounted for the heterogeneity of the practices, the model was 
unable to estimate the effects of each practice. By contrast, the Bayesian model incorpo-
rates both the variability within practices   and between practices. This allows us to estimate 
regression parameters for practices and practice variables. Hence, the Bayesian model can 
provide the uncertainty at both levels.   
The frequentist model did not fit the data completely according to the pattern of the observed 
residuals. In the frequentist approach, the analysis of hierarchical data is affected by the 
sample size.  The hierarchical structure makes some categories with small numbers lead to 
limitations in fitting the data to the model. The standard errors also become bigger.  Conse-
quently, more information is  needed to estimate the parameters (798, 830). By contrast, the 
Bayesian approach can use information from spare data as it is joined with previous informa-
tion. The model is more flexible producing more accurate estimators (830). For instance, the 
standard errors of ethnic groups with small size (South Asian, other Asian and other ethnic-
ity) are bigger in the Frequentist model than those in the Bayesian model.  In the Bayesian 
model the standard deviation is the equivalent of the standard error produced by the Fre-
quentist model.  
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In the Bayesian framework, the credible interval describes the distribution of the estimator in 
the study population. This distribution also gives the probability of obtaining each value. For 
instance, the figure 35 shows the HR of having controlled blood pressure for black patients 
compared with white patients. One can observe that the probability of having a HR between 
0.95 and 1.0 is around 30% for black patients. Similarly the probability of having a HR below 
1.02 is 97.5%. One can infer the following statements. The probability of having controlled 
pressure was similar between black and white patients as for some black patients the HR 
could lay at the value of 1.00. However, for most of the black patients the HR of having con-
trolled pressure lay in the values below 1.00. In other words, although there was no a signifi-
cant statistical difference in the risk of having controlled blood pressure between black and 
white patients, black patients clinically may require more intensive blood pressure control. In 
conclusion, the lack of statistically significant difference may not detract attention from at-
tempting improvements in blood pressure control for black patients. This is one of the most 
important benefits from using a Bayesian statistical framework, particularly in clinical areas. 
Knowing the distribution of the probability of the outcome in a population allows us taking 
decisions beyond the interpretation of p values or significant differences (831).  
 
9.6 Strengths and limitations  
 
The model  
The innovation of this analysis is the use of a Bayesian framework. Not also the hierarchical 
frailty survival model allows analysing recurrent events but also takes into account the het-
erogeneity between individuals due to factors not to measure in the dataset (809). The inclu-
sion of the initial blood pressure status also account for the individual basal risk of achieving 
the blood pressure targets. Additionally, using the Bayesian framework allows using data 
from variables with low frequencies in the dataset. The assessment of blood pressure control 
as an event recurrent over a period of time is in line with the natural variation of blood pres-
sure.(8) Then the inclusion of different measurements of blood pressure over long time has 
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been recommended to obtain a more accurate representation of the blood pressure control 
occurring in clinical settings.  
The model also accounts for the correlation observed among individuals nested into prac-
tices. The need for taking into account this correlation into the analysis of dataset from 
health services has been recognised. It improves the accuracy of the estimations and also 
the possibility to find differences between groups (832). The omission of this condition could 
result in underestimating the possible impact of some associations or interventions.  
The current analysis illustrated the use of a Bayesian approach in the analysis of data col-
lecting daily in clinical settings.  The clinical registers have mainly been analysed using a 
Frequentist framework. However, using this framework has led to some concerns when the 
data is not sample based collected (794). Then, the Bayesian framework emerges as an 
alternative which provides a closer estimation of the uncertainty contained in the data.  
 
The limitations may rely on the prior distributions selection.  I used informative priors for both 
hierarchical variances. The informative priors could be used cases of groups of low frequen-
cies (811). This is the case for the first hierarchical level as some individuals have only two 
repeated measurements of blood pressure.  Additionally, it has been observed that the vari-
ance of blood pressure increase over the time after starting antihypertensive therapy. (806) 
However the results were consistent by using different samples from the data set and also 
using vague distributions for the hierarchical variance for practices.  
 
Some limitations are related to data. The blood pressure measurement was performed in 
clinical visits using sphygmomanometer or an Omron device. Although these are the stan-
dard of blood pressure measurement, some authors are reported digital preference in the 
register of blood pressure levels (699). However I used all the measurements available 
which can correct for this measurement bias. The data contained missing valuables in some 
variables such as cholesterol levels and body index mass. I did not replace it to reduce the 
influence of external parameters into the analysis. I compared instead of different popula-
tions from the data set to assess the associations. Finally, nor I did have information on ad-
herence to therapy neither information on the use of non-pharmacological interventions on 
the management of these patients. However this information reflects what is currently hap-
pening in primary care. In these contexts the use of non-pharmacological interventions is not 
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recorded as well as pharmacological interventions. Nevertheless, the adjustment for depriva-
tion index could be a proxy for conditions related to non-pharmacological interventions such 
as individual behaviour. It has been observed a direct association between behaviour and 
socio economic status (833).  
 
9.7 Conclusion  
 
Over a ten year period, the analysis of 11373 hypertensive patients revealed that individual 
factors such age and BMI are negatively associated with having controlled blood pressure. 
Compared to white, other ethnic groups were equally or more likely to have controlled pres-
sure but those of black origin tended to have uncontrolled blood pressure. None of the vari-
ables at practice level were significantly associated with the risk of having controlled blood 
pressure. Patients registered after the introduction to QOF were more likely to have con-
trolled blood pressure. Finally, the analysis adds evidence on the impact of continuity of 
care. Thus, these hypertensive patients continually managed by the same provider had re-
ductions in blood pressure levels over the study period.  
I illustrated the use of a Bayesian framework in the analysis of clinical records taking in cur-
rent clinical settings. This could be an alternative in the analysis of this data with regard to its 
hierarchical structure. The use of this framework allows assessing the uncertainty present in 
the data.  
 
Key points 
 A Bayesian analysis to assess factors affecting blood pressure control was per-
formed using a data set of hypertensive patients being managed in 28 practices lo-
cated in Wandsworth, London.  
 A Bayesian survival Weilbull frailty hierarchical model was developed using event re-
current times as an outcome. The model fit the data. 
 A cohort of 11373 hypertensive patients was used for the analysis 
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 Over the period the period there has been an improvement in blood pressure control. 
The percentage of patients with controlled hypertension increased from 37% to 
62.4%. 
 Increases in age, BMI and cholesterol levels were found negatively associated with 
blood pressure control.  
 Compared to white, patients of other ethnic origin have a similar risk of having blood 
pressure control. Those of other ethnic origin were more likely to have controlled 
blood pressure and those of black origin tended to have uncontrolled blood pressure.  
 Patients registered after the introduction of QOF were more likely to have controlled 
blood pressure.  
 The results add evidence on the benefit of continuity of care on the management of 
hypertensive patients in primary care. 
 This study illustrated the use of the Bayesian approach in the analysis of clinical 
data.  
 This approach is an alternative method particularly in cases when the data is not 
sample based collected.  
 The Bayesian approach allows assessing the uncertainty presented in the data which 
could be more informative for health workers.
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Chapter 10 General discussion, conclusion 
and future work 
 
10.1 Summary of main findings 
 
Study 1: Blood pressure control and blood pressure targets definition. Cross 
sectional study  
 
In 2007, among 15761 hypertensive patients registered with 28 general practices, 79.5% of 
them were classified as patients with controlled hypertension by using the QOF target of 
150/90 mmHg. By comparison, the percentage is 60.7% when the NICE target of 140/90 
mmHg was used.  
 
Overall, 59.4% of men had controlled hypertension by using the NICE target and 78.5% had 
controlled hypertension by using the QOF target. The percentage of women with controlled 
hypertension was 80.7% and 61.7% using the QOF and NICE target respectively. Regard-
less of the target, the percentage of men with controlled hypertension increased with age. By 
contrast, the percentage of women with controlled hypertension rose with age using the 
QOF target but decreased using the NICE target. The probability of achieving a blood pres-
sure target varied between sex across age categories.  
 
Between ethnic groups, the highest percentage of percentage of PCH’s was in those of 
South Asian origin, 1184 (82.2%) and 990 (68.8%) using the QOF target and the NICE tar-
get respectively. For men mean systolic blood pressure was 138.2 mmHg (sd 16.30 and 
mean diastolic blood pressure was 80.3 mmHg (sd 11.8). For women was 137.4 mmHg 
(16.7) and mean diastolic blood pressure was 79.3 mmHg (sd 10.3). Patients of south Asian 
had lower blood pressure levels and patients of black origin had higher blood pressure le-
vels. 
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Study 2: Impact of ethnic-specific guidelines in antihypertensive 
prescribing. Longitudinal analysis  
Between 1998 and 2007, there was an increase in the percentage of patients who were pre-
scribed antihypertensive medication for 17245 hypertensive patients with race/ethnic record. 
Thus, the percentage of patients not being prescribed antihypertensive medication de-
creased from 49.0% in 1998 to 14.8% in 2007. By contrast, the percentage of patients being 
prescribed two or more antihypertensive medication increased from 21.2% in 1998 to 54.7% 
in 2007. 
 
Over the study period, the most noticeable variation in drug class prescribing has been the 
decline in the use of the beta blocker as monotherapy in all NICE patient groups.  ACEI has 
been the most frequently antihypertensive prescribed as monotherapy mainly for younger 
non-black and older non-black. CCB has been the most common monotherapy used for 
black patients. After the introduction of the guidelines there was an increase in first line NICE 
recommended monotherapy (OR 1.44, 95% CI 1.18 – 1.75) compared with the underlying 
trend. Compared to black patients, an increase in recommended monotherapy was observed 
in younger non-black patients (OR 1.49, 95% CI 1.17 – 1.90) but not in older non-black pa-
tients. Over the study period, black patients were more likely to be prescribed recommended 
monotherapy treatment than younger non-black (OR 0.16, 95% CI 0.12 – 0.21) and older 
non-black patients (OR 0.49, 95% CI 0.37 – 0.65). 
 
Study 3 Factors affecting blood pressure control: a survival longi-
tudinal study using a Bayesian framework 
 
Among 11373 hypertensive patients included in the survival analysis, there was a significant 
reduction in systolic and diastolic blood pressure levels from 1998 to 2007. Mean systolic 
blood pressure was 148.5 mmHg (sd) in the first year observation and 137.4 mmHg (sd 
14.8) in the last year (10th). Similarly, mean diastolic blood pressure was 85.9 (10.3) mmHg 
at first year registration and 78.9 mmHg (10.1) in the last year observation. The percentage 
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of hypertensive patients with controlled blood pressure increased from 37% to.62.4% over 
ten years period.  
Over the period, increases in age were negatively associated with having controlled blood 
pressure. Compared to patients of white origin, those of other ethnic origin were more likely 
to have controlled pressure over the period, hazard ratio 1.09 (95% credible interval 1.0 -
1.19). Although there were no significant differences, patients of black origin tended to have 
uncontrolled blood pressure. Increases in body index mass tended to reduce the risk of hav-
ing controlled pressure even though the estimators did not achieve significance (Figure 11). 
Higher levels in cholesterol were negatively associated with controlled blood pressure. For 
those patients with very high levels of cholesterol (over 6.1 mmol/L), the hazard risk was 
0.94 (95% credible interval 0.91 – 0.98). Patients registered after the introduction of QOF 
were more likely to have controlled blood pressure. The risk of having controlled blood pres-
sure was higher for patients registered after the introduction of QOF, hazard ratio 2.05 (95% 
credible interval 1.94 – 2.16). The use of NICE guidelines recommended treatment tended to 
improve blood pressure control.  
 
10.2 Comparison with previous research 
 
Blood pressure control rates  
The control of blood pressure improved in Wandsworth, south west London between 1998 
and 2007. A similar trend has been reported by the Health Survey for England (284). The 
percentage of hypertensive patients with controlled blood pressure is similar to what has 
been observed in others general practices-based studies in the UK. In a cross sectional 
study of 315 practices in Scotland, Simpson et al reported that nearly 50% of hypertensive 
patients achieved blood pressure levels equal to or below 140/90 mm Hg (834). Among 148 
practices located in East London, Mathur et al found that almost 70% of patients with cardio-
vascular comorbidity had controlled  blood pressure (535). By comparison, the percentage of 
hypertensive of controlled blood pressure has been reported between 25 and 50% among 
general practices from countries with well-developed primary care services (286-287, 474, 
835).  
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Continuity of care may be a key aspect for the control of blood pressure in this patient co-
hort. It could be argued that I did not have a control group to establish this consideration. 
However the constant improvement of the outcome suggests that patients exposed to the 
health system could reduce blood pressure levels. Evidence from clinical trials conducted in 
primary care reported that access to service and periodical visits were the most significant 
factors associated with better blood pressure control (280, 447, 820, 836). Richard et al simi-
larly illustrated the impact of primary care on the control of chronic kidney disease. They 
found that a reduction in the fall of glomerular filtration rate and reduction in blood pressure 
levels associated with interventions that were part of a primary care based program (495). 
Visiting the same health provider, maintaining clinical records and having regular clinical 
visits are features present in the current primary care settings which have been associated 
with a better control of chronic diseases (837), for instance hypertension (820). By contrast, 
a lack of continuity care has led to poor blood pressure control (474).  
 
Factors affecting blood pressure control 
Individual factors 
Become older was negatively associated with achieving blood pressure levels equal to or 
below 140/90 mmHg. The association was observed in both the cross sectional analysis and 
the longitudinal analysis. Increases in age have consistently and negatively associated with 
poor blood pressure control among hypertensive patients treated in primary care services. In 
a study conducted in ten primary care services from Sweden, Hedblad et al found that the 
percentage of hypertensive patients with blood pressure levels over 140/90 mmHg were 
higher in those aged 75 years and over (84%) than in those aged below 65 years (68%) 
(314). Among a representative sample of hypertensive patients being treated in German 
primary care services, Labeit et al reported that increases in age reduce the risk of having 
controlled blood pressure by 43% in patients aged 75 years and over compared to those 
aged between 18 and 24 years (287). The association has also been observed in different 
health care contexts. Meng et al identified a significant trend of declining blood pressure con-
trol with increases in age  among hypertensive patients sampled from general population in 
China (838). Similar to the current findings, uncontrolled blood pressure has been mainly 
due to high systolic blood pressure levels (314). Although the constant increase in blood 
pressure with age can explain limitations in lowering blood pressure among older patient 
(73), other factors may account for the high blood pressure levels in these patients. Among 
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hypertensive patients aged 75 years and older, Krousel-Wood et al found lower blood pres-
sure was associated with decline in the use of antihypertensive treatment (839). The de-
crease in use was attributed to depression symptoms (839).   
 
The result showed that physicians switch to a new antihypertensive treatment less frequently 
in older patients than in younger patients.  In a survey of ambulatory hypertensive patients, 
De Giusti et al reported that older hypertensive patients were less likely to receive antihyper-
tensive treatment than younger (840). In primary care services from Spain, Gil-Gillen et al 
reported that older hypertensive patients have been given less antihypertensive treatments 
than younger patients (841). Treatment resistant hypertension has also been found as a 
potential cause for poor blood pressure control in older patients. In the analysis of the 
NHANES 1998 to 1994 and 1999 to 2008, Egan et al found that older age was a risk factor 
for having apparent treatment resistant to hypertension (842). In other words, older patients 
did not achieve blood pressure targets though they receive more than two antihypertensive 
medications.  
 
I found that those with high scores of BMI had uncontrolled blood pressure over the study 
period. Among those without antihypertensive treatment, the association was significant for 
overweight hypertensive patients. BMI has been consistently reported as a risk factor for 
poor blood pressure control. In a cohort of hypertensive patients being treated in primary 
care services, Suarez et al found that hypertensive patients who gained weight could not 
remain with controlled blood pressure over one year follow up period (374). In a cohort anal-
ysis of 150000 patients registered with 35  family practices in Ontario, Petrella et al found 
that hypertensive overweight patients were less likely to achieve controlled blood pressure 
compared to those with normal weight  (373). Data from cross sectional studies also has 
reported this association. In a survey of hypertensive patients treated in French primary care 
services, Roux et al documented that for each 14 kgr increase in weight, there has been a 
reduction of 10% in the risk of having controlled blood pressure, odds ratio (0.90 95% CI 
0.81 – 0.99)  (372). The observation has been documented in different populations. In sam-
ple of hypertensive patient from Chilean primary care services, Sandoval et al reported that 
having a BMI equal to or higher than 30 kg/m² is a risk factor for having blood pressure 
over140/90 mm Hg (292).  
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The relationship between BMI and poor blood pressure control may be expected. Increases 
in BMI are found a risk factor for having hypertension. In the Framingham study, Kannel et al 
found that the incidence of hypertension rise with increases in body mass index regardless 
of age and sex (828). In a study a population with a diverse ethnic origin, Foulds et al found 
that both BMI and in waist circumference are factors predisposing to hypertension. But the 
strength of association varied across ethnic groups. Among aboriginal people the incidence 
of hypertension is higher than that observed in those of Caucasian or East Asian origin at 
same levels of BMI (120). In a UK population of 12090 participants, Dexter et al identified 
that blood pressure levels increases with increases in both waist hip ratio and in BMI. The 
association between waist hip ratio and blood pressure levels was independent of body 
mass index levels and consistent in both men and women (118). This association may result 
in a need for using more antihypertensive drugs in overweight hypertensive individuals. Saito 
et al showed that hypertensive patients with higher levels of body mass index achieve similar 
blood pressure control rates than those with lower levels of body mass index but using more 
antihypertensive medication (843).  
Patients with very high cholesterol levels (>= 6.1 mmol/L) were less likely to have controlled 
pressure over the period. In a cross sectional study of hypertensive patients managed in 
primary care services in Pakistan, Saleheen et al reported that those with cholesterol higher 
than 200 mg/dL were associated with poor blood pressure control (327). In 4235 hyperten-
sive patients treated in Spanish primary care services, Llisterri et al documented that those 
with low density lipoprotein cholesterol higher than 115 mg/dL were less likely to have blood 
pressure below 140/90 mmHg  (381). Similar observations have reported by Sandoval et al 
(292) and Suarez et al (374). The positive association between high cholesterol levels and 
developing hypertension could make it difficult to achieve lower blood pressure levels in 
these patients. Among 4953 women with a ten years follow-up period, Sesso et al demon-
strated that the incidence of hypertension increased with increases in cholesterol levels. Al-
though there was a significant trend across blood pressure levels, the associated relative 
risk was particular significant for those with high cholesterol levels (cholesterol total>= 240 
mg/dL) (844). The association becomes less strong after adjustment for BMI but remain sig-
nificant. Similar observations have reported in men (845). The impact of high cholesterol 
levels on the incidence of hypertension has been more notorious in those with high normal 
blood pressure (846). In an analysis of 2864 hypertensive with hypercholesterolemia from 
the 2001-2002 NHANES survey, Wong et al found that only 9% of those achieve targets for 
both clinical conditions. Individuals aged 80 years and over had the worst control rates for 
both comorbidities (847). However, among hypertensive patients aged 80 years and over 
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from New Zealand primary care, Senior et al those with hypercholesterolemia were more 
likely to have controlled pressure (386). Hence it seems that high cholesterol levels at base-
line may be a negative factor for achieving blood pressure targets but this association may 
change with regard to cholesterol treatment. 
 
Having an additional cardiovascular comorbidity such as diabetes, stroke, heart failure, atrial 
fibrillation or chronic renal disease, was not associated with variations in the risk of having 
controlled blood pressure in the survival analysis. However those with an additional comor-
bidity were more likely to deep in the category of those with controlled blood pressure in the 
cross sectional study. As expected, differences between cross sectional studies and longitu-
dinal studies may reflect the time lag effect of the variable on the outcome. In other words, in 
a long time the probability of achieving a blood pressure target may not depend on the pres-
ence of an additional comorbidity. In a cross sectional analysis of patients registered with 
148 general practices in East London, Mathur et al found that there were no significant dif-
ferences in the achievement blood pressure targets between those with one and more than 
one associated comorbidity. Differences in the probability of having controlled pressure were 
attributed to race/ethnicity background (535). In contrast, in a cross sectional study  of hyper-
tensive patients from primary care services among 16 practices from Wandsworth, London, 
Millet et al reported that hypertensive patients with and additional cardiovascular comorbidity 
were more likely to have blood pressure below 140/90 mm Hg than those without cardiovas-
cular comorbidity (496).  
 
Evidence from a diverse of observational studies showed that among hypertensive patients 
treated in primary care, those with an additional comorbidity have been found to have worse 
blood pressure control (323, 325, 332, 344, 379, 381) or better blood pressure control (373, 
385-386). Some surveys particularly reported that hypertensive patients with diabetes are 
less likely to have controlled blood pressure (286, 325, 332). These discrepancies may re-
flect differences in quality of care. Peterson et al compared the quality of care among hyper-
tensive patients treated in eight Veteran Affairs primary care services. They found hyperten-
sive patients with an additional cardiovascular comorbidity were more likely to have blood 
pressure below 140/90 mmHg than those without cardiovascular comorbidity at first entry. 
Over the a six months follow up period, they also received better health care resulted in 
higher probability of having controlled blood pressure compared to those without comorbidity  
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(OR 2.25 95% CI  2.13 to 2.36) (387). In a follow up study including 6083 elderly hyperten-
sive patients, Chowdhury et  found that those with comorbidity such as increased plasma 
creatinine were more likely to achieve blood pressure targets (397). Of note, in clinical trials 
hypertensive patients with diabetes have been able to achieve blood pressure targets below 
135/85 mm Hg though the clinical impact of achieving these targets is unclear (199).  Hence, 
the discrepancies between studies may reflect differences in health care offered to hyper-
tensive patients with an additional comorbidity. 
 
Compared to white, lower blood pressure control rates in race/ethnic minorities were not 
observed in the current analysis. In fact, in the cross sectional study patients of South Asian 
origin and those of other Asian origin were more likely to be classified as hypertensive pa-
tients with controlled blood pressure. And among hypertensive patients without additional 
cardiovascular comorbidity, the survival analysis showed that those of South Asian origin 
were more likely to have controlled blood pressure over the period. Those of other 
race/ethnicity were more likely to have controlled in the model included only those on hyper-
tensive treatment. There were not significant differences in the risk of having controlled 
blood pressure between ethnic groups in the results from the survival model adjusted for all 
include variables. Reductions in blood pressure control inequalities between ethnicity groups 
have been observed in the UK. In the 1998-2005 Health Survey for England there were no 
differences in the probability of having controlled blood pressure between race/ethnic 
groups. They compared those of Irish, Caribbean, Indian, Pakistani, Bangladeshi or Chinese 
origin to whites (495). Similarly Mathur et al reported that patients of South Asian origin were 
more likely to have controlled blood pressure compared to those of white origin (535).  
 
Particularly, I did not find a significant difference in the risk of having control blood pressure 
between hypertensive black patients and white patients. Other studies conducted in primary 
care settings have shown that patients of black origin were less likely to achieve blood pres-
sure targets (496-497). These studies were a cross sectional analysis and without adjust-
ment for other factors such as body mass index or smoking status. The current results rely 
on a longitudinal analysis including a range of individual factors and using a hierarchical 
model. Kressin et al conducted a retrospective study of hypertensive patients aged 21 years 
and over managed in primary care settings to assess factors explaining differences in blood 
pressure control between white and black patients. They found that after adjustment for phy-
 314 
 
sician care, clinic care, patient income, patient education, patient health insurance, patient 
adherence to medical interventions, perception of discrimination and personal beliefs black 
origin was no longer associated with poor blood pressure control (352). 
 
However the survival analysis revealed that black patients tended to have uncontrolled blood 
pressure as the distribution of hazard ratios show lower values for black patients than those 
observed in other race/ethnic over the study period. Other factors different from being pre-
scribed on antihypertensive treatment may account for low blood pressure control rates in 
black patients. In a study of hypertensive patients treated in 30 primary Durham Veterans 
Affairs Medical Center Primary Care Clinics, Bosworth et al found that compared to white 
black patients had lower adherence to antihypertensive medication (OR 1.47 95% CI 1.02 – 
2.01) compared to white (848). Similarly, Gerber et al reported lower adherence to physician 
instructions on antihypertensive medication among elderly black patients compared to white, 
(OR 2.49 95% CI 1.07 – 5.80). (849). Misbelieves about hypertension such as the need of 
taking pill only under perceiving symptoms may account for their lower blood pressure con-
trol rates among patients of black origin (352, 400).    
 
Smoking was not associated with lower blood pressure control. The relation between smok-
ing and blood pressure control has varied across the studies. For instance, among 631 
hypertensive patients managed in primary care, Majernick et al did not find a significant dif-
ference in the risk of having controlled pressure between smokers and non smokers (332).  
By contrast, among hypertensive patients on treatment  recruited from 33 communities in 
China, Tian et al found that current smokers were less likely to have controlled blood pres-
sure, (OR 0.49 95% CI 0.26 – 0.91) (295). Differences in sample size and prevalence of 
smoking between studies could account for these discrepancies.  
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Physician factors  
I assessed physician factors by means of analyzing prescribing patterns of antihypertensive 
medication over the study. Additionally, I quantified the use of recommended treatment es-
tablished in the 2006 NICE guidelines. Both the number of hypertensive patients on antihy-
pertensive treatment and the number of antihypertensive medications prescribed for each 
patient increased over the period. It seems that inertia clinical may not be a relevant factor 
associated with poor blood pressure control in this patient cohort. In England, improvements 
in antihypertensive prescribing have been observed (284). From the Health survey for Eng-
land, Falaschetti et al reported that the percentage of hypertensive patients on antihyperten-
sive treatment increased from 48% to 57% between 2003 and 2006 (284). This is consistent 
with improvements in the management of stroke. In a cohort analysis of 32151 patients with 
stroke, Lee et al found that the percentage of patients on antihypertensive treatment conti-
nually increased from 1999 to 2008 (781).  Comparing data from NHANES 1998 to 1994 and 
1999 to 2008, Egan et al observed that the percentage of hypertensive patients without anti-
hypertensive medication decreased from 42% in 1998 to 28% in 2008 (842). 
 
I found that after the introduction of the 2006 NICE guideline, there was an additional in-
crease in the use of recommended NICE monotherapy treatment.  Toschke, et al also have 
documented increases in antihypertensive prescribing may related to the implementation of 
BHS guidelines (759). In an analysis of 28320 hypertensive patients managed in general 
practices form Lamberth, London, Schofield et al have reported nearly 50% of hypertensive 
patients were prescribed with 2006 recommended treatment (761). The impact of clinical 
guidelines on the management of hypertension has been observed elsewhere (451, 721, 
725). Campbell et al showed the use of antihypertensive medication increased by 58% be-
tween 1998 and 2003 among hypertensive citizens from Ontario (Canada) (723). This in-
crease was associated with the Canadian Hypertension Education Program because the 
prescribing trends were in the line with the recommendations establish in these guidelines 
(723).  
 
The national guidelines could also have an impact on improvements in blood pressure con-
trol. The results showed that patients being prescribed the recommended treatment at first 
entry tended to have better controlled blood pressure compared to those without antihyper-
tensive medication. By contrast, those not being prescribed other antihypertensive medica-
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tion were less likely to have controlled blood pressure. Toschke et also found that patients 
being prescribed the NICE recommended treatment had lower recurrence of stroke com-
pared to those prescribed a different treatment (759). In an intervention taken in community 
services from China, Wang et al found the group which used hypertension guidelines 
achieved higher reductions in systolic blood pressure (21.4 mmHg) compared to those under 
standard care (16.0 mmHg) (850). In a implementation of a quality improvement including 
the use of hypertension guidelines, Vallez-Fernandez et al revealed that hypertensive pa-
tients under intervention had an 92% increase in the odds of having controlled blood pres-
sure compare to control group (451).  
 
Health services factors   
Pay for performance has been advocated as strategy for improvement blood pressure con-
trol (824). The analysis reported that those hypertensive patients who were registered after 
the introduction of QOF were more likely to have controlled hypertension. The association 
was consistent after adjustment for all included variables. The association was also present 
in all models and by using different priors. That could be interpreted as a possible cohort 
effect related to the introduction of QOF (851). Then, patients at same age exposed to varia-
tions in care observed after the introduction of QOF were more likely to have controlled 
blood pressure. Other studies assessing the effect of QOF on hypertension control have 
contradictory results. After the introduction of QOF,  Millet et al found that ethnic differences 
in blood pressure control remained with black patients less likely to have controlled blood 
pressure (496). Similar findings was reported by  Lee et al (852).  Serumaga et at did not 
find variation in blood pressure control rates comparing before and after periods of the intro-
duction of QOF (683). Simpson et al neither found differences in blood pressure control rates 
after the introduction of QOF among patients being treated in Scottish general practices 
(834). By contrast, a reduction in the percentage of patients with blood pressure above 
150/90 mmHg was reported in an analysis of blood pressure measurements from 236467 
patients taken between 2000 and 2005 (699). Also improvements in blood pressure control 
particularly in practices located in the most deprived areas has been associated with the 
introduction of QOF (498).  
 
The referred studies used aggregated data to make comparisons. The studies also com-
monly used the target of 150/90 mmHg which may prevent from identifying differences be-
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tween periods. The discordant results may also  be due to the fact that hypertension control 
is a complex health outcome (288). The lack of including other explanatory variables, the 
presence spatial and temporal correlation of the outcome, the insufficiency time periods and 
the comparability of the populations are of the most common limitations compromising the 
ability of before and after  studies to find differences (853-854). The current analysis used 
the individual data with a model allowing taking into account the individual heterogeneity 
(809). In addition to, the analysis included all individual measurements of the outcome rather 
using a point estimation of the blood pressure.  
 
I did not find significant differences in the individual hazard risk of having controlled blood 
pressure between practices located at least deprived area and those located at the most 
affluent areas. Then there seems that there were no differences in health care between gen-
eral practices. In a cross sectional study of 13330 patients with heart failure registered with 
GPRD, Hawkins et al did not find differences in treatment or case fatality across socio eco-
nomic strata. The treatment offered to patients with heart failure improved over two years 
regardless of socioeconomic circumstances (616). In a model to assess the decline of coro-
nary heart disease in England, Bajekal et al demonstrated that one of the major contributors 
to this decline was the fell in blood pressure at population level. A reduction of nearly 2.5 mm 
Hg in systolic blood pressure for men and 5.5 mm Hg in systolic blood pressure for women 
were observed across all socio economic areas between 2000 and 2007 (613). Ashworth et 
al reported a reduction in differences between quality of blood pressure monitoring after the 
introduction of QOF across general practices after the introduction of QOF (498).  Similarly, 
McLean et at did not find differences in the QOF blood pressure indicators between prac-
tices located in the most and least deprived areas in Scotland (628). Using information from 
2003 and 2006 Health Survey for England, Crawley et al documented that blood control 
rates (target<150/90 mm Hg) were similar between manual and non manual worker before 
and after the introduction of QOF (855). The participation of nurses and pharmacists in the 
delivery of care has been associated with reduction in inequalities between practices (856-
857) . 
 
The differences between the percentages of patients with controlled blood pressure between 
practices located at different socio-economic strata and the individual hazard risk of having 
controlled blood pressure over the period may be explained by the following reasons. Firstly 
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the included populations differ between both analyses. The study presented in chapter 
seven is a cross-sectional study including all patients without missing blood pressure values 
in 2007. They could have only one measure of blood pressure as they could be registered in 
2007. By comparison, in the survival study those who had only one measure were excluded. 
The sample included those with at least two blood pressure measurements. Secondly, the 
survival analysis used more than one measure of blood pressure to assess the control of 
blood pressure over the period (471, 858). The cross-sectional analysis used only one 
measured which may not completely capture the effect of primary care interventions over a 
long time follow-up.  Thirdly whereas the percentage of patients with controlled blood pres-
sure measurement in each practice is a group outcome, the hazard risk is an outcome 
measured individual level. The socioeconomic status was also a variable measures at prac-
tice level. This discrepancy could illustrate the fallacy concept. In essence, factors associ-
ated with an outcome at population or group level, may not always be associated with the 
outcome at individual level (859-860).  
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10.3 The implications of current model  
 
A diversity of factors affecting blood pressure control  are identified in cross sectional studies 
which have been useful to establish national strategies to improve blood pressure control  
One can count more than twenty conditions influencing the likelihood of blood pressure con-
trol. However the impact of some factors may vary between population and individuals. The 
principle that factors associated with the incidence of disease at population level may not 
explain the presence of disease at individual level (861) could also happen in the analysis of 
factors affecting blood pressure control. For instance, a gradient of blood pressure control 
across individual income categories have been frequently reported in cross sectional studies 
conducted at population level. However, these associations have less frequently identified 
among patients being treated in primary care settings and also contradictories. For instance, 
whereas Ostchega et al reported that those with low income were less likely to have con-
trolled blood pressure (313), Majernick et al did not find differences in the likelihood of hav-
ing controlled blood pressure between those currently employed and those not working 
(332).. Therefore, among hypertensive patients undertaken in primary care, the improvement 
of blood pressure control could be benefit from the analysis of local data from these patients.  
 
The current analysis was done among hypertensive patients treated in primary care condi-
tions over a long follow up period. This analysis not only estimate associations between 
some factors and blood pressure control but also could provide information to predict the 
achievement of a blood pressure target. In primary care the prediction of an outcome is an 
essential part of the management. In other words, physician may need going beyond the 
diagnosis of the disease to improve a long term outcome (862). The current model offers a 
ground for constructing a prediction rule of blood pressure control. Firstly, the model has 
internal validity as the associations have demonstrated across different subpopulations from 
the dataset. Altman et al have pointed out that analysing different samples from a dataset is 
a strategy for assessing the internal validity of the results (863). Secondly, the risk of having 
controlled blood pressure was evaluated over a long follow up period using at least two 
measurements of blood pressure. Additionally, the baseline individual characteristics were 
used to assess the outcome. Thirdly, the model was based on multiple factors which allow 
us take into account for the variability among the included patients  (864)  
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The Bayesian model gives the posterior distribution of the estimators.  Consequently, it is 
possible to know the spectrum of the response. This information could better inform physi-
cians on what would be expected from the estimated associations. In other words, it allows 
for knowing the uncertainty of the result. For instance, the results revealed that there were 
no significant differences in the hazard risk of having controlled blood pressure between 
women and men. It was observed that the posterior probability of  the hazard risk was 1.0 
(95% credible interval 0.96 – 1.03)  so that there may be cases in which women be less 
likely to have controlled blood pressure and other in which they may more likely to have con-
trolled blood pressure compare to men.  
 
10.3 Strengths and Limitations 
 
The strength and innovations of the studies I have undertaken are as follows: the large num-
ber of patients and the long term follow period, the number of blood pressure control meas-
urements having for each patient and the availability of information about the most frequent 
variables affecting blood pressure control. Additionally, the use of a longitudinal analysis 
allows assessing the long term relationship between factor and blood pressure control. That 
assessment is relevant when an outcome is attained progressively over the time. 
 
The assessment of factors affecting blood pressure control has been mainly reported from 
cross-sectional studies (283, 285, 319, 349)  or prevalence studies (284, 344, 865). Despite 
the important information provided, they could not properly assess the temporal relationship 
between variables and outcomes (866). That is relevant when the outcome is a chronic con-
dition which may be affected by long term exposures (866). Hence, a key aspect of under-
standing the control of blood pressure at individual level is to identify long term modifiable 
factors. Then, an important aspect of the present study is the use of all available factors hav-
ing by the patient at first entry. It provides a potential profile of the hypertensive patient who 
is less or more likely to have controlled pressure over the time.  
 
The use of a hierarchical model is a relevant characteristic of the model. The model included 
two levels the individual level and practice level. It is known that individuals being treated at 
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the same practice are likely to have similar outcome. There is a high correlation of the out-
come between individuals nested with each practice (799). Blood pressure control is a com-
plex outcome which depends on the interaction between patient factors, physician factors 
and health system factors (317). The Bayesian framework could deal with hierarchical struc-
tures better than the Frequentist framework. Not only the Bayesian framework models the 
random effects present among all hierarchical levels, but also it takes into account the uncer-
tainty in all parameters´ estimations  (867). 
 
The use of a Bayesian framework gives strength to the described associations. The Bayes-
ian framework has been proposed as an alternative to analyse observational studies with 
data not sample based collected (794). Integration of prior information in the analysis of ob-
servational data has been considered as strategy to assess the validity of information con-
tained in the data (471). Additionally, the frailty survival model allows taking into account 
heterogeneity due to unobserved confounders (809). The model fit to data producing results 
coherent to what has been observed. Moreover, the results reflect the true probability of the 
expected associations.  
 
The Bayesian framework has been postulated as an option in the analysis of the observa-
tional studies. Trend estimations of the cardiovascular risk factors have been performed by 
using this framework (34, 868).  The benefits of using the Bayesian framework in the analy-
sis of administrative datasets have been reported (869-870). The Bayesian framework also 
allows for assessing multiple bias analyses. I illustrated the consistency of relevant associa-
tions across the different samples from the dataset and by using different prior distributions 
for the precision of the random effects.  
 
There are two important limitations of the study. Firstly, there was a lack of information on 
patient adherence to pharmacological and non-pharmacological interventions. It is known 
that hypertensive patients often fail to follow these recommendations over long term periods 
(300). However, I expected this unmeasured information to be randomly distributed among 
included patients. Second, there was as lack of information on why the general practitioner 
chose the antihypertensive medication used. Therefore, I cannot provide reasons for the 
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differences between the guideline recommendations and some of the reported trends of an-
tihypertensive use. 
 
Other limitations are related to observational studies in general. Firstly I may have meas-
urement error in blood pressure measurements. There has been observed that blood pres-
sure measurements taking clinical settings may be subject to error due to inadequate meas-
urement technique or the white coat effect (871-872). However those conditions might 
equally affect to all hypertensive patients so that it may not be biased the results. Secondly, 
the use of a year period meaning the blood pressure control status over the year could also 
be considered as a measurement error. That due to the fact that one annual measurement 
could not assess the blood pressure status having by the patient over the mentioned period 
(807)   That situation again compromised all patient in a same way so that I can consider the 
this was  a non-differential error. Thirdly, there could be a bias selection in the sample popu-
lation using for the assessment of factors affecting blood pressure control. Both hypertensive 
patients without variation in the outcome and those with only one measurement had less 
follow up over the study period. Then, these groups were less exposed to interventions over 
the period so that the assessment of interventions could be less attainable. Additionally, the 
group, that did not have variation in the outcome, was already included in the analysis per-
formed in the cross sectional study.  
 
10.4 Future research  
 
The control of blood pressure is defined by the achievement of a blood pressure target. The 
definition of a target is a matter of uncertainty without supportive evidence for any of the rec-
ommended targets. Current guidelines differ in the recommended blood pressure target.  For 
instance for all hypertensive patients the 2011 NICE hypertension guidelines (144) and the 
2003 US  hypertension guideline recommend a target of below 140/90 mm Hg for all hyper-
tensive patients aged below 85 years but the lowest threshold needed is undefined (13). In 
comparison, the 2009 European hypertension guidelines recommend a target of 30-139/80-
85 mm Hg (243). These discrepancies have led to confusion in the management of hyper-
tensive patients among physicians and may account for some of the differences in blood 
pressure control rates. Of note individuals with blood pressure levels below 140/90 mm Hg 
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markedly contribute to the morbidity and mortality associated with hypertension (47). Evi-
dence clarifying the target for the management of hypertensive patients particularly younger 
is needed. That may result in a better blood pressure control rates and lower hypertension-
related comorbidity rates.  
To further improve blood improve blood pressure control in primary care, the concept of a 
universal target may need to be revaluated. Evidence supports that the probability of achiev-
ing a blood pressure target highly depends on patient age (274). I observed that an increase 
in one year age reduces the probability of having controlled blood pressure. I also found that 
the probability of achieving a target varies across age between sexes (interaction effect). 
Blood pressure levels varied between race/ethnicity as individuals of black origin tend to 
have higher blood pressure levels and those of South Asian origin tend to have lower blood 
pressure levels compared to whites (81, 90). Considering this variations, a universal target 
for all hypertensive patients may be questionable. Research on age and race/ethnic ap-
proach in the management of hypertension could contribute to clarify the current differences 
in blood pressure control between race/ethnicity and age-groups.  
 
Hypertensive patients commonly have other cardiovascular comorbidities. For instance, dia-
betes and hypertension are closely linked (873). The results from this research added evi-
dence on the negative association between poor blood pressure control and obesity. How-
ever, the current guidelines are disease-related guidelines (144, 225). Moreover the concept 
of control highly relies on the achievement of a specific-disease blood pressure target. But it 
may distract physician from intensively intervening other risk factors and also analysing the 
reasons for not having controlled blood pressure. It has been reported that physician did not 
intensify treatment when the level of blood pressure is slightly above the target (434).  For 
example, a hypertensive patient may have controlled blood pressure but simultaneously is 
overweight. The hypertension guidelines commonly advice on weight loss but a standardised 
approach is not sufficiently provided. That information usually is available in an independent 
guideline. It could be useful to explore the benefit of using a guideline incorporating a wider 
approach for the management of hypertension. That guideline could also integrate a moni-
toring of reductions in cardiovascular risk.  
 
The lack of information on adherence highlighted the loss of information for improving blood 
pressure control. It is known that regardless of the method used, patient adherence to phar-
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macological and non-pharmacological interventions is not satisfactory (306). Monitoring ad-
herence to clinical recommendations in primary care is needed. Interventions on how to 
cope with poor adherence could provide light on reasons for not having controlled blood 
pressure. This certainly is an area which has not been well explored yet.  
My findings show the impact of the guidelines on the management of hypertension. National 
hypertension guidelines have been proved to be a useful resource for improving blood pres-
sure control (723). However, the observed differences between the guidelines and some 
prescribing patterns need to be clarified. Studies evaluating the use of the guidelines to de-
termine the effectiveness of the guidelines on blood pressure control are needed. The re-
sults from these studies could provide a useful for including modifications in the guidelines. 
This is an area for conducting research in primary care.  
 
The analysis of blood pressure control may need to incorporate long term follow up periods 
to identify risk factors for achieving blood pressure targets. The analysis may use previous 
information with regard to the available information about blood pressure control. This study 
used a Bayesian framework in the analysis of data. It provides the true probability of the es-
timators given the data. The models presented could be an input to be used in posterior 
studies. The Bayesian framework has become a useful method particularly in the analysis of 
data which is not based sample collected.    
 
10.5 Implications for policy and practice 
10.5.1 The assessment of blood pressure control in pri-
mary care 
 
The first consideration is the definition of a blood pressure target. The study revealed that 
the QOF target of 150/90 mm Hg could not identify differences in blood pressure control be-
tween practices. Similarly, Calvert et al found that the QOF targets for diabetes did not prop-
erly capture variations in diabetes control comparing periods before and after the introduc-
tion of QOF (874). Additionally, blood pressure control rates have improved in England 
(284). It is expected that most hypertensive patients have blood pressure levels below the 
QOF target levels. Hence the blood pressure targets established in the NICE hypertension 
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guidelines could be more suitable for the assessment of blood pressure control in England 
primary care. For adults, the 140/90 mmHg blood pressure target, as established in the last 
updated NICE guideline (144), could be the more appropriate blood pressure target. It is also 
the international blood pressure target and there is currently no evidence supporting a lower 
blood pressure target for those at middle or low cardiovascular risk (17).  
The use of two different targets could mislead the control of blood pressure in primary care. 
Physicians may not achieve further lower reductions in blood pressure after achieving the 
higher target because it is the measurement of quality of care. Then the achievement of that 
target also pushes health workers meeting a target regardless of hypertension population 
needs. Also practices achieving higher blood pressure control rates with lower targets may 
be rewarded similarly to those achieving higher blood pressures control rates with higher 
blood pressure targets. That may discourage health workers to attempt improvements in 
blood pressure control. 
 
The assessment of blood pressure control in general practices could be benefit from using 
additional indicators. The percentage of patients with controlled blood pressure does not 
provide information on where is a problem needed to intervene. I suggest four potential indi-
cators to assess the quality of blood pressure control in primary care services. One is related 
to the use of antihypertensive medication. A measurement of the percentage of patients who 
have not received intensification of treatment despite visiting periodically a general practitio-
ner has been proposed (402). The inclusion of other indicators such as percentage of pa-
tients on therapy or percentage of patients being prescribed recommended treatments could 
provide a complementary assessment of the management of hypertensive patients in pri-
mary care settings. Assessment of antihypertensive prescribing may provide additional in-
formation on the quality of care provided by general practices. This indicator also allows for 
identifying factors potentially modifiable and carrying out more appropriate comparisons of 
performance between practices (402).  
 
 
My findings confirmed that hypertensive patients had variability in their blood pressure con-
trol status. Therefore, other potential indicator of the blood pressure control at practice level 
may be the analysis of individual records over a period of time  (807). The periods may be 
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longer than three months. An assessment of the number of clinical visits in which the patient 
had controlled or uncontrolled blood pressure by the total of clinical visits by year could be 
useful to monitor the sustainability of the control. This evaluation might reflect more accu-
rately the quality of care provided by the practices. Another indicator may be the registration 
of non-pharmacological interventions and advice measured as a numbers of people given 
advices by the number of attending a practice or clinic. An assessment of the number of 
clinical visits in which the patient had controlled or uncontrolled blood pressure by the total of 
clinical visits by year could be useful to monitor the sustainability of the control.  
The indicators might be analysed by age, sex, race/ethnicity and socio-economic strata with 
regard to population characteristics. Consistently older patients have been found less likely 
to have controlled blood pressure (205, 287). Then, general practices with older patients 
could report lower achievement of blood pressure targets than those practices with younger 
patients. 
 
 
10.5.2 The orientation of blood pressure control in pri-
mary care 
 
The identification of factors affecting blood pressure control could need more information 
from local services. Although national surveys are an essential tool of monitoring blood pres-
sure control rates, they reported associations between some factors and blood pressure 
control may not be replicated at individual level. It may reflect ecological fallacy (859). Thus 
factors affecting health population outcomes not always explained the achievement of health 
outcome at individual level. Hence, the control of blood pressure could further improve with 
strategies to tackle individuals with risk factors for uncontrolled blood pressure in local set-
tings 
The assessment of factor affecting blood pressure in local level could help to identify pa-
tients at higher risk of not having controlled blood pressure. For instance, the current analy-
sis shows that hypertensive patients with high body mass index and older patients were less 
likely to have controlled blood pressure over the period. These patients may need a particu-
lar approach to reduce blood pressure levels. The current approach based on general rec-
ommendation establish in the guidelines could fail to improve blood pressure control in these 
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patients. They may need complex interventions with regard to their particular conditions to 
low their blood pressure.  
There was a lack of information about adherence to pharmacological and non pharmacologi-
cal interventions. Hypertensive patients have been known to fail the recommendations given 
by physicians (296-297). This led to low blood pressure control rates among hypertensive 
patients. Hence health providers may consider establishing surveillance strategies to moni-
toring adherence to these interventions. These systems could contribute to monitor factors 
influencing adherence to medications. Because a diversity of factors has been associated 
with patient adherence to medications, the interventions of improving adherence should be 
based on the assessment of local data. This information may drive future interventions to 
tackle local conditions affecting blood pressure control among hypertensive patients with 
uncontrolled blood pressure. It is expected that higher blood pressure control rates could be 
achieved after introducing strategies led to improve adherence to pharmacological and non-
pharmacological interventions.   
The control of blood pressure generally takes place in primary care. This study showed im-
provements in blood pressure control among hypertensive patients being managed in pri-
mary care settings. Then, it reinforces the key role of primary care in the management of 
hypertensive patients. Periodical visits, medical register and patient continuity with the same 
provider seems to be effective in the control of blood pressure (317, 340, 836). Hence, there 
seems a consistent evidence supporting that primary care service may be grounded on 
these characteristics. Policy planners may take into account the observed conditions when 
planning care for hypertensive in primary care.  
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10.6 Conclusion  
 
This is one of the largest analyses of hypertensive patients assessing factors affecting blood 
pressure control over a long follow up period. Being older and increases in BMI and choles-
terol were negatively associated with having controlled blood pressure. Compare to white, 
patients of race/ethnicity different origin did not significantly differ in the risk of having con-
trolled blood pressure. Patients of black origin tended to have uncontrolled blood pressure 
over the period.  
 
The percentage of hypertensive patients with controlled blood pressure increased over the 
period. Some possible reasons for this change may include aspects related to health system 
factors. There was a decrease in the percentage of hypertensive patients not being pre-
scribed antihypertensive medication. The implementation of the NICE guidelines was asso-
ciated with an increase in the use of the NICE recommended monotherapy treatment. Pa-
tients registered after the introduction of QOF were more likely to have controlled blood 
pressure. The improvement may reflect the effect of continuity of care on blood pressure 
control.  
 
Blood pressure control in primary care could be improved by using information about adher-
ence to pharmacological and non-pharmacological interventions. Currently, there is neither a 
standard to monitor adherence nor guidelines to deal with situations in which poor adher-
ence is identified as a cause of poor blood pressure control.  
The assessment of blood pressure control in primary care may use a lower blood pressure 
than that established in the QOF guidelines. The 150/90 mmHg may not capture the differ-
ences in blood pressure control rates between general practices. The inclusion of other indi-
cators such adherence to medication, and the number of visits with controlled blood pres-
sure could give information on what interventions could be needed to improve blood pres-
sure control.  
 
 329 
 
Finally, the study added evidence on the positive impact of primary care on blood pressure 
control. The continuity of care resulted in a significant reduction in blood pressure levels for 
patients include in the cohort. 
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Millett.  'Impact of ethnic-specific guidelines for antihypertensive prescribing in primary care 
in England: longitudinal study' on submission 
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Appendix C Model code 
 
Model  { 
 
 for (j in 1:N) { 
 
   timeobserv[j] ~ dweib(shape, Scale[j]) I(timecensor[j],) 
 
    HRx[j]<-Scale[j]*shape*pow(timeobserv[j], shape-1) 
 
   S[j]<-exp(-Scale[j]*pow(timeobserv[j], shape))  
 
 
log(Scale[j])<-alfa1*(firstage[j]-mean(firstage[])) + beta[1]*firstsex[j] + u[Lastethnic[j]] + 
beta[2]*FirsTTO[j] + beta[3]*FirsCom[j] + beta[4]*FirstNOCCOM[j] + beta[5]*firstsmoker2[j]+ 
beta[6]*QOF[j] +  alfa3[Firstcatecholesterolt[j]] + alfa2[catefirstBMIt[j]] +  b[newid4[j]] 
 
}  
  # Random effects on individuals into practice 
 
   or (z in 1:M) {b[z]  ~ dnorm(mu[z],  tau.b[practice4[z]]) 
 
                                     mu[z]<-a[practice4[z]] }  
 
 
#Random effects on practices  
 
 for (p in 1:T) {a[p] ~dnorm(mup[p], tau) 
         mup[p]<-alfa0 + alfa[practicelistfirst[p]] + d[deprivation[p]] 
                  
} 
  
 
# Priors distribution for variance parameter of each practice 
 
for (p in 1: T) { 
       tau.b[p] ~ dgamma (0.5, 0.5)   
        sigmap[p]<-1/tau.b[p] 
          sigmap2[p]<-sqrt(sigmap[p]) }  
 
#Priors distribution for overall variance parameter of the practices       
 
        tau ~ dgamma (1, 0.5) 
         sigma <-1/tau 
        sigmab<-sqrt(sigma)   
   
 #Prior distribution of baseline hazard function  
    shape ~dgamma(1, 0.01) 
 
    #Prior on betas 
      for (k in 1: 6) { 
    beta[k] ~ dnorm (0, 0.01) }             
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   #Prior on u 
      u[1]<-0 
     for (e in 2:6) {u[e] ~dnorm (0, 0.001)} 
 
   #Prior on deprivation  
     d[1]<-0 
     for (t in 2:3) {d[t] ~ dnorm(0, 0.001) } 
 
 
  #Prior on practice list 
     alfa[1]<-0 
     for (l in 2:3) {alfa[l] ~ dnorm (0, 0.001)} 
      
 #Prior on intercept 
     alfa0 ~ dnorm (0, 0.01) 
  #Prior on alfa age 
    alfa1 ~ dnorm (0, 0.01) 
 
 
   #Prior on alfa2(BMI) 
      alfa2[1]<-0 
      for (o in 2:5) {alfa2[o]~dnorm(0, 0.001)} 
 
   #Prior on alfa3(CHOL) 
        alfa3[1]<-0 
     for (c in 2:3) {alfa3[c]~dnorm(0, 0.001)}  
 
 #Exponential coefficients  
 
          Exp.alfa0<-exp(alfa0) 
         Exp.alfa1<-exp(alfa1) 
   for (l in 2:3) {Exp.alfa[l]<-exp(alfa[l])} 
   for (k in 1:6) {Exp.beta[k]<-exp(beta[k])} 
    for (e in 2: 6) {Exp.u[e]<-exp(u[e])} 
     for (t in 2:3) {Exp.d[t]<-exp(d[t])} 
     for (o in 2:5) {Exp.alfa2[o]<-exp(alfa2[o])} 
      for (c in 2:3) {Exp.alfa3[c]<-exp(alfa3[c])} 
        
  } 
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Model parameters 
 
alfa  Coefficient for the categories of the number of patients registered with each prac-
tice.  
alfa0 Overall intercept for practices 
alfa1  Coefficient for age  
alfa2 Coefficient for BMI categories 
alfa 3  Coefficient for cholesterol categories  
beta[1] Coefficient for sex 
beta[2] Coefficient for being prescribed any antihypertensive 
beta[3] Coefficient  for having an additional cardiovascular  
beta[4] Coeffcient for having an additional no cardiovascular comorbidity  
beta[5] Coefficient for being current smoker 
beta[6] Coefficient for being registered before the introduction of QOF  
d Coefficient for deprivation index in tertiles  
mup[p] overall effect of the practices  
u Coefficient for race/ethnicity   
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